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Abstract 
Current approaches to sampling and analysis are thought to be unsuitable for 
investigative monitoring under the auspices of the European Union’s Water 
Framework Directive. During this study, new sampling and analytical techniques 
were developed and tested that provide a ‘toolkit’ that can be utilised by most 
laboratories engaged in regulatory analysis of water samples. The techniques 
developed include;  
 
i) Targeted screening methodology based on passive sampling in-conjunction 
with comprehensive two-dimensional chromatography mass spectrometry was 
developed and successfully applied to the broad-scope detection and 
determination of non-polar emerging pollutants and related contaminants in 
environmental waters. This method was found to be superior to existing 
approaches based on spot sampling and one dimensional gas chromatography.  
 
ii) Modifications to the Chemcatcher® passive sampler to allow for the sampling 
of polar pollutants present in the water environment. Statistical analysis of the 
data obtained demonstrated that sampler performance was equivalent to that 
of the established POCIS passive sampler but with greater physical robustness 
together with simplified preparation and extraction procedures.  
 
iii) Targeted screening methodology based on modifications to the existing 
Chemcatcher® passive sampler in-conjunction with liquid chromatography-
high resolution mass spectrometry techniques for the identification of polar 
pharmaceutical residues present in the effluents of waste water treatment 
iii 
 
plants located in south west Wales. Identification of analytes was strengthened 
through the development, validation and application of a novel accurate mass 
data-independent acquisition method and the high degree of analyte 
identification assurance obtained confirmed it to be analogous to traditional 
collision-induced dissociation transitions.  
 
iv) The targeted application was supplemented through the development and 
application of a novel in silico methodology for retention time prediction 
which was successfully used to identify additional compounds in an extract 
obtained from a Chemcatcher passive sampler, and, thus, the preliminary 
identification of potential emerging contaminants.  
 
Overall, this work has furthered the knowledge and capability of the sampling and 
analysis of existing and newly emerging contaminants in environmental waters.  
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POCIS data. 
Figure 4.6 Overlaid scatter plots with regression lines of the averaged peak areas 
for ‘unknowns’ obtained from POCIS and Chemcatcher® for all WWTPs. 
Figure 4.7 Overlaid scatter plots with regression lines of the averaged Log10 peak 
areas for ‘unknowns’ obtained from POCIS and Chemcatcher® for all WWTPs. 
Figure 4.8 Fitted line and plots of standardised residuals obtained from least 
squares regression analysis of ‘unknowns’ in all replicates of POCIS and 
Chemcatcher®. 
Figure 4.9 Fitted line and plots of standardised residuals obtained from 
orthogonal regression analysis of ‘unknowns’ in all replicates of POCIS and 
Chemcatcher®. 
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Figure 4.10 Fitted line and plots of standardised residuals obtained from least 
squares regression analysis of the averaged Chemcatcher® and POCIS ‘unknowns’ 
data. 
Figure 4.11 Fitted line and plots of standardised residuals obtained from 
orthogonal regression analysis of the averaged Chemcatcher® and POCIS ‘unknowns’ 
data. 
Figure 4.12   Plot of mass versus retention time for features identified in the 
Chemcatcher® (a) and POCIS (b) samplers deployed at the Carmarthen WWTP. 
Figure 4.13   Plot of mass versus retention time for features identified in the 
Chemcatcher® (a) and POCIS (b) samplers deployed at the Gowerton ‘1’ WWTP. 
Figure 4.14   Plot of mass versus retention time for features detected in the 
Chemcatcher® (a) and POCIS (b) samplers deployed at the Gowerton ‘2’ WWTP. 
Figure 4.15 Plot of mass versus retention time for features detected in the 
Chemcatcher® (a) and POCIS (b) samplers deployed at the Llanelli WWTP. 
Figure 4.16 ‘Zoomed-in’ section of the mass versus retention time plot (14.5–20 
min, 420–900 Da) for the Chemcatcher® (a) and POCIS (b) samplers deployed at the 
Llanelli WWTP. 
Figure 4.17 Plot of mass versus retention time for features detected in the 
Chemcatcher® (a) and POCIS (b) field blanks used at the Carmarthen WWTP. 
Figure 4.18    Retention time/feature (a) and mass/feature (b) histograms for the 
Chemcatcher® and POCIS samplers deployed at the Carmarthen WWTP. 
Figure 4.19 Retention time/feature (a) and mass/feature (b) histograms for the 
Chemcatcher® and POCIS samplers deployed at the Gowerton ‘1’ WWTP. 
Figure 4.20 Retention time/feature (a) and mass/feature (b) histograms for the 
Chemcatcher® and POCIS samplers deployed at the Gowerton ‘2’ WWTP. 
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Figure 4.21 Retention time/feature (a) and mass/feature (b) histograms for the 
Chemcatcher® and POCIS samplers deployed at the Llanelli WWTP. 
 
Figure 5.1  Correlation between experimental and calculated retention times of 
1453 compounds in the ‘training set’ database.  
Figure 5.2  Distribution of retention time errors from both prediction models. 
Figure 5.3 Regression plots of calculated versus measured retention times using 
the best 50 compounds fit. a) = forced through the origin, b) = origin not included. 
Figure 5.4    Regression plots of calculated versus measured retention times using 
the all compounds fit. a) = forced through the origin, b) = origin not included. 
Figure 5.5  Structures and chemical formula for Irbesartan and three of its 
metabolites (M4, M5 and M6) tentatively identified in a Chemcatcher® passive 
sampler extract. 
Figure 5.6 Accurate mass extracted ion chromatograms for Irbesartan and three 
of its common metabolites (Irbesartan M4, M5 and M6). 
Figure 5.7    Structure and chemical formula for the common fragment ion of 
Irbesartan and three of its metabolites.  
 
 
Figure A1 Fitted line regression and plots of standardised residuals obtained from 
least squares regression analysis of the averaged Log10 transformed Chemcatcher
® 
and POCIS pharmaceutical data. 
Figure A2 Fitted line regression and plots of standardised residuals obtained from 
the orthogonal regression analysis of the averaged Log10 transformed Chemcatcher
® 
and POCIS pharmaceutical data.  
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Figure B1 Fitted line and plots of standardised residuals obtained from least 
squares regression analysis of the averaged Chemcatcher® and POCIS ‘unknowns’ 
data after application of DFITS. 
Figure B2 Fitted line and plots of standardised residuals obtained from 
orthogonal regression analysis of the averaged Chemcatcher® and POCIS ‘unknowns’ 
data after standardised residuals filtering. 
Figure C1 Fitted line and plots of standardised residuals obtained from least 
squares regression analysis of Log10 transformed data for ‘unknowns’ in all POCIS 
and Chemcatcher® replicates. 
Figure C2 Fitted line and plots of standardised residuals obtained from 
orthogonal regression analysis of Log10 transformed data for ‘unknowns’ in all 
POCIS and Chemcatcher® replicates. 
Figure C3 Fitted line and plots of standardised residuals obtained from least 
squares regression analysis of the averaged Log10 transformed Chemcatcher
® and 
POCIS ‘unknowns’ data. 
Figure C4 Fitted line and plots of standardised residuals obtained from 
orthogonal regression analysis of the averaged Log10 transformed Chemcatcher
® and 
POCIS ‘unknowns’ data. 
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“There are known knowns. These are things we know that we know. There are known 
unknowns. That is to say, there are things that we know we don't know. But there 
are also unknown unknowns. There are things we don't know we don't know.” 
 
Donald Rumsfeld 
United States Secretary of Defense (2001-2006) 
 
 
 
 
 
Chapter 1 
 
Literature review 
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1.1 The European Union’s Water Framework Directive 
In December 2000, the European Union’s Water Framework Directive (WFD) came 
into force across the community and formally became part of law in the United 
Kingdom in December 2003 (1). The WFD has the key mandated objective of 
providing for the planning and delivery of a better aquatic environment across the 
European Member States through the application of river basin management plans  
(2, 3). The directive sets out three cycles of ‘River Basin Planning and Management’ 
leading towards the eventual achievement of ‘good ecological status’. The WFD aims 
to help protect and further enhance the quality of surface freshwater (including lakes, 
rivers and streams), groundwater, estuaries and coastal waters up to one nautical mile 
off shore. Various types of monitoring activities are described including: 
investigative, operational and surveillance (1, 4-6). In addition to improving the 
ecological health of water bodies, the WFD sets out to achieve chemical quality 
standards that will help to deal with diffuse and point source pollution that remain a 
serious environmental concern (7, 8). Furthermore, the Marine Strategy Framework 
Directive came into force in June 2008, and its key aims are similar; to protect and 
enhance the environmental status of the marine waters bounding the Member States 
by 2020 (9-12). 
 
Most of the strategies currently used for the identification of pollutants in water 
bodies, within the context of the WFD, focus on the measurement of the 
concentrations of substances specified in a priority pollutant list.  In 2008, an initial 
list of 33 priority chemicals and eight other pollutants were specified in “Directive 
2008/105/EC on environmental quality standards in the field of water policy” (13).  
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The same directive introduced eleven additional compounds and two compound 
groups (polychlorinated biphenyls and dioxins) for possible identification as priority 
substances or priority hazardous substances in any future directive.  
 
A subsequent EU directive 2013/39, introduced in 2013, incorporated many of these 
compounds into mandatory operational or surveillance monitoring programmes, and 
introduced the concept of a ‘Watch list’ of substances selected from amongst those 
for which the information available indicates that they may pose a significant risk to 
the aquatic environment and for which current monitoring data are insufficient (14). 
17-alpha-ethinylestradiol, 17-beta-estradiol and diclofenac were included in the first 
WFD watch list, which was extended by a further 13 compounds in 2015 through EU 
Decision 2015/495 (15).  
 
Substance or compound lists in the various EU directives are mainly organic 
compounds together with the following metals: cadmium, lead, mercury and nickel. 
The measured concentrations in water samples are compared with the prescribed 
environmental quality standards set by the European Commission for each of these 
pollutants, however, each subset (e.g. polyaromatic hydrocarbons, specific classes of 
pesticides) of pollutants may require a separate water sample to be taken in the field 
and the combined cost of these analyses can prove labour intensive and hence costly. 
In such surveillance monitoring campaigns, many compounds will, however, remain 
unidentified, but which could have a significant toxicological impact on the fauna and 
flora within the given aquatic environment resulting in poor ecological status. This 
could mean that the environmental objectives for a water body are unlikely to be met 
and further investigative monitoring may have to be undertaken to gather additional 
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information on the likely reason for the failure (13). Further, within the WFD, the 
practice of taking low volume (1 – 5 L) bottle, grab or spot samples of water followed 
by their laboratory analysis may not always provide a useful indication of the 
environmental status of a water course and alternative approaches (e.g. bio-
monitoring, sensors, passive sampling) and strategies may be warranted (16-19).  
 
 
1.2 Monitoring under the WFD 
Monitoring programmes under the auspices of the WFD can be of three types, as 
described below. 
 
(i) Surveillance monitoring: This is undertaken to provide information for the 
assessment of long-term changes resulting from widespread anthropogenic 
activity. In addition, information gained from surveillance monitoring is used 
to supplement and validate the impact assessment procedure detailed in the 
WFD and allow for the efficient and effective design of future monitoring 
programmes. 
 
(ii)    Operational monitoring: This is to determine the status of water bodies 
identified as being at risk of failing to meet their environmental objectives and 
assess any changes in the status of such bodies resulting from the programmes 
of measures. 
 
(ii) Investigative monitoring: This is carried out when reasons of any exceedance 
for ecological and chemical status is unknown and where surveillance 
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monitoring indicates that the objectives for a water body are not likely to be 
achieved. Investigative monitoring therefore tries to determine the causes and 
ascertain the magnitude and impacts of unknown pollution. 
 
 
1.3 Existing approaches to WFD investigative monitoring of organic 
chemicals 
No clear guidance exists for this type of monitoring as it must be tackled on a 'case-
by-case' basis and for several years has involved the analysis of spot samples of water 
for unknown (non-target) organic chemical pollutants. This is usually accomplished 
by low resolution gas chromatographic-mass spectrometric (GC-MS) analytical 
methods using simple mass spectral library searching routines (20-22). GC-MS is a 
powerful technique for the separation and determination of volatile and semi-
volatile compounds, yet even with the use of high resolution capillary columns, it is 
unable to resolve the multitude of compounds that can be present in complex 
environmental samples (23-25). Screening of samples via low unit mass resolution 
GC-MS is also susceptible to interference from other compounds of a similar 
molecular mass (21, 26-29). This implies that when using conventional single 
quadrupole GC-MS techniques many compounds will remain unidentified, but which 
could have a significant aquatic toxicity (30-33). It is, therefore, desirable to introduce 
other instrumental techniques to improve the quality of environmental assessments 
and to benefit from resource saving as further analytical developments become 
available (17, 34, 35). 
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1.4 Sampling techniques for the determination of organic contaminants 
in the aquatic environment 
Regulatory water monitoring programmes for directives such as the WFD, typically 
entail active sampling at specific locations and points of time as defined in the 
monitoring programme. Active sampling refers to techniques or methods that require 
physical intervention or external energy input for sample collection, extraction or 
trapping of compounds in the exposure medium. e.g. the taking of samples in specific 
bottles or containers more commonly known as spot sampling (36-38). Spot samples 
are nearly always extracted with organic solvents i.e., liquid-liquid extraction (LLE) 
or solid-phase extraction (SPE) and where necessary clean-up is employed to remove 
potential interferences. Spot sampling techniques are well developed and are known 
to provide very good accuracy with well documented quality control procedures (39).  
Spot sampling methods do, however, suffer from potential problems with sample 
preservation such as losses due to volatilisation, sorption to container walls, chemical 
degradation and loss of analyte during filtration (40). 
 
Spot sampling is arguably the most widely used and validated sampling technique, 
but it has many shortcomings. For example, spot water sampling provides only a 
‘snapshot’ of the situation at the set time of sampling and episodic events such as 
storm water runoff, pesticide runoff or accidental spills are often missed as 
contaminants can dissipate between sampling intervals (41, 42). Spot sampling 
therefore fails to detect and account for temporal variation in pollutant concentrations 
and may not provide a truly representative picture of the extent of contamination (43). 
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Despite allowing for the determination of total contaminant spot sampling fails to 
consider the bioavailability of pollutants in water and especially so for compounds 
with high Log10 Kow’s which readily partition onto suspended particles present in the 
watercourse. Bioavailability, and the accumulation of sediment contaminants in 
aquatic organisms, depends upon desorption and diffusion processes into and from 
the sediment particles, partitioning into water and into biological membranes. 
Therefore, the fraction of the total waterborne residues characterised by the dissolved 
phase or bioavailable phase is not distinguished from other waterborne phases by spot 
sampling (44).  
 
Sample sizes, typically ≤ 2 L, may also be inadequate for the analysis of ultra-trace 
levels of contaminants as specified in EU Decision 2015/495 (15), e.g. Cypermethrin 
and Hepatchlor (plus its epoxide) which have EQS values of 8.5 x10-5  and 2.0 x10-7 
respectively. As spot sampling in a watercourse is generally relevant only to a few 
points in time (i.e. monthly sampling), it does not provide time-weighted average 
(TWA) concentrations which are useful indicators of organism exposure to pollutants 
(45). However, measurement of TWA concentrations over specified time periods 
requires continuous, additive extraction (i.e., integrative sampling). Notwithstanding 
the significant financial costs in purchasing automatic sampling systems that can take 
sufficient repetitive samples to formulate estimates of TWA concentrations, their 
installation and operation in remote areas can present significant logistical and site 
security difficulties (43). 
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1.5 Extraction techniques for organic contaminants in water 
1.5.1 Liquid/Liquid Extraction 
Liquid–liquid extraction is an important extraction technique for environmental, 
clinical, and industrial laboratories where the target or compounds of interest partition 
between two immiscible phases. One phase is usually aqueous and the other phase is 
an organic solvent (e.g. dichloromethane or hexane) and because the phases are 
immiscible they form two layers, with the denser phase on the bottom. After 
extraction, the target compound is present in the organic phase with the percentage 
extracted determined by the equilibrium constant between the two phases. The 
extraction efficiency for acidic and basic compounds can be influenced by the pH of 
the aqueous phase and acidification of the aqueous phase is generally undertaken prior 
to extraction to prevent degradation of compounds during storage. Despite the 
introduction of alternative extraction techniques for aqueous samples, such as SPE, 
liquid-liquid extraction methods, including regulatory methods such as those used by 
the United States Environmental protection Agency (USEPA) remain very popular 
for the extraction of non-polar compounds (46-49).  
 
 
1.5.2   Solid-Phase Extraction 
SPE uses a solid sorbent to remove analytes of interest from various liquid samples 
which can include surface waters, effluents and biological samples and is based on 
specific interactions between the sorbent particles, which contains the stationary 
phase, and the analyte present in the matrix of interest (50). There is a vast number of 
different types of sorbents available allowing the processing of many different sample 
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types and the nature of the sorbent stationary phase dictates the mode of SPE whether 
it be normal-phase, reverse-phase, ion-exchange (51-53).  
 
Extraction of aqueous samples is typically performed in reversed-phase mode where 
a non-polar sorbent is used to retain mid to non-polar compounds from a polar matrix 
such as water. Compound retention is achieved through non-polar interactions such 
as van der Waal forces. Ion-exchange SPE is also used for the extraction of 
compounds from water and involves electrostatic interactions between charged 
functional groups on the compound to be retained and oppositely charged groups on 
the sorbent surface. Ion-exchange is therefore used for the extraction of acids and 
bases with a wide range of pKa values. Sorbents can either contain cation exchange 
groups such as sulphonic acid, which are used to extract bases from water, or anion 
exchange groups such as amines to extract acids from water. 
 
The past decade has seen an emergence of polymeric sorbents that allow retention of 
a wider range of compounds through a combination of different interactions (54). A 
common polymeric sorbent is polystyrene divinylbenzene (PSDVB) whose surface 
can be modified to provide varying functionality to allow mixed mode retention of 
compounds (55, 56). These polymeric sorbents allow for the retention of neutral and 
some charged species through a variety of interactions including π-π, dipole-dipole 
and van der Waals forces. The most frequently used polymer sorbent for the 
extraction of compounds from aqueous environmental samples is the patented 
divinylbenzene-N-vinylpyrrolidone copolymer which allows the retention of 
compounds across a wide polarity range. The commercial product employing this 
polymer is the Waters Oasis® hydrophilic-lipophilic balanced (HLB) sorbent which 
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is made from a balanced ratio of two monomers, the hydrophilic N-vinylpyrrolidone 
and the lipophilic divinylbenzene; its structure is shown in Figure 1.1 (57). 
 
A non-targeted analytical method such as qualitative screening should extract as many 
compounds within a single sample as possible, allowing for a maximum 
representation of the sample components to be obtained (58). The Waters OASIS® 
HLB sorbent, and other similar sorbents are ideal for qualitative non-target screening 
in addition to its application to quantitative analysis of target compounds.  
 
Of increasing use in environmental based SPE are the molecularly imprinted 
polymers (MIP’s) which have robust molecular recognition elements which can 
mimic natural recognition entities such as biological receptors, and are therefore 
useful to trap and separate target compounds from highly complex matrices such as 
biological fluids and environmental samples (59). These would cover a limited range 
of compounds with similar structures and have limited application to non-target 
screening. 
 
The SPE approach also includes the 3M range of Empore™ disks and Horizon 
Technology’s range of Atlantic® SPE disks (60-62). These disks or membranes 
consist of a Teflon fibril (Empore™ disks) or glass fibre matrix (Atlantic® SPE disks) 
loaded with the SPE sorbents but the particle size of these sorbents is typically smaller 
than those used with standard SPE cartridges. In cases where water samples contain 
significant particulates, they are generally filtered through glass fibre filters first to 
avoid clogging of SPE cartridges during extraction. The presence of particulates has 
much less of an impact when using SPE disks as the surface area in contact with the 
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water is considerably higher. The 3M range of Empore™ disks have been used 
extensively with the Chemcatcher passive sampler since its development in 2000, and 
more recently Horizon Technology’s Atlantic® SPE disk (containing Waters Oasis® 
HLB Sorbent) has seen use with the Chemcatcher for the determination of polar 
organic micro-pollutants in wastewater effluents (42, 63, 64). 
 
 
 
Figure 1.1 Structure of the patented divinylbenzene-N-vinylpyrrolidone 
copolymer used in Waters OASIS® HLB SPE products. Reproduced with 
permission from (57) copyright 2008, John Wiley and Sons. 
 
 
 
1.5.3 Other extraction techniques  
Solid phase micro-extraction (SPME) methods have been used extensively in 
environmental analysis since its introduction in the early 1990’s (65-68). The SPME 
approach has several advantages over active sampling methods, which includes the 
elimination of the SPE filtration step or LLE typically required for sample 
preparation, and allows for the direct introduction and desorption of the adsorbed 
compounds into a GC for analysis. However, the use of SPME methods for 
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monitoring contaminants at very low ng/L concentrations in water is very challenging 
(69). 
 
Aliquots of the prepared extracts obtained from LLE and SPE are typically introduced 
into a gas or liquid chromatograph for analysis whilst SPME allows for the direct 
injection of the total sample extracted into the chromatographic system. Various 
detection systems are used including mass spectrometry (MS) and elemental selective 
detectors such as the electron capture detector (ECD) for halogen containing 
compounds, or the nitrogen phosphorous detector (NPD) for phosphorous and 
nitrogen containing compounds (70).  
 
 
1.6 Passive sampling 
According to Górecki and Namieśnik, passive sampling can be defined as “any 
sampling techniques based on free flow of analyte molecules from the sampled 
medium to a collecting medium, as a result of a difference in chemical potential of 
the analytes between the two media” (71). 
 
Prior to the mid-1980’s, passive sampling was mainly used for gas and air sampling 
and it was not until 2002 that the number of publications for passive sampling in water 
exceeded ten. Figure 1.2 shows the number of publications on passive sampling of 
the aquatic environment between 2000 and 2017. The increase in publications was 
mainly driven by the capability of passive samplers to achieve pg/L time weighted 
average concentrations in the aqueous environment and to identify new and emerging 
contaminants which had previously remained unidentified (72). 
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Passive sampling devices can be used for the determination of both organic and 
inorganic compounds in various matrices, including water. Passive methods may 
generally be classified as either based on adsorption or absorption with adsorptive 
methods involving the transfer of analytes usually through a membrane and the 
physical or chemical retention of contaminants by the surface of the adsorbent (71, 
73). The chemical retention may be based on Van der Waal, π-π, ion-exchange or 
hydrogen bonding interactions. Absorptive methods involve not only involve surface 
phenomena, but also analyte permeation in the interceding material, hence providing 
the possibility of compound discrimination due to the membrane’s physicochemical 
characteristics. 
 
 
Figure 1.2 Number of publications on passive sampling of the aquatic 
environment between 2000 and 2017 (from an advanced search using SCOPUS 
using search terms “passive-sampling, water, river, groundwater and effluent” 
in title, abstract or key words of article). 
 
 
Membranes used in absorptive passive sampling are the most critical component of 
the sampler and mass transfer of compounds through the membrane is greatly 
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influenced by the nature of the membrane material (74, 75).  Compound molecules 
flow from one medium to the other until equilibrium is reached in the sampler or until 
the sampling deployment is terminated, thus the quantity of the compound collected 
by the sampler is dependent on both its concentration in the sampled medium and the 
exposure time (71). The ratio of analyte distribution between the two media involved, 
or the experimental calibration of the device, can then be used to determine the 
analyte’s concentration. 
 
The use of passive samplers can provide an estimate of TWA concentrations of 
pollutants of interest and permits sequestration of residues from episodic events 
commonly not detected with grab sampling. In addition, the technique can allow the 
concentration of ultra-trace, yet, toxicologically relevant contaminant mixtures to be 
determined over extended periods of time (43). 
 
The uptake of compounds from water into a passive sampler can be described by a 
first-order, one compartment mathematical model as shown in Equation 1.1 (76). 
 
    𝐶𝑠(𝑡) = 𝐶𝑤
𝑘1
𝑘2
(1 − 𝑒−𝑘2𝑡)                       -       1.1  
 
Where Cs(t) is the concentration of the analyte in the sampler at time t, Cw is the 
concentration of the analyte in the aqueous environment and k1 and k2 are the upload 
and offload rate constants respectively. This equation can be further simplified 
depending on whether the sampler used is in the linear, curvilinear or equilibrium 
phase as shown in Figure 1.3 (44). 
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For equilibrium passive samplers, where a rapid achievement of equilibrium between 
contaminants in the water to be sampled and contaminants inside the passive sampler 
is established, Equation 1.1 reduces to Equation 1.2 (77). 
 
                            𝐶𝑠 = 𝐶𝑤
𝑘1
𝑘2
= 𝐶𝑤𝐾𝑠𝑤             -       1.2
   
Where Ksw is the sampler-water partition coefficient. When Ksw is known it is possible 
to estimate the concentration of the dissolved analytes and as such determine the 
TWA for the water body in question (78). 
 
For integrative passive samplers (also termed kinetic passive samplers), it is assumed 
that the rate of mass transfer between both mediums is linearly proportion to the 
difference in chemical activity of the analyte for both media. Equation 1.1 can then 
be reduced to, 
 
                          𝐶𝑠(𝑡) = 𝐶𝑤𝑘1𝑡                          -       1.3 
 
This can in turn be rearranged to an equivalent relationship, 
 
                      𝑀𝑠(𝑡) = 𝐶𝑤𝑅𝑠𝑡               -       1.4  
 
Where Ms(t) is the mass of analyte accumulated in the receiving phase as exposure 
for length of time (t), Rs is the sampling rate which is the product of the first order 
rate constant for uptake of pollutant (k1) and the volume of water that gives the same 
chemical activity as the volume of the receiving phase. When Rs is known, Cw (the 
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TWA concentration of a compound in the water phase) may be calculated from the 
sampling rate Rs, the amount Ms (t) of the analyte trapped by the receiving phase and 
the exposure time (t). For most devices operating in the linear mode, Rs does not vary 
with Cw but is affected by water flow, turbulence, temperature and biofouling (43, 76, 
79). A passive sampling device is left in the water for a few days to several weeks, 
during which it sequesters hydrophobic or hydrophilic water-borne contaminants 
depending on the sampler design and, at the end of the period, the sampler is removed 
and then analysed for the contaminants. Passive samplers combine sampling, 
selective analyte isolation, pre-concentration and in some cases, speciation 
preservation in one step; reducing sample preparation costs and the potential for 
contamination with spot samples which must typically undergo several extraction and 
concentration steps in the laboratory (80). Moreover, decomposition of the sample 
during transport and storage and/or changes during sample enrichment are also 
minimised (74).  
  
 
1.6.1 Passive sampling devices for organic compounds  
  
Four types of commonly used passive samplers for organic compounds are discussed 
in the following section.  
 
 
1.6.1.1 The semipermeable membrane device   
  
The semi-permeable membrane device (SPMD) was developed by Huckins et al. as 
technique for the monitoring of lipophilic compounds and is the most widely used 
passive sampler used for investigative monitoring in the aqueous environment (81). 
The SPMD is a bi-phasic sampler for water comprising of a lay-flat low density 
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polyethene (LDPE) which is a non-porous material with no fixed pores having only 
transient cavities with typical size of 1 nm tubing enclosing a thin film of high purity 
synthetic triolein (82).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 Plot of the three phases of passive sampler uptake, i) linear phase, 
ii) curvilinear phase and iii) equilibrium phase. Time is given in half lives. 
Adapted with permission from (44), copyright 2006, Springer. 
 
 
In an aquatic environment, SPMDs passively accumulates hydrophobic organic 
compounds with partition coefficients (Log10 Kow) in the range of 3.0 to 6.0, such as 
polynuclear aromatic hydrocarbons (PAHs), polychlorinated biphenyls (PCBs), 
organotin compounds plus various pesticides (including organochlorines, 
organophosphates and synthetic pyrethroid pesticides) and many other non-polar 
chemicals (83-86). In general, any hydrophobic compound with Log10 Kow > 3 and a 
cross-sectional diameter less than 10 Å (1 nm) can be sampled by SMPDs in water 
C
o
n
ce
n
tr
at
io
n
 i
n
 t
h
e 
sa
m
p
le
r 
(C
s)
 
Linear 
phase 
Curvilinear 
phase 
Equilibrium phase 
Time 
18 
 
(87). Uptake of contaminants by SPMDs is strongly dependent on the compound’s 
physical and chemical properties and can be greatly influenced by factors such as 
temperature, flow rate and biofouling (86).  
  
SPMDs have several advantages over spot sampling, these include long sampling 
times without approaching equilibrium and accurate representation of the freely 
dissolved fraction of the analyte in water (74). However, its main shortcoming is the 
lengthy and complex sample preparation procedure required to recover the 
accumulated compounds from the receiving phase including dialysis of the SPMD 
followed by size exclusion chromatography; this latter step is required to remove the 
triolein which would otherwise interfere with the GC analysis (44, 88). The entire 
procedure also consumes large amounts of hazardous high-purity solvents and is seen 
by many as environmentally unfriendly.  
    
 
1.6.1.2   The silicon rubber or polydimethylsiloxane sampler 
The silicon rubber (SR) sampler consists of a single phase based on 
polydimethylsiloxane (PDMS) and, like other hydrophobic samplers such as the 
SPMD, are suitable for compounds with Log10 Kows greater than 3 (89). The surface 
area and thickness of the sampler can be varied to adjust the sampling rate and, for 
compounds with Log10 Kows up to 4 or 5, equilibrium can be reached with long 
deployment times (90). Nine cm x 5cm is the most commonly used size for 
deployments, but Allan et al. produced a SR sampler with the same dimensions and 
surface area as that of an SPMD, allowing the use of the same holders and protective 
cages (91). The SR samplers are cheap, robust, and have a huge advantage over the 
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SPMD in that it can be used several times, making it a very cost effective sampler. 
The samplers must, however, be thoroughly pre-extracted with an organic solvent 
such as ethyl acetate to remove oligomers before they can be used otherwise 
contamination or damage to gas chromatography column can occur and even low 
concentration of oligomers can cause interference with gas chromatographic analysis 
(92). Extraction of the absorbed substances from the silicone rubber sampler after 
exposure is straightforward, usually involving Soxhlet extraction with methanol, 
acetonitrile or mixtures of  polar and non-polar solvents (93). Brockmeyer et al. 
successfully used accelerated solvent extraction (ASE) to facilitate the pre-cleaning 
and extraction process of silicone sheets and significantly decreased time and solvent 
usage compared to the commonly used Soxhlet extraction methods (92). 
Silicone rubber samplers have seen a sharp rise in their use over the past decade for 
the monitoring of hydrophobic pollutants in rivers and in marine waters and have 
been successfully applied for the monitoring of PAHs, PCBs, hexachlorobenzene as 
well as organophosphate pesticides (86, 94, 95). Allan et al. tested silicone rubber and 
LDPE strips for the screening of a wide range of chemicals and showed that the 
former is less discriminating than LDPE for polar substances such as 
organophosphate compounds (89).  
 
1.6.1.3 The polar organic chemical integrative sampler  
The polar organic chemical integrative sampler (POCIS), shown in Figure 1.4, was 
developed by Alvarez in 1999 for sampling water soluble (polar or hydrophilic) 
organic micropollutants from aquatic environments (96). The POCIS is an adsorption 
type sampler and typically consists of 200 mg of sorbent enclosed between two 
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microporous polyethersulphone (PES) diffusion-limiting membranes. To prevent 
sorbent loss, two compression rings are used to firmly sandwich the PES membranes. 
The rings are made of either aluminium, as in the original design, but stainless-steel 
is now the preferred material as, unlike aluminium, it resists corrosion. The rings are 
firmly secured in place using a combination of thumb screws, bolts, nuts or clips. PES 
is a porous membrane characterised by fixed pores of about 0.1 µm diameter which 
allow molecules to diffuse through it (based on size exclusion) to the sorbent where 
they are adsorbed; larger materials, with cross-sectional diameters of less than 0.1 
µm, such as particulate material, macromolecules and bacteria are therefore excluded 
(96, 97). Figure 1.5 shows most of the barriers to chemical uptake by the POCIS 
sorbent. Mass transfer of the solutes from the water include the following steps: 
movement of solutes from the water and diffusion through the water boundary layer, 
diffusion through the water filled membrane pores and through the membrane matrix, 
and finally, diffusion through any water boundary layers associated with the inside of 
the membrane and sorbent particles (98). 
  
POCIS has an effective surface area of 45.8 cm2 and contains a sorbent mass of 200 
mg and typically adsorbs organic contaminants with Log10 Kow values between 
approximately 0.1 and 3, although compounds with higher Log10 Kows, such as 
hormones and steroids, are also known to accumulate within POCIS devices (99, 
100). 
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1.6.1.3.1 Types of sorbents used with POCIS  
 
Two configurations of POCIS are commonly used, each containing a different 
sorbent(s). A configuration for pesticides, hormones and wastewater related 
chemicals consists of a triphasic admixture of Isolute ENV+ polystyrene 
divinylbenzene resin (80% by weight) and Ambersorb 572 carbon, lightly dispersed 
on S-X3 Biobeads (20% by weight) (41, 101). 
 
 
           
 
 
 
 
 
 
 
 
 
 
Figure 1.4 The polar organic chemical integrated sampler (POCIS) for 
sampling water soluble organic micropollutants from aquatic environments. 
Photo taken in authors laboratory in 2014.  
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Figure 1.5 Process of compound diffusion and barriers to chemical uptake 
into the POCIS and polar Chemcatcher® samplers. The line shows the chemical 
concentration gradient in the water through each barrier. Reproduced with 
permission from (98), copyright 2007, Elsevier. 
 
The alternative configuration termed ‘Pharmaceutical POCIS’ contains 200 mg of a 
single hydrophilic-lipophilic balanced sorbent (Waters Oasis® HLB) which is a water-
wettable reversed phase sorbent comprising of a specific ratio of two linked 
monomers namely N-vinylpyrrolidone (hydrophilic) and divinylbenzene (lipophilic) 
(102). This mixture forms a macroporous poly(dinylbenzene-co-N-vinylpyrolidone) 
polymer that exhibits both hydrophilic and lipophilic retention characteristics capable 
of adsorbing both polar and non-polar compounds. Oasis® HLB sorbent is 
characterised by enhanced retention of polar analytes and a relative hydrophobic 
retention capacity that is about three times higher than that of traditional silica based 
SPE sorbents (98). Oasis HLB is by far the most commonly used sorbent incorporated 
into POCIS and has found wide application for sampling pesticides, pharmaceuticals 
and personal care products (PPCP’s) plus many industrial chemicals in water (103-
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106). POCIS has also been used as a targeted screening tool for determining the 
possible sources and relative amounts of organic contaminants in surface water and 
wastewater and drinking water (102).  POCIS samplers remain in the integrative 
phase of sampling for much shorter exposure periods than SPMD or SR samplers with 
typical deployment periods of around 14 days but longer periods of at least 30 days 
have been reported (98, 102).  
 
 
1.6.1.4      The Chemcatcher® 
 
The Chemcatcher® passive sampler was developed in 2000 (42) and has been adapted 
for various types of water contaminants (e.g., trace metals, organometallics, 
pesticides, pharmaceutical residues and various emerging contaminants) making it 
the most flexible of all passive samplers currently used (63, 107, 108). 
 
As the Chemcatcher® body is manufactured from PTFE it has a low sorption capacity 
for most environmental contaminants allowing it to be used to sample a wide variety 
of contaminants (42). PTFE is also a robust material allowing it to be used in any 
environment and they have been reused over a hundred times in the author’s 
laboratory keeping operational monitoring and replacement costs low. 
 
The Chemcatcher® retains a membrane layer covering a solid receiving phase in the 
form of a 47 mm SPE disk and the receiving phase or solid sorbent within the disk is 
immobilised in a PTFE fibril matrix (as is the case with the 3M Empore™ disk) (63, 
109) but can also be incorporated into a glass fibre matrix as with the Horizon 
Technology, HLB disk (64). A comprehensive range of commercially available 
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sorbents (within disks) can be chosen for increasing the range of compounds sampled 
or for making highly selective phases for use with the Chemcatcher® (63). 
 
There are two configurations of Chemcatcher® on the market; organic and inorganic 
both having an active sampling area of 17.5 cm2 (110). For the organic Chemcatcher®, 
both polar and non-polar organic compounds can be sampled and this method has 
found many applications with deployment periods generally ranging from 7 to 30 
days, with 14 days being common enabling the measurement of TWA concentrations 
(111). The accumulation of compounds from the surrounding environments into the 
Chemcatcher® is influenced by the choice of a favourable adsorbent receiving phase. 
Selected analytes permeate through the diffusion membrane phase before being 
adsorbed or absorbed onto the receiving phase (107). The diffusion membrane used 
for the Chemcatcher®   depends on the nature of the analyte to be sampled with LDPE 
being used in many cases to sample for hydrophobic contaminants (112) while a 
cellulose acetate (CA) membrane can be used for organo-metallic species such as the 
organo-tins (113), and a polyethersulphone (PES) membrane for polar compounds 
(114).  
 
 
1.6.1.4.1 Non-polar Chemcatcher® 
The non-polar Chemcatcher® is an integrative passive sampler, consisting of a C8 or 
C18 Empore
® disk receiving phase saturated with n-octanol and fitted with a low-
density polyethylene diffusion membrane, which can be calibrated for the 
measurement of time-weighted average concentrations of hydrophobic 
micropollutants, including PAHs, PCBs and OCs, in the aqueous environment (112). 
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Following retrieval of the sampler, the disassembly of the sampler and extraction of 
the disks is very straightforward using relatively low volumes (≤ 20 mL) of organic 
solvent (115). 
 
In calibration experiments for non-polar compounds the effect of physicochemical 
properties e.g. compound hydrophobicity, water turbulence and temperature etc, have 
been investigated and it has been found that the rate of uptake of compounds from 
water to the receiving phase is related to the rate at which they offload to the water 
(42, 116). This enables the use of performance reference compounds (PRCs), pre-
loaded on to the receiving phase disk, to be used and to adjust uptake rates for the 
effects of temperature and hydrodynamic conditions in the field (107). Calibration 
data is available for many non-polar chemicals and it is also possible to predict uptake 
rates based on a model produced by Vrana et al. (110). A non-linear regression was 
performed for the Log10 of the sampling rate from a series of nine calibration 
experiments using a third order polynomial function of Log10 Kow. The plot obtained 
(Figure 1.6) showed good correlation for sampling rates of compounds with Log10 
Kow in the range from 3.7 to 6.8. Further details on calibration are mentioned in section 
1.6.2. 
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Figure 1.6   A plot of Log10 RSi - Pi (as a function of the sampling rate) versus 
Log10 Kow for the non-polar Chemcatcher from a series of nine calibration 
experiments using a third order polynomial function. Reproduced with 
permission from (110), copyright 2007, Elsevier. 
 
 
 
1.6.1.4.2 Polar Chemcatcher® 
The Chemcatcher® is typically used with a modified styrene-divinylbenzene (SDVB) 
adsorbent for polar to medium polarity compounds such as pesticides, 
pharmaceuticals and industrial chemicals with most researchers using the SDVB-RPS 
or SDVB-XC adsorbent bound in a PTFE matrix disk with the exposed surface 
normally covered with a thin diffusion-limiting polyethersulphone (PES) membrane 
(86, 109, 111, 117, 118).  
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Recently Petrie et al. (2016), investigated the suitability of the Chemcatcher® sampler 
for monitoring organic compounds, including pharmaceuticals, in wastewater 
effluent containing a Horizon Technology, Atlantic HLB disk for the first time (64). 
The existing PTFE body was modified to accommodate the thicker HLB disk, which 
is approximately 3–4 mm thick, without altering the existing sampling area or 
hydrodynamics of the sampler; the modified sampler was named the polar 
Chemcatcher®.  
 
The Atlantic disk is estimated to contain a very similar amount of Waters Oasis® HLB 
sorbent to that used with the POCIS sampler. Using the HLB sorbent is an obvious 
choice for the receiving material because it is the preferred sorbent for analytical 
methods involving extracting a broad range of polar organic pollutants in spot or 
composite water samples (119-121). This has been demonstrated in numerous 
previous studies using POCIS (≥ 21), with > 90 individual pharmaceuticals detected 
(122); moreover, the Chemcatcher® with a HLB receiving phase is highly desirable 
because it combines the proven ability of HLB as a sorbent for a broad range of polar 
organic pollutants with the handling benefits of the Chemcatcher®.  
 
The Atlantic HLB disk configuration was preferred over POCIS for this work (which 
contains an approximate equivalent mass of sorbent as a powder) because loose 
sorbent within POCIS can sag toward the base of the device during deployment in the 
vertical plane, potentially reducing the active sampling surface area and increasing 
variability in uptake rate (123). As the sorbent is immobilized in the HLB disk, 
variability of field data should be minimized while improving ease of use; this 
configuration will also overcome potential issues with the loss of sorbent during 
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assembly, deployment or subsequent extraction. The polar Chemcatcher® devices 
were deployed in the final effluent stream of a waste water treatment plant (WWTP) 
in the south west of England. 
 
In-situ calibration was undertaken and is recommended for determining 
representative uptake rates because it can be conducted in the exact location where 
future measurements are to be taken. This approach can be considered as essential 
for quantitative purposes because it accounts for site-specific factors (e.g., matrix 
composition) that cannot be adequately replicated under laboratory conditions (122). 
Once calibrated in-situ, the determined uptake rates can be applied to estimate 
pollutant concentrations in future studies at the same site. In-situ calibration offers 
other advantages as an extensive experimental laboratory setup need not be required 
and maintained. Moreover, it avoids the need to purchase relatively large quantities 
of target micropollutants for laboratory experiments, which may be cost-prohibitive 
(123). From the 66 compounds detected in composite samples during the 8-day 
calibration study, 65 were found in every composite sample. Furthermore, the 
majority exhibited inter-day concentration variations of <20% (n = 8). Linear uptake 
was observed for most of the detected compounds over the 9 days of deployment and 
sampling rates (Rs), determined for 59 compounds, were generally in the range of 
0.01-0.10 L/day. 
 
The concentration of compounds measured using passive samplers was generally 
within ±20% of that determined from composite samples taken during the 9-day 
deployment. The concentrations for many of the micropollutants determined by the 
passive samplers were underestimated (52 of 62), albeit not greatly (maximum = 
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−25%). This may have been due to a lag between deployment and the start of 
micropollutant uptake.  
 
A comparison of Rs values obtained from Petrie and co-workers work was made 
against sampling rates for the POCIS gathered from published values; the data are 
presented in Table 1.1. As the Chemcatcher® has a sampling area of 3.01 less than the 
POCIS (sampling areas of 15.2 cm2 and 45.8 cm2 respectively) the Rs values for the 
Chemcatcher® were adjusted accordingly to also allow a comparison based on 
sampler surface area. Rs values obtained from Petrie et al. were in very good 
agreement with the literature values for 5 of the 16 pharmaceuticals, these were 
Atenolol, Caffeine, Diclofenac, Ketoprofen and Naproxen. Seven others fell between 
the lowest and highest literature values and 5 others fell outside literature values.  
 
The comparison between samplers is complicated by the fact that the POCIS typically 
uses a 0.1 µm PES membrane whilst the Chemcatcher employs a 0.2 µm PES 
membrane. This is not expected to make a significant difference in uptake rates as 
most molecules under 1000 Da are expected to pass through the smaller pores 
unhindered. The use of a protective cage for deployment may also affect the uptake 
rate as well as the orientation of the sampler.  
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Compound  Compound class Rs ± SD L/d Corrected Rs ± SD L/d Type of calibration  Ref 
Estrone Hormone 0.071c (Chemcatcher) 0.214 In-situ (WWTP effluent) (64) 
  0.120 (±0.018)  Laboratory (124) 
  0.699 (±0.087)  Laboratory (125) 
  0.636 (±0.068)  Laboratory (125) 
  0.601 (±0.022)b  Laboratory (125) 
  0.363 (±0.065)a  Laboratory (125) 
  0.28  In-situ (WWTP effluent) (126) 
Ketoprofen NSAID 0.037c (Chemcatcher) 0.111 In-situ (WWTP effluent) (64) 
  0.135 (±0.035)  Laboratory (127) 
  0.083 (±0.078)a  Laboratory (127) 
Ibuprofen  0.048c (Chemcatcher) 0.144 In-situ (WWTP effluent) (64) 
  0.348 (±0.052)  Laboratory (125) 
  0.254 (±0.019)  Laboratory (125) 
  0.204 (±0.004)b  Laboratory (125) 
  0.197 (±0.013)a  Laboratory (125) 
Naproxen   0.048c (Chemcatcher) 0.144 In-situ (WWTP effluent) (64) 
  0.392 (±0.024)  Laboratory (125) 
  0.298 (0.016)  Laboratory (125) 
  0.239 (±0.009)b  Laboratory (125) 
  0.200 (±±0.037)a  Laboratory (125) 
  0.116 (±0.053)  Laboratory (127) 
                                      continued 
Table 1.1 A comparison of Rs values obtained from Petrie et al (64) for the polar Chemcatcher against published sampling rates for the POCIS sampler 
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Compound  Compound class Rs ± SD L/d Corrected Rs ± SD L/d Type of calibration  Ref 
Diclofenac  0.044c (Chemcatcher) 0.132 In-situ (WWTP effluent) (64) 
  0.166 (±0.052)  Laboratory (127) 
  0.092 (±0.055)a  Laboratory (127) 
  0.12  In-situ (river downstream) (126) 
  0.16  In-situ (WWTP effluent) (126) 
Atenolol Beta-blocker 0.034c (Chemcatcher) 0.102 In-situ (WWTP effluent) (64) 
  0.094 (±0.015)  Laboratory (125) 
  0.087 (±0.003)b  Laboratory (125) 
  0.073 (±0.013)a  Laboratory (125) 
  0.040 (±0.070)  Laboratory (127) 
  0.037 (±0.064)a  Laboratory (127) 
  0.090 (±0.064)  In-situ (128) 
Metoprolol  0.050c (Chemcatcher) 0.151 In-situ (WWTP effluent) (64) 
  0.465 (±0.039)  Laboratory (125) 
  0.309 (±0.106)  Laboratory (125) 
  0.156 (±0.034)a  Laboratory (125) 
  0.599 (±0.270)  Laboratory (127) 
  0.097 (±0.066)a  Laboratory (127) 
  0.270 (±0.140)  In-situ (128) 
Propranolol  0.114c (Chemcatcher) 0.343 In-situ (WWTP effluent) (64) 
  0.917 (±0.084)  Laboratory (125) 
  0.646 (±0.029)  Laboratory (125) 
  0.484 (±0.063)b  Laboratory (125) 
    continued   
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Compound  Compound class Rs ± SD L/d Corrected Rs ± SD L/d Type of calibration  Ref 
  0.271 (±0.066)a  Laboratory (125) 
  0.980 (±0.345)  Laboratory (127) 
  0.147 (±0.129)a  Laboratory (127) 
  0.06  In-situ (river downstream) (126) 
  0.12  In-situ (WWTP effluent) (126) 
  0.250 (±0.133)  In-situ (128) 
Venlafaxine Antidepressants 0.065c (Chemcatcher) 0.196 In-situ (WWTP effluent) (64) 
  0.521 (±0.033)  Laboratory (125) 
  0.388 (±0.038)  Laboratory (125) 
  0.167 (±0.065)b  Laboratory (125) 
  0.104 (±0.039)a  Laboratory (125) 
Fluoxetine  0.032c (Chemcatcher) 0.096 In-situ (WWTP effluent) (64) 
  0.974 (±0.045)  Laboratory (125) 
  0.694 (±0.009)  Laboratory (125) 
  0.484 (±0.012)b  Laboratory (125) 
  0.433 (±0.058)a  Laboratory (125) 
  1.37 (±0.35)  Laboratory (127) 
  0.223 (±0.130)a  Laboratory (127) 
Sertraline  0.116c  (Chemcatcher) 0.349 In-situ (WWTP effluent) (64) 
  0.868 ±0.054)  Laboratory (125) 
  0.622 (±0.026)  Laboratory (125) 
  0.602 (±0.036)b  Laboratory (125) 
  0.471 (±0.044)a  Laboratory (125) 
    continued  
33 
 
 
      
Compound  Compound class Rs ± SD L/d Corrected Rs ± SD L/d Type of calibration  Ref 
Citalopram  0.069c (Chemcatcher) 0.208 In-situ (WWTP effluent) (64) 
  0.758 (±0.033)  Laboratory (125) 
  0.735 (±0.015)  Laboratory (125) 
  0.354 (±0.020)b  Laboratory (125) 
  0.314 (±0.086)a  Laboratory (125) 
Desmethyl-citalopram  0.149c (Chemcatcher) 0.448 In-situ (WWTP effluent) (64) 
  0.707 (±0.024)  Laboratory (125) 
  0.598 (±0.044)  Laboratory (125) 
  0.401 (±0.082)b  Laboratory (125) 
  0.355 (±0.035)a  Laboratory (125) 
Carbamazepine Anti-convulsant 0.045c (Chemcatcher) 0.135 In-situ (WWTP effluent) (64) 
  0.561 (±0.024)  Laboratory (125) 
  0.397 (±0.018)  Laboratory (125) 
  0.230 (±0.016)b  Laboratory (125) 
  0.235 (±0.046)a  Laboratory (125) 
  0.348 (±0.116)  Laboratory (127) 
  0.112 (±0.023)a  Laboratory (127) 
  0.1  In-situ (river downstream) (126) 
  0.21  In-situ (WWTP effluent) (126) 
Temazepam Benzodiazepine 0.326c (Chemcatcher) 0.981 In-situ (WWTP effluent) (64) 
  0.421 (±0.101)  Laboratory (127) 
  0.128 (±0.062)a  Laboratory (127) 
      
    continued   
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Compound  Compound class Rs ± SD L/d Corrected Rs ± SD L/d Type of calibration  Ref 
Caffeine Stimulant 0.037c (Chemcatcher) 0.111 In-situ (WWTP effluent) (64) 
  0.127 (±0.021)  Laboratory (125) 
  0.151 (±0.018)  Laboratory (125) 
  0.096 (±0.008)b  Laboratory (125) 
Key      
a Unstirred condition     
b Temperature ≤10 °C     
c Temperature of effluent 8.4 
± 0.5 °C 
 
     
 
Sampling rate (Rs) for POCIS with 45.8 cm2 exposure and HLB 
sorbent. Standard conditions: unsalted water, stirred, between 
15 °C and 25 °C, except when specified. 
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1.6.1.5 Other types of passive sampler for organic compounds  
 
The DGT is constructed from two layers and compound uptakes and kinetics are 
different. During the deployment of DGT’s, the analyte in solution diffuses through 
the diffusive boundary layer and a material diffusion layer comprising of a filter 
membrane and hydrogel; finally, the analyte is taken up by a binding layer. As the 
diffusion layer is thicker than the typical thickness of the diffusive boundary layer, 
this makes the DGT measurement insensitive to the hydrodynamic conditions of the 
water.  
 
In 2012 Chen et al. developed the first configuration of DGT (diffusive gradients in 
thin-films) for measuring organic chemicals (termed the o-DGT) (129) and, in 
subsequent research, investigated the fate and behaviour of 40 antibiotics in the 
environment by deploying o-DGT’s in a UK WWTP (130). Of the 14 antibiotics 
detected with spot samples, 10 were detected in the o-DGT devices deployed for more 
than 7 days. o-DGT has also been use to investigate various other organic compounds 
including pesticides, phenols, bisphenols using various binding gels such as activated 
charcoal, Oasis® HLB, Oasis®  HLB-MAX, and a molecularly imprinted polymer 
(131-135). Despite having normalized surface area sampling rates of 0.54−5.74 
mL/d/cm2, which are comparable with other polar passive samplers, o-DGT is less 
sensitive than active sampling methods due to its low sampling rate; however, 
sensitivity could be increased by pooling binding layers from parallel samplers. 
However, a significant advantage of the DGT over other passive samplers is that 
calibration is not required, rather, the diffusional characteristics are obtained in the 
laboratory as fundamental physical properties. 
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1.6.2 Uptake of analytes by passive samplers and determination of 
aqueous TWA concentrations  
To obtain TWA concentrations of target compounds extensive calibrations are 
required to characterise the uptake of various compounds into passive samplers (113, 
136, 137). Compound uptake rates depend on their physico-chemical properties and 
on the sampler design and can also be influenced by environmental variables such as 
flow rate, (a measure of turbulence) that affects the thickness of the water boundary 
layer, temperature and bio-fouling (123, 138).  These variables pose a challenge when 
comparing estimated water concentrations of pollutants sequestered by non-polar and 
polar passive samplers deployed at different sites experiencing different sets of 
environmental conditions (88). Figure 1.7 compares an SPMD that has been bio-
fouled, after deployment in a river for a period of a month, and an unused SPMD.  
 
Booij et al. described a procedure for estimating the uptake kinetics in non-polar 
samplers by spiking them prior to deployment with several (PRCs) that did not occur 
in nature but had very similar properties to the target compounds, (e.g. mass labelled 
analogues). These PRCs can compensate for all of the environmental variables 
described above and by doing so, the in-situ sampling rates of target compounds can 
be determined more accurately than with laboratory calibration (139). Ideally, the 
incorporation of PRCs into POCIS and Chemcatcher samplers could yield accurate 
in-situ uptake rates and therefore correct estimates of compound TWAs. However, 
estimation of TWAs using the PRC approach is complicated by strong compound 
sorption to the sampler sorbent and desorption or offload kinetics are thought to be 
non iso-kinetic with the uptake. 
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Figure 1.7   A bio-fouled SPMD (on holder) retrieved from a watercourse after 
a deployment period of one month (left) and an unused SPMD (right). Photo 
taken by the author in 2014.  
 
 
Attempts have been made to use PRCs with POCIS and polar Chemcatcher samplers 
and work undertaken by Shaw et al. with the Chemcatcher concluded that while 
compound uptake was linear and reproducible, PRC loss was not linear, indicating 
that the dissipation rates of the PRCs could not be exploited to estimate field exposure 
conditions on uptake rates (118). An alternative in-situ calibration technique tested 
using PRC loaded polydimethylsiloxane (PDMS) disks deployed alongside the 
Chemcatcher samplers showed some promise (118). Vermeirssen et al. tested the 
uptake and release kinetics of 22 polar organic chemicals in the Chemcatcher and 
concluded that as sorption and desorption did not show isotropic kinetics, it was not 
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possible to develop robust PRCs for adsorbent material such as SDB disks (109). 
Kaserson et al. unsuccessfully used PRC’s with their work on per-fluorinated 
chemicals (PFCs) confirming widespread concern as to their applicability with polar 
samplers such as POCIS (140). Only Fauvelle et al. were able to successfully employ 
a PRC (deuterated deisopropylatrazine) for 10 herbicides in river waters using POCIS 
containing HLB sorbent (141); therefore reliable calculation of in-situ compound 
uptake rates using the PRC approach for adsorption based passive samplers may only 
be possible for a very limited number of compounds (e.g. compounds within a specific 
group or those with very similar structures). Although the parameters in a laboratory 
calibration may not be completely identical to field conditions, uptake rates for most 
compounds will continue to be determined in this manner for adsorption based passive 
samplers (123). A further drawback of the polar passive samplers is that, for all 
compounds, the sampling rate has to be determined separately with all sorbents for 
every application (142).  
 
 
1.7 Analytical separations and detection techniques 
 
1.7.1 One-dimensional gas chromatography 
 
Gas chromatography is a technique that has continually evolved since its inception in 
1951 (144) and the introduction of the first commercial systems by Griffin and George 
(London, UK) in 1954. It is used for the separation of volatile and semi-volatile 
compounds with minimal degradation and this includes compounds which can be 
volatilised within the temperature range of the gas chromatograph, typically ambient 
to 400 °C but can go as low as -25 °C with cryogenic cooling. GC can also be used to 
analyse semi-volatile and non-volatile compounds which are initially derivatised to 
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make them volatile. e.g. compounds that contain active and/or labile hydrogens such 
as carboxylic acids, amides, amines and thiols (145-149). 
 
A sample or aliquot of an extract is introduced into a heated injector (typically 200–
350 °C) using a syringe, where the sample is vaporised (if a liquid) and the gas 
transferred onto the chromatographic column via a carrier gas such as helium, 
nitrogen and more recently hydrogen. The carrier gas transports the sample through 
the column which is housed within a heated compartment or oven that is either 
maintained at a constant temperature (isocratic) or temperature programmed. The 
sample is separated inside the column - usually a long silica based column with small 
internal diameter and the internal wall coated with a thin polymeric layer or liquid. 
 
The column dimensions vary significantly in length and diameter, typically 10–30 m 
in length, 0.1–0.53 mm internal diameter and a stationary phase thickness of 0.1–5.0 
µm. The stationary phase can vary greatly from non-polar columns such as 
polydimethylsiloxane to highly polar columns which employ ionic liquids and the 
choice of phase depends on the chemistry and properties of the compound(s) being 
analysed. The individual components of the sample are separated by differential 
partition between the mobile and stationary phases as they travel down the column, 
based on their relative vapour pressure and solubility in the immobilised liquid 
stationary phase. 
 
The ‘partition or distribution coefficient’ (𝐾) measures the tendency of an analyte to 
be attracted to the stationary phase as expressed in Equation 1.5.  
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𝑘 =  
𝐶𝑠
𝐶𝑚
= 𝑘𝛽                            -            (1.5) 
 
where Cs  and Cm are the equilibrium concentration of analyte in the stationary phase 
and in the mobile phase (carrier gas) respectively. The partition coefficient can be 
calculated using the retention factor (𝑘) and the phase ratio (β). Analytes which have 
a higher affinity for the stationary phase have a larger distribution coefficient and will 
therefore take longer to elute from the column (i.e. they will have a longer retention 
time). As analytes partition coefficients are temperature dependent, using oven 
temperature programmes is highly effective in obtaining effective and efficient 
separations as coefficients can vary enormously from highly volatile to semi-volatile 
compounds such as those commonly found in GC-MS screening methods. 
 
The partition coefficient is determined from the phase ratio of the column and from a 
compounds retention factor with the latter describing the elution rate of an analyte 
through a column and can be determined from the analytes retention time and the 
retention time of an un-retained species such as air (Equation 1.6). 
 
𝑘 =  
𝑡𝑟−𝑡𝑚
𝑡𝑚
                      -          (1.6) 
 
The phase ratio, β, is the ratio of the volume of the carrier gas to the volume of the 
stationary phase as shown in (Equation 1.7) where the phase ratio can be calculated 
using the column internal radius (𝑟𝑐) and the film thickness (𝑑𝑓). 
 
𝛽 =  
𝑣𝑚
𝑣𝑠
  = 
𝑟𝑐
2𝑑𝑓
      -        (1.7) 
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On elution from the column, the analytes pass into a detector, which responds to some 
physicochemical property of the analyte and generates an electronic signal measuring 
the amount of analyte present. A data system then produces an integrated 
chromatogram of response against retention time. 
 
There are many types of detector available for gas chromatography which can be 
described as universal or selective which only responds to certain elements (such as 
halogens) or compound types (aromatics). The most common types of universal 
detector used in environmental analysis are the mass spectrometer, the thermal 
conductivity detector and the flame ionisation detector which responds to compounds 
containing carbon. Examples of selective detectors used in environmental analysis 
include the electron capture detector which is selective to compounds such as 
pesticides that contain halogens as well as some organo-phosphate pesticides; the 
nitrogen phosphorous detector which is specific for nitrogen and phosphorous; the 
flame photometric detector which is selective for sulphur, phosphorous and tin. 
 
The most important factor in GC, as well as other chromatographic techniques, is to 
obtain resolution in the minimum amount of time. Resolution (RS) is calculated using 
the separation of two adjacent analyte peaks relative to their peak widths as described 
in Equation 1.8.  
 
𝑅𝑆 =  
(𝑡𝑅2−𝑡𝑅1)
(𝑤𝑏1+𝑤𝑏2)/2
 = 2 
(𝑡𝑅2−𝑡𝑅1)
(𝑤𝑏1+𝑤𝑏2)
            -              (1.8) 
      
where tR1 and tR2 are the retention times of the earlier and later eluting analytes 
respectively; wb1 and wb2 are the peak widths of the earlier and later eluting analytes 
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respectively at the base. The width at the base of each peak is the segment of the peak 
base intercepted by the tangents drawn to the inflexion points on either side of the 
peaks and, in the case of two adjacent peaks, it may be assumed that the peak widths 
at the base are equal and thus the width of the second peak may be substituted for the 
average value. A resolution of 1.5 or greater between two peaks will ensure good 
separation, but can be improved by maximising the three terms in Equation 1.9: where 
N is the degree of column efficiency also known as the theoretical number of plates, 
α is the selectivity factor and k is the retention factor. 
 
𝑅𝑆 =  
1
4
 √𝑁 𝑥 
∝ −1
∝
 𝑥 
𝑘
1+𝑘
       -              (1.9) 
 
The plate number (N) is primarily a measure of the peak dispersion in the GC column, 
reflecting the columns performance. N is derived from fractional distillation, where 
the column or ‘fractioning tower’ is divided into ‘theoretical plates’, and can be 
calculated from the analytes retention time (tR) and its peak width (wb) at the baseline 
as shown in Equation 1.10.  
 
𝑁 = 16 (
𝑡𝑟
𝑤𝑏
)
2
                          -           (1.10) 
 
Similarly, for a fractioning tower of a given length (L) the higher the number of plates, 
the lower will be the distance between each plate. Therefore, for high efficiency 
separations the plate number (N) will be high and the plate height (H) low. H is also 
described in the literature as height equivalent to a theoretical plate or HETP. The two 
terms are related through the expression, H=L/N, therefore column efficiency, and 
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thus resolution, can be improved by increasing the column length, L. Very often this 
will increase the analysis time required especially when dealing with a complex 
matrix as efficiency has a square root dependence (Equation 1.9). Therefore, a four-
fold increase in efficiency (i.e. quadrupling the length of the column) will result only 
in a two-fold improvement in resolution. Changing the column’s stationary phase, 
thus altering the interactions between the phase and the analytes, is another means to 
improve the resolution. 
 
A final measure of column efficiency is peak capacity and is simply the theoretical 
maximum number of separated peaks that can be fitted into a chromatogram of 
defined retention time between the column void volume and the last eluting peak of 
interest at a specified resolution. The column capacity is calculated using equation 
1.11. 
 
𝑛𝑐 =  
𝑡𝑟,max − 𝑡𝑚
𝑤𝑏 𝑅𝑠
            -         (1.11) 
 
Where tr, max is the last eluting peak, tm is the column void volume or dead time, wb 
is the width at the base and Rs is the resolution. Due to the random distribution of 
peaks, which can lead to many overlapping peaks occupying the same space, the 
maximum peak capacity cannot be realised and a complex environmental sample 
would quickly exceed the available peak capacity of a one dimensional single column 
technique (150). Even for a moderately complex analysis such as the separation of all 
209 PCB congeners, no single GC column has yet been developed to separate them 
all. Therefore, a multidimensional approach involving the use of more than one 
column is required (151-155). 
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1.7.2 Multidimensional gas chromatography 
The capability of multidimensional separation in terms of peak capacities and the 
analysis of complex samples has been recognised for decades and has come to be 
unsurpassed by any other analytical approach (156). The theory behind 
multidimensional separations was mainly developed by Giddings and co-workers in 
the 1980’s – 1990’s and continues to be discussed over 20 years later (153, 157). 
 
Multidimensional separations based on gas chromatography are categorised as either 
comprehensive or heart-cutting with the latter only sampling a fraction of the analytes 
present in the sample passed on for further separation (158-165). Comprehensive 
multidimensional separations, on the other hand, subjects the whole injected sample 
to each separation dimension so that the resulting chromatogram can be considered 
as being representative of the entire sample being analysed (166-168). Heart-cutting 
can therefore be considered as being suitable only for target based analysis, whereas 
comprehensive multidimensional separations can be considered as suitable for sample 
profiling, target based studies plus general screening (169-171). 
 
 
1.7.3 Comprehensive two-dimensional gas chromatography  
 
Two-dimensional comprehensive gas chromatography (GCxGC) was first introduced 
by Liu and Phillips in 1991 (172) and has been used extensively since then for the 
analysis of various complex mixtures where conventional 1-D separations are 
typically used, for example, crude oil and petroleum products (173-177), forensics 
(170, 178, 179), clinical (180-182), metabolomics (183, 184) and environmental 
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analysis (185-190). A comprehensive 2-D separation can separate many more 
components of a complex mixture in less time than a 1-D separation and GCxGC 
allows for improved separation and resolution due to its inherent superior peak 
capacity. Peak capacity for 1-D separations is equal to the capacity of a single column 
(nc), whereas in GCxGC theoretical peak capacity is equal to the product of the 
individual peak capacities for the primary and secondary columns (nc1 x nc2).  
 
To put the potential peak capacity gain of GC × GC into some perspective relative to 
1-D GC; if one was to try and obtain a 10-fold peak capacity gain from a 40 m column 
its length would have to be 100 times longer at 4 km, the inlet pressure at around 1400 
psi (with helium carrier gas) and the analysis time 1.5 months instead of 
approximately 1 hour. A modest 2-fold peak capacity increase would require a 160 m 
long column, 280 psi inlet pressure, and a minimum 8 h analysis (191). The separation 
power gap, that exists between GCxGC and 1-D GC, is probably even bigger than 
between the capillary and packed column (153). 
 
In addition to increased peak capacity, GCxGC offers improvements in sensitivity 
through increased signal-to-noise ratios for analytes due to interfering compounds 
being separated from the analytes of interest. Improvements in analyte detection are 
also seen due to the high peak compression occurring at the modulator (see section 
1.7.3.1) resulting in very sharp peaks, as shown in Figure 1.8, especially with 
thermal/cryogenic modulators but less so with pneumatic and valve modulators (192). 
Moreover, structurally related compounds such as PAHs, PCBs, short chained 
chlorinated paraffins (SCCPs), polychlorinated terphenyls (PCT’s), polybrominated 
diphenyl ethers (PBDE’s) elute with highly distinctive patterns resulting in ordered 
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chromatograms which can greatly assist in sample characterisation and compound 
identification (34, 80, 152, 187, 193-198). 
 
 
1.7.3.1     Enabling GCxGC capability with existing GC chromatographs 
 
As shown in Figure 1.9, enabling existing 1-D gas chromatographs for GCxGC use 
involves some relatively straightforward modifications to the oven compartment. 
These include a modulator, a secondary column and a small secondary oven but the 
latter is not always considered a prerequisite for successful GCxGC chromatography 
(157). Typically, the two columns used in GCxGC are of different selectivity, where 
the column in the first dimension is non-polar (e.g. dimethyl polysiloxane or 5 % 
phenyl methyl polysiloxane) whilst the second column is generally polar (e.g. 50 % 
diphenyl dimethyl polysiloxane). As long as the columns provide orthogonal 
selectivity, analysts are not confined to this configuration, and polar/non-polar, 
chiral/polar and other specialised combinations have been used (199-202). Columns 
used in the first dimension are of similar dimensions to those used in conventional 1-
D GC while columns used in the second dimension are much shorter (0.5–2 m) with 
narrower internal diameters, typically 0.1–0.25 mm when used with the common 
thermal or cryogenic modulator. The modulator is positioned at the junction of the 
dual column set and depending on the type of modulator, cryogenic cooling and / or 
heating is used to trap (and compress) the eluting bands of analytes from the first-
dimension column and transfer them as a narrow ‘packets’ to the second-dimension 
column. When a ‘packet’ is analysed in the second dimension column, the modulator 
prevents further elution from the first column and therefore segregates analytes into 
fractions according to the frequency of modulation which is typically 1–5 s. Ideally, 
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the modulator will collect a sufficient number of fractions over the duration of the 
eluting peak to preserve the separation achieved in the first dimension and, as for most 
chromatographic techniques, achieve ten data points which is considered a minimum 
for quantitative work (203). Separation of analytes in the second dimension must be 
undertaken quickly so that each transferred ‘packet’ has completely eluted from the 
secondary column before the following ‘packet’ is introduced to prevent a 
phenomenon called wrap-around from occurring. This happens when the analytes 
retention time in the second dimension exceeds the modulation period (153, 191). 
 
 
1.7.3.2     Coupling of GCxGC to time-of-flight mass spectrometry (GCxGC 
TOF-MS) 
 
Narrow second dimension peaks obtained from cryogenic modulation require a mass 
spectrometer capable of very fast scanning rates (> 50 Hz) for acceptable compound 
identification (204). Therefore, the coupling of fast-scanning TOF-MS with 
comprehensive 2-D GC provides the capabilities necessary for identification of 
compounds within a complex matrix and with the addition of automatic spectral 
deconvolution, co-eluting compounds can be distinguished based on mass spectral 
differences (153, 205).  The ability of TOF-MS instruments to collect data over a wide 
mass range (> 1000 Da) gives them the potential to undertake non-targeted screening 
in addition to the simultaneous determination of targeted compounds (194, 206).  
Obtaining useful information from the analysis of these mixtures, which may contain 
literally thousands of different compounds, requires a reliable and relatively rapid 
technique to identify compounds of concern. 
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The suitability of TOF-MS for the detection of extremely narrow peaks was 
demonstrated in the later part of the 1990’s by Van Ysacker et al., in which 14 volatile 
compounds were separated in about 40 s with a spectral acquisition rate of 20 Hz 
(207). In 2000, van Deursen et al. used a reflectron-type TOF-MS (Leco Pegasus II) 
in an ultra-fast GC experiment where 10 volatile solvents were separated in 500 ms 
on a microbore column using a spectral acquisition rate of 500 Hz over a 40–200 Da 
mass range. Even though peak widths were extremely narrow at around 12 ms, 
software peak re-construction was excellent. The system deconvolution algorithm 
could separate two partially co-eluting compounds, (octane and cis-1,4-
dimethylcyclohexane) proving its ability to successfully deconvolute unresolved 
peaks based on mass spectral differences. Excellent library similarity factors (798-
957) were obtained for most of the compounds when compared against the NIST 
library clearly demonstrating the effectiveness of the system under challenging 
conditions (208). Unlike quadrupole based MS systems that scan from high to low 
mass, TOF-MS achieves high-speed full-spectrum acquisition, without mass spectral 
skewing (i.e. spectral patterns do not change across the chromatographic peak) 
allowing for accurate mass library search results (209, 210). 
 
In contrast, quadrupole based MS systems operated under relatively fast-scanning 
conditions in a series of GC×GC experiments by Shellie and Marriott in 2003 could 
acquire spectra only at a rate of 20 scans/s in a reduced range of 41–228.5 Da for the 
detection of oxygenated sesquiterpenes in ginseng. The authors reported that reliable 
quantitative data could not be derived with only three to four data points per peak but 
did allow for identification. However, higher molecular weight compounds could not 
be identified due to the limited mass range used (211). 
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In 2004, Debonneville and Chaintreau reported the first example of quantitation in a 
GCxGC application using a quadrupole based MS systems for fragrance allergens, by 
monitoring selected ions in pre-defined retention-time windows. A detection 
frequency of 30.7 Hz was reported and affirmed to be sufficient for peak quantitation 
as GCxGC data were in good agreement with those data derived from a 1-D GC-MS 
system (212). Despite being successfully applied to known target analytes, the 
sampling rate is insufficient for the proper construction of the narrower GCxGC 
analyte bands (50–100 ms). 
 
In 2005, Adahchour et al., described the principles, practicability, and potential of 
rapid-scanning quadrupole instrumentation in GCxGC by employing a Shimadzu 
QP2010, whose detector was characterized by a scan speed of up to 10,000 amu/s and 
could even reach 50 spectra/s, but this work was again over a restricted mass range of 
only 95 Da (213). Even in 2016, the maximum scan speeds attainable from a 
quadrupole mass spectrometer was only 20,000 amu/s (214). 
 
As well as being applied for targeted analysis GCxGC has been used for the screening 
of non-target compounds (215-220). The highly structured chromatograms obtained 
from GCxGC can be used very effectively as fingerprints to characterize sources of 
pollution with detailed congener specific data provided for pollutant classes such as 
polychlorinated dibenzo-p-dioxins (PCDDs), polychlorinated dibenzofurans 
(PCDFs) and non-ortho substituted polychlorinated biphenyls (PCBs) (217). 
However, the use of GCxGC MS in the forensic domain has remained relatively 
scarce since its introduction by Liu and Phillips in 1991 (172). A review of GCxGC 
MS applications in forensics investigations undertaken by Sampat et al. in 2016 
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recorded only 36 peer reviewed articles by 12 research groups between 2001 and 2015 
(170). Figure 1.10 shows a plot obtained from an advanced SCOPUS search on the 
number of publications employing GCxGC MS analysis between 2000 and 2016 
using the following search criteria. 
 
i) GCxGC MS (all matrices) 
ii) GCxGC MS (environmental matrices, targeted compound analysis only)  
iii) GCxGC MS Screen (all matrices including environmental, forensic, 
petrochemical, toxicology and biology) 
iv) GCxGC MS Screen (environmental matrices only) 
 
The output from the search (Figure 1.10, identified a total of 1315 publications using 
GCxGC MS (numbers for TOF-MS detection in parentheses) for the analysis of all 
matrix types with 957 (601) for GCxGC MS target compound analysis in all matrices, 
172 (115) for targeted environmental analysis, 148 (103) for GCxGC MS screening 
in all matrices but only 38 (29) publications for the screening of environmental 
samples. The number of publications peaked in 2011 - 2012 with only 6 and 5 
publications respectively and fewer than this have appeared in subsequent years. 
Moreover, only11 publications were found for the target and screening analysis of 
passive sampler extracts using GCxGC MS between 2000 – 2016. 
 
Despite the unparalleled peak capacity that GCxGC MS offers over 1-D GCMS and 
the highly successful determination of complex environmental, petrochemical and 
biological matrices for targeted compounds, there has been a tremendous 
underutilisation of the technique for screening of environmental matrices. This may 
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be due to the higher costs associated with TOF-MS systems compared with 
quadrupole MS systems; this however is likely to change rapidly with the recent 
introduction of bench-top GC-TOF-MS systems by Markes International (Llantrisant, 
UK) and LECO (Saint Joseph, MI, USA) which are in the same price range (£120,000 
– 150,000) as triple quadrupole mass spectrometers.  
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1-D chromatographic peak  
Comprehensive GCxGC peak 
widths are typically 0.05 – 0.10 s 
whereas narrow 1-D 
chromatographic peak widths 
are approximately 1 s wide 
Figure 1.8  Simulation of a typical GCxGC chromatogram with typical peak widths of 0.05–0.10 sec, highlighting the 
requirement for high speed detection systems. Adapted with permission from Leco UK.  
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Orthogonal Hot  
Jets 
Cold Jets 
2nd dimension column 
  
Figure 1.9  Simple modifications to an existing 1-D gas chromatographs to enable its use for GCxGC. Adapted with permission from 
Leco UK. 
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Figure 1.10  Number of publications between 2000 and 2016 for GCxGC obtained from advanced SCOPUS search using criteria listed 
above. 
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1.7.3.3    Comprehensive GCxGC and low energy or soft electron ionisation 
Mass spectrometers when used in conjunction with gas chromatography typically 
employ electron impact (EI) ionisation at 70 eV which imparts a large amount of 
energy onto the molecule when ionised, usually resulting in extensive but spectral rich 
fragmentation patterns (21, 22). The benefit of such fragmentation is that the spectra 
are easily compared with mass spectral libraries such as NIST and/or Wiley for 
compound identification (22). However, some compounds remain difficult to identify 
at 70 eV due to absent molecular ions or their similar spectra. With electron ionisation, 
the molecular ion is weak or absent in about 30% of the compounds in the NIST 
library and this substantially decreases the confidence in assigning the molecular mass 
of a compound (221). The lack of the molecular ion signal and non-specific 
fragmentation patterns of many organic species, especially aliphatic hydrocarbons and 
their many isomers, make them spectrally indistinguishable (222). 
 
Electron ionisation is considered as a hard ionisation, however, by suitable control of 
the main causes leading to dissociation of the molecular ion, EI can be controlled to 
deliver a highly informative soft ionisation technique (223). According to Amirav et 
al., “The electron ionization process imparts up to several electron volts of intra-
molecular-ion internal energy that leads to molecular ion dissociation. This added 
vibrational energy can originate via direct excitation of high lying vibrational states 
of the lowest electronic state of the molecular ion or via the excitation of additional 
high lying electronic states of the molecular ion which undergo internal conversion 
into highly excited vibrational states of the ground electronic state of the molecular 
ion thus leading to dissociation” (223). The higher lying electronic states, though, can 
become inaccessible at lower electron energies therefore reducing the amount of 
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dissociation of the molecular ion. Nevertheless, lowering the electron energy for 
certain compounds (e.g. herbicides which contain many heteroatoms) does not affect 
the compounds mass spectrum as the higher lying electronic states are inaccessible 
but the ionisation yield is significantly reduced. Thus, there is a continual demand for 
robust soft (low energy) ionisation techniques for MS, in order to retain the molecular 
ion signal and aid identification of spectra.  
 
 
1.7.3.4     Soft ionisation techniques  
Common soft ionisation methods are listed below and all have been subject to recent 
review (224-226). Chemical ionisation (CI) is the most common of all soft ionisation 
techniques employed for GC-MS and GCxGC MS amenable compounds and takes 
place when the analyte molecules are ionised by chemical ion-molecule reactions 
initiated by ionised reagent gases such as methane, isobutane and ammonia (227-233). 
Photo-ionisation (PI) and field ionisation (FI) have also been coupled with GCxGC 
MS, however, both ionisation techniques are rarely used in environmental analysis 
and are mainly limited to specialised applications within petroleum and particulate 
composition analysis (222, 226, 234-237). Until recently few of these soft ionisation 
MS techniques have been coupled to GC×GC (235, 238-241) but with the arrival of 
powerful computing systems and the introduction of relatively inexpensive, reliable, 
easy to use modulators and soft ionisation sources, researchers are finding it easier to 
undertake routine complex multi-dimensional analysis (222, 242-244). 
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1.7.3.5   Chemical ionisation 
Chemical ionisation (CI) has been a widely used analytical technique since its 
discovery by Munson and Field over 50 years ago (245-247) and has developed into 
a powerful and flexible technique for the identification of organic molecules. Positive 
and negative CI are soft ionisation techniques which produce significantly less 
fragmentation than EI, and in the vast majority of cases retains the pseudo-molecular 
ion and structural information typically absent with EI (248). Fragmentation can be 
controlled in CI mode by using reagent gases with different proton affinities such as 
ammonia, iso-butane and methane, with the former having the highest proton affinity 
leading to little or no fragmentation and methane having the lowest proton affinity 
and consequently the greatest amount of fragmentation. Iso-butane offers a good 
compromise between the two but readily fouls the ion source and shortens the lifetime 
of the electron filaments to hours or days of use. Methane on the other hand can be 
used for weeks or months before a filament requires replacement (232). Other 
parameters such as ion source temperature and pressure can be adjusted to control 
fragmentation where high ion source temperature favours fragmentation diminishing 
the relative intensity of the quasi-molecular ion. High reagent gas pressures reduces 
the relative intensities of fragment ions enhancing the relative abundancies of the 
quasi-molecular adduct ions (249). 
 
When using ammonia CI, it is imperative to use the highest purity available so that 
amount of water present can be kept to an absolute minimum (≤ 5 ppm) as the presence 
of water in ammonia will result in very short filament lifetimes.  Ammonia gas also 
reacts with water in the oil to raise the pH and attack the pump seals so it is necessary 
to ballast the rough pump daily to remove any residual ammonia gas and frequent 
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vacuum system maintenance is necessary. Little et al. found a CI reagent gas mixture 
of 3 % methylamine in methane to be very useful in obtaining molecular weight 
information with positive ion GCMS as some labile compounds, even when using 
ammonia CI, fragmented extensively by elimination and substitution reactions 
yielding no molecular weight information (250). 
 
CI has, in-conjunction with gas chromatography, found extensive applications in 
fields of chemistry and biochemistry including the determination of pesticides, 
endocrine disruptors, illicit drugs, anabolic steroids in food, body fluids and various 
environmental matrices (228, 251-258).  
 
 
1.7.3.6   Supersonic molecular beams (SMB) and soft cold EI 
Since the late 1990’s, Amirav and co-workers have developed and explored the 
capabilities of a supersonic molecular beam (SMB), which interfaces the outlet of a 
gas chromatograph to a mass spectrometer, is a process that produces vibrationally 
cold sample molecules (i.e. molecules cooled by supersonic expansion through a 
shaped nozzle) which then enter the mass spectrometers for ionisation and detection. 
With ionisation taking place at 70 eV, SMB is not classed as a soft ionisation 
technique but compound MS spectra typically have strong molecular ions together 
with library searchable EI fragment ions and is best described as ‘Cold EI’. The SMB 
has become a commercial product, successfully interfaced with various mass 
spectrometer systems and typically used for petroleum, food and environmental 
analysis (221, 223, 240, 259). Figure 1.11 shows a schematic diagram of such a SMB 
interfaced with a pulsed flow comprehensive 2-D GC system (241) whilst Figure 1.12 
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shows a ‘Cold EI’ mass spectrum (obtained from a SMB) of a linear chain hexadecane 
(n-C16H34) along with its NIST library mass spectrum obtained at 70 eV (240). Despite 
a reduction in the match factor, the probability match is slightly higher for the cold EI 
spectrum than for the NIST spectrum due to a much larger response for the molecular 
ion and reduced fragmentation between 150–200 m/z (240, 260). Kochmann et al. 
observed a similar reduction in the match factors obtained for a range of pesticides 
with standard 70 eV libraries (such as NIST), unless cold EI MS library spectra were 
included within the library itself. However, superior identification probabilities were 
obtained as the likelihood of the same or a similar spectrum within the NIST library 
for the pesticides was reduced (261). Cold ionisation is often seen as the only soft 
ionisation method that is compatible with library based identification as it improves 
library identification probabilities. 
 
Amirav also explored SMB ‘Cold EI’ at low electron energies (18 eV), a process he 
described as ‘Soft Cold EI’ where the spectra for squalene (C30H62) and tetracosane 
(n-C24H50) showed little to no fragmentation (223). Figure 1.13 compares the ‘Cold 
EI’ plus ‘Soft Cold EI’ mass spectra obtained for squalene together with its NIST 
library mass spectrum obtained at 70 eV.  
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Figure 1.11   A schematic diagram of the supersonic molecular beam 
interface coupled to a Varian 1200 GCMS (top) and a detailed zoomed in 
section of the interface (bottom). Reproduced with permission from (241), 
copyright 2008, Elsevier. 
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Figure 1.12      A comparison of cold EI mass spectrum of a linear chain 
hexadecane (n-C16H34) (upper trace) with its NIST library mass spectrum 
(bottom trace). Reproduced with permission from (262) copyright 2008, 
John Wiley and Sons.  
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Figure 1.13     Comparison of ‘Soft Cold EI’ mass spectrum (upper trace), 
‘Cold EI’ mass spectrum (middle trace) and NIST library mass spectrum 
(bottom trace) of squalene. The ‘Cold EI’ mass spectrum shown in the 
middle trace was obtained at 70 eV electron energy while the ‘Soft Cold EI’ 
mass spectrum shown in the upper trace was obtained at 18 eV electron 
energy. Reproduced with permission from (223) copyright 2008, John Wiley 
and Sons. 
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1.7.3.7   Variable electron ionisation source 
As stated earlier in this chapter, in a conventional electron source there is a potential 
difference of 70 V between the positively charged ion chamber and the negatively 
charged filament (‘electron gun’) (21). This potential difference accelerates 
thermionic electrons away from the surface of the filament and through an aperture 
in the ion chamber wall (Figure 1.14a) for efficient ionisation of analytes eluting from 
the GC. Achieving low electron energies with a conventional EI ion source requires 
a lower accelerating potential, which is insufficient to draw electrons into the ion 
chamber and results in the clustering of electrons around the filament known as the 
‘space-charge limitation’ (Figure 1.14b). This inefficient channelling of electrons into 
the ion chamber results in a small number of ions being generated leading to an 
unacceptable loss of sensitivity. To overcome this, a new ion source technology called 
Select-eV® has been developed which uses a high potential difference to accelerate 
the electrons away from the filament, but then reduces their energy before they arrive 
in the ion chamber (Figure 1.14c). By introducing an additional electrostatic element 
between the filament and the ion chamber, the electron ionisation energy can be varied 
from the conventional value of 70 eV to lower energies without loss of sensitivity 
(244). This ‘lower energy’ EI provides repeatable, simplified spectra, containing 
enhanced diagnostic and molecular ions, which retain enough fragmentation to allow 
robust library searching and isomer speciation.   
 
The new ion source also allows the ionisation energy to be tuned between 10 and 70 
eV and unlike CI and FI, no reagent gases, adjustments in pressure, or switching of 
ionisation sources is required (244).  
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Figure 1.14  Schematic diagram showing the effects of different electron 
ionisation energies of ion flow (a) operation of a conventional ion source at 70 
eV, (b) operation of a conventional ion source at lower ionisation energies’ (c) 
operation of the variable-energy source showing how it overcomes the space-
charge effect at low ionisation energy [reproduced with permission from Select-
eV® technical note (244)]. 
 
 
 
 
(a) 
(b) 
(c) 
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1.7.4     High Performance Liquid Chromatography  
High Performance Liquid Chromatography (HPLC) is a separation technique which 
has gained immense popularity in applications covering pharmaceuticals, foods, life 
sciences and environmental analysis. As the name suggests HPLC uses a liquid 
mobile phase and are generally mixtures of solvents of compatible polarities whereas 
in gas chromatography the mobile phase is a single high purity gas. 
 
The fundamental resolution equation for gas chromatography described in section 
1.5.1, and shown below, equally applies to liquid chromatography and is affected by 
the same three important parameters; selectivity, efficiency and retention. 
 
𝑅𝑆 =  
1
4
 √𝑁 𝑥 
∝ −1
∝
 𝑥 
𝑘
1+𝑘
                                
 
The most effective and convenient way to alter the retention factor of a compound 
peak is to adjust the ‘solvent strength’ of the chromatographic mobile phase. This is 
typically achieved in reverse phase chromatography (the most commonly used 
technique in analytical HPLC) by altering the amount of organic solvent in the mobile 
phase. Reversed phase HPLC columns have a non-polar stationary phase, where 
increasing the polarity of the mobile phase (low organic but high aqueous content) 
will increasingly repel the hydrophobic (non-polar) sections of the analyte molecules 
into the stationary phase and the analyte will be retained for longer on the column. 
The converse is also true where decreasing the polarity of the mobile phase (low 
aqueous but high organic content) will reduce analyte retention on the column. When 
retention factors are very high or very low (e.g. < 1), the quality of the separation is 
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reduced and the separation will be poor. As with GC, the largest gain in resolution is 
achieved when the 𝑘 value is between 1 and 5. 
 
The selectivity of a separation in HPLC is highly dependent upon the chemistry of the 
analyte, mobile phase and column stationary phase and all of these factors may be 
altered in order to change or optimise the selectivity of a HPLC separation. The 
mobile phase pH can have a drastic effect on the selectivity of a separation especially 
when acidic or basic compounds are analysed as the degree of ionisation affects their 
hydrophobicity and therefore their retention on the column stationary phase. In 
addition, parameters such as solvent strength, column stationary phase and 
temperature will also impact on selectivity. 
 
Gas chromatography separations are mainly carried out on compounds ranging in 
molecular weights up to a few hundred Daltons and compounds separate on 
differences in their volatilities. On the other hand, compounds separated using HPLC 
have higher molecular weights ranging from a few hundred daltons to several million 
for large polymers and biomolecules.  
 
HPLC separations are typically carried out at ambient or close to ambient 
temperatures on columns which have much shorter and wider dimensions in 
comparison to GC columns. Typical HPLC columns used in environmental analysis 
are between 50-250 mm in length and 2-4 mm in diameter. HPLC column packings 
are typically 1.7-5 µm in diameter and give significantly greater resistance to flow of 
liquids in comparison to gases. The current trend is towards faster analysis so columns 
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used for HPLC can be as short as 1 cm in length and contain particles as small as 1.5 
µm in diameter.  
 
Detectors used with HPLC include ultra-violet, refractive index, photodiode array 
detectors, conductivity and mass spectrometry; the latter detector is the most 
commonly used for routine targeted and non-targeted environmental analysis.  
 
1.7.4.1     HPLC with high resolution mass spectrometry (HPLC HRMS) 
Several approaches have been adopted for routine targeted and non-targeted 
environmental analysis using liquid chromatography in combination with mass 
spectrometry (LC/MS or LC/MS/MS) employing various atmospheric pressure 
ionisation sources including electrospray ionisation (ESI), atmospheric pressure 
chemical ionisation (APCI) and atmospheric pressure photo-ionisation (APPI) (103, 
263-267). All the above mentioned ionisation source can be used for general screening 
but ESI is by far the most commonly used for the identification of small molecules 
(268).  
 
The application of single-stage quadrupole or ion-trap mass spectrometers for the 
purposes of screening is limited and not recommended because of disturbances by 
high matrix burden and co-eluting peaks which have similar or identical masses to 
those of targeted compounds. By using triple-quadrupole (QQQ) mass spectrometers 
many of these problems have been resolved but can only be performed as multi-
targeted screening which means that compounds can be detected only if they are 
included in the methods (269). The number of substances in such a procedure is 
limited by the minimum dwell time for each compound’s MS/MS (or fragmentation) 
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transition included in one measurement cycle. This process is commonly termed a 
multiple reaction monitoring (MRM) experiment and is accomplished by specifying 
the parent mass of the compound for MS/MS fragmentation and then specifically 
monitoring for a single fragment ion. 
 
Nevertheless, powerful screening procedure with hundreds of compounds in a single 
chromatographic run have been developed by Dresen et al. who used a hybrid QQQ 
linear ion-trap mass spectrometer together with information dependent acquisition 
and enhanced product ion scan (at three different three collision energies) to obtain a 
library searchable mixed mass spectrum (270). This procedure, however, requires the 
approximate retention time of the compound to be known and placed within discrete 
two-minute time windows so that sufficient time is allocated to each compound for 
fragmentation. 
 
Generally, LC QQQ screening with MS/MS identification consists of a survey scan 
to detect the analytes and a dependent scan for measurement of the corresponding 
MS/MS spectra which are library searched for identification. Survey scan and 
dependent scan can be accomplished within the same analytical run by automatic 
selection of precursor ions and measurement of the MS/MS spectra immediately after 
their detection in the survey scan. In ‘data-dependent acquisition’ this is determined 
only by the actual MS data whereas ‘information-dependent acquisition’ is restricted 
to a list of preselected precursors included in the method (271-275). 
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1.7.4.2     Matrix effects 
LC-MS/MS analysis has been shown to be influenced by matrix effects which alters  
ionisation efficiency due to the presence of co-eluting substances in the sample extract 
and is considered to be a major drawback to qualitative and quantitative analyses 
using ESI (276). Matrix effects can lead to signal suppression or enhancement of the 
analyte signal, and ultimately to relatively high detection limits and reduced method 
repeatability (277). Ion suppression refers to the phenomenon of the analyte signal 
being suppressed by apparent competition in the ionisation process and subsequent 
reduction in the analyte MS signal. The phenomenon of signal enhancement can also 
occur, where the analyte signal is increased due to the presence of the interfering 
species (277). Natural organic matter, salts and non-target contaminants have all been 
shown to cause ion suppression effects and the complexity of the matrix influences 
the degree of matrix effect observed and can differ from analyte to analyte within the 
same sample due to differences in the ability of the compound to ionise. 
 
There are several approaches that can be applied in order to compensate for any 
apparent matrix effect, these include improving the sample extraction and 
chromatographic separation, limiting the concentration factor in SPE, reducing the 
injection volume, diluting the sample and applying a variety of calibration techniques 
(278, 279). Suitable calibration techniques can help to minimise the matrix effects 
and can be achieved by means of ‘matrix-matched’ external calibration, standard 
addition or internal standard calibration using either structurally similar or mass 
labelled analogues (280, 281).    
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1.7.4.3     TOF and Orbitrap mass spectrometric detectors for HPLC 
The availability of accurate mass TOF and Orbitrap mass spectrometers in the past 
decade or so has been a real game changer, with much improved mass resolution and 
mass accuracy and have provided new possibilities in the use of LC–MS for 
toxicological, forensic and environmental screening (282-284). TOF, TOF with a 
quadrupole-based collision cell (Q-TOF) and Orbitrap instruments enable 
comprehensive recording of all data within a specified mass range, and there is no 
limitation of the compounds included in the search procedure as long as they elute 
within the chromatogram and have a measurable response. Table 1.2 provides an 
overview of the technical specifications, characteristics and performance of hybrid 
TOF and Orbitrap HRAM systems currently used for accurate mass analysis. The 
increased mass resolution of recently introduced systems such as Bruker’s Impact 
QTOF and the Sciex Triple TOF 6600, also provide high selectivity for overlapping 
peaks in complex matrices. The biggest advantage is that molecular formulae of 
compounds are directly available from the accurate molecular mass and the isotope 
peak pattern, this therefore allows for the development of very large theoretical 
databases which can be used for substance identification using the compound’s 
molecular formula (282, 285-287). Databases of toxicologically relevant compounds 
with up to 50,500 substances including metabolites (288) or ‘in-house’ databases 
containing many hundreds of substances have been created (289-294). 
 
However, the molecular formula of an eluted unknown substance in a chromatogram 
is only a first step of the identification, because of the huge number of possible 
isomers, as can easily be shown by use of chemical software. For instance, according 
to ‘Molgen’ (on-line molecular structure generation software) for the nominal 
71 
 
molecular mass of 149 Da, 27 different molecular formulas are theoretically possible 
if only the elements C, H, N, and O are included (295). HRAM with mass accuracy < 
3 ppm (i.e. absolute mass error <  0.45 mDa) can clearly distinguish between these 27 
possibilities one of which is C9H11NO with a monoisotopic mass of 149.084060. 
Based on the rules of chemical bonds, 25,895,621 structural isomers (stereoisomers 
not included) can be theoretically calculated, and ‘Chemspider’ (an on-line searchable 
database) shows the structural formulae of 1270 compounds with the molecular 
formula C9H11NO. Among them are 4-(dimethylamino)benzaldehyde, 1-methyl-
1,5,6,7-tetrahydro-4H-indol-4-one and norephedrone an amphetamine type stimulant 
found in the shrub catha edulis (296). 
 
It is very important to be aware of this almost unlimited structural diversity of organic 
chemistry when commencing systematic screening analysis, therefore, much more 
evidence is required in order to distinguish between isomers. It is for this reason that 
retention times under defined chromatographic conditions have been measured for 
hundreds of substances in some ‘in-house’ libraries (292, 294). Structure-specific 
information should also be obtained from collision-induced dissociation (CID) 
fragment spectra (in-source or from collision cells) and even special software can also 
been used for fragmentation prediction in order to differentiate between structural 
isomers (297). 
 
If no previous information is available, identification of compounds based only on 
accurate mass and mass fragmentation data will be very challenging and the amount 
of accurate mass spectral information for environmental contaminants in currently 
available accurate mass libraries and databases is far from comprehensive but is 
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steadily improving. The situation is quite different for EI mass spectra; the current 
NIST 14 reference library contains approximately 276,259 EI mass spectra of 242,477 
compounds (298), whereas the Wiley Registry (eleventh edition) contains 775,500 
spectra from 599,700compounds (299). Therefore, the approach to suspect or non-
target screening will have to rely on general chemical databases and deal with the lack 
of MS library information. 
 
 
1.7.4.4     LC HRMS libraries and databases for organic water pollutants 
As already mentioned, a simple but reliable approach for the successful identification 
and confirmation of unknowns is the comparison of measured accurate 
product/fragment ion mass spectra with accurate mass spectra of authentic reference 
compounds, as it provides additional selectivity instead of using only the exact mass 
and the corresponding isotopic pattern. 
 
A variety of commercially available and user-defined mass spectral libraries have 
been developed for certain MS instrument types and settings but, as various collision 
energies are applied in tandem mass spectra, the relative intensities of ions can differ 
considerably. Consequently, mass spectral matching fails if the signal intensity is a 
criterion, but is successful if only the fragment ion pattern is considered. Several 
studies have shown the potential for transferability of tandem mass spectra for use 
with multiple instrument types and that instrument-independent tandem mass spectra 
can be obtained by application of multiple collision energies for fragmentation (300, 
301).  
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A library of CID spectra of 319 substances measured with an LC Q-TOF-MS 
instrument at ten collision energies was described by Pavlic et al. (302) and Broecker 
et al. developed a library of CID accurate mass spectra of more than 2,500 compounds 
for systematic toxicological analysis by LC Q-TOF-MS (269). In 80 % of all cases, 
the mass spectrum of an unknown compound could be assigned to a structure if it was 
compared with two or more reference mass spectra recorded with different 
instruments or with different collision energies (303-305). Hence, a considerable 
collection of tandem mass spectra obtained with different collision energies and with 
different instruments can improve the overall performance of a successful library 
search (275). 
 
Several commercially and publicly available spectral libraries aim to identify 
compounds independently of the instrument type and settings. Most of the LC-MS 
libraries have been developed and published by researchers in life sciences (e.g. 
proteomics and metabolomics). A recent review on computational MS for 
metabolomics summarized existing compound libraries containing ESI mass spectra, 
which include the commercially available NIST reference library, the freely 
accessible metabolite libraries METLIN, Human Metabolome Database (HMDB) and 
MassBank (268). Only the NIST, METLIN, and ‘MassBank’ reference libraries 
contain unit-resolution mass spectra and accurate mass spectral data. The ‘NIST’ 
reference library, released in 2014, contains 183,068 high and low resolution tandem 
mass spectra of 14,835 different ions from 7,692 compounds and also includes 
environmentally relevant compounds. 
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METLIN is a metabolite database currently containing accurate tandem mass spectra 
from over 14,000 compounds and metabolites; the tandem mass spectra are recorded 
with an Agilent Technologies Q-TOF-MS instrument, in both positive and negative 
ESI modes, using four different collision energies (0, 10, 20, and 40 eV) (268). As of 
August 2015, ‘MassBank’ contained nearly 28,000 high resolution MS/MS spectra in 
negative mode obtained with different types of instruments, settings, and ionisation 
modes (306). It has many options for searching for a mass spectrum, such as by peak, 
compound name, exact mass, molecular formula, substructure, instrument type, single 
or multiple fragmentation, and type and mode of ionisation. One of the major 
advantages of ‘MassBank’ is its free accessibility and the possibility to upload both 
nominal and accurate mass spectra in common and different data formats. This allows 
the collection of a considerable amount of useful mass spectral information from a 
broad research community, which might help to improve the overall performance of 
successful suspect or non-target analysis (306). 
 
Although some data entries on metabolites are useful for research on emerging 
contaminants, the mass spectral information associated with environmental pollutants 
is rather scarce. Nevertheless, computational techniques and tools for a reliable library 
search are well developed, and the spectrum-matching tools and search functions are 
already optimized for ESI MS/MS library search. It is therefore possible to extend 
databases with information on environmental pollutants and ‘MassBank’ has been 
significantly expanded in recent years with data for environmental pollutants 
collected by the NORMAN network of reference laboratories (307).  
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A database for water pollutants with emphasis on non-target screening is the DAIOS 
database, which contains numeric information on the nominal and accurate masses of 
precursor and product ions and, as with ‘MassBank’ mentioned above, the mass 
spectral data can be searched for precursor and product ions (308).  
 
 
1.7.4.5    Data independent MS/MS acquisition 
Data independent MS/MS acquisition, such as all-fragment-ion techniques have 
recently gained attention in the analysis of small molecules (309-311). Novel mass 
spectrometers with fast duty cycles and acquisition times up to 100 MS/MS scans per 
second over a wide mass range and at high resolution has allowed for the development 
of these techniques (312). Figure 1.15 illustrates the process of data independent 
MS/MS acquisition for a Q-TOF-MS where the collision cell rapidly alternates 
between low and high collision energies. One advantage is that very low intensity 
precursor ions are fragmented, even if they would not trigger intensity thresholds (as 
in data-dependent MS/MS). Even if there are co-eluting molecules with higher 
intensities (that are usually triggered first in data-dependent MS/MS), low abundant 
ions are still fragmented. Hence, in principle, all molecules in data-independent 
MS/MS will undergo fragmentation. The obvious disadvantage for all-fragment-ion 
techniques analyses is that the direct link between a specific precursor ion and its 
corresponding product ions is broken, therefore, mixed product ion spectra are 
generated, that originate from multiple precursor ions. Precursor ion determination 
when using the all-fragment-ion technique requires mass spectral deconvolution on 
the MS2 level and retention time information. However, when working with suspect 
lists, where the compound’s monoisotopic mass and potential adducts (arising from 
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API techniques) and fragment ions are known, then the task of identification is made 
considerably easier. When used in-conjunction with retention time prediction 
software the technique becomes a very powerful tool for the identification of 
compounds suspected to be present in samples.   
 
 
1.7.5      Retention time prediction 
 
As stated earlier, large libraries of high resolution, accurate mass spectra (including 
MS/MS fragment ion data) have been developed are now becoming commercially 
available for use with automated library searching and comparison tools for suspect 
pollutant screening (313). Differentiation of structural isomers, however, is not 
possible by accurate mass measurement alone. Fragment ions obtained from collision 
induced dissociation can provide useful verification that a suspect compound is 
present but one major weakness in ‘suspect’ or ‘known unknown’ screening 
approaches is the lack of chromatographic retention times associated with these 
libraries. These are essential for tentative compound identification but unequivocal 
identification, can only be provided by analysing a reference standard under the same 
chromatographic conditions (284, 314).  
 
The lack of reference standards for new pharmaceuticals, metabolites, pesticides and 
the plethora of industrial chemicals, however, forces the analyst to find alternative 
tools for tentative compound identification (314). A review of the literature indicated 
that in-silico tools can help in predicting the suspect compounds retention time in the 
chromatographic system employed.  
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Extensive information about retention phenomena can be obtained from quantitative 
structure–retention relationship (QSRR) models (315, 316). The aim of these models 
is to discover the relation between the molecular descriptors, calculated from the 
chemical structure, and retention. QSRR models describe chromatographic retention 
in single chromatographic systems. QSRR analyses can identify the most useful 
structural descriptors in a molecule, detect the molecular mechanism of retention of a 
given compound, compare the separation mechanisms of various chromatography 
columns, calculate the physicochemical properties of the analytes, and estimate 
biological activity of xenobiotics. QSRR models have been used for predicting the 
retention times of drug compounds in order to determine their retention behaviours 
(317). Despite the advantages of QSRR models, they have not yet become part of 
routine LC method development or of compound identification. A crucial challenge 
is to select the most informative molecular descriptors from a large number of 
possibilities; Dragon software (Talete, Milano, Italy) for example, calculates almost 
5000 molecular descriptors (318). The evaluation of prediction performance is an 
important and critical phase in model validation and the understanding and use of 
QSRR requires personnel fully conversant with computational modeling. Several 
researchers have produced ‘in-house’ software based on QSRR models but none have 
so far been employed in routine analysis. There is therefore a need for easy to use 
retention time prediction software for routine use with liquid chromatography mass 
spectrometry for the identification of suspect compounds where a reference material 
is unavailable or prohibitively expensive to purchase or synthesise.  
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Table 1.2  Overview of the technical specifications, characteristics and performance of hybrid TOF and Orbitrap HRAM systems. 
 
Analyser Type Manufacturer Instrumental name Resolving power 
(FWHM) at defined 
m/z value 
Approximate 
resolution 
(Δm/z)  
Mass Accuracy (ppm) m/z range Acquisition 
speed (Hz) 
Internal 
calibration 
External 
calibration 
Q-TOF Bruker 
Daltonics 
MicroOTOF-Q II 20,000 (m/z 922) 0.05 <2  <5 50-20,000 20 
  
Maxis Impact  50,000 (m/z 922),  0.01 <1 <3 50-20,000 50 
  
Maxis 4G 60,000 (m/z 1222) 0.02 <0.6 <2 50-20,000 30 (MS), 10 
(MS/MS) 
         
 
Waters  XEVO G2 Q-TOF 22,500 (m/z 956) 0.04 <1 - 20-16,000 30 
   
Synapt G2-S HDMS 50,000 (m/z 956) 0.02 <1 - 20-100,000 30 
         
 
Agilent  6500 Q-TOF series 42,000 (m/z 922) 0.02 <1 - 50-10,000 50 
         
 
Sciex  Triple TOF 4600 30,000 (full m/z range) - <0.5 <1 5-40,000 100 
  
Triple TOF 5600 35,000 (full m/z range) - <0.5 <2 5-40,000 100 
  
Triple TOF 6600 40,000 (full m/z range) - <0.5 <2 5-40,000 100 
         
IT-TOF Shimadzu LC-MS-IT-TOF 10,000 (m/z 1000) 0.1 3 5 50-5,000 10 
 
continued 
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Q-Orbitrap Thermo Fisher 
Scientific 
Q-Exactive 140,000 (m/z 200) 0.001 <1 <5 50-4,000 12 (at RP of 
17,500) 
LTQ-Orbitrap 
 
Orbitrap Elite 240,000 (m/z 400) 0.002 <1 <3 50-4,000 8 (at RP of 
17,500) 
Tribrid-
Orbitrap 
 
Orbitrap Fusion 
Lumos Tribrid 
500,000 (m/z 200) 0.0004 <1 <3 50-4,000 18 (at RP of 
17,500) 
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Figure 1.15    Process of ‘data independent MS/MS acquisition’ for a Q-TOF-MS where the collision cell rapidly 
alternates between low and high collision energies. Diagram used with permission from Bruker UK Ltd.  
 
 
Collision cell rapidly 
alternates between low and 
high collision energies 
Precursor ion identified from low 
collision energy channel. 
 
 
 
Fragment ions identified from 
higher collision energy channel. 
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1.8     Conclusions from the literature review 
 
The occurrence of contamination of the environment by pollutants continues to be 
actively researched with greater knowledge required on their presence especially 
within environmental waters where very low concentrations of pollutants such as 
pesticides, pharmaceuticals and industrial chemicals are known to be present but 
remain undetected with traditional sampling and analytical techniques. Despite their 
low concentration many have a deleterious effect on various flora and fauna. 
Therefore, the targeted approach to the analysis of aqueous environmental samples 
probably leads to an underestimation of the true breadth of contamination.  
 
It can be concluded from the preceding sections that spot sampling has many 
shortcomings and that alternatives such as passive sampling may offer a better 
alternative. Even though passive sampling is not specifically mentioned as a 
monitoring method in the WFD, the guidance document on surface water chemical 
monitoring does refer to passive sampling as a complementary method that can be 
used for both surveillance and investigative monitoring. The WFD states that when 
no analysis methods are available that fulfil the minimum 'performance criteria', the 
best available techniques not entailing excessive costs must be used. Passive sampling 
may be the best available technique for very low concentrations of pollutants that are 
not detectable in spot samples. In addition, passive sampling can also be used in 
conjunction with spot sampling to confirm or refute the results obtained from the latter 
technique and particularly in situations where pollutant concentrations fluctuate 
considerably over time; passive sampling can also play this role in investigative 
monitoring. An ongoing issue is that the compliance checking of water quality under 
the WFD with respect to organic compounds is based on total water concentrations 
82 
 
while passive sampling measures the freely dissolved (bio-available) concentration 
that is needed for risk assessments. Many emerging contaminants such as 
pharmaceuticals and pesticides are polar in nature and passive samplers have been 
developed to sample them from the aquatic environment. A popular polar passive 
sampler is the POCIS, but one of its shortcomings is the lack of robustness for 
deployment in rivers without considerable protection to avoid puncturing the 
membrane, which leads to a loss of sorbent. The sorbent is sandwiched between two 
membranes but will sag to the bottom of the sampler presenting an inconsistent 
surface area for pollutants to be adsorbed. The sampler can also lose sorbent during 
deployment or when disassembling in the laboratory. An alternative passive sampler 
is the polar Chemcatcher® which uses a disk containing an identical sorbent to that 
used with the POCIS (Oasis® HLB). The sorbent within the disk is immobilised within 
a glass fibre matrix presenting a consistent surface area during the entire deployment 
period. As the disk is supported on a PTFE base, the possibility of puncturing the 
membrane is reduced and there is very little chance of damaging the disk and losing 
the sorbent.  
 
Despite the unparalleled peak capacity that GCxGC MS offers over 1-D GCMS and 
the highly successful determination of complex environmental, petrochemical and 
biological matrices for targeted compounds, there has been a tremendous 
underutilisation of the technique for screening of environmental matrices. This may 
be due to the higher costs associated with TOF-MS systems compared to quadrupole 
MS systems; this, however, is likely to change rapidly with the recent introduction of 
bench-top GC-TOF-MS systems by Markes International (Llantrisant, UK) and 
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LECO (Saint Joseph, MI, USA) which are in the same price range as triple quadrupole 
mass spectrometers.  
 
The emerging use of HRMS and combined use of targeted and suspect screening/non-
targeted approaches have been shown to be essential complementary approaches to 
allow capture and identification of high concentration and potentially environmentally 
relevant compounds. The acquisition of high-resolution accurate-mass full-scan data 
permits the ability to perform retrospective analysis, in which the data can be 
reprocessed at a later date without the need to reanalyse samples.  The use of HRMS 
will also allow a historical picture of pollutant release and environmental exposure of 
a potentially unlimited number of contaminants to be gained over an unlimited 
number of years. Retrospective analysis can also be performed after the completion 
of the proposed solution, allowing a before and after overview of the system to be 
gained; this is of huge benefit to investigative monitoring.  
 
QSRR models have been used for predicting the retention times of compounds in 
order to determine their retention behaviours with both liquid and gas 
chromatography. Despite the advantages that retention time prediction brings, they 
have not yet become part of routine LC method development or of compound 
identification. There is a need for easy to use retention time prediction software for 
routine use with liquid chromatography mass spectrometry to aid in the identification 
of suspect compounds and reduce the enormous burden of determining which 
compounds are likely to be present in sample chromatograms.  
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1.9     Aims and objectives 
The aim of this work was to investigate alternative sampling and analysis techniques 
for investigative monitoring. The main objectives are discussed below: 
 
i) Investigate the use of comprehensive GCxGC-MS analysis for the analysis of 
complex SPMD passive sampling extracts and establish if the technique would 
identify more targeted pollutants, and emerging contaminants thought to be 
present in the SPMD, with greater confidence than one dimensional GC-MS. 
In addition, explore the use of standard and soft electron ionisation in-
conjunction with comprehensive GCxGC-MS analysis as a complimentary 
pollutant identification and confirmation tool, by analysing targeted 
pollutants, and emerging contaminants thought to be present in the SPMD 
extracts.  
 
ii) Develop an accurate mass database and fragment ion library for the 
identification of pharmaceutical residues and personal care products in 
passive sampling extracts obtained from POCIS and a prototype ‘polar’ 
Chemcatcher sampler using a new and novel LC Q-TOF-MS technique. In 
addition, evaluate the ease of use of both samplers for deployment and 
subsequent extraction and analysis. 
 
 
iii) Determine, via a combination of LC Q-TOF-MS analysis and statistical tools, 
the reproducibility of chromatographic peak areas of targeted pharmaceuticals 
identified in extracts obtained from two polar passive samplers (POCIS and 
polar Chemcatcher) deployed in a waste water effluent stream. In addition, 
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statistically determine whether the relative uptake rates, and range of 
molecular masses for ‘unknown’ compounds were similar for both samplers.  
 
iv) Investigate retention time prediction software, in conjunction with LC Q-
TOF-MS analysis, and evaluate its applicability for the accurate prediction of 
retention times for pharmaceutical metabolites.  
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Chapter 2 
 
Identification of pollutants in non-polar passive 
sampling devices using comprehensive two-
dimensional gas chromatography and variable 
energy electron ionisation time-of-flight mass 
spectrometry 
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2.1    Introduction 
 
The purpose of this chapter was to address the analytical challenges associated with 
the tentative identification of ‘suspect’ or ‘known unknowns’ pollutants, present in 
non-polar passive samplers deployed in the aquatic environment, using gas 
chromatography mass spectrometric techniques. 
 
Analysis of water sample extracts for unknown (non-target) organic chemical 
pollutants is usually undertaken by full scan one-dimensional gas chromatography-
mass spectrometry (GC-MS) using simple mass spectral library searching routines 
(20, 319). However, GC-MS is unable to resolve the many thousands and large 
variety of compounds that can be present in water samples and a more sophisticated 
approach is therefore required to identify any potential substances that may be 
responsible for ecological failures. Recently, several advanced instruments have been 
developed to identify pollutants in water samples, for example, comprehensive two-
dimensional gas chromatography time-of-flight mass spectrometry (GCxGC TOF-
MS) which offers enhanced separation capacity with highly sensitive full scan 
detection. 
 
Electron ionisation at 70 eV has been adopted as the standard for GC-MS analysis, 
due to the production of reproducible, fragment-rich mass spectra that are searchable 
against ‘in-house’ or large commercially available libraries. However, some 
compounds remain difficult to identify at 70 eV due to their similar spectra, complex 
fragmentation or weak/absent molecular ions. With electron ionisation, the molecular 
ion is weak or absent in about 30 % of the compounds in the NIST library and this 
substantially decreases the confidence in assigning the molecular mass of a 
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compound. Chemical ionisation may overcome this but spectra typically contain only 
the molecular ion, making speciation of isomers and library searching impossible. 
 
Due to a potential difference of 70 V between the positively charged ion chamber and 
the negatively charged filament (‘electron gun’) in a conventional EI source, 
electrons are accelerated from the surface of a negatively charged filament toward a 
positively charged ion chamber thereby efficiently ionizing compounds eluting from 
GC column. Reducing this potential difference (for soft ionisation) typically results 
in a dramatic loss of sensitivity due to the inefficiency of drawing electrons into the 
ion chamber and the clustering of electrons around the filament. In a recently 
developed variable ionisation source, named ‘Select eV®’, ion optics are used to 
retain the high potential difference, thus accelerating the electrons away from the 
filament but reducing their energy prior to their arrival at the ion chamber. This 
allows the ionisation energy to be tuned between 10 and 70 eV. 
 
This chapter explored the use of GCxGC-TOF MS with variable-energy EI, to assess 
its use in detecting priority and emerging contaminants in complex extracts obtained 
from the deployment of passive samplers in river water.  To the author’s knowledge, 
this is the first use of this novel analytical technology for the analysis of complex 
extracts from passive samplers as part of a water quality investigation. The future 
potential of this approach for investigative monitoring within the context of the WFD 
was explored. 
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2.2      Aims and objectives 
 
i) Using automated deconvolution and library search algorithms, establish if 
comprehensive GCxGC-MS analysis of a complex passive sampling sample 
extract would identify a known list of target compounds with greater 
confidence than the traditional one dimensional GC-MS screening approach. 
This would be undertaken by analysing extracts (spiked with solutions of 
various pollutants at known concentrations) obtained from semi-permeable 
membrane devices deployed in a water course and compare the data obtained 
from both techniques. In addition, establish if comprehensive GCxGC-MS 
analysis would identify several emerging contaminants thought to be present 
in the SPMD with greater confidence than one dimensional GC-MS. 
 
ii) Explore the use of soft electron ionisation as a complimentary pollutant 
identification and confirmation tool to standard 70 eV electron ionisation by 
analysing extracts (spiked with solutions of various pollutants at known 
concentrations and known to contain emerging contaminants) from semi-
permeable membrane devices deployed in a water course using 
comprehensive two-dimensional gas chromatography time of flight mass 
spectrometer under standard electron ionisation and soft ionisation 
conditions. 
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2.3     Experimental 
2.3.1  Reagents and standards 
All reagents and solvents were of analytical reagent grade and pesticide residue grade 
respectively. Acetone, dichloromethane, n-hexane, propan-2-ol, hydrochloric acid (36 
% w/v), anhydrous sodium sulphate, were obtained from Fisher Scientific UK Ltd. 
(Loughborough, Leicestershire, UK). Ultrapure water was obtained from an in-house 
source (ELGA Purelab Ultra) and was used in all laboratory procedures (Elga Process 
Water, Marlow, Buckinghamshire, UK).  The ultrapure water system was equipped 
with a UV lamp, carbon and membrane filter to remove trace organic compounds, 
ionic species and particulates. Custom mixes of polychlorinated biphenyls (Restek 
Corp., Bellefonte, PA, USA), polyaromatic hydrocarbons (Spex Certiprep Group LLC, 
NJ, USA), organochlorine, organophosphate and triazine pesticides (Restek Corp.) were 
used to prepare a standard solution (10 ng/µL) for which the full list of compounds 
appears in Table 2.1. The solution facilitated in the optimisation of the 2-D GC 
acquisition method and ensuring that compounds of interest would be seen in the 
resulting 1-D and 2-D GCxGC TOF-MS chromatograms obtained from the work 
detailed in section 2.3.4 and 2.3.5. Also, many compounds present in the standard 
solution, including organophosphate pesticides, have weak molecular ions and were 
chosen as representative compounds from which improvements in the signal-to-noise 
ratio of the molecular ion could be assessed when using low electron ionisation 
energies as detailed in section 2.3.6. SPMDs (91.4 cm × 2.5 cm) containing 1 mL of 
ultra-high purity triolein, spiked with performance reference compounds (10 µg 
fluorene-d10, phenanthrene-d10 and pyrene-d10) were obtained from Environmental 
Sampling Technologies (St. Joseph, MO, USA). SPMDs were shipped in gas-tight metal 
containers flushed with argon and kept at < –18 °C until deployment.  
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Table 2.1     List of 117 compounds investigated in SPMD samplers using one dimensional and GCxGC TOF-MS techniques.  
 
Compound CAS No. Compound CAS No. Compound CAS No. 
Pentachlorobenzene 608-93-5 2,3,5-trimethylnaphthalene 2245-38-7 2,2',3,4,4',5,5'-Heptachlorobiphenyl 35065-29-3 
Alpha-HCH 319-84-6 1,4,6,7-tetramethylnaphthalene 13764-18-6 3,3',4,4',5,5'-Hexachlorobiphenyl 32774-16-6 
Hexachlorobenzene 118-74-1 1-methylfluorene 1730-37-6 2,2',3,3',4,4',5-Heptachlorobiphenyl 35065-30-6 
Beta- HCH 319-85-7 9-n-propylfluorene 4037-45-0 Chlorpyrifos methyl 5598-13-0 
Gamma- HCH 58-89-9 Dibenzothiophene 132-65-0 Parathion methyl 298-00-0 
Delta- HCH 319-86-8 1,7-dimethylfuorene 442-66-0 Fenitrothion 122-14-5 
Triallate 2303-17-5 2-methyldibenzothiophene 20928-02-3 Pirimiphos ethyl 23505-41-1 
Aldrin 309-00-2 1,2-dimethyldibenzothiophene 31317-14-3 Malathion 121-75-5 
Isodrin 465-73-6 1-methylphenanthrene 832-69-9 Fenthion 55-38-9 
Endosulfan I 959-98-8 3-methylphenanthrene 832-71-3 Chlorpyrifos 2921-88-2 
Dieldrin 60-57-1 3,6-dimethylphenanthrene 1576-67-6 Parathion 56-38-2 
Endrin 72-20-8 2-methylfluoranthene 33543-31-6 Chlorfenvinphos 470-90-6 
Endosulfan II 33212-65-9 1,2,6-trimethylphenanthrene 30436-55-6 Iodofenphos 18181-70-9 
2,4’-DDT 789-02-6 1,2,6,9-tetramethylphenanthrene 204256-39-3 Triazophos 24017-47-8 
4,4’-DDT 50-29-3 Triphenylene 217-59-4 Carbophenothion 786-19-6 
2,4’-DDD 53-19-0 Benz(b)anthrance 92-24-0 Azinphos ethyl 2642-71-9  
4,4’-DDD 72-54-8 2,4,7-trimethyldibenzothiophene 216983-03-8 Azinphos methyl 86-50-0 
2,4’-DDE 3424-82-6 Perylene 198-55-0 Pirimiphos methyl 29232-93-7 
      continued 
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4,4’-DDE 72-55-9 1-methylchrysene 3351-28-8 Ethion 563-12-2 
Hexachlorobutadiene 87-68-3 6-ethylchrysene 2732-58-3 Buprimate 41483-43-6 
Acenaphthene 83-32-9 1,3,5-trimethylchrysene 1586755-28-3 Coumaphos 56-72-4 
Acenaphthylene 208-96-8 Benzo(e)pyrene 192-97-2 Fenchlorphos 299-84-3 
Anthracene 120-12-7 6-n-butylchrysene 6901-71-9 Desisopropylatrazine 1007-28-9 
Benz(a)anthrance 56-55-3 2,4'-Dichlorobiphenyl 34883-43-7 Desethylatrazine 6190-65-4 
Benzo(a)pyrene 50-32-8 2,4',5-Trichlorobiphenyl 16606-02-3 Simazine 122-34-9 
Benzo(b)fluoranthene 205-99-2 2,4,4'-Trichlorobiphenyl 7012-37-5 Atrazine 1912-24-9 
Benzo(g,h,i)perylene 191-24-2 2,3,3'-Trichlorobiphenyl 38444-84-7 Propazine 139-40-2 
Benzo(j)fluoranthene 205-82-3 2,2',5,5'-Tetrachlorobiphenyl 35693-99-3 Trietazine 1912-26-1 
Benzo(k)fluoranthene 207-08-9 3,3',4-Trichlorobiphenyl 37680-69-6 Desmetryn 1014-69-3 
Chrysene 218-01-9 2,2',4,5,5'-Pentachlorobiphenyl 37680-73-2 Prometryn 7287-19-6 
Dibenz(ah)anthracene 53-70-3 3,3',4,4'-Tetrachlorobiphenyl 32598-13-3 Terbutryn 886-50-0 
Fluoranthene 206-44-0 2,2',3,4',5',6-Hexachlorobiphenyl 38380-04-0 Cyanazine 21725-46-2 
Fluorene 86-73-7 2,3',4,4',5-Pentachlorobiphenyl 31508-00-6 Irgarol 1501 28159-98-0 
Indeno(1,2,3-c,d)pyrene 193-39-5 2,2',4,4',5,5'-Hexachlorobiphenyl 35065-27-1 Dichlorvos 62-73-7 
Naphthalene 91-20-3 2,3,3',4,4'-Pentachlorobiphenyl 32598-14-4 Mevinphos 7786-34-7 
Phenanthrene 85-01-8 2,2',3,4,4',5'-Hexachlorobiphenyl 35065-28-2 Dimethoate 60-51-5 
Pyrene 129-00-0 3,3',4,4',5-Pentachlorobiphenyl 57465-28-8 Fonofos 944-22-9 
1-methylnaphthalene 90-12-0 2,2',3,3',4,4'-Hexachlorobiphenyl 38380-07-3 Propemtamphs 31218-83-4 
1,3-dimethylnaphthalene 575-41-7 2,3,3',4,4',5-Hexachlorobiphenyl 38380-08-4 Diazinon 333-41-5 
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2.3.2      Deployment of SPMDs 
 
Duplicate SPMD passive samplers were deployed for 28 days between the 8th August 
and 6th September 2012 at a site 1.3 km downstream (51.7606, -4.0080) of a waste water 
treatment plant (51.7706, -3.9998). An SPMD field blank was also used at this location. 
The waste water treatment plant was located near to the village of Garnswllt in South 
West Wales with a population equivalent of approximately 35,000. The works is a 
conventional activated sludge plant with the effluent discharging via an outfall to the 
River Loughor (Figure 2.1). 
 
SPMDs, held in argon flushed 300 mL solvent rinsed steel tins, were transported to the 
deployment sites in cool boxes containing frozen ice packs. The SPMDs were attached 
to stainless-steel holders and then placed inside a protective stainless-steel cage which 
was rapidly placed beneath the surface of the river so as to minimize exposure to 
atmospheric contaminants. The protective stainless-steel cage was secured to a nearby 
tree trunk using chains and padlocks. 
 
After the defined exposure, the SPMDs were retrieved, sealed in the shipping containers 
and transported to the laboratory in cool boxes and stored frozen at < –18 °C until 
extracted. Field blank SPMDs were used at both sites to account for contamination 
during transport, both to and from study sites, and exposure to airborne contaminants 
during deployment and retrieval of exposed SPMDs. The field blank was treated in 
exactly the same way as the deployed SPMD with the exception that they were not 
exposed to the matrix of interest at the study sites and were stored frozen during the 
exposure period. 
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Figure 2.1. Satellite image showing the locations of the waste water treatment 
plant, final effluent discharge point into the river and the downstream SPMD 
deployment site (scale not given). Taken from Imagery© 2016, Bluesky, 
DigitalGlobe, Getmapping plc, Infoterra Ltd & Bluesky, Landsat, The 
GeoInformation Group Map data© Google. 
 
 
 
 
 
 
 
WWTW  
(51.7706, -3.9998) 
Discharge point 
(51.7682, -4.0047) 
Deployment point 
(51.7606, -4.0090) 
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2.3.3    Extraction of SPMDs 
 
The extraction procedure is based on the procedure developed by Huckins et al. (44). 
The 250 mL steel tins containing the SPMDs were removed from the freezer and 
allowed to thaw. Surface bio-fouling on the exposed SPMDs was removed by adding 5 
mL of hexane to each tin and shaking for five seconds before discarding the hexane. 
The SPMDs were removed from the tins and placed in a sequence of 500 mL wide 
necked glass jars for 20-30 s containing 150 mL of the following solvents: 
 
i) Water 
ii) 1 molar hydrochloric acid 
iii) Water 
iv) Acetone 
v) Propan-2-ol 
 
Following the final propan-2-ol rinse, the SPMDs were removed from the jar, allowed 
to air dry in a laminar fume cupboard for 10 min and transferred to individual glass 
500 mL beakers containing 250 mL of hexane. The beakers were covered with 
aluminium foil, sealed using rubber bands, and placed in an incubator for 18 h at 20 
°C. The hexane was poured into a pre-rinsed large (250 mL) glass tubes and the 
hexane evaporated with the aid of a Turbo-Vap nitrogen blow down evaporator (set 
at 40 °C) to approximately 3-5 ml (Turbovap, Biotage AB, Uppsala, Sweden). A 
further 250 mL of hexane was dispensed into the 500 mL glass beaker containing the 
SPMDs and sealed in the same manner as previously outlined and returned to the 
incubator for a further six hours. Following the second six-hour dialysis the second 
250 mL extracts were poured into the same turbo-vap tubes, containing the initial 3-
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5 mL dialysate, evaporated to a final volume of 5 mL and dried over anhydrous sodium 
sulphate. The extracts were then transferred to glass vials. 
 
To remove triolein, which is incorporated into the SPMD, dialysates were cleaned-up 
using a size-exclusion chromatography system comprised of a quaternary pump, auto-
sampler, variable wavelength detector and a fraction collector (Agilent 1200 series 
HPLC, Agilent Technologies, Wilmington, DE, USA).  The preparative clean-up column 
was a 300 mm × 21.2 mm i.d. PL Gel column (10 µm particle size, 100 Å pore size), 
equipped with a 50 mm × 21.2 mm i.d. PL Gel guard column (Agilent Technologies). 
The mobile phase was 1:1 (v/v) n-hexane–dichloromethane (5 mL/min). The clean-up 
column was calibrated using a mixture of corn oil, diethyl hexyl phthalate (DEHP) and 
perylene. The collection time for the eluate was set just prior to the elution of DEHP and 
one minute after the elution of perylene which resulted in a total eluate volume of 60 mL 
which was evaporated to a final volume of 5 mL as described above. 
 
Aliquots of the extracts (3.6 mL) were loaded onto the clean-up system and the fraction 
containing compounds of low molecular mass (typically <1000 Da) collected and 
evaporated to approximately 500 µL, as described previously, and then made up to 1 mL 
using n-hexane.  The field blank samplers were processed identically. The extracts from 
the duplicate SPMDs were split into two equal aliquots; one aliquot was transferred to 
an auto-sampler vial and the second aliquot spiked (5 µL) with the standard solution 
prepared in section 2.3.1. One duplicate would be used for the analysis outlined in section 
3.6 and 3.7 (one dimensional GC and GCxGC) and the second duplicate used for the 
analysis outlined in section 3.8 (GCxGC TOF-MS analysis with Select eV). 
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2.3.4 Conventional one dimension GC analysis (experimental conditions) 
SPMD extracts, including the un-spiked, spiked and field blanks together with a 
mixed compound standard solution, were analysed using a BenchTOF-dx® TOF MS 
(ALMSCO International, Llantrisant, U.K.) coupled to a 7890A GC (Agilent 
Technologies, Santa Clara, CA, USA). 
 
Injector: PTV; Liner: 1.8 mm (i.d.) baffled; Carrier gas: He, constant flow at 1.5 
mL/min; Mode: Splitless for 2 min (then 100 mL/min purge); Temperature: 60 °C 
for 0.05 min, 300 °C/min to 320 °C (1 min), 720 °C/min to 360 °C (cleaning phase) 
held to end of run; Septum purge: On, 3 mL/min; Injection volume: 1µL; Column: 
SGE BPX5 (30 m × 0.25 mm × 0.25 µm film thickness); Oven temperature 
programme: 50 °C (2 min), 12 °C/min to 320 °C (8 min), total run time: 32.5 min. 
 
TOF MS: Filament voltage: 1.6 V; Ion source: 300 °C; Transfer line: 300 °C; Mass 
range: 45–400 amu; Data rate: 4 Hz. 
 
Data files were processed using Target View which utilises dynamic baseline 
compensation followed by peak deconvolution. The dynamic baseline correction 
algorithm selectively eliminated ions due to chromatographic background noise (e.g. 
column bleed). This minimised interference in the total ion chromatogram and 
improved compound spectra related data. After eliminating the background, a 
deconvolution algorithm was applied to distinguish between co-eluting compounds 
and assigned each respective mass ion to the appropriate individual compound. 
Principal component analysis was then applied to the de-convoluted spectra to 
highlight characteristic ion fragmentation patterns, which were then compared with 
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compound spectra within the NIST target library to determine matches. A minimum 
library match factor of 650 (out of a 1000) was used for compound identification. In 
addition, data files were processed without peak deconvolution to determine its 
effectiveness on the quality of the library match factors. 
 
 
 
2.3.5 GCxGC TOF-MS analysis (experimental conditions) 
SPMD extracts, including un-spiked, spiked and field blanks together with a mixed 
compound standard solution, were analysed using a BenchTOF-dx® TOF MS 
(ALMSCO International, Llantrisant, U.K.) coupled to a 7890A GC (Agilent 
Technologies, Santa Clara, CA, USA) fitted with a ZX1 cryogenic modulator (Zoex 
Corp., Houston, TX, USA). Oven programming and modulation parameters were 
adjusted to yield wide analyte volatility range and high peak capacity. 
 
Injector: PTV; Liner: 1.8 mm (i.d.) baffled; Carrier gas: He, constant flow at 1.5 
mL/min; Mode: Splitless for 2 min (then 100 mL/min purge); Temperature: 60 °C 
for 0.05 min, 300 °C/min to 320 °C (1 min), 720 °C/min to 360 °C (cleaning phase) 
held to end of run; Septum purge: On, 3 mL/min; Injection volume: 1µL. 
 
Column set: 1st dimension: SGE BPX5, (27 m × 0.25 mm × 0.25 µm film thickness), 
2nd dimension: SGE BPX50, (1.95 m × 0.1 mm × 0.1 µm film thickness) (SGE 
Analytical Science Pty. Ltd.) 
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Modulation loop: Column set: As for 2nd dimension; equivalent pneumatic 
impedance to 60 m × 0.2 mm (calculated from impedance factor look-up charts for 
1st- and 2nd-dimension columns used). 
 
GC×GC temperature programme and modulation: Main oven: 50 °C (2.0 min), 5 
°C/min to 320 °C (8 min); Secondary oven: Not applicable; Hot jet: 150 °C (2.0 min), 
5 °C/min to 400 °C (hold time matched to total run time); Cold jet: Dewar fill high 
60%, Dewar fill low 50%; Cold jet flow: 15 L/min, Modulation period: 5 s; Hot-jet 
pulse 350 ms; Total run time: 64 min. 
 
TOF MS: Filament voltage: 1.6 V; Ion source: 300 °C; Transfer line: 300 °C; Mass 
range: 40–500 amu; Data rate: 50 Hz. 
 
Software: The platform-neutral software package GC Image (GC Image LLC, Lincoln, 
NE, USA) was used to visualize and process the GCxGC-TOF-MS data. Default method 
parameters were used and the peak mass spectra were searched against the NIST 11 mass 
spectral library with a library match factor of 650 used for compound identification. 
 
   
 
2.3.6   GCxGC-TOF MS analysis with Select eV (experimental conditions) 
 
SPMD extracts, including un-spiked, spiked and field blanks together with a mixed 
compound standard solution, were analysed using a Bench TOF-Select-eV® TOF MS, 
(Markes International, Llantrisant, UK) coupled to a 7890A GC (Agilent Technologies) 
fitted with a ZX1 thermal loop modulator (Zoex Corp.).  Oven programming and 
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modulation conditions were adjusted to permit analysis of a wide volatility range of 
analytes and give a high peak capacity as detailed below.  
 
Injector: PTV; Liner: 1.8 mm (i.d.) baffled; Carrier gas: He, constant flow at 1.5 
mL/min; Mode: Pulsed splitless for 1.5 min (then 100 mL/min purge); Temperature: 
60 °C min, 720 °C/min to 320 °C (1 min), 720 °C/min to 360 °C (cleaning phase) 
held to end of run; Septum purge: On, 3 mL/min. Injection volume: 1 µL. 
 
Column set: 1st dimension: SGE BPX-5, (27 m × 0.25 mm × 0.25 µm film thickness), 
2nd dimension: SGE BPX-50, (1.95 m × 0.1 mm × 0.1 µm film thickness) (SGE 
Analytical Science Pty Ltd., Victoria, Australia) Modulation loop: As for 2nd 
dimension (0.95 m). 
 
GC×GC temperature programme and modulation: Main oven: 60 °C (2.0 min), 2.5 
°C/min to 320 °C (10 min); Secondary oven: Not applicable; Hot jet: 150 °C (2.0 
min), 2.5 °C/min to 410 °C (hold time matched to total run time); Cold jet: Dewar fill 
high 60%, Dewar fill low 50%; Cold jet flow: 15 L/min, Modulation period: 8 s; Hot-
jet pulse 350 ms; Total run time: 110 min. 
 
TOF MS: Filament voltage: 1.8 V; Ion source: 280 °C; Transfer line: 300 °C; Mass 
range: 40–500 amu; Data rate: 50 Hz; Electron ionisation energy: variable (10–70 
eV). 
 
Software: The platform-neutral software package GC Image (GC Image LLC, Lincoln, 
NE, USA) was used to visualize and process the GCxGC-TOF-MS Select-eV® data. 
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Default method parameters were used and peak mass spectra were searched against the 
NIST 14 mass spectral library. 
 
 
2.4     Results and discussion  
2.4.1     Compounds identified from conventional one dimensional GC analysis 
Spiking values equivalent to an aqueous sample concentration of 50 ng/L (assuming 
an uptake rate of 1–2 L per day) were chosen to reflect the concentrations of many 
pollutants that could be present in a passive sampler deployed for a period of 
approximately one month. For compounds, such as the PCBs and PAHs, which 
typically have strong responses under 70eV conditions, aqueous concentrations as 
low as 0.01–0.03 ng/L can therefore be detected using the applied SPMD full scan 
approach for the screening of pollutants.  
 
Of the 56 pesticides added to the SPMD extract, 23 were identified (using the criteria 
set in section 3.3.4) by one dimensional chromatography respectively with eight 
pesticides remaining unidentified. The list of identified compounds from each 
technique are shown in Table 2.2 with the library match factors obtained shown in 
Table 2.3. 
 
Seventeen of the 33 pesticides not identified by one dimensional GC have molecular 
ions which are ≥ 30 % of the base peak whilst the remaining 15 have molecular ions 
which are ≤ 8 % of the base peak in the 70 eV mass spectrum. This result would 
suggest that the presence of an abundant molecular ion in a compounds EI spectrum 
is not a prerequisite for accurate identification in a complex extract, such as that 
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obtained from the SPMD sampler, when using the traditional one dimensional GC 
approach. This observation is indicative of the enhanced matrix interferences of the 
SPMD extract having an impact on the deconvolution process and subsequent library 
match as the extract may contain several thousand compounds many of which could 
co-elute and share identical masses with the analytes of interest resulting in poor 
library matches. In addition, the SPMD extract also contains residues of triolein, 
methyl oleate and its degradation compound, oleic acid plus numerous polyethylene 
oligomers which can suppress target compound ionisation if present at significant 
concentrations (high µg/SPMD). Figure 2.2 shows the total ion chromatogram 
obtained from the one-dimensional GC analysis of the spiked SPMD extract with 
several large peaks clearly visible. Figure 2.3 shows the view of the boxed area in 
Figure 2.2 illustrating the highly complex one-dimensional GC MS-TOF 
chromatogram containing a profusion of co-eluting peaks many of which have very 
large peak responses. Four-hundred and eighty peaks were identified using the 
standard peak extraction software, however, when using the deconvolution option, a 
further 298 compounds were identified proving the usefulness of the advanced peak 
picking algorithm. 
 
The molecular ions for pentachlorobenzene and cyanazine, which were not identified 
using either automated technique, were observed by manually extraction their 
respective ions from the chromatograms tentatively confirming their presence in the 
SPMD extract. Of the 33 compounds not identified, 14, 9 and 10 are classed as 
organo-phosphate, organo-nitrogen and organo-chlorine pesticides respectively and 
no single class of compound appears to be more readily identifiable than another. 
 
103 
 
Despite several pairs of co-eluting compounds, 24 of the 42 PAHs present in the 
SPMD extract returned library search values of greater than 650 and these are 
highlighted in Table 3.4. Only 18 PAHs were fully resolved in the 1st dimension with 
benzo(k)fluoranthene and benzo(j)fluoranthene co-eluting and only partially resolved 
from benzo(b)fluoranthene, however all returned library match scores greater than 
650. Chrysene and triphenylene also co-eluted with both returning high match scores 
greater than 800 and dibenz(a,h)anthracene, which co-eluted with indeno(1,2,3-
cd)pyrene, was misidentified for dibenz(a,j)anthracene as their MS spectra are 
identical. Despite PAHs having strong molecular ions, most of the alkyl substituted 
5–6 ring PAHs were not identified and this may be in part due to the complex mass 
spectrum obtained from alkylated PAHs making individual ions difficult to de-
convolute from the matrix background. 
 
All 19 PCBs added to the SPMD extract were correctly identified by one dimensional 
chromatography with 2,4',5-Trichlorobiphenyl and 2,4,4’-Trichlorobiphenyl co-
eluting but both congeners returned library match scores above 650. The presence of 
strong molecular ions with intense chlorine isotope patterns makes the deconvolution 
and subsequent identification of PCBs far easier than for compounds which do not 
contain chlorine or other halogens. However, with 209 possible congeners many 
PCBs will have very similar properties making conventional one dimensional GC 
analysis highly challenging. Despite the introduction of speciality GC columns (e.g. 
SGE HT-8) many congeners remain difficult to resolve from each other and will often 
co-elute leading many regulatory laboratories to undertake multiple one dimensional 
GC analyses on different columns in order to separate and identify all 209 congeners. 
Figure 2.4 gives a graphic illustration, from the one-dimensional GC analysis 
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undertaken, of the potential for chlorinated biphenyls to co-elute. Even with 
deconvolution the highlighted peak at 16.90 min from the spiked blank analysis would 
report as either a trichlorinated biphenyl, with a match penalty due to the presence of 
an ion cluster at m/z 292, or a tetrachlorinated biphenyl with a match penalty due to 
an over-abundance of ions clustered around m/z 256. 
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Figure 2.2  Total ion chromatogram of 1-D GC MS-TOF analysis of spiked SPMD extract. 
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Figure 2.3 Total ion chromatogram of spiked SPMD extract analysed by one dimensional GC TOF-MS 
showing the highly complex nature of the sample. 
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Table 2.2 Comparison of compounds identified using GC TOF-MS and GCxGC TOF-MS from a deployed SPMD sampler, extracted 
and spiked with 55 pesticides. 
 
                
Elution 
order 
Pesticide CAS No. 
GC TOF MS 
Retention time 
(min) 
GC×GC–TOF 
MS First-
dimension (min) 
GC×GC–TOF 
MS Second-
dimension (s) 
Intensity of molecular 
ion relative to base 
peak in mass spectrum 
at 70 eV (%) 
Intensity of molecular 
ion relative to base peak 
in mass spectrum at 12 
eV (%)  'Select eV' 
1 Hexachlorobutadiene 87-68-3 10.45 23.76 1.16 34 85 
2 Dichlorvos 62-73-7 10.97 24.51 2 5 15 
3 Mevinphos 7786-34-7 13.58 29.43 2.14 3 9 
4 Desethylatrazine 6190-65-4 ni 35.35 2.62 32 57 
5 alpha-BHC 319-84-6 16.99 36.51 2.08 <1 <1 
6 Hexachlorobenzene 118-74-1 17.15 36.68 1.82 bp bp 
7 Simazine 122-34-9 17.41 37.1 2.44 bp bp 
8 Atrazine 1912-24-9 17.54 37.18 2.18 55 bp 
9 Propazine 139-40-2 — 37.26 1.94 58 bp 
10 Propemtamphos 31218-83-4 — 37.43 1.78 <1 1 
11 Diazinon 333-41-5 18.16 37.6 1.68 61 67 
12 Trietazine 1912-26-1 — 37.6 2.02 53 bp 
13 gamma-BHC 319-85-7 17.6 37.93 2.3 1 1 
14 beta-BHC 58-89-9 17.6 38.01 2.22 1 1 
15 Fonofos 944-22-9 — 38.01 2.18 33 73 
       
continued 
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16 Desisopropylatrazine 1007-28-9 — 38.6 2.55 bp bp 
17 delta-BHC 319-86-8 16.99 39.35 2.48 <1 <1 
18 Desmetryn 1014-69-3 — 39.76 2.58 bp bp 
19 Chlorpyrifos methyl 5598-13-0 — 39.93 2.3 2 9 
20 Parathion methyl 298-00-0 — 40.35 2.44 90 bp 
21 Prometryn 7287-19-6 — 40.52 2.1 bp bp 
22 Fenchlorphos 299-84-3 — 40.6 2.06 <1 1 
23 Pirimiphos methyl 29232-93-7 — 40.76 2.04 76 bp 
24 Terbutryn 886-50-0 19.67 41.01 2.24 53 73 
25 Fenitrothion 122-14-5 19.73 41.18 2.44 70 bp 
26 Malathion 121-75-5 19.96 41.18 2.2 <1 <1 
27 Chlorpyrifos 2921-88-2 20.18 41.6 2.02 10 nd 
28 Fenthion 55-38-9 — 41.93 2.58 bp bp 
29 Parathion 56-38-2 — 42.02 2.1 bp bp 
30 Pirimiphos ethyla 23505-41-1 20.63 42.1 1.9 bp bp 
31 Aldrin 309-00-2 20.02 42.1 1.88 1 2 
32 Chlorfenvinphos 470-90-6 — 43.18 2.26 <1 1 
33 Isodrin 465-73-6 — 43.35 2.1 7 11 
34 Irgarol 1051 28159-98-0 — 43.52 2.46 89 bp 
35 2,4'-DDE 3424-82-6 — 44.43 2.28 43 bp 
36 Iodofenphos 18181-70-9 — 45.27 2.7 <1 <1 
37 Buprimate 41483-43-6 — 45.52 2.32 30 83 
38 4,4'-DDE 72-55-9 21.45 45.6 2.16 93 bp 
39 2,4'-DDD (TDE) 53-19-0 — 45.93 2.46 2 4 
40 Dieldrin 60-57-1 — 46.1 2.34 4 10 
41 Ethion 563-12-2 23 46.85 2.5 14 14 
       continued 
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42 Endrin 72-20-8 22.56 46.93 2.6 4 10 
43 4,4'-DDT 50-29-3 22.25 47.27 2.52 <1 2 
44 Triazophos 24017-47-8 23.24 47.6 3.53 15 38 
45 Carbophenothion 786-19-6 — 48.02 2.68 32 46 
46 Azinphos methyl 86-50-0 — 51.85 4.61 <1 <1 
47 Azinphos ethyl 2642-71-9 — 52.77 4.29 <1 <1 
48 Coumaphos 56-72-4 26.68 53.69 3.81 bp bp 
49 2,4'-DDT 789-02-6 ni ni ni <1 2 
50 4,4'-DDD 75-54-8 ni ni ni <1 2 
51 Cyanazineb 21725-46-2 ni ni ni 34 32 
52 Dimethoate 60-51-5 ni ni ni 8 8 
53 Endosulfan I 959-98-8 ni ni ni <1 <1 
54 Endosulfan II 33212-65-9 ni ni ni <1 4 
55 Pentachlorobenzeneb 608-93-5 ni ni ni bp bp 
56 Triallate 2303-17-5 ni ni ni <1 <1 
 
ni = identified 
nd = not determined 
bp = base peak 
a  = equal in response to fragment ion in compound mass spectrum 
b  = library match factor < 650 but seen in the manually extracted ion chromatogram for the molecular ion 
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Table 2.3 NIST library match factors obtain from different data analysis techniques for pesticides, PAHs and PCBs. 
            
Compound CAS No. Class GCxGC 
1D GC (no 
deconvolution) 
1D GC (with 
deconvolution) 
Acenaphthylene 208-96-8 PAH 932 722 Not found 
Fluoranthene 206-44-0 PAH 944 936 927 
3,3',4,4'-Tetrachlorobiphenyl 32598-13-3 PCB 870 819 800 
2,2',3,4',5',6-Hexachlorobiphenyl 38380-04-0 PCB 844 795 776 
4,4’-DDT 50-29-3 
Organo-chlorine 
pesticide 
835 801 790 
Dieldrin 60-57-1 
Organo-chlorine 
pesticide 
842 Not found Not found 
Atrazine 1912-24-9 
Organo-nitrogen 
pesticide 
842 680 Not found 
Desmetryn 1014-69-3 
Organo-nitrogen 
pesticide 
817 Not found Not found 
Chlorpyrifos 2921-88-2 
Organo-phosphorous 
pesticide 
824 701 684 
Parathion methyl 298-00-0 
Organo-phosphorous 
pesticide 
803 693 Not found 
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Figure 2.4 Extracted ion profiles for the chlorinated biphenyl compounds 
obtained from the analysis of the spiked SPMD extract. Highlighted peaks at 
16.90 min in the trichlorinated and tetrachlorinated biphenyl traces exhibit 
perfect co-elution of analytes. 
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2.4.2   Deconvolution 
 
Table 2.2 shows the library search results for selected compounds from various 
pollutants classes with and without deconvolution. For the majority of compounds 
only small improvements are observed when using deconvolution but for two 
compounds, acenaphthylene and atrazine, they were only identified above the set 
threshold only when using the deconvolution algorithm. Deconvolution removes 
chemical noise, and significantly improves the detectability of the two compounds in 
the SPMD extract; this can also be viewed as increasing signal-to-noise ratio through 
improved selectivity versus the background.  
 
 
 
2.4.3   Comprehensive GC×GC analysis 
Following the conventional one dimensional GC analysis, the column set was 
changed, as detailed in the experimental section, and the analyses repeated. Figures 
2.5 to 2.7 show the GC Image-rendered GCxGC contour plots of the field blank, un-
spiked and spiked SPMD extracts.  Figure 2.8 shows a three dimensional view of the 
boxed area in Figure 2.7 illustrating extreme sample complexity with a concentrated 
number of co-eluting peaks occurring in the first dimension. 
 
 
2.4.4   Pesticides identified with GCxGC analysis 
Of the 56 pesticides spiked to the SPMD extract, 48 were correctly identified by 
comprehensive GCxGC with the same 8 pesticides, listed in Table 2.1, remaining 
unidentified from both techniques. GCxGC identified over twice as many compounds 
as one dimensional GC and this was a result of its orthogonal separation capability 
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and superior resolving power which resulted in the improved separation of the 
interfering matrix from the pesticides of interest resulting in significantly improved 
library match factors. 
 
Figure 2.9 shows an expanded view of a GC Image-rendered contour plot for the 
spiked SPMD extract, with the pesticides circled using the ‘blob’ tool in GC Image. 
The compounds are well separated in both dimensions with the more polar pesticides 
exhibiting longer retention times due to the use of a polar column in the second 
dimension. For example, the polar atrazine metabolite, desethylatrazine, has a short 
first dimension retention time of 35.35 min but a relatively long second dimension 
retention time of 2.62 s when compared to diazinon which has a slightly longer first 
dimension retention time but a much shorter second dimension retention time of      
1.68 s. 
 
There are several pesticides that have multiple stereoisomers and 
hexachlorocyclohexane (HCH) is one such pesticide, having alpha-, beta-, gamma- 
and delta- isomers, which are relatively indistinguishable spectrally. Figure 2.10 
shows the GC Image-rendered contour plot and 3D surface plot for extracted ion 219 
(0.5 amu) showing clear separation of the four stereoisomers of HCH in the spiked 
SPMD extract analysis. The separation in the 2nd dimension is again based on isomer 
polarity. 
 
Figures 2.11 to 2.13 give examples of NIST library spectral matches for a range of 
pesticides along with the peak shape recorded in GC Image. Excellent peak shapes 
and spectral quality together with high scores for the library matches were obtained 
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for 3 pesticides that were not identified using one-dimensional GC. This is reflected 
in the reverse fit library match scores of 810, 811 and 867 and probability scores of 
88.4 %, 91.5 % and 94.8 obtained for parathion, irgarol 1051 and chlorpyrifos-methyl 
respectively.  
 
Eight pesticides out of 56 remained unidentified although the molecular ions for 
pentachlorobenzene and cyanazine could be seen by manual extraction of their 
respective ions, tentatively confirming their presence in the SPMD extract. Five of 
the eight pesticides have molecular ions which are < 1 % of the base peak and of these 
endosulfan I, endosulfan II and cyanazine have mass spectra which are highly 
fragmented presenting considerable difficulties in matching compound spectra to 
those contained in the reference NIST library.   
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Figure 2.5  GC Image rendered contour plot obtained from GCxGC analysis of the extract from the SPMD field blank for the 
deployment at Garnswllt WWTP. 
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Figure 2.6  GC Image rendered contour plot obtained from GCxGC analysis of the extract from the un-spiked SPMD (deployed 
at Garnswllt WWTP). 
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Figure 2.7  GC Image rendered contour plot obtained from GCxGC analysis of the extract from the spiked SPMD (deployed at 
Garnswllt WWTP). 
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Figure 2.8 3D view of the boxed area in Figure 3.7 illustrating sample 
complexity and significant number of co-eluting peaks that occur in the first 
dimension. 
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Figure 2.9  GC Image rendered contour plot obtained from GCxGC analysis of the extract from the spiked SPMD (deployed at 
Garnswllt WWTP) with pesticides circled. 
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Figure 2.10 GC Image rendered contour plot and 3-D surface plot for extracted ion 219 (0.5 amu) showing separation of the 
four stereoisomers of hexachlorocyclohexane for the spiked SPMD extract analysis. 
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Figure 2.11    NIST 2011 library match and 3-D rendered peak for parathion 
taken from the spiked SPMD extract analysis. 
 
 
 
 
 
      
 
 
 
 
 
 
 
 
Figure 2.12   NIST 2011 library match and 3-D rendered peak for 
chloropyriphos-methyl taken from the spiked SPMD extract analysis. 
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Figure 2.13    NIST 2011 library match and 3-D rendered peak for irgarol 
1051 taken from the spiked extract sample analysis. 
 
 
2.4.5 PAHs identified with GCxGC analysis    
Forty out of 42 PAHs were correctly identified using GCxGC with 37 being fully 
resolved in the 2nd dimension. Table 2.4 gives a detailed description of the 
assignments made, including retention times in both dimensions and the general 
elution order. Five PAHs that co-eluted in the first and second dimension, but 
achieved a library match score of 650, are included in Table 2.4 as being tentatively 
identified. Two PAHs, spiked into the SPMD extract, were not identified and these 
were 2,4,7-trimethyldibenzothiophene, which is not in the NIST 11 database, and 
perylene, which has a molecular ion of m/z 252, common to numerous PAHs. In all 
probability, perylene could not be distinguished from benzo(a)pyrene and the 
benzo(b)/(k)/(j)fluoranthenes isomers due to co-elution. It was not, however, reported 
as a potential candidate compound in the library search. 
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Figure 2.14 shows an expanded view of a GC Image-rendered contour plot for the 
spiked SPMD extract, with the PAHs circled using the ‘blob’ tool in GC Image. Three 
compounds; indeno(1,2,3-cd)pyrene, benzo(ghi)perylene and dibenz(a,h)anthracene 
exhibited a phenomenon called ‘wrap-around’ and these are highlighted in red. Wrap-
around occurs when compounds have not eluted from the secondary column before 
the end of the modulation period and appear in the following modulation. Compounds 
that have ‘wrapped’ in the second dimension typically show peak broadening. ‘Wrap- 
around’ can be avoided by increasing the oven temperature gradient but this will lead 
to higher first-dimension elution temperatures, thus decreasing secondary retention 
times if the primary and secondary columns are in the same oven or subject to the 
same temperature. To maintain resolution in the first dimension, a dual oven system 
can be employed to house the secondary column and this is used with a positive 
temperature offset in the second dimension reducing the possibility of ‘wrap around’.  
 
Examples of 4-ring PAHs are given in Figure 2.15 and because of their similar 
structure almost identical retention times are obtained in the first dimension. 
Fragmentation patterns, obtained under electron ionisation conditions, are very 
similar and accurate assignment without running individual standards to determine 
retention times is very difficult. It is for this reason that benz[a]anthracene, 
benz[b]anthracene, chrysene and triphenylene have been labelled as ‘tentative 
assignment’ in Table 2.4. Figure 2.16 shows a surface plot for the entire separation 
space of extracted ion 228 (the molecular ion for the above PAHs’). As can be seen, 
there are only two significant peaks in the separation space area, with one being 
approximately three times larger in volume than the other, suggesting that, with the 
spiking levels being the same, two or more of these compounds co-elute. Figures 2.17 
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to 2.20 show the inherent spectral quality obtained from GCxGC analysis with 
examples of the NIST library matches obtained for the 3-, 4-, and 5-ring PAHs. 
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Table 2.4    PAH assignment based on the spiked SPMD extract analysis. 
 
Elution 
order 
PAH CAS No. Col. I RT (min) Col. II RT (s) 
1a Naphthalene 91-20-3 23.5086 1.8229 
2a 1-Methylnaphthalene 90-12-0 27.0932 1.843 
3a 1,3-Dimethylnaphthalene 575-41-7 29.9276 1.7027 
4a Acenaphthalene 208-96-8 30.9279 2.1835 
5a Acenaphthene 83-32-9 31.7616 2.0833 
6a 2,3,5-Trimethylnaphthalene 2245-38-7 33.4288 1.7228 
7a Fluorene 86-73-7 34.179 2.1031 
8 1,4,6,7-Tetramethylnaphthalene  13764-18-6 36.0965 1.7728 
9 1-Methylfluorene  1730-37-6 36.8647 2.0833 
10 9-n-Propylfluorene  4037-45-0 38.0138 1.843 
11a Dibenzothiophene 132-65-0 38.1806 2.524 
12 Phenanthrene 85-01-8 38.7641 2.524 
13a Anthracene 120-12-7 38.9308 2.524 
14 1,7-Dimethylfluorene  442-66-0 39.2643 1.9832 
15 2-Methyldibenzothiophene  20928-02-3 40.5147 2.3838 
16 3-Methylphenanthrene  832-71-3 41.5151 2.6242 
17a 1-Methylphenanthrene 832-69-9 41.5985 2.5441 
18a 3,6-Dimethylphenanthrene 1576-67-6 42.9323 2.3237 
    
continued 
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19a 1,2-Dimethyldibenzothiophene 31317-14-3 44.016 2.6843 
20a Fluoranthene 206-44-0 44.2661 2.9047 
21a Pyrene 129-00-0 45.35 3.185 
22 2-Methylfluoranthene  33543-31-6 46.2668 2.8245 
23a 1,2,6-Trimethylphenanthrene 30436-55-6 46.3502 2.5841 
24a 1,2,6,9-Tetramethylphenanthrene 204256-39-3 48.3509 2.6042 
25b Benz[a]anthracene 56-55-3 50.8518 3.5657 
26a,b Benz[b]anthracene 56-55-3 50.8518 3.5657 
27a,b Chrysene 218-01-9 50.8518 3.5657 
28a,b Triphenylene 217-59-4 50.9351 3.746 
29a 1-Methylchrysene 3351-28-8 53.186 3.9063 
30 6-Ethylchrysene  2732-58-3 53.6861 3.8061 
31c Benzo[a]pyrene 50-32-8 55.5201 4.5673 
32c Benzo[e]pyrene 192-97-2 55.5201 4.5673 
33 6-n-Butylchrysene  6901-71-9 56.0203 3.9463 
34 1,3,5-Trimethylchrysene  na 56.2704 4.4471 
35a,d Benzo[b]fluoranthene 205-99-2 56.6039 0.4607 
36a,d Benzo[k]fluoranthene 207-08-9 56.8539 0.6611 
37a,d Benzo[j]fluoranthene 205-82-3 57.1874 1.1218 
38d Indeno[1,2,3-cd]pyrene 193-39-5 61.1391 1.1819 
39a,d,e Dibenz[a,h]anthracene 53-70-3 61.7583 1.211 
40d Benzo[ghi]perylene 191-24-2 63.4396 3.7059 
    
continued 
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na 2,4,7-trimethyldibenzothiophene na ni ni 
na Perylene 198-55-0 ni ni 
 
 
aIdentified with 1-D GC chromatography   bTentative assignment, potential co-elution; cTentative assignment, potential co-elution; dWrap-around 
observed, eMis-identified as dibenz[a,j]anthracene, nanot applicable – not in NIST library, ninot identified 
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Figure 2.14    GC Image rendered contour plots of the spiked SPMD extract with PAHs circled. Wrapped compounds are 
highlighted in red. 
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                                       Benz[a]anthracene                                Chrysene 
 
 
 
 
 
 
 
 
       Triphenylene              Benz[b]anthracene 
Figure 2.15    Spectral comparison of NIST 2011 library spectra of four 4-ring PAHs to show the spectral similarities. 
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Figure 2.16    GC Image-rendered surface for the extracted ion 228 (0.5 amu) of 
the 4-ring PAHs present in the spiked SPMD extract analysis. 
 
 
 
       
 
 
 
 
 
 
 
Figure 2.17   NIST 2011 library match and 3-D rendered peak for acenaphthylene 
taken from the spiked extract sample analysis. 
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Figure 2.18   NIST 2011 library match and 3-D rendered peak for 3,6-
dimethylphenanthrene taken from the spiked extract sample analysis. 
 
 
 
 
 
       
 
 
 
 
 
 
 
Figure 2.19    NIST 2011 library match and 3D-rendered peak for 6-
ethylchrysene (reported as 5-ethyl because the structure is not in the NIST 
library) taken from the spiked SPMD extract analysis. 
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Figure 2.20   NIST 2011 library match and 3D-rendered peak (extracted ion 
252) for benzo[k]fluoranthene taken from the spiked extract sample analysis. 
 
 
2.4.6     PCB analysis 
Twenty-two PCBs were identified in the analysis with only19 PCBs present in the 
standard solution used to spike the SPMD extract. Of the three extra non-targeted 
PCBs identified, two were tetrachlorinated and one was heptachlorinated. Table 2.5 
gives a detailed description of the assignments made, including retention times in both 
dimensions and the general elution order. The spectra for congeners from the same 
level of chlorination are very similar; however, it has been shown that by using a 
combination of molecular ion and ion ratio information it is possible to confidently 
identify individual congeners. However, specifying individual congeners within a 
chlorination level is more difficult without prior knowledge of elution orders. For the 
three non-targeted PCBs the chlorine substitution pattern assignment was based on a 
linear retention index  (320). 
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Figure 2.21 shows an expanded view of GC Image-rendered contour plots for the 
spiked extract samples, with the PCBs labelled by level of chlorination. Figure 2.22 
shows a 3D-rendered image based on the extracted molecular ions of the PCBs 
detected with potentially two additional PCBs present highlighted in the inset 
included in Figure 2.22, however, the separation is not sufficiently optimised to 
confirm this with certainty. Enhanced chemometric peak deconvolution may be 
successful in separating co-eluting congeners but use of specialised GC columns, in 
both the first and second dimensions may be the better option to separate closely co-
eluting PCB pairs (200). 
 
Comprehensive GC×GC has provided the resolution necessary to separate the two 
PCBs that previously co-eluted during the 1D analysis. This co-elution may have been 
alleviated, in the 1-D analysis, using different oven temperature programming during 
the separation, but this may in turn have then led to other compounds co-eluting.  
 
Figures 2.23 to 2.26 again show the inherent spectral quality obtained from GCxGC 
analysis for the PCBs with examples of spectral library matches obtained from NIST, 
together with an inset of the excellent 3-D peak shape from GC Image. 
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Table 2.5     GCxGC PCB assignment based on the spiked SPMD sample analysis. 
 
Elution 
order 
               PCB CAS No. Col. I RT (min) Col. II RT (s) 
1 2,4'-Dichlorobiphenyl 34883-43-7 36.5133 2.0032 
2 2,4',5-Trichlorobiphenyl 16606-02-3 38.1806 2.0633 
3 2,4,4'-Trichlorobiphenyl 7012-37-5 40.1813 1.9832 
4 2,3,3'-Trichlorobiphenyl 38444-84-7 40.5147 2.1635 
5 2,2',5,5'-Tetrachlorobiphenyl 35693-99-3 41.4317 2.0032 
6 3,3',4-Trichlorobiphenyl 37680-69-6 42.1820 2.1434 
7 2,2',4,5,5'-Pentachlorobiphenyl 37680-73-2 44.5995 2.1034 
8 3,3',4,4'-Tetrachlorobiphenyl 32598-13-3 46.1834 2.3838 
9 2,2',3,4',5',6-Hexachlorobiphenyl 38380-04-0 46.6836 2.3638 
10 2,3',4,4',5-Pentachlorobiphenyl 31508-00-6 46.9337 2.2436 
11 2,2',4,4',5,5'-Hexachlorobiphenyl 35065-27-1 47.6006 2.1835 
12 2,3,3',4,4'-Pentachlorobiphenyl 32598-14-4 47.9341 2.5841 
13 2,2',3,4,4',5'-Hexachlorobiphenyl 35065-28-2 48.6010 2.5040 
14 3,3',4,4',5-Pentachlorobiphenyl 57465-28-8 49.1012 2.4239 
15 2,2',3,3',4,4'-Hexachlorobiphenyl 38380-07-3 49.6013 2.8446 
16 2,3,3',4,4',5-Hexachlorobiphenyl 38380-08-4 50.4350 2.5841 
17 2,2',3,4,4',5,5'-Heptachlorobiphenyl 35065-29-3 50.8518         2.5040 
    
     continued 
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18 3,3',4,4',5,5'-Hexachlorobiphenyl 32774-16-6 51.6854 2.5641 
19 2,2',3,3',4,4',5-Heptachlorobiphenyl 35065-30-6 51.8521 2.8646 
 
Untargeted analytes – Chlorination level assignment based on molecular ion data; substitution pattern assignment based on linear retention index. 
i. 2,2',4,6'-Tetrachlorobiphenyl 68194-04-7 42.1820 2.2636 
ii. 3,3',5,5'-Tetrachlorobiphenyl 33284-52-5 43.8493 2.1835 
iii. 2,2',3,3',5,6,6'-Heptachlorobiphenyl 52663-64-6 49.0178 2.3438 
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Dichlorobiphenyls   
 
Trichlorobiphenyls   
 
Tetrachlorobiphenyls   
 
Pentachlorobiphenyls   
 
Hexachlorobiphenyls   
 
Heptachlorobiphenyls 
Figure 2.21  GC Image rendered contour plots of the spiked SPMD extract samples with chlorinated biphenyls coloured by 
chlorination level. The red oval highlights what would be a co-elution in 1-D GC (see Figure 3.4 for 1-D chromatogram).  
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Figure 2.22    GC Image 3-D surface plot for PCB extracted ions 222, 256, 292, 
326, 360 and 394 (1 amu) for the spiked extract. Inset highlight possible 
presence of two more PCB congeners. 
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Figure 2.23   NIST 2011 library match and 3-D rendered peak for a 
tetrachlorinated biphenyl taken from the spiked extract sample analysis. 
 
 
 
 
 
       
 
 
 
 
 
 
 
Figure 2.24    NIST 2011 library match and 3-D rendered peak for a 
pentachlorinated biphenyl taken from the spiked extract sample analysis. 
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Figure 2.25    NIST 2011 library match and 3-D rendered peak for a 
hexachlorinated biphenyl taken from the spiked extract sample analysis. 
 
 
 
 
 
       
 
 
 
 
 
 
 
Figure 2.26 NIST 2011 library match and 3-D rendered peak for a 
heptachlorinated biphenyl taken from the spiked extract sample analysis. 
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2.4.7    Emerging contaminants 
 
The focus of this work was also to evaluate GCxGC for the identification of 
compounds of emerging concern, such as those from personal care products and 
industrial chemicals.  Many of the emerging contaminants (not spiked into the extract) 
were present at a low concentration in the SPMD extract, making identification more 
complicated. The emerging contaminants referred to below were not spiked into the 
SPMD extracts.  
 
 
2.4.7.1 Polycyclic musks, UV sunscreen filters and phosphate fire retardants 
identified in the SPMD extract 
Polycyclic musks are widely used in detergents and personal hygiene products and 
are considered as emerging aquatic pollutants which are very toxic to aquatic life and 
are known to induce oxidative and genetic damage in the zebra mussel (321). HHCB 
(4,6,6,7,8,8-Hexamethyl-1,3,4,6,7,8-hexahydrocyclopenta[g]isochromene) and 
AHTN (1-(3,5,5,6,8,8-hexamethyl-5,6,7,8-tetrahydro-2-naphthalenyl)ethanone) are 
polycyclic musks that are commonly found in waste water treatment effluents and the 
former has several diastereoisomers (see Figure 2.27) and structural analogues at 
much lower concentration than the intended product, and all have similar mass spectra 
(322).  
 
As AHTN has the same molecular formula, a similar mass spectrum, and an almost 
identical first dimension retention time, separation from HHCB is very difficult using 
traditional 1-D GC. Even sophisticated mass spectrometry (high resolution or tandem 
mass spectrometry) would not provide an adequate separation with 1-D GC as all the 
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compounds concerned are isomers, thus isobaric signals (peaks from compounds with 
identical mass) would be obtained.  However, GCxGC in this work, was used to 
successfully separate the five diastereoisomers of HHCB plus AHTN as shown in 
Figure 2.28. Excellent library match scores of 879 and 809 were obtained for HHCB 
and AHTN respectively as shown in Table 2.6. With one dimensional GC and 
deconvolution a library match score just above the set threshold of 650 was obtained. 
Without deconvolution, however, AHTN was not identified and this may have been 
due to its almost complete co-elution with HHCB in the first dimension. As HHCB 
produced a larger response than AHTN, and shares the same molecular ion, the mass 
spectrum without peak deconvolution would predominantly be that of HHCB and 
would probably explain why only HHCB was identified in the library search.  
 
UV sunscreen filters, Octinoxate (2-ethylhexyl (2E)-3-(4-methoxyphenyl) acrylate), 
which was not identified using one dimensional GC, Homosalate (3,3,5-
trimethylcyclohexyl salicylate) and Octocrylene (2-ethylhexyl 2-cyano-3,3-
diphenylacrylate) were confidently identified with high (> 870) library match factors 
when using GCxGC as shown in Table 2.6.  However, small differences were 
observed in the library match factors for both Octocrylene and Homosalate using 
either GC technique in this work. The organo-phosphate fire retardants, amgard 
TMCP [tris(2-chloro-1-methylethyl) phosphate] and octicizer [2-ethylhexyl diphenyl 
phosphate, both considered to be toxic to aquatic organisms and/or potential 
carcinogens (323), were also identified in the SPMD extracts as shown in Table 2.6. 
Despite extensive fragmentation, and the lack of a molecular ion, very little difference 
was observed in the library match factors for amgard TMCP and octicizer using either 
GC technique.  
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Table 2.6    NIST library match factors obtain from different data analysis techniques for emerging contaminants identified 
in the SPMD extract. 
 
 
Compound CAS No. Class GCxGC 
1-D GC (no 
deconvolution) 
1-D GC (with 
deconvolution) 
HHCB 1222-05-5 Polycyclic musk 879 835 835 
AHTN 21145-77-7 Polycyclic musk 809 ni 651 
Octinoxate 5466-77-3 UV sunscreen filter 875 ni ni 
Octocrylene 6197-30-4 UV sunscreen filter 880 857 868 
Homosalate 118-56-9 UV sunscreen filter 899 893 903 
Amgard TMCP 13674-84-5 Organo-phosphate fire retardant 869 817 844 
Octicizer 1241-94-7 Organo-phosphate fire retardant 858 857 865 
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                                                 Figure 2.27   Diastereoisomers of HHCB and AHTN separated using GCxGC. 
4,6,6,7,8,8-Hexamethyl-1,3,4,6,7,8-
hexahydrocyclopenta[g]isochromene;  
[HHCB]; CAS No. 1222-05-5 
6-Ethyl-4,6,8,8-tetramethyl-1,3,4,6,7,8-
hexahydrocyclopenta[g]isochromene;  
CAS No. 78448-48-3 
8-Ethyl-4,6,6,8-tetramethyl-1,3,4,6,7,8-
hexahydrocyclopenta[g]isochromene;  
CAS No. 78448-49-4 
 
4,7,7,8,9,9-Hexamethyl-1,3,4,7,8,9-
hexahydrocyclopenta[h]isochromene;    
CAS No. 114109-63-6 
 
1,7,7,8,9,9-Hexamethyl-1,2,4,7,8,9-
hexahydrocyclopenta[f]isochromene;     
CAS No. 114109-62-5 
1-(3,5,5,6,8,8-hexamethyl-5,6,7,8-tetrahydro-
2-naphthalenyl)ethanone                                 
[AHTN]    CAS No. 21145-77-7 
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Figure 2.28    Combined two-dimensional extracted ion chromatogram for m/z 213 and 159, showing the identification of the polycyclic 
musks AHTN and HHCB, and related structural analogues of HHCB in the SPMD extract. 
 
 2.4.8 Variable-energy electron ionisation 
The use of GCxGC in-conjunction with soft electron ionisation as a complimentary 
identification and confirmation tool was investigated for the emerging contaminants 
and the pesticides identified in the SPMD extract. A few changes were made to the 
GCxGC method outlined in section 2.3.6 in order to prevent ‘wrap around’ occurring 
in the second dimension and these included a longer modulation period of 8 s and the 
following oven temperature ramp: 60 °C (2.0 min), 2.5 °C/min to 320 °C (10 min). 
The changes resulted in a significantly longer chromatographic run time of 110 min 
over the original 64 min. Automated deconvolution in-conjunction with library 
searching was not possible as, to the best of the author’s knowledge, no commercial 
library yet exists for spectra obtain at lower electron ionisation energies. If attempted, 
low energy spectra searched against the NIST library would return very low match 
scores as many fragment ions would be missing or their ratios significantly changed 
under low ionisation energies. Improvements in using lower ionisation energies were 
therefore demonstrated by calculating the signal-to-noise ratios for the molecular ions 
and comparing to those obtained using 70eV in the same analytical run. This was 
possible due to the fast ionisation energy switching capability of the Select-eV 
ionisation source. 
 
2.4.8.1 Molecular ion intensity and signal-to-noise ratio improvements for 
the molecular ions of pesticides  
 
Table 2.2 (in section 2.4.1) shows the percentage intensity of the molecular ions for the 
pesticides relative to the base peak for the mass spectra acquired at 70 and 12 eV. Large 
increases of around 200 – 400 % in the intensities of the molecular ions were observed 
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at 12 eV for many pesticides especially where the intensity of the molecular ion was 
between 2–5 % in the 70 eV spectrum. These compounds included dichlorvos and 
mevinphos (Figure 2.29), 2,4-TDE and 4,4-DDE (Figure 2.30), with chlorpyrifos-
methyl having the largest increase from around 2 to 9 % for the molecular ion in the 12 
eV spectrum as can be clearly seen in Figure 2.31. Simplified fragment ions spectra 
were obtained for all compounds and especially so for aromatic compounds such as 
hexachlorobenzene and hexachlorobutadiene. More modest improvements were 
obtained for desethylatrazine, carbophenothion, diazinon, terbutryn and isodrin. 
Generally, little to no improvements were seen for compounds where the molecular ion 
was ≤ 1 % of the base peak, examples include azinphos ethyl, azinphos methyl, 
dimethoate, iodofenphos and triallate. Cyanazine even showed a slight drop of 2 % in 
the molecular ion response compared to the base peak at 12 eV. There was no clear 
relationship, in terms of class of compound, where the largest increases in molecular 
ion intensity were observed. 
 
Pesticides which showed the largest increases in molecular ion intensity also showed 
the largest improvements in the signal-to-noise ratios at an ionisation energy of 12 eV. 
Mevinphos, an organophosphate pesticide, showed the largest improvement (70-fold), 
whilst 2,4-TDE and dichlorvos showed improvements of >20 fold. Even 4,4-DDE with 
a relative abundance of >50% for the molecular ion exhibited a >10-fold improvement 
in its signal-to-noise ratio as shown in Table 2.8. The dramatic increase in the response 
of the molecular ion at 12 eV and the noticeable decrease in low mass fragment ions for 
all the aforementioned compounds, and especially for 4,4’-DDE, are clearly observed 
in Figure 3.30.  
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Table 2.7 Signal-to-noise ratios of the molecular ions of pesticides spiked into 
the SPMD extract at different electron ionisation energies. 
 
 
Compound (m/z) Electron ionisation energy 
70 eV  12 eV 
Mevinphos (224) 8  563 
2,4 TDE (318) 59  1,392 
Methyl chlorpyrifos (321) 62  671 
Dichlorvos (220) 157  3,425 
4,4 DDE (316) 2,551  26,270 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
                         Dichlorvos                                       Mevinphos 
 
Figure 2.29 Comparison of signal-to-noise ratios (S/N) for the molecular ions of the organo-phosphate pesticides 
dichlorvos and mevinphos present in the SPMD extract at 70 eV and 12 eV ionisation energies. 
S/N = 157, (70 eV) 
S/N = 3,425, (12 eV) 
M
+
= 220 
S/N = 8, (70 eV) 
M
+
= 224 
S/N = 563, (12 eV) 
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                            2,4’-TDE                                                 4,4’-DDE 
 
Figure 2.30 Comparison of signal-to-noise ratios (S/N) for the molecular ions of the organo-chlorine pesticides 2,4’-TDE 
and 4,4’-DDE present in the SPMD extract at 70 eV and 12 eV ionisation energies. 
S/N = 2,551, (70 eV) 
M
+
= 316 
S/N = 26,270, (12 eV) 
S/N = 59, (70 eV) 
M
+
= 318 
S/N = 1,392, (12 eV) 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.31 Comparison of signal-to-noise ratios (S/N) for the molecular 
ion of the organo-phosphate chlorpyrifos methyl present in the SPMD extract 
at 70 eV and 12 eV ionisation energies. 
 
 
S/N = 671, (12 eV) 
S/N = 62, (70 eV) 
M
+
= 321 
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2.4.8.2 Signal-to-noise ratio improvements for the molecular ions of 
emerging contaminants  
The molecular ions for the UV filters Homosalate, Octinoxate and Octocrylene (m/z 
262, 290 and 360 respectively) are relatively weak when compared to the base peak 
in the 70 eV spectrum. By lowering the ionisation energy stepwise from 70 eV to 12 
eV the response of the molecular ion for all three compounds (mass spectra shown in 
Figures 2.32 and 2.33) increased relative to the base peak, but especially so for 
Octinoxate where a ten-fold improvement in the signal-to-noise ratio was observed. 
Similar significant increases in the signal-to-noise ratios for Homosalate and 
Octocrylene were also observed at lower ionisation energies (> 7 and > 4 respectively) 
as shown in Table 2.7. The molecular ion for HHCB was approximately 20 % of the 
base peak in the 70 eV spectrum but rose to > 80 % at 12 eV as shown in Figure 2.33 
and at 10 eV the molecular ion becomes the base peak. 
 
Extensive fragmentation of alkylated phosphates occurs under 70 eV ionisation 
potential which can compromise their accurate identification. Positive ion chemical 
ionisation has been used in conjunction with GC-MS but the technique requires a high 
degree of operator experience and precludes the use of direct mass spectral searching 
of commercial libraries such as NIST within the same chromatographic run. Amgard 
TMCP, identified in the SPMD extract, does not produce a molecular ion even at 12 
eV but the fragment ion at m/z 291, due to the loss of a single chlorine atom, shows 
an increase of approximately 90-fold in its signal-to-noise ratio when compared with 
70eV. As the mass spectrum at 12 eV was extensively fragmented it was searched 
against the NIST library and returned a search score of 910. The ion at m/z 291 when 
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used in-conjunction with the other fragment ions (as shown in Figure 2.34), was 
therefore highly influential in confirming the compounds identity.  
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Table 2.8 Signal-to-noise ratios for the molecular ions of the emerging 
contaminants identified in the SPMD extract at different electron ionisation 
energies. 
 
 
Compound (m/z) Electron ionisation energy 
70 eV 14 eV 12 eV 
Octocrylene (361)  61 252 270 
Homosalate (262)  63 151 303 
Octinoxate  (290) 170 500 1137 
Amgard TMCP (291)a 46 381 4154 
HHCB (258) 1308 5855 6960 
 
 
a  = fragment ion  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
              Homosalate (3,3,5-Trimethylcyclohexyl salicylate)                                 Octinoxate (2-Ethylhexyl (2E)-3-(4-methoxyphenyl)acrylate) 
 
Figure 2.32 Comparisons of the mass spectra obtained for Homosalate and Octinoxate, present in the SPMD extract, 
measured at three different ionisation energies (12, 14 and 70 eV). 
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S/N = 1137 (12 eV) 
 
M
+
= 262 M
+
= 290 
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Octocrylene (2-Ethylhexyl 2-cyano-3,3-diphenylacrylate)                              
M
+
= 258 M
+
= 361 
S/N = 1308 (70 eV) 
 
S/N = 5855 (14 eV) 
 
S/N = 6960 (12 eV) 
 
S/N = 61 (70 eV) 
 
S/N = 252 (14 eV) 
 
S/N = 270 (12 eV) 
 
HHCB  (4,6,6,7,8,8-Hexamethyl-1,3,4,6,7,8-
hexahydrocyclopenta[g]isochromene) 
Figure 2.33 Comparisons of the mass spectra obtained for HHCB and Octocrylene, present in the SPMD extract, 
measured at three different ionisation energies (12, 14 and 70 eV). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.34 Mass spectrum of Amgard TMCP, present in the SPMD extract, at 
electron ionisation energies of 70, 14 and 12eV. 
 
 
 
 
 
M
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2.4.8.3      Reduced spectral ‘noise’  
At lower energies, ionisation of carrier and background gases were eliminated, 
resulting in much lower spectral ‘noise’.  In the 12 eV spectrum for the pesticide 
chlorpyrifos methyl, shown in Figure 2.31, carbon dioxide CO2
+• (m/z 44) and oxygen 
O2
+• (m/z 32) are entirely absent. The greatly reduced interference from ionised carrier 
and background gases, along with the reduction in fragmentation of analytes, results 
in much cleaner spectra at lower energies. The lower incidence of commonly 
encountered smaller fragment ions, means that closely eluting target compounds can 
be distinguished far more readily than at 70 eV. 
 
 
 
2.5    Conclusions 
The work undertaken in this chapter has demonstrated that, when chosen carefully, 
the GCxGC analytical technique can enhance the inherent advantages of passive 
sampling of watercourses over more traditional 1-D GCMS. In particular, the higher 
compound loadings resulting from the use of SPMDs were satisfactorily dealt with 
by GC×GC, allowing separation of compounds that would otherwise co-elute. The 
high data rate and sensitivity of TOF MS, in-conjunction with GC×GC, produced 
high-quality mass spectra enhancing confidence in compound identification. 
 
Of the 56 pesticides added to a SPMD extract, 23 and 48 were identified by 1-D and 
GCxGC respectively and results suggested that the presence of significant matrix 
interference could only be dealt with efficiently by GCxGC’s higher peak capacity and 
increased resolution capability. Dieldrin, which was not identified using 1D GC (with 
or without deconvolution) was readily identified using GCxGC with a high match 
factor of 842. Other pesticide compound classes including organo-chlorine and 
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organo-nitrogen pesticides, were confidently detected with atrazine and chlorpyrifos 
seeing significant improvements in library match factors. 
 
Of 42 PAHs added to the SPMD extract only 24 were identified by 1-D GCMS and 
of these only 18 were fully resolved. GCxGC, on the other hand, identified 40 PAHs 
with 37 fully resolved.  22 PCBs were identified using GCxGC, three of which were 
not identified with 1-D GCMS. Improved resolution and higher library match scores 
were obtained with GCxGC for the polycyclic musks which have been the focus of 
recent studies into emerging contaminants. The above results clearly demonstrate the 
superior separation of the technique by separating target and non-target analytes from 
interfering compounds with similar mass spectra. 
 
The variable-energy ionisation technology described in this work has been shown to 
be a reliable technique that provided significant increases in the intensity of the 
molecular ion and also produced considerably higher signal-to-noise ratios for all 
classes of pollutants including the emerging contaminants in the SPMD extract at 
lower ionisation energies. The ability to easily switch between hard and soft electron 
ionisation within the same chromatographic run allows regular 70 eV spectra to be 
generated for matching against existing libraries alongside lower-energy spectra, 
generating complementary information on the molecular ion and structurally 
significant fragment ions. 
 
The use of GCxGC together with the variable-energy ionisation source can be seen 
as increasing the ‘dimensionality’ of the analysis thereby increasing confidence in the 
identification of pollutants when undertaking investigations into emerging 
contaminants or target lists monitoring programmes under the auspices of the water 
framework directive.  Furthermore, the reduced fragmentation of analytes, matrix 
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interferences and carrier gases significantly improves signal-to-noise ratios for target 
substances, and should allow lower limits of detection to be achieved.  
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Chapter 3 
 
Development of a novel ‘all ions’ MS/MS screening 
method for the reliable identification of 
pharmaceuticals in polar passive sampler extracts 
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3.1 Introduction 
 
Pharmaceuticals are ubiquitous in surface waters because of continuous discharges from 
municipal wastewater treatment plants and we still do not know which pharmaceuticals 
(including those not currently monitored) are reaching the environment, the size of the 
problem for exposed fauna, nor what the effects, if any, of that exposure may be. Of the 
200 different pharmaceuticals that have been reported in river waters globally, the >5000 
pharmaceuticals approved for use in Europe represents just a snapshot of the total, i.e. < 
4 % of pharmaceuticals have been analysed for or detected in surface waters (324). It 
demonstrates a clear need for future research to be expanded across the less well studied 
compounds, particularly those which may pose environmental risks (56, 325, 326). 
 
The purpose of this chapter was to develop and test a new approach to suspect target 
screening where full scan MS and MS/MS spectra, acquired within the same analytical 
run, are used in conjunction with an ‘in-house’ database to identify pharmaceutical 
residues present in passive samplers deployed in the final effluent of a sewage treatment 
works.  
 
Targeted LC-MS analytical methods employing triple quadrupole mass spectrometers 
are being increasingly complemented by high resolution accurate mass (HRAM) 
systems including time-of-flight (TOF), quadrupole time-of-flight (Q-TOF) and 
Orbitrap systems.  This is mainly due to an increasing interest in the occurrence of 
contaminants of emerging concern and the need for high confidence in reporting 
results for regulatory compliance. For most of the LC-MS amenable compounds 
specified in the European Union’s Water Framework and Drinking Water Directives, 
method detection limits in the low ng/L range can now be achieved with HRAM 
systems (327). The cost of purchasing such systems has also reduced significantly in 
recent years making the purchase of such high-performance systems more feasible. 
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TOF-MS, Q-TOF-MS and Orbitrap instruments satisfy the need for full spectrum 
acquisition with high sensitivity but only TOF and Q-TOF systems can acquire data 
at high sampling rates above 3 Hz without sacrificing resolution. High resolution is 
essential to obtain information on molecular ions, isotope patterns, and fragments 
with narrow peaks (≤ 1 s) obtained from modern ultra-high performance liquid 
chromatography (UHPLC) systems. 
 
Two different approaches are currently used for compound identification in 
environmental screening analysis in combination with high resolution accurate mass 
LC-MS, these are targeted MS/MS and auto-MS/MS (328).  These two approaches 
have significant disadvantages, namely: targeted MS/MS operation performs MS/MS 
only on what is included in the target list and never on unknown or unexpected targets 
and with auto MS/MS desired precursors can be missed where multiple adducts  are 
formed by adduction of an ionic species to a molecule (typically the protonated 
molecule but they can also originate from alkali metals) are formed in highly complex 
sample extracts. This chapter looks at alternative methodology based on ‘all ions’ 
MS/MS which overcomes the disadvantages of the other two approaches.  
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3.2 Aims and objectives 
 
i) Identify and obtain the most commonly prescribed pharmaceuticals in Wales 
for 2014 based on prescription cost analysis data produced by Welsh 
Government.  
 
ii) Develop an accurate mass and fragment ion database for the pharmaceuticals 
identified in 3.2 (i) for use with a novel LC Q-TOF-MS method for the 
identification of pharmaceuticals and personal care product ingredients in the 
aquatic environment.   
 
iii) Evaluate a prototype ‘polar’ Chemcatcher® alongside POCIS samplers in the 
effluent streams of three local waste water treatment plants and identify 
pharmaceutical residues present in the extracts. 
 
3.3 ‘All ions’ MS/MS 
With the ‘all ions’ MS/MS technique, high resolution accurate mass data is acquired 
using a minimum of two different collision energies, formed of a low value and one 
or more higher energy values. Target compounds are fragmented without precursor 
selection in very fast sequential steps and accurate mass precursor and fragment data 
are recorded for all collision energies. The result of alternating the collision energy is 
a data file with a low energy channel that contains predominantly precursor ions and 
one or several high-energy channels that contain precursor and fragment ions. Only 
the most stable compounds will have a precursor ion present at the highest collision 
energy setting. Figure 3.1a shows a spectrum of trimethoprim from a passive sampler 
extract with a collision energy of 0 eV where the precursor ion at 291.1459 is 
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prominently featured. Figure 3.1b shows an averaged spectrum of collision energies 
at 0, 20 and 40 eV for trimethoprim in the same extract which contains the precursor 
as well as several fragment ions (displayed in green). Figure 3.1c shows a summed 
‘cleaned’ MS/MS spectrum of the higher collision energies which shows only the 
known fragment ions obtained for trimethoprim. The known MS/MS fragment ions 
for trimethoprim at the various collision energies were obtained experimentally from 
analysing pure standards that were then entered into a searchable pharmaceutical 
compound database or library. 
 
Analysis of data files acquired using the ‘all ions’ MS/MS technique involves 
correlating the elution profile of the precursor ion in the low energy channel (0 eV) 
with those of the fragments generated under higher energy conditions (20 eV and 40 
eV). The fragments from MS/MS spectra in the searchable pharmaceutical compound 
database were used to form individual extracted ion chromatograms that were 
overlaid with the precursor extracted ion chromatogram. A co-elution score was 
derived for each fragment ion from an algorithm that calculates a number based on 
abundance, peak shape (symmetry), peak width and retention time as shown in Table 
3.1. The normalized ratio of the fragment ions to the precursor ion intensity are 
plotted over the retention time and displayed in a co-elution plot as seen in Figure 3.2 
for trimethoprim that is from the same passive sampling extract as that shown in 
Figure 3.1. 
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Figure 3.1 Mass spectra for trimethoprim at 0 eV (a), averaged mass 
spectrum from collision energies of 0, 20 and 40e V (b) and summed ‘cleaned’ 
MS/MS spectrum of the higher collision energies (c) for the Chemcatcher® 
sampler at the Carmarthen site.
a 
b 
c 
  
 
Table 3.1 Co-elution scores for the individual trimethoprim fragment ions, together with scores for the precursor mass accuracy, mass and 
retention time differences. 
 
 
Name Formula m/z Mass 
Mass 
(Tgt) 
Diff (ppm) 
Score 
(Tgt) 
RT 
RT 
(Tgt) 
RT 
Diff 
Score 
(RT) 
Species 
Trimethoprim C14H18N4O3 291.1459  290.1385 290.1379 -2.27 98.68 6.31 6.306 0.004 99.87 (M+H)
+  
            
            
Coelution 
Score 
CE Flags(FIs) Height m/z Name RT 
RT 
Diff 
SNR    
99.4 20 Qualified 29948.4 230.1162 Trimethoprim 6.319 0.009 48.9    
99.8 40 Qualified 27805.2 261.0982 Trimethoprim 6.302 0.009 86.3    
98.1 40 Qualified 9595.2 229.1084 Trimethoprim 6.302 0.009 17.4    
99.1 40 Qualified 15527.5 257.1033 Trimethoprim 6.302 0.009 37.3    
99.4 20 Qualified 18458 275.1139 Trimethoprim 6.319 0.009 27.2    
            
Score (iso. 
abund) 
Score (mass) 
Score 
(MS) 
Score 
(iso. 
spacing) 
Height Species m/z      
98.97 96.76 98.11 99.78 147135.8 (M+H)+ 291.1459      
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Figure 3.2 Overlaid un-normalised extracted ion chromatograms for the fragment ions 
of trimethoprim (a) and normalized ratios of the fragment ions to the precursor ion intensity 
(m/z 291.1452) plotted versus retention time and displayed in a co-elution plot (b).
b 
 
 
a 
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3.3.1 Find by formula algorithm 
The find by formula algorithm in Mass Hunter qualitative analysis software is used 
in conjunction with the ‘all ions’ MS/MS technique. The algorithm starts with the 
formula of a compound and calculates the monoisotopic mass and isotope pattern. If 
the compound is suspected to be present in the data file, the find by formula algorithm 
verifies that the mass accuracy, isotope patterns and isotope spacing are consistent 
with the database formula. It then constructs extracted ion chromatograms based on 
the most abundant isotopes for each selected charge carrier (or adduct) including 
those for multimers, integrates and groups them. Scoring criteria for mass accuracy, 
isotope patterns and isotope spacing can be manually set providing a cut-off point 
where the analyst can be satisfied that the compound is indeed present.  
 
3.3.2 Formation of the database 
To curate the database that would be used with the LC Q-TOF-MS system, a search 
was undertaken to identify the most prescribed pharmaceuticals in Wales in 2014 that 
may be present in final effluents and watercourses receiving discharges from sewage 
works. Information on prescription items dispensed in 2014, which were prescribed 
by general medical practitioners (GPs) in Wales, was obtained from the Welsh 
government website http://gov.wales/statistics-and-research/prescriptions-dispensed-
community/. This information is produced by Welsh government to provide statistical 
information for current prescribing policies in Wales. 
 
For reasons of practicality it was decided to include only individual pharmaceuticals 
(by chemical name) in the database where the total number of prescriptions for each 
exceeded 25,000 that year; these appear in  Table D1 (Appendix D). Prescribed items 
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such as prosthetic medical devices, dressings (including those that contained 
antimicrobials or other active drugs) were excluded. The list was further refined by 
excluding compounds that were not amenable to reversed phase liquid 
chromatography conditions typically used in LC-MS methods and those exhibiting 
very poor solubility in water or organic solvents. These compounds included sugars, 
metal-based compounds, vitamins and other dietary supplements, oils, oxidisers, 
solvents, insulin and common inorganic salts. Pharmaceuticals previously analysed at 
the authors laboratory (for the UKWIR Chemical Investigation Programme) were also 
included giving a total of 164 compounds; the full list of pharmaceuticals for which 
reference materials were purchased appear in Table 3.2.  
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Table 3.2 Full list of pharmaceuticals for which reference materials were purchased for Q-TOF-MS analysis. 
 
Pharmaceutical 
class  
Compound determined CAS RN Chemspider ID Systematic (IUPAC) name for compound determined - obtained from PubChem 
Analgesic Sumatriptan  103628-46-2 5165 1-[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-N-methylmethanesulfonamide 
 
Tramadol  27203-92-5 31105 (1R,2R)-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexan-1-ol 
Antacid Ranitidine  66357-35-5 571454 (E)-1-N'-[2-[[5-[(dimethylamino)methyl]furan-2-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine 
Anti-arrhythmic  Amiodarone 1951-25-3 2072 (2-butyl-1-benzofuran-3-yl)-[4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl]methanone 
 
Flecainide  54143-55-4 3239 N-(piperidin-2-ylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide 
Anti-asthmatic  Cromolyn  16110-51-3 2779 5-[3-(2-carboxy-4-oxochromen-5-yl)oxy-2-hydroxypropoxy]-4-oxochromene-2-carboxylic acid 
 
Ipratropium (as the cation) 60205-81-4 3615 [(1S,5R)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate 
 
Salbutamol 18559-94-9 1999 4-[2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol 
 
Salmeterol  89365-50-4 4968 2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol 
Anti-biotic Amoxicillin 26787-78-0 31006 (2S,5R,6R)-6-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 
 
Cefalexin 15686-71-2 25541 (6R,7R)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid 
 
Chloramphenicol 56-75-7 5744 2,2-dichloro-N-[(1R,2R)-1,3-dihydroxy-1-(4-nitrophenyl)propan-2-yl]acetamide 
 
Chlortetracycline 57-62-5 10469370 (4S,4aS,5aS,6S,12aR)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide 
 
Clarithromycin 81103-11-9 4447591 (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-12,13-dihydroxy-4-
[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-7-methoxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione 
 
Doxycycline  564-25-0 10469369 (4S,4aR,5S,5aR,6R,12aR)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide 
 
Erythromycin 114-07-8 12041 (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-
[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione 
 
Nitrofurantoin 67-20-9 5036498 1-[(E)-(5-nitrofuran-2-yl)methylideneamino]imidazolidine-2,4-dione 
 
Nystatin 34786-70-4 10468627 (1S,3R,4R,7R,9R,11R,15S,16R,17R,18S,19E,21E,25E,27E,29E,31E,33R,35S,36R,37S)-33-[(3-Amino-3,6-dideoxy-beta-D-mannopyranosyl)oxy]-
1,3,4,7,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabic yclo[33.3.1]nonatriaconta-19,21,25,27,29,31-hexaene-36-carboxylic acid 
 
Ofloxacin 82419-36-1 4422 9-Fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid 
 
Oxytetracycline  79-57-2 10482174 (4S,4aR,5S,5aR,6S,12aR)-4-(dimethylamino)-1,5,6,10,11,12a-hexahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide 
 
Penicillin V  87-08-1 6607 (2S,5R,6R)-3,3-dimethyl-7-oxo-6-[(2-phenoxyacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 
 
Trimethoprim 738-70-5 5376 5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine                                                                                                                                       continued 
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Anti-coagulant Dipyridamole  58-32-2 2997 2-[[2-[bis(2-hydroxyethyl)amino]-4,8-di(piperidin-1-yl)pyrimido[5,4-d]pyrimidin-6-yl]-(2-hydroxyethyl)amino]ethanol 
 
Warfarin 81-81-2 10442445 4-hydroxy-3-(3-oxo-1-phenylbutyl)chromen-2-one 
Anti-convulsant Carbamazepine 298-46-4 2457 Benzo[b][1]benzazepine-11-carboxamide 
 
Lamotrigine 84057-84-1 3741 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine 
 
Phenytoin  57-41-0 1710 5,5-diphenylimidazolidine-2,4-dione 
Anti-depressant Amitriptyline  50-48-6 2075 3-(5,6-dihydrodibenzo[2,1-b:2',1'-f][7]annulen-11-ylidene)-N,N-dimethylpropan-1-amine 
 
Citalopram  59729-33-8 2669 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile 
 
Clomipramine  303-49-1 2699 3-(2-chloro-5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine 
 
Dosulepin  113-53-1 4445580 (3Z)-3-(6H-benzo[c][1]benzothiepin-11-ylidene)-N,N-dimethylpropan-1-amine 
 
Fluoxetine 54910-89-3 3269 N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine 
 
Lofepramine 23047-25-8 3810 1-(4-chlorophenyl)-2-[3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)propyl-methylamino]ethanone 
 
Mirtazapine 61337-67-5 4060 2-Methyl-1,2,3,4,10,14b-hexahydropyrazino[2,1-a]pyrido[2,3-c][2]benzazepine 
 
Paroxetine  61869-08-7 39888 (3S,4R)-3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidine 
 
Sertraline  79617-96-2 61881 (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine 
 
Trazodone  19794-93-5 5332 2-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one 
 
Venlafaxine (Venlaxafine) 93413-69-5 5454 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexan-1-ol 
Anti-diabetic  Gliclazide 21187-98-4 3356 1-(3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-2-yl)-3-(4-methylphenyl)sulfonylurea 
Anti-diarrhoeal  Loperamide  53179-11-6 3818 4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-N,N-dimethyl-2,2-diphenylbutanamide 
Anti-emetic Cyclizine / Marzine  82-92-8 6470 1-benzhydryl-4-methylpiperazine 
 
Metoclopramide  364-62-5 4024 4-amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxybenzamide 
 
Scopolamine  51-34-3 10194106 (1R,2R,4S,5S,7s)-9-Methyl-3-oxa-9-azatricyclo[3.3.1.0~2,4~]non-7-yl (2S)-3-hydroxy-2-phenylpropanoate  
Anti-estrogen Tamoxifen 10540-29-1 2015313 2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine 
Anti-fungal Clotrimazole 23593-75-1 2710 1-[(2-chlorophenyl)-diphenylmethyl]imidazole 
 
Fluconazole 86386-73-4 3248 2-(2,4-difluorophenyl)-1,3-bis(1,2,4-triazol-1-yl)propan-2-ol 
 
Ketoconazole 65277-42-1 401695 1-[4-[4-[[(2S,4R)-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]ethanone 
 
Miconazole  22916-47-8 4044 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole 
 
Terbinafine  91161-71-6 1266005 (E)-N,6,6-trimethyl-N-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine 
Anti-glaucoma Latanoprost 130209-82-4 4470740 Propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate                                                    continued 
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Anti-histamine Cetirizine  83881-51-0 2577 2-[2-[4-[(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]acetic acid 
 
Chlorpheniramine 132-22-9 2624 3-(4-chlorophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine 
 
Fexofenadine  83799-24-0 3231 2-[4-[1-hydroxy-4-[4-[hydroxy(diphenyl)methyl]piperidin-1-yl]butyl]phenyl]-2-methylpropanoic acid 
 
Hydroxyzine  68-88-2 3531 2-[2-[4-[(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]ethanol 
 
Loratadine 79794-75-5 3820 Ethyl 4-(8-chloro-5,6-dihydrobenzo[1,2]cyclohepta[2,4-b]pyridin-11-ylidene)piperidine-1-carboxylate 
 
Promethazine  60-87-7 4758 N,N-dimethyl-1-phenothiazin-10-ylpropan-2-amine 
 
Cinnarizine 298-57-7 1264793 1-benzhydryl-4-[(E)-3-phenylprop-2-enyl]piperazine 
Anti-hypertensive Alfuzosin 81403-80-7 2008 N-[3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]propyl]oxolane-2-carboxamide 
 
Amlodipine  88150-42-9 2077 3-O-ethyl 5-O-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate 
 
Atenolol 50-78-2 2162 2-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetamide 
 
Bisoprolol  66722-44-9 2312 1-(propan-2-ylamino)-3-[4-(2-propan-2-yloxyethoxymethyl)phenoxy]propan-2-ol 
 
Candesartan 139481-59-7 2445 2-ethoxy-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylic acid 
 
Carvedilol  72956-09-3 2487 1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy)ethylamino]propan-2-ol 
 
Celiprolol 56980-93-9 2563 3-[3-acetyl-4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl]-1,1-diethylurea 
 
Clonidine  4205-90-7 2701 N-(2,6-dichlorophenyl)-4,5-dihydro-1H-imidazol-2-amine 
 
Diltiazem-Cis  42399-41-7 35850 [(2S,3S)-5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3-dihydro-1,5-benzothiazepin-3-yl] acetate 
 
Doxazosin  74191-85-8 3045 [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(2,3-dihydro-1,4-benzodioxin-3-yl)methanone 
 
Enalapril  75847-73-3 4534998 (2S)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]pyrrolidine-2-carboxylic acid 
 
Felodipine 72509-76-3 3216 5-O-ethyl 3-O-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate 
 
Irbesartan 138402-11-6 3618 2-butyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one 
 
Labetalol 36894-69-6 3734 2-hydroxy-5-[1-hydroxy-2-(4-phenylbutan-2-ylamino)ethyl]benzamide 
 
Lisinopril 76547-98-3 4514933 (2S)-1-[(2S)-6-amino-2-[[(1S)-1-carboxy-3-phenylpropyl]amino]hexanoyl]pyrrolidine-2-carboxylic acid 
 
Losartan  114798-26-4 3824 [2-butyl-5-chloro-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol 
 
Metoprolol  37350-58-6 4027 1-[4-(2-methoxyethyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol 
 
Moxonidine  75438-57-2 4645 4-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methylpyrimidin-5-amine 
 
Nebivolol 99200-09-6 64421 1-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)-2-[[2-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)-2-hydroxyethyl]amino]ethanol 
 
Nifedipine 21829-25-4 4330 Dimethyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate 
 
Oxprenolol 6452-71-7 4470 1-(propan-2-ylamino)-3-(2-prop-2-enoxyphenoxy)propan-2-ol                                                                                                                                   continued 
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Perindopril  82834-16-0 96956 (2S,3aS,7aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxopentan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid 
 
Propranolol 525-66-6 4777 1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol 
 
Ramipril 87333-19-5 4514937 (2S,3aS,6aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[b]pyrrole-2-carboxylic acid 
 
Sotalol  3930-20-9 5063 N-[4-[1-hydroxy-2-(propan-2-ylamino)ethyl]phenyl]methanesulfonamide 
 
Telmisartan 144701-48-4 59391 2-[4-[[4-methyl-6-(1-methylbenzimidazol-2-yl)-2-propylbenzimidazol-1-yl]methyl]phenyl]benzoic acid 
 
Timolol  26839-75-8 31013 (2S)-1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol 
 
Valsartan 137862-53-4 54833 (2S)-3-methyl-2-[pentanoyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid 
 
Verapamil 52-53-9 2425 2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]-2-propan-2-ylpentanenitrile 
Anti-infective Chlorhexidine 55-56-1 2612 (1E)-2-[6-[[amino-[(E)-[amino-(4-chloroanilino)methylidene]amino]methylidene]amino]hexyl]-1-[amino-(4-chloroanilino)methylidene]guanidine 
Anti-malarial Quinine  130-95-0 84989 (R)-[(2S,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol 
Anti-neoplastic  Anastrozole 120511-73-1 2102 2-[3-(2-cyanopropan-2-yl)-5-(1,2,4-triazol-1-ylmethyl)phenyl]-2-methylpropanenitrile 
Anti-obesity Orlistat 96829-58-2 2298564 [(2S)-1-[(2S,3S)-3-hexyl-4-oxooxetan-2-yl]tridecan-2-yl] (2S)-2-formamido-4-methylpentanoate 
Anti-platelet  Clopidogrel  113665-84-2 54632 Methyl (2S)-2-(2-chlorophenyl)-2-(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)acetate 
Anti-psychotic Amisulpride 71675-85-9 2074 4-amino-N-[(1-ethylpyrrolidin-2-yl)methyl]-5-ethylsulfonyl-2-methoxybenzamide 
 
Chlorpromazine  50-53-3 2625 3-(2-chlorophenothiazin-10-yl)-N,N-dimethylpropan-1-amine 
 
Haloperidol 52-86-8 3438 4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one 
 
Risperidone 106266-06-2 4895 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one 
Anti-rheumatic / 
Anti-malarial 
Hydroxychloroquine  118-42-3 3526 2-[4-[(7-chloroquinolin-4-yl)amino]pentyl-ethylamino]ethanol 
Anti-malarial Sulfasalazine 599-79-1 10481900 (3Z)-6-oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid 
Anti-spasmodic Mebeverine  630-20-3 3891 4-[ethyl-[1-(4-methoxyphenyl)propan-2-yl]amino]butyl 3,4-dimethoxybenzoate 
 
Oxybutynin 5633-20-5 4473 4-(diethylamino)but-2-ynyl 2-cyclohexyl-2-hydroxy-2-phenylacetate 
 
Procyclidine  77-37-2 4750 1-cyclohexyl-1-phenyl-3-pyrrolidin-1-ylpropan-1-ol 
Bronchodilator Terbutaline  23031-25-6 5210 5-[2-(tert-butylamino)-1-hydroxyethyl]benzene-1,3-diol 
 
Theophylline 58-55-9 2068 1,3-dimethyl-7H-purine-2,6-dione 
Cardiotonic drug Digoxin 20830-75-5 2006532 3-[(3S,5R,8R,9S,10S,12R,13S,14S,17R)-3-[(2R,4S,5S,6R)-5-[(2S,4S,5S,6R)-5-[(2S,4S,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-
methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-12,14-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-
tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one 
Cholinergic 
antagonist 
Alverine  150-59-4 3550 N-ethyl-3-phenyl-N-(3-phenylpropyl)propan-1-amine                                                                                                                                                continued 
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Corticosteroid Betamethasone  378-44-9 9399 (4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-6b-Glycoloyl-5-hydroxy-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-
naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one 
 
Betamethasone-17-valerate 2152-44-5 15673 [(8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-
octahydrocyclopenta[a]phenanthren-17-yl] pentanoate 
Diuretic Amiloride  2609-46-3 15403 3,5-diamino-6-chloro-N-(diaminomethylidene)pyrazine-2-carboxamide 
 
Bendroflumethiazide 73-48-3 2225 3-benzyl-1,1-dioxo-6-(trifluoromethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 
 
Bumetanide 28395-03-1 2377 3-(butylamino)-4-phenoxy-5-sulfamoylbenzoic acid 
 
Furosemide 54-31-9 3322 4-chloro-2-(furan-2-ylmethylamino)-5-sulfamoylbenzoic acid 
 
Hydrochlorothiazide 58-93-5 3513 6-chloro-1,1-dioxo-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 
 
Indapamide 26807-65-8 3574 4-chloro-N-(2-methyl-2,3-dihydroindol-1-yl)-3-sulfamoylbenzamide 
 
Spironolactone 52-01-7 5628 S-[(7R,8R,9S,10R,13S,14S,17R)-10,13-dimethyl-3,5'-dioxospiro[2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-17,2'-oxolane]-7-yl] 
ethanethioate 
Dopamine agonist Ropinirole  91374-21-9 4916 4-[2-(dipropylamino)ethyl]-1,3-dihydroindol-2-one 
Laxative Bisacodyl 603-50-9 2299 [4-[(4-acetyloxyphenyl)-pyridin-2-ylmethyl]phenyl] acetate 
 
Dioctyl sulfosuccinate  10041-19-7 10862 1,4-bis(2-ethylhexoxy)-1,4-dioxobutane-2-sulfonate 
Lipid regulator Atorvastatin  134523-00-5 54810 (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid 
 
Bezafibrate 41859-67-0 35728 2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methylpropanoic acid 
 
Fenofibrate 49562-28-9 3222 Propan-2-yl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate 
 
Pravastatin  81093-37-0 49398 (3R,5R)-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid 
 
Simvastatin 79902-63-9 49179 [(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate 
Local anasthetic Lidocaine  137-58-6 3548 2-(diethylamino)-N-(2,6-dimethylphenyl)acetamide 
Nicotinic 
antagonist 
Varenicline  249296-44-4 4470510 (1R,12S)-5,8,14-Triazatetracyclo[10.3.1.0~2,11~.0~4,9~]hexadeca-2,4,6,8,10-pentaene 
Nootropic agent Donepezil 120014-06-4 3040 2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxy-2,3-dihydroinden-1-one 
NSAID Acetaminophen 103-90-2 1906 N-(4-Hydroxyphenyl)acetamide 
 
Acetylsalicylic acid 50-78-2 2157 2-Acetoxybenzoic acid 
 
Benzindamine  642-72-8 12036 3-(1-benzylindazol-3-yl)oxy-N,N-dimethylpropan-1-amine 
 
Celecoxib 169590-42-5 2562 4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide 
 
Diclofenac  15307-86-5 2925 2-[2-(2,6-dichloroanilino)phenyl]acetic acid 
 
Ibuprofen 15687-27-1 3544 2-[4-(2-methylpropyl)phenyl]propanoic acid                                                                                                                                                               continued 
175 
 
 
 
 
  
Ketoprofen 22071-15-4 3693 2-(3-benzoylphenyl)propanoic acid 
 
Mefenamic acid 61-68-7 3904 2-(2,3-dimethylanilino)benzoic acid 
 
Meloxicam  71125-38-7 10442740 4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-1,2-benzothiazine-3-carboxamide 
 
Naproxen   22204-53-1 137720 (2S)-2-(6-methoxynaphthalen-2-yl)propanoic acid 
 
Piroxicam 36322-90-4 10442653 4-Hydroxy-2-methyl-N-(2-pyridinyl)-2H-1,2-benzothiazine-3-carboximidic acid 1,1-dioxide  
 
Salicylic acid 69-72-7 331 2-hydroxybenzoic acid 
PDE5 inhibitor Sildenafil  139755-83-2 5023 5-[2-ethoxy-5-(4-methylpiperazin-1-yl)sulfonylphenyl]-1-methyl-3-propyl-4H-pyrazolo[4,3-d]pyrimidin-7-one 
Proton pump 
inhibitor 
Lansoprazole 103577-45-3 3746 2-[[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl]-1H-benzimidazole 
 
Omeprazole 73590-58-6 4433 6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1H-benzimidazole 
 
Pantoprazole  102625-70-7 4517 6-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methylsulfinyl]-1H-benzimidazole 
Steroidal anti-
androgen 
Cyproterone acetate 427-51-0 9496 (1R,3aS,3bR,7aR,8aS,8bS,8cS,10aS)-1-Acetyl-5-chloro-8b,10a-dimethyl-7-oxo-1,2,3,3a,3b,7,7a,8,8a,8b,8c,9,10,10a-
tetradecahydrocyclopenta[a]cyclopropa[g]phenanthren-1-yl acetate 
Steroidal anti-
asthmatic  
Beclomethasone  4419-39-0 19276 (8S,9R,10S,11S,13S,14S,16S,17R)-9-chloro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-
octahydrocyclopenta[a]phenanthren-3-one 
 
Beclomethasone 
dipropionate 
08-09-34 20396 [2-[(8S,9R,10S,11S,13S,14S,16S,17R)-9-chloro-11-hydroxy-10,13,16-trimethyl-3-oxo-17-propanoyloxy-6,7,8,11,12,14,15,16-
octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] propanoate 
Steroidal anti-
inflammatory  
Budesonide 51333-22-3 36566 (4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-6b-Glycoloyl-5-hydroxy-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-
naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one  
 
Clobetasol propionate 25122-46-7 30399 [(8S,9R,10S,11S,13S,14S,16S,17R)-17-(2-chloroacetyl)-9-fluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-
octahydrocyclopenta[a]phenanthren-17-yl] propanoate 
 
Clobetasone-17-butyrate 25122-57-0 64481 [(8S,9R,10S,13S,14S,16S,17R)-17-(2-chloroacetyl)-9-fluoro-10,13,16-trimethyl-3,11-dioxo-7,8,12,14,15,16-hexahydro-6H-cyclopenta[a]phenanthren-17-yl] 
butanoate 
 
Dexamethasone  50-02-2 5541 (8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-
octahydrocyclopenta[a]phenanthren-3-one 
 
Dexamethasone-21-acetate 1177-87-3 206624 [2-[(8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-
yl]-2-oxoethyl] acetate 
 
Flumethasone 2135-17-3 15632 (6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-
octahydrocyclopenta[a]phenanthren-3-one  
Fluticasone-17-Propionate 80474-14-2 49297 [(6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-17-(fluoromethylsulfanylcarbonyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-
octahydrocyclopenta[a]phenanthren-17-yl] propanoate 
 
Fusidic acid 1859-24-0 2271900 (2Z)-2-[(3R,4S,5S,8S,9S,10S,11R,13R,14S,16S)-16-acetyloxy-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1H-
cyclopenta[a]phenanthren-17-ylidene]-6-methylhept-5-enoic acid 
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Hydrocortisone 50-23-7 5551 (8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-
one  
Hydrocortisone-21-acetate 50-03-3 5542 [2-[(8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-
oxoethyl] acetate  
Mometasone furoate 83919-23-7 390091 [(8S,9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-
octahydrocyclopenta[a]phenanthren-17-yl] furan-2-carboxylate  
Prednisolone 50-24-8 5552 (8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one 
Steroidal 
contraceptive 
Desogestrel 54024-22-5 37400 (8S,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-11-methylidene-1,2,3,6,7,8,9,10,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-ol 
Steroidal estrogen 17-alpha-estradiol 57-91-0 61840 (8R,9S,13S,14S,17R)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol 
 
17-beta-estradiol 50-28-2 5554 (8R,9S,13S,14S,17S)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol 
Steroidal hormone Progesterone 57-83-0 5773 (8S,9S,10R,13S,14S,17S)-17-acetyl-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one 
Steroidal 
progestin 
Medroxyprogesterone-17-
acetate 
71-58-9 6043 [(6S,8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate 
 
Nor-ethisterone (19-
Norethindrone) 
68-22-4 5994 (8R,9S,10R,13S,14S,17R)-17-ethynyl-17-hydroxy-13-methyl-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one 
Steroidal 
reductase inhibitor 
Finasteride 98319-26-7 51714 (1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-tert-butyl-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide 
Vasodilator Betahistine 5638-76-6 2276 N-methyl-2-pyridin-2-ylethanamine 
α1a adrenergic 
receptor 
antagonist  
Tamsulosin  106133-20-4 114457 5-[(2R)-2-[2-(2-ethoxyphenoxy)ethylamino]propyl]-2-methoxybenzenesulfonamide 
    
 
Key    
 
CASRN - Chemical Abstracts Service Registry Number 
(https://www.cas.org/content/chemical-substances) 
 
Chemspider - Royal Society of Chemistry 
(http://www.chemspider.com/)  
 
IUPAC - International Union of Pure and Applied 
Chemistry (http://iupac.org/)  
 
PubChem - National Center for Biotechnology Information 
(https://pubchem.ncbi.nlm.nih.gov/) 
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3.4 Experimental 
3.4.1 Reagents and reference materials 
All reagents of analytical reagent grade otherwise specified. All solvents were of LC-
MS or HPLC grade. Acetone, ammonium acetate, ammonium formate, 
dichloromethane, formic acid, methanol and methyl-tert-butyl ether (MTBE) were 
purchased from Fisher Scientific UK (Loughborough, Leicestershire, UK) or Sigma-
Aldrich (Gillingham, Dorset, UK). Ultrapure water was obtained from an ‘in-house’ 
source (ELGA Purelab Ultra) and was used in all laboratory procedures (Elga Process 
Water, Marlow, Buckinghamshire, UK).  The ultrapure water system was equipped 
with a UV lamp, carbon and membrane filter to remove trace organic compounds, 
ionic species and particulates. Supor® 200 polyethersulphone membrane was 
obtained as a 30 cm by 15 m roll from Pall Corporation (Portsmouth, Hampshire, 
UK). Oasis HLB sorbent was obtained from Waters Ireland as a lose powder (Santry, 
Dublin, Ireland) and ‘316’ grade stainless-steel rings, for the preparation of POCIS 
devices, were manufactured by A.T. Engineering (Tadley, Hampshire, UK). All 
glassware was silanised to reduce surface activity and potential loss of analytes 
through adsorption onto glass surfaces. The glassware was rinsed initially with 
methanol followed by toluene before being soaked in Sylon CT™ solution (5% 
dimethylchlorosilane in toluene) according to the instructions provided. After 
soaking the glassware was rinsed twice with toluene, methanol and then allowed to 
air dry in a fume hood. 
 
For acquisition of high quality accurate mass spectra, all pharmaceutical reference 
compounds were purchased as secondary reference materials from Sigma-Aldrich in 
5 mg quantities with a purity of at least 95%.  Stock standard solutions were prepared 
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by dissolving the reference compounds in either acetone, acetonitrile, DMF, DMSO, 
ethanol, methanol, sodium hydroxide solution or water depending on the 
physicochemical properties of the substance (329). 
 
17-alpha-estradiol, 17-beta-estradiol, Beclomethasone di-propionate, Betamethsone-
17-valerate, Bisacodyl, Cinnarizine, Clobetasone-17-butyrate, Cyproterone acetate, 
Dexamethasone, Felodipine, Fenofibrate, Flumethasone, Hydrocortisone-21-acetate, 
Hydroxyzine, Ketoprofen, Medroxyprogesterone -17-acetate, Mometasone furoate, 
Naproxen, Nifedipine, Nitrofurantoin, Norethisterone and Warfarin were dissolved 
in 5 mL of acetone. Carvedilol, Diltiazem-cis, Dipyridamole, Dosulepin, Finasteride, 
Hydrocortisone, Losartan, Progesterone, Promethazine, Salbutamol, Scopolamine, 
Simvastatin, Spironolactone, Terbutaline and Verapamil were dissolved in 5 mL of 
ethanol. Cetirizine, Dioctyl sulfosuccinate, Flecainide, Hydroxychloroquine, 
Penicillin V and Trazadone were dissolved in 5 mL of water. Chlorhexidine and 
Donepezil were dissolved in 5 mL of acetonitrile. Nystatin, Doxazosin and 
Mefenamic acid were dissolved in 5 mL of dimethylformamide, dimethylsulfoxide 
and 1 M sodium hydroxide respectively. All remaining pharmaceutical compounds 
were dissolved in 5mL of methanol. 
 
Many of the reference compounds were available only as salts e.g. chloride or acetate. 
All subsequent dilutions of the individual stock solutions were corrected taking into 
consideration the percentage of salt and water of crystallization present in each 
solution thus ensuring accurate preparation of standard solutions ahead of LC-MS 
analysis. The individual stock standard solutions were stored until use at –18 °C. 
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3.4.2 Intermediate and working standard solution mixes 
An intermediate stock standard solution mix was prepared in methanol at a 
concentration of 1 ng/uL and was found to be stable for at least one month at 3-5 °C. 
The solution was diluted 100-fold in mobile phase and used as a working standard 
solution mix. The working solution was prepared as and when required. 
 
 
 
3.4.3 Preparation of the mobile phase for LC Q-TOF-MS analysis 
Ten M ammonium acetate was prepared by dissolving 77.083 g in 90 mL of water 
and making up to 100 mL with water in a volumetric flask. Mobile phase components 
A and B were prepared by adding 200 µL of the 10 M ammonium acetate solution 
and 100 µL of formic acid. to individual HPLC mobile phase reservoir bottles (1.2 
L) containing exactly 1 L of water and methanol respectively.  
 
 
3.4.4     Preparation of POCIS samplers 
3.4.4.1     Preparation and cleaning of membranes for POCIS 
Supor® 200 polyethersulphone membrane was cut into 9 cm by 18 cm rectangular 
pieces and folded in two. Twenty-five cut membranes were placed into a cleaned, 
solvent rinsed 2 L beaker containing 1.5 L of 20% methanol in water. The membranes 
were dispersed in the solvent and prevented from sticking together in a large mass 
with the use of a large glass rod. The beaker was covered with aluminium foil and 
allowed to soak for 24 h in an incubator at 40 ºC to aid in the cleaning. The solvent 
was discarded and the above step repeated with a second aliquot of 1.5 L of 20% 
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methanol in UHP water. The solvent was discarded the entire procedure repeated 
twice using 1.5 L of methanol. The methanol was discarded and the membranes 
placed on a piece of solvent rinsed aluminium foil to air dry (~ 8 h). Once dry they 
were placed in a solvent rinsed aluminium foil envelope and stored in a clean metal 
can flushed with argon gas and kept in a freezer at -18ºC until POCIS devices were 
ready to assemble.  
 
 
3.4.4.2       Cleaning of the Oasis® HLB phase sorbent 
 
Fifty mL of methanol was placed into a solvent rinsed, 19 mm × 61 cm, glass 
chromatography column with a fritted disk and stopcock. Six g of Oasis® HLB 
sorbent (enough for 30 POCIS devices) was slowly added to the column and allowed 
to settle on the fritted disk. The stopcock was opened and the methanol allowed to 
percolate through the sorbent until the meniscus was approximately 10 mm from the 
surface of the sorbent and the stopcock closed. The sorbent was allowed to soak for 
30 min and a further 200 mL of methanol was slowly added to the column before the 
stopcock was opened again and the methanol allowed to percolate through the 
sorbent. The stopcock was closed just as the methanol entered the sorbent. The 
procedure was repeated using 250 mL aliquots of methyl-tertiary-butyl ether (MTBE) 
and dichloromethane followed by a final 250 mL aliquot of methanol and allowed to 
drain completely out of the column after the final 30 min soak. The sorbent was 
forced out of the column and into a glass flask by applying positive pressure with 
nitrogen gas at the outlet of the column. The flask was placed into a Genevac Rocket™ 
centrifugal rotary vacuum evaporator set at medium boiling point and the clean 
sorbent dried for a period of 1 h. The cleaned and dried sorbent was placed into a 
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clean solvent rinsed glass jar and covered with aluminium foil and sealed with a PTFE 
lined screw cap lid. 
 
 
3.4.4.3     Assembly of POCIS samplers  
 
Two-hundred ± 2 mg, of the purified Oasis® HLB was weighed out for each POCIS 
device required and transferred into a clean glass weighing boat. The folded 
membrane was put over one clean solvent rinsed stainless-steel POCIS ring and a 
sharp steel awl used to make holes in the membrane over the three bolt holes as shown 
in the left-hand image in Figure 3.3. The folded membrane was opened and sorbent 
placed on one half of the membrane as shown in the right-hand image in Figure 3.3. 
The membrane was folded back over and the second solvent rinsed POCIS ring 
placed on top ensuring the holes for the two POCIS rings were aligned and bolts 
pushed through each hole in the rings and folded membrane. A stainless-steel nut was 
placed on the end of each bolt and tightened as much as possible to obtain the 
assembled POCIS device as shown in Figure 3.4.  Excess membrane was removed 
with a scalpel blade and the POCIS device completed. The prepared devices were 
wrapped in aluminium foil and stored frozen in clean 5 L metal cans until they were 
ready to be deployed. 
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Figure 3.3 Preparation of in-house POCIS samplers. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4  Fully assembled POCIS sampler. 
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3.4.5   Cleaning of the Chemcatcher® bodies, rings and transport caps 
Chemcatcher® bodies were fully disassembled and all components soaked overnight 
in 10% Decon® detergent in tap water overnight in a 10 L plastic bucket. The 
Chemcatcher® components were removed from the detergent solution and rinsed 
thoroughly with copious quantities of tap water ensuring that all traces of the 
detergent were removed. All components were then rinsed with de-ionised water and 
dried with clean paper towels before being placed in a clean solvent rinsed glass 
container containing methanol for 5 min. All Chemcatcher® bodies and components 
were removed from the beaker and allowed to dry on a large piece of solvent rinsed 
aluminium foil. 
 
 
3.4.6 Conditioning of the HLB-L disks for the polar Chemcatcher® 
Twenty Horizon Technology, Atlantic HLB-L disks were soaked in 1 L of methanol 
overnight in a clean solvent rinsed 2 L glass beaker after which the methanol was 
discarded and the disks allowed to air dry on aluminium foil.  
 
Acetone rinsed PTFE disk supports and glass support bases were mounted onto a 
stainless-steel vacuum manifold. Pre-soaked and dried Atlantic HLB-L disks were 
centred onto the disk supports and the glass reservoir secured onto the glass support 
base with the aid of a metal sprung clamp. Fifty mL of methanol was added to each 
reservoir and allowed to soak into the disk under gravity until a small volume of 
methanol remained on the disk. Fifty mL of ultra-pure water was then added to each 
disk and a slight vacuum was applied to draw the first 5 - 10 mL of water into the 
disk with the remaining water allowed to flow completely though the disk under 
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gravity. The clamp was removed and, with the aid of tweezers, the conditioned 
Atlantic HLB disks were removed from the manifold and placed in ultra-pure water 
until assembled into the Chemcatcher® body. 
 
 
3.4.7 Preparation of membranes for the Chemcatcher®  
Supor® 200 polyethersulphone membrane was cut into 9 cm x 9 cm square pieces and 
a piece of clean aluminium foil was placed in between each layer of PES membrane 
to prevent them sticking to each other. A 51 mm diameter wad-punch, together with 
a hammer, was then used to ‘punch-out’ a sufficient number of PES membranes for 
the deployments. PES membranes were cleaned and stored using the same procedure 
as outlined in section 3.4.4.1 (Preparation and cleaning of membranes for POCIS). 
 
 
3.4.8 Chemcatcher® assembly 
Conditioned HLB-L disks were placed on a Chemcatcher® body and a clean PES 
membrane centred on the top of the disk. A PTFE retaining ring, which holds the disk 
and membrane in place, was screwed onto the Chemcatcher® body and firmly hand 
tightened. The fully assembled Chemcatcher® samplers were placed in a large 
Tupperware box containing deionised water and stored refrigerated at 3–5ºC until 
they were ready to be deployed. 
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3.4.9 Deployment of samplers at the waste water treatment plants 
 
Triplicate Chemcatcher® and POCIS samplers were attached to stainless-steel 
holders prior to being placed in protective steel housings approximately 30 cm tall. 
Figure 3.5 shows the prototype version of the polar Chemcatcher® used in the 
deployments. Permission to deploy the samplers was obtained from the site operators 
Dwr Cymru Welsh Water and all samplers were deployed at all three sites on the 4th 
of August 2014 and were retrieved on the 25th of August 2014, a deployment period 
of 21 days. Five mm thick chain was used to securely fasten the deployment cages to 
the stainless-steel platform covering the final effluent channels at the three sites. 
Figure 3.6 shows the location of the Gowerton co-deployments where the sampler 
housing was placed into the final effluent stream via an access hatch.  
 
 
3.4.10     Extraction of POCIS samplers 
 
On return to the laboratory the housings containing the POCIS samplers were 
removed from the holder and cleaned under a gentle flow of running tap water to 
remove any sediment. Excess water was removed with laboratory blue roll and the 
sampler was allowed to dry overnight at room temperature before extraction. The two 
membrane layers were separated and the exposed sorbent was allowed to air dry 
before being removed from the membrane by carefully brushing into a tared 15 mL 
glass vial with the aid of a glass filter funnel. Figure 3.7a and Figure 3.7b clearly 
shows that the sorbent within the two sets of POCIS samplers (deployed at Gowerton 
WWTP) is not evenly distributed between the two membranes and tends to ‘flow’ 
when the membrane layers are separated leading to potential losses. As the POCIS 
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sorbent is electrostatic when dried, precautions were taken to minimise these losses 
by discharging any static build up by ‘earthing’ a large sheet of aluminium foil that 
was used for holding any glass vials, containing the dried sorbent, and other 
equipment prior to weighing. Once all the sorbent had been removed from both 
membranes the glass vial was weighed and the mass of sorbent recovered from each 
POCIS sampler is shown below in Table 3.3. Significantly lower amounts of sorbent 
were recovered from the Carmarthen A and Llanelli B POCIS devices, 103.8 mg and 
97.0 mg, respectively. An overall average of 69.6% of sorbent was recovered out of 
the original 200 mg added with an RSD of 15.4%.  
 
The sorbent from each sampler was then transferred into a labelled methanol rinsed 
15 mL polypropylene SPE cartridge fitted with a PTFE frit at the bottom. Once the 
sorbent was transferred a second PTFE frit was gently pushed on top of the sorbent. 
A stainless-steel solvent guide was placed at the bottom of a flow control valve 
located on a 24 position SPE vacuum box.  The male Luer fitting of the SPE tube was 
inserted firmly into the female hub of the flow control valve which was set to the 
fully ‘open’ position. A labelled 50 mL screw cap glass vial was placed inside the 
vacuum box with the stainless-steel solvent guide approximately 1 cm into the vial. 
This was done in order to catch the eluate from the SPE cartridge. Five mL of 
methanol was added to the glass vial to transfer any remaining sorbent onto the SPE 
cartridge. A disposable glass Pasteur pipette was used to transfer the methanol to the 
SPE cartridge. Once the methanol had percolated, under gravity, into the sorbent a 
further 5 mL of methanol was added to the SPE cartridge and this was again allowed 
to percolate into the sorbent. The flow control valve then turned to the fully ‘closed’ 
position.  
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A 75 mL methanol rinsed polypropylene reservoir was then attached to the top of the 
SPE cartridge using an adaptor. Thirty mL of methanol was poured into the reservoir. 
The flow control valve was opened slowly and the flow of eluate, dripping into the 
glass vial, adjusted to approximately 1 mL/min. The entire elution solvent was 
allowed to pass through the cartridge under gravity flow. Once all the eluent has been 
passed through the cartridge, a syringe with an airtight seal was attached to the SPE 
cartridge in order to push any remaining solvent out of the sorbent and into the 50 
mL glass vial.  
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Figure 3.5 Prototype version of the polar Chemcatcher® placed in the 
protective housing. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6 Location of the Gowerton deployments in the final effluent 
stream. 
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Figure 3.7 Sorbent within the POCIS sampler after disassembly of one of the 
Gowerton ‘1’ (a) and Gowerton ‘2’ (b) samplers showing uneven distribution of 
material. 
 
 
a 
b 
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Table 3.3 Ratios of POCIS sorbent recovered against the original added. 
 
Site Mass of 
sorbent added 
(mg) A 
Mass of sorbent 
recovered     
(mg) B 
% of 
sorbent 
recovered 
Carmarthen A 200 ± 2 103.8 52.0 
Carmarthen B 200 ± 2 140.9 70.5 
Carmarthen C 200 ± 2 146.0 73.0 
Gowerton 1A 200 ± 2 144.0 72.0 
Gowerton 1B 200 ± 2 145.5 72.8 
Gowerton 1C 200 ± 2 126.2 63.1 
Gowerton 2A 200 ± 2 147.0 73.5 
Gowerton 2B 200 ± 2 151.4 75.7 
Gowerton 2C 200 ± 2 142.7 71.4 
Llanelli A 200 ± 2 177.5 88.8 
Llanelli B 200 ± 2 97.0 48.5 
Llanelli C 200 ± 2 146.7 73.4 
 
 
 
3.4.11     Extraction of HLB-L Disks from Chemcatcher® samplers 
On return to the laboratory the Chemcatcher® samplers were cleaned under a gentle 
flow of running tap water to remove any sediment. The Chemcatcher® samplers were 
disassembled using the reverse process as outlined in section 3.7 and the HLB-L disk 
(Figure 3.8) placed into the polypropylene disk elution apparatus. The elution 
apparatus used, which is positioned on top of a vacuum box, prevented the loss of 
eluate that can typically occur with vacuum manifold where the SPE disk is secured 
to a glass reservoir with a sprung clamp. A stainless-steel solvent guide was placed 
at the bottom of a flow control valve located on a 24 position SPE vacuum box.  The 
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male Luer fitting of the disk elution apparatus was inserted firmly into the female hub 
of the flow control valve as shown in Figure 3.9. The flow control valve was set to 
the fully ‘open’ position. Full vacuum was applied to the vacuum box for 1 h to dry 
the HLB-L disk. 
 
The HLB-L disk was eluted in a similar manner to that of the SPE cartridge in section 
4.3–4.4. Five mL of methanol was added to the disk and once it had percolated, under 
gravity, into the disk a further 5 mL of methanol was added and this was again 
allowed to percolate into the disk. The flow control valve then turned to the fully 
‘closed’ position. Thirty mL of methanol was poured into the reservoir and the flow 
control valve opened fully.  The entire elution solvent was allowed to pass through 
the disk under gravity flow. Once the entire eluent has been passed through the disk, 
slight vacuum was applied to the vacuum box in order to pull any remaining solvent 
out of the disk and into the labelled 50 mL glass vial. 
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Figure 3.8 HLB-L disks from retrieved Chemcatcher® samplers at the 
Gowerton WWTP. 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Figure 3.9 Apparatus used for the elution of adsorbed compounds from the 
Chemcatcher® HLB-L disk. 
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3.4.12     Creation of the searchable database using Agilent personal compound 
database and library (PCDL) software 
 
Accurate mass MS spectra for the protonated adducts [M+H]+ in positive ion mode 
and de-protonated adducts [M-H]- for each compound were acquired using flow 
injection in MS mode with a collision energy of 0eV. Accurate mass spectra were 
also acquired for the [M+Na]+ and [M+K]+ adducts in positive ion mode, or [M-
HCOO]- and (M+CH3COO]
- adducts in negative ion mode, when they were observed 
in significant abundance. Accurate mass fragment ion spectra for the protonated and 
de-protonated adducts were again acquired using flow injection in MS/MS mode with 
a collision energy of 20 eV and 40 eV. Fragment ion spectra for other adducts, 
especially those for sodium and potassium were not always obtained as they tend to 
be unstable (330, 331). To eliminate mass assignment errors, fragment masses in the 
acquired spectra were compared with the theoretical fragment formulas and where 
necessary corrected to their theoretical masses and possible structures. Theoretical 
masses for fragment ions and potential structures were generated using ACD Labs 
Mass Fragmenter software that calculates theoretical fragmentation pathways for 
compounds under specific ionisation conditions (332). MS/MS spectra below 1% of 
the base peak for each collision energy were removed from the database. Full details 
of all the MS adducts and MS/MS fragment ion species are shown in Table 3.4. 
 
A searchable database (PCDL) was created by populating it with the accurate mass 
MS and MS/MS data, acquired above, for the 164 target compounds.  In addition, the 
compound database library was populated with compound information including the 
name, formula, accurate mass, structure, database identifiers such as the CAS number 
and Chemspider ID number and retention times which were obtained from 
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chromatographic analysis of the working standard solution mix of pharmaceuticals. 
Figure 3.10 shows a screen capture of the PCDL Manager software along with the 
accurate mass MS/MS spectrum of Meloxicam acquired in positive ionisation mode 
with a collision energy of 20 eV.  
 
The spectra of the following pharmaceuticals, obtained from the analysis of pure 
standards, showed significant abundances of adducts of potassium and ammonium 
that were at least 50% of the base peak (typically the sodiated adduct): 
Bendroflumethiazide, calcipotriol, cefalexin, chloramphenicol, digoxin, docusate, 
hydrochlorthiazide, hydrocortisone-21-acetate, ketoprofen, nitrofurantoin, orlistat, 
pravastatin and spironolactone. 
 
However, with the exception of one compound, docusate, the use of adducts of 
potassium and ammonium when screening for pharmaceuticals in POCIS or 
Chemcatcher® extracts against an accurate mass database did not result in an increase 
in the number of compounds identified or in the score obtained over the use of only 
protonated and sodiated adducts. Use of only adducts of potassium and ammonium 
in the positive ion accurate mass database search produced low scores, typically well 
below the set acceptable threshold. Also, the spectra for the above compounds in 
POCIS and Chemcatcher® extracts did not show the same ratio of sodium to 
potassium and ammonium as observed in standards. It was decided, therefore not to 
include potassium and ammonium adducts in any further investigations.  
 
 
 
195 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10 PCDL software showing the accurate mass MS/MS spectrum of meloxicam acquired in positive 
ionisation mode with a collision energy of 20 eV. 
 
196 
 
 
 
Table 3.4 MS adducts and MS/MS fragment ion species for the pharmaceuticals in the personal compound database and library. 
 
Compound determined Molecular 
formula 
Monoisotopic 
Mass 
Retention 
time (min) 
(M-H)- (M+HCOO)- (M+CH3COO)- Most abundant fragment ions (CE 20eV)  Most abundant fragment ions (CE 40eV) 
  negative ionisation mode       
Chloramphenicol C11H12Cl2N2O5 322.0123 10.41 321.0051   152.0353, 151.0269, 194.0459, 321.0051, 148.0404  151.0269, 152.0353, 148.0404, 122.0248, 135.0326 
Fusidic acid C31H48O6 516.3451 23.21 515.3378   515.3378, 455.3167, 473.3272, 425.3061, 321.1707  455.3167, 473.3272, 193.1598, 139.1128, 205.1598 
Dioctyl sulfosuccinate C20H38O7S 422.2338 22.66 421.2265   Unstable fragment ions observed  Unstable fragment ions observed 
Hydrochlorothiazide C7H8ClN3O4S2 296.9645 4.34 295.9572   295.9572, 268.9463, 204.9844, 231.9953, 216.9844  204.9844, 202.9687, 203.9766, 123.9960, 189.9735 
Ibuprofen C13H18O2 206.1307 17.39 205.1234 251.1289 265.1445 159.1179, 161.1336, 205.1234  Fragmentation too extensive 
Mefenamic acid C15H15NO2 241.1103 19.69 240.1030   196.1132, 240.1030, 194.0975  196.1132, 194.0975, 120.0819, 144.0819, 118.0662 
Pravastatin  C23H36O7 424.2461 16.38 423.2388   321.1707, 217.1234  161.0972, 217.1234, 227.1289 
Salicylic acid C7H6O3 138.0317 5.50 137.0244   No fragment ions observed  No fragment ions observed 
          
Compound determined  Monoisotopic 
Mass 
Retention 
time (min) 
(M+H)+ (M+Na)+ (M+K)+ Most abundant fragment ions (CE 20eV)  Most abundant fragment ions (CE 40eV) 
  positive ionisation mode       
17-alpha-estradiol C18H24O2 272.1776 18.07 273.1849 295.1669  No fragmentation observed  145.0659, 239.1441, 253.1598, 269.1547, 183.0815 
17-beta-estradiol C18H24O2 272.1776 17.79 273.1849 295.1669  No fragmentation observed  145.0659, 239.1441, 253.1598, 269.1547, 183.0815 
Acetaminophen C8H9NO2 151.0633 4.44 152.0706   110.0600, 93.0335, 65.0386, 92.0495, 152.0706 65.0386, 109.0522, 80.0495, 92.0495, 67.0417 
Acetylsalicylic acid C9H8O4 180.0423 8.29 181.0495 203.0315  93.0346, 59.0139, 137.0244  93.0346, 59.0139, 65.0397, 75.0240 
Alfuzosin C19H27N5O4 389.2063 10.84 390.2136   235.1190, 156.1019, 71.0491, 275.1503  71.0491, 235.1190, 156.1019, 219.0877, 220.0955 
Alverine  C20H27N 281.2144 14.47 282.2216   91.0542, 164.1434, 119.0855  91.0542, 65.0386, 58.0651 
Amiloride  C6H8ClN7O 229.0479 5.24 230.0552   171.0068, 60.0570, 143.0119, 116.0010, 230.05516 116.0010, 60.0570, 63.9949, 108.0431, 88.9901 
Amiodarone C25H29I2NO3 645.0237 21.13 646.0310   100.1121, 58.0651, 86.0964, 73.0886, 72.0808 58.0651, 100.1121, 86.0964, 72.0808, 73.0886 
Amisulpride C17H27N3O4S 369.1722 6.63 370.1795   242.0482, 112.1121, 196.0063, 129.1386, 155.1179 242.0482, 196.0063, 112.1121, 214.0169, 149.0471 
Amitriptyline  C20H23N 277.1831 15.34 278.1903   233.1325, 91.0542, 105.0699, 117.0699, 191.0855 91.0542, 105.0699, 117.0699, 191.0855, 203.0855 
Amlodipine  C20H25ClN2O5 408.1452 15.50 409.1525 431.1344  238.0629, 206.0367, 294.0892, 220.0524, 377.1263 170.0600, 165.0102, 208.0609, 149.0153, 220.0524 
Amoxicillin C16H19N3O5S 365.1045 7.22 366.1118 388.0938  114.0008, 134.0600, 160.0427, 70.0651, 208.0400 114.0008, 134.0600, 86.0059, 70.0651, 107.0491 
Anastrozole C17H19N5 293.1641 12.97 230.0246   225.1386, 210.1152  157.0886, 168.0808, 129.0699, 115.0542, 131.0855 
Atenolol C14H22N2O3 266.1630 4.15 267.1703   190.0863, 145.0648, 74.0600, 116.1070, 72.0808 145.0648, 56.0495, 74.0600, 133.0648, 91.0542 
Atorvastatin  C33H35FN2O5 558.2530 19.11 559.2603   440.2220, 466.2013, 422.2115, 292.1496, 250.1027 250.1027, 276.1156, 292.1496, 380.1657, 362.1551 
Beclomethasone C22H29ClO5 408.1704 16.77 Absent 431.1596  395.1829, 431.1596, 377.1723  Unstable fragment ions observed 
Beclomethasone-
dipropionate 
C28H37ClO7 520.2228 21.18 521.2301 543.2120  503.2195, 393.2060, 429.1827, 373.1565, 411.2166  147.0804, 135.0804, 185.0961, 121.0648, 159.0804 
Bendroflumethiazide C15H14F3N3O4S2 421.0378 13.38 422.0451 444.0270  No fragmentation observed  341.0566, 405.0185 
Benzindamine  C19H23N3O 309.1841 14.11 310.1914   86.0964, 58.0651, 265.1335, 174.0788  86.0964, 58.0651, 91.0542, 146.0475, 174.0788 
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Betahistine C8H12N2 136.1001 2.35 137.1073   94.0651, 106.0651, 78.0338, 53.0386  Fragmentation too extensive 
Betamethasone  C22H29FO5 392.1999 16.49 393.2072 415.1891  319.1704, 337.1798, 279.1755, 301.1598, 147.0804  147.0804, 185.0961, 159.0804, 135.0804, 153.0910 
Betamethasone-17-
valerate 
C27H37FO6 476.2574 20.77 477.2647 499.2466  279.1743, 337.1798, 319.1693, 147.0804, 291.1743 147.0804, 171.0804, 263.1430, 159.0804, 279.1743 
Bezafibrate C19H20ClNO4 361.1081 17.03 362.1154 384.0973  138.9945, 121.0648, 316.1099, 276.0781, 161.0961 138.9945, 121.0648, 110.9996, 93.0699, 77.0386 
Bisacodyl C22H19NO4 361.1314 17.16 362.1387 384.1206 400.0946 184.0757, 226.0863, 320.1281, 167.0730  184.0757, 167.0730, 183.0679, 156.0808, 166.0651 
Bisoprolol  C18H31NO4 325.2253 11.63 326.2326   116.1070, 74.0600, 72.0808, 98.0964, 56.0495 74.0600, 56.0495, 107.0491, 72.0808, 116.1070 
Budesonide C25H34O6 430.2355 19.16 431.2428   147.0804, 413.2323, 173.0961, 323.1642, 225.1274 147.0804, 173.0961, 121.0648, 171.0804, 225.1274 
Bumetanide C17H20N2O5S 364.1093 16.05 365.1166 387.0985  240.1383, 184.0757, 284.12812, 196.0730, 212.1434 Fragmentation too extensive 
Candesartan C24H20N6O3 440.1597 22.14 441.1670   263.1305, 207.0917, 235.1190, 192.0808, 352.1094 192.0808, 207.0917, 190.0651, 180.0808, 165.0699 
Carbamazepine C15H12N2O 236.0950 14.60 237.1022   194.0964, 192.0808, 193.0886, 179.0730  193.0886, 194.0964, 179.0730, 192.0808, 165.0699 
Carvedilol  C24H26N2O4 406.1893 13.69 407.1965   224.1281, 100.0757, 222.0913, 283.1441, 180.1019 100.0757, 56.04948, 194.0964, 222.0913, 184.0757 
Cefalexin C16H17N3O4S 347.0940 16.09 348.1013   Unstable fragment ions observed  Unstable fragment ions observed 
Celecoxib C17H14F3N3O2S 381.0759 19.01 382.0832   362.0769, 303.1065, 300.0831, 302.0987, 301.0909 362.0769, 282.0925, 281.0847, 301.0909, 300.0831 
Celiprolol C20H33N3O4 388.1554 10.63 389.1626   251.1179, 307.1652, 74.0600, 306.1812, 324.1918 74.0600, 56.0495, 74.0964, 100.0757, 72.0444 
Cetirizine  C21H25ClN2O3 388.1554 16.72 389.1627 411.1446  201.0466, 166.0777, 165.0699, 187.1077  166.0777, 201.0466, 165.0699, 199.0309 
Chlorhexidine C22H30Cl2N10 504.2032 14.20 505.2105   336.1698, 184.1557, 201.1822, 353.1964, 170.0480 170.0480, 125.1073, 184.1557, 167.1291, 159.1604 
Chlorpheniramine C16H19ClN2 274.1237 11.88 275.1310   230.0731, 167.0730, 202.0418  167.0730, 230.0731, 201.0340, 118.0651, 125.0153 
Chlorpromazine  C17H19ClN2S 318.0958 16.32 319.1030   86.0964, 58.0651, 246.0139, 239.0763, 274.0452 58.0651, 86.0964, 214.0418, 246.0139, 211.0450 
Chlortetracycline C22H23ClN2O8 478.1143 11.03 479.1216 501.1035  444.0845, 462.0950, 154.0504, 479.1216, 371.0317 98.0605, 154.0504, 303.0419, 275.0470, 301.0262 
Cinnarizine C26H28N2 368.2253 17.90 369.2325   167.08553, 165.0699, 152.0621, 117.0699  167.0855, 165.0699, 152.0621, 166.0777, 151.0542 
Citalopram  C20H21FN2O 324.1638 12.52 325.1711   109.0448, 262.1027, 234.0714, 116.0495, 58.0663 109.0448, 234.0714, 116.0495, 247.0792, 246.0714 
Clarithromycin C38H69NO13 747.4769 17.23 748.4842   158.1176, 590.3899, 558.3637, 116.1070, 83.0491 158.1176, 83.0491, 116.1070, 116.0706, 98.0964 
Clobetasol propionate C25H32ClFO5 466.1922 19.70 467.1995   278.1677, 355.1459, 263.1442, 279.1755, 147.0816 263.1442, 147.0816, 171.0804, 121.0659, 159.0816 
Clobetasone-17-butyrate C26H32ClFO5 478.1922 20.52 479.1995   71.0491, 343.1459, 279.1380, 371.1409, 329.1303 266.1665, 251.1430, 261.1274, 159.0804, 71.0491 
Clomipramine  C19H23ClN2 314.1550 16.64 315.1623   86.0964, 58.0651, 242.0731, 270.1044, 235.1356 58.0651, 86.0964, 227.0496, 242.0731, 220.1121 
Clonidine  C9H9Cl2N3 229.0174 5.22 230.0246   No fragmentation observed  159.9715, 144.9606, 123.9949, 132.9606, 135.9949 
Clopidogrel  C16H16ClNO2S 321.0590 20.65 322.0663   184.0519, 212.0473, 152.0257, 183.0207, 155.0258 155.0258, 125.0153, 152.0257, 91.0542, 183.0207 
Clotrimazole C22H17ClN2 344.1080 20.22 345.1153 367.0972  277.0779, 165.0699, 242.1090, 241.1012, 199.0309 165.0699, 241.1012, 199.0309, 242.1090, 239.0855 
Cromoglicic acid C23H16O11 468.0693 8.54 469.0765 491.0585  245.0445, 207.0288, 263.0550, 451.0660, 57.0335 207.0288, 245.0445, 57.0335, 163.0390, 217.0495 
Cyclizine / Marzine  C18H22N2 266.1783 13.23 267.1856   167.0855, 165.0699, 152.0621, 166.0777  152.0621, 165.0699, 167.0855, 166.0777, 151.0542 
Cyproterone acetate C24H29ClO4 416.1755 19.68 417.1827   417.1827, 357.1616, 321.1849, 313.1354, 315.1510  277.1587, 313.1354, 237.1274, 321.1849, 159.0804 
Desogestrel C22H30O 310.2297 24.48 311.2369   311.2369, 293.2264, 159.1168, 177.1274, 185.1325  119.0855, 159.1168, 185.1325, 199.1479, 177.1274 
Dexamethasone  C22H29FO5 392.1999 16.48 393.2072 415.1891  237.1274, 147.0804, 355.1904, 279.1743, 337.1798 147.0804, 121.0659, 171.0804, 119.0855, 222.1039 
Dexamethasone-21-
acetate 
C24H31FO6 434.2105 17.99 435.2177   237.1274, 147.0804, 291.1743, 319.1693, 227.1430 147.0804, 121.0659, 171.0804, 237.1274, 159.0804 
Diclofenac  C14H11Cl2NO2 295.0167 18.99 296.0240   215.0496, 214.0418, 250.0185  214.0418, 215.0496, 180.0808, 179.0730, 178.0651 
Digoxin C41H64O14 780.4296 17.31 781.4369 803.4188 819.3928 97.0648, 113.0597, 131.0703, 391.2479, 373.2373 97.0648, 113.0597, 131.07023, 95.0491, 69.0335 
Diltiazem-Cis  C22H26N2O4S 414.1613 13.96 415.1686   178.0321, 370.1108, 310.0896, 150.0372, 312.1053 178.0321, 150.0372, 109.0107, 72.0808, 137.0597 
                                                        continued 
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Dipyridamole * C24H40N8O4 504.3173 17.48 505.3245   No fragmentation observed  429.2721, 385.2459, 487.3140, 460.2905, 399.2589                                                
Donepezil C24H29NO3 379.2147 12.13 380.2220   91.0542, 362.2115, 288.1509, 243.1380, 151.0992 91.0542, 65.0386, 243.1380, 151.0754, 105.0699 
Dosulepin  C19H21NS 295.1395 14.13 296.1467   223.0576, 218.1090, 225.0733, 251.0889, 58.0651 203.0855, 221.0420, 217.1012, 178.0777, 202.0777 
Doxazosin  C23H25N5O5 451.1856 14.25 452.1928   344.1717, 247.1190, 290.1612  344.1717, 247.1190, 290.1612, 221.1033, 98.0600 
Doxycycline  C22H24N2O8 444.1533 11.59 445.1605 467.1425  428.1340, 429.1418, 430.1371, 410.1234, 154.0499 98.0600, 267.0652, 154.0499, 201.0546, 321.0758 
Enalapril  C20H28N2O5 376.1998 13.86 377.2071   234.1489, 303.1703, 160.1121, 130.0863, 117.0699 117.0699, 91.0542, 56.0495, 160.1121, 130.0863 
Erythromycin C37H67NO13 733.4612 15.45 734.4685   158.1176, 576.3742, 558.3637, 83.0491, 522.3425 158.1176, 83.0491, 116.1070, 116.0706, 98.0964 
Felodipine C18H19Cl2NO4 383.0691 20.06 384.0764 406.0583  338.0345, 352.0502, 324.0189, 340.0371, 384.0764 278.0134, 243.0445, 324.0189, 288.0422, 242.0367 
Fenofibrate C20H21ClO4 360.1128 22.07 361.1201   233.0364, 138.9945, 121.0284, 235.0309, 234.0442 138.9945, 121.0284, 110.9996, 140.9949, 93.0335 
Fexofenadine  C32H39NO4 501.2879 15.08 502.2952   484.2846, 466.2741, 171.1168, 262.1590, 131.0855 171.1168, 466.2741, 131.0855, 262.1590, 484.2846 
Finasteride C23H36N2O2 372.2777 18.87 373.2850   317.2224, 318.2216, 305.2587, 72.0444, 57.0699 72.0444, 317.2224, 57.0699, 305.2587, 69.0335 
Flecainide  C17H20F6N2O3 414.1378 12.76 415.1451   398.1185, 98.0964, 301.0294, 81.0710, 232.0968 301.0294, 98.0964, 81.0699, 398.1185, 232.0968 
Fluconazole C13H12F2N6O 306.1041 9.77 307.1113   238.0787, 220.0681, 169.0460, 239.0802, 289.1008 70.0400, 139.0354, 127.0354, 121.0448, 151.0354 
Flumethasone C22H28F2O5 410.1905 16.04 411.1978 433.1797  253.1223, 121.0648, 277.1587, 235.1117, 237.1274 121.0648, 235.1117, 135.0804, 253.1223, 91.0542 
Fluoxetine C17H18F3NO 309.1341 15.61 310.1413   148.11208  Fragmentation too extensive 
Fluticasone-17-
Propionate 
C25H31F3O5S 500.1844 19.74 501.1917 523.1737  293.1536, 275.1430, 313.1598, 205.0659, 265.1587 121.0648, 275.1430, 107.0855, 179.0855, 171.0804 
Furosemide C12H11ClN2O5S 330.0077 11.98 Absent 352.9969  310.9888, 328.9993, 233.9622, 251.0344, 313.9884 249.0187, 214.0499, 231.0082, 168.0444, 170.0003 
Gliclazide C15H21N3O3S 323.1304 16.62 324.1376 346.1196  110.0964, 127.1230, 91.0542, 153.1022, 155.0161 91.0542, 110.0964, 127.1230, 111.1043, 153.1022 
Haloperidol C21H23ClFNO2 375.1401 13.45 376.1474   165.0710, 358.1369, 123.0241, 194.0868, 95.0292 123.0241, 165.0710, 95.0292 
Hydrocortisone C21H30O5 362.2093 15.24 363.2166   121.0648, 327.1955, 309.1849, 267.1743, 97.0648 121.0648, 97.0648, 105.0699, 145.1012, 91.0542 
Hydrocortisone-21-
acetate 
C23H32O6 404.2199 16.89 405.2272 427.2091  327.1955, 309.1849, 111.0441, 241.1587, 129.0546 111.0441, 55.0542, 83.0491, 121.0648, 101.0597 
Hydroxychloroquine  C18H26ClN3O 335.1764 5.55 336.1837   247.0997, 158.1539, 102.0913, 179.0366, 191.0366 179.0366, 247.0997, 102.0913, 191.0366, 69.0699 
Hydroxyzine  C21H27ClN2O2 374.1761 15.33 375.1834   201.0466, 166.0777, 165.0699, 173.1285  166.0777, 201.0466, 165.0699, 199.0309 
Indapamide C16H16ClN3O3S 365.0601 13.23 366.0674   132.0808, 91.0542, 117.0573, 133.0886  91.0542, 132.0808, 117.0573, 118.0651, 65.0386 
Ipratropium (cation) C20H30NO3 332.2226 7.04 332.2226   166.1590, 124.1121, 290.1751, 93.0699, 96.0808 124.1121, 93.0699, 166.1590, 96.0808, 91.05423 
Irbesartan C25H28N6O 428.2325 17.94 429.2397   207.0917, 195.1492, 386.2214, 401.2336, 180.0808 207.0917, 180.0808, 206.0839, 192.0754, 84.0808 
Ketoconazole C26H28Cl2N4O4 530.1488 18.15 531.1560   489.1455, 82.0526  82.0526, 489.1455, 255.0082, 112.0757, 177.1022 
Ketoprofen C16H14O3 254.0943 16.38 255.1016   105.0335, 209.0961, 77.0386, 177.0546, 194.0726 77.0386, 105.0335, 103.0542, 51.0229, 165.0699 
Labetalol C19H24N2O3 328.1787 11.22 329.1860   162.0550, 294.1489, 91.0542, 311.1754, 207.1128 91.0542, 162.0550, 134.0600, 106.0651, 147.0441 
Lamotrigine C9H7Cl2N5 255.0079 9.25 256.0151   210.9824, 166.0292, 171.9715, 186.9824, 158.9763 144.9606, 58.0400, 156.9606, 158.9763, 210.9824 
Lansoprazole C16H14F3N3O2S 369.0759 16.09 370.0832 392.0651  252.0330, 119.0615, 205.0731, 234.0195, 136.0768 136.0768, 234.0195, 119.0615, 107.0741, 204.0653 
Latanoprost C26H40O5 432.2876 20.74 433.2949 455.2768  337.2162, 207.1380, 379.2632, 131.0855, 171.1168   131.0855, 133.1012, 171.1168, 147.1168, 145.1012  
Lidocaine  C14H22N2O 234.1732 7.27 235.1805   86.0964, 58.0651  86.0964, 58.0651 
Lisinopril C21H31N3O5 405.2264 5.89 406.2336   114.0561, 386.2085, 91.0553, 289.1558  114.0561, 91.0553, 68.0506 
Lofepramine C26H27ClN2O 418.1812 20.38 419.1885   224.0837, 196.0524, 208.1121, 168.0575, 236.1434 125.0153, 208.1121, 196.0524, 168.0575, 193.0886 
Loperamide  C29H33ClN2O2 476.2231 16.36 477.2303   266.1539, 210.1277, 267.1510  266.1539, 210.1277, 72.0449, 238.1226, 115.0542 
Loratadine C22H23ClN2O2 382.1448 20.96 383.1521   337.1102, 267.0809, 259.1356, 294.1044, 281.0966 267.0809, 259.1356, 266.0731, 280.0888, 281.0966 
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Losartan  C22H23ClN6O 422.1622 16.50 423.1695   179.0866, 127.0064, 157.0533, 187.0630, 156.0455 127.0064, 157.0533, 179.0866, 187.0630, 113.9985 
Mebeverine  C25H35NO5 429.2515 13.68 430.2588   149.0961, 121.0648, 100.1121, 165.0546, 430.2588 121.0648, 149.0961, 91.0542, 93.0699, 165.0546 
Medroxyprogesterone-
17-acetate 
C24H34O4 386.2457 20.13 387.2530 409.2349  123.0804, 327.2319, 285.2213, 97.0648, 267.2107 123.0804, 97.0648, 214.1352, 145.1012, 95.0855                                                                                    
 
Meloxicam  C14H13N3O4S2 351.0348 15.21 352.0420   115.0325, 141.0117, 73.0107, 184.0539, 194.0270 115.0325, 141.0117, 73.0107, 88.0216, 153.0005 
Metoclopramide  C14H22ClN3O2 299.1401 7.59 300.1473   227.0582, 184.0160, 183.0315, 212.0347  184.0160, 212.0347, 183.0315, 227.0582, 140.9976 
Metoprolol  C15H25NO3 267.1834 9.05 268.1907   74.0600, 116.1070, 72.0808, 98.0964, 56.0495 56.0495, 103.0542, 74.0600, 91.0542, 105.0699 
Miconazole  C18H14Cl4N2O 413.9860 22.03 414.9933   158.9745, 160.9668, 69.0447, 227.0132, 159.9823 158.9745, 160.9668, 159.9823, 69.0447, 99.0445 
Mirtazapine C17H19N3 265.1579 10.15 266.1652   195.0917, 72.0808, 209.1073, 235.1230, 223.1230 195.0917, 194.0839, 72.0808, 92.0495, 209.1073 
Mometasone furoate C27H30Cl2O6 521.1492 19.78 521.1492   355.1459, 263.1430, 279.1743, 278.1665, 503.1387 95.0128, 263.1430, 147.0804, 135.0804, 121.0648 
Moxonidine  C9H12ClN5O 241.0730 4.09 242.0803   206.1036, 199.0381, 56.0495, 137.0822, 149.0822 56.0495, 136.0505, 199.0381, 150.0536, 69.0447 
Naproxen   C14H14O3 230.0943 16.87 231.1016   185.0961, 170.0726, 153.0699, 154.0777, 155.0855 141.0699, 153.0699, 170.0726, 115.0542, 152.0621 
Nebivolol C22H25F2NO4 405.1752 15.50 406.1824   406.1824, 151.0554, 388.1719, 224.1081, 238.1238 151.0554, 123.0605, 406.1824, 125.0397, 177.0710 
Nifedipine C17H18N2O6 346.1165 16.10 347.1238   254.1050, 239.0815, 253.0972, 195.0917, 211.0866 195.0917, 194.0839, 223.0866, 193.0760, 253.0972 
Nitrofurantoin C8H6N4O5 238.0338 6.75 239.0411 261.0230  77.0033, 152.0102, 124.0040, 64.0193, 99.0200 77.0033, 64.0193, 65.0033, 50.0162, 119.0224 
Nor-ethisterone  C20H26O2 298.1933 17.72 299.2006   109.0648, 231.1743, 83.0491, 119.0855, 171.1168 109.0648, 91.0542, 79.0542, 83.0491, 105.0699 
Nystatin C47H75NO17 925.5035 19.82 926.5108 948.4927  908.5002, 691.3715, 727.3985, 371.0941, 673.3641 355.0660, 357.0632, 341.0139, 297.1274, 356.0679 
Ofloxacin C18H20FN3O4 361.1438 7.51 362.1511   318.1612, 261.1034, 344.1405, 316.1456, 58.0651 261.1034, 221.0709, 219.0564, 58.0651, 205.0408 
Omeprazole C17H19N3O3S 345.1147 14.97 346.1220   198.0583, 151.0992, 136.0757, 180.0478, 168.1019 136.0757, 180.0478, 150.0913, 121.0886, 108.0808 
Orlistat C29H53NO5 495.3924 25.20 496.3997 518.3816  319.2995, 160.0968, 337.3101, 193.1951, 142.0863  114.0913, 123.1168, 319.2995, 193.1951, 142.0863  
Oxprenolol C15H23NO3 265.1678 5.14 266.1751   72.0808, 116.1070, 56.0495, 74.0600, 98.0964 72.0808, 56.0495, 74.0600, 58.0651, 105.0699 
Oxybutynin C22H31NO3 357.2304 16.32 358.2377   124.1121, 142.1226, 72.0808, 97.0284, 54.0338 72.0808, 58.0651, 142.1226, 105.0335, 54.0338 
Oxytetracycline  C22H24N2O9 460.1482 8.59 461.1555 483.1374  426.1183, 381.0605, 444.1289, 443.1449, 337.0666 201.0506, 283.0561, 98.0574, 350.0381, 337.0666 
Pantoprazole  C16H15F2N3O4S 383.0751 14.66 384.0824   138.0550, 200.0376, 153.0784, 107.0730, 152.0706 138.0550, 136.0393, 107.0730, 200.0369, 152.0706 
Paroxetine  C19H20FNO3 329.1427 14.41 330.1500   192.1183, 70.0651, 151.0390, 123.0605, 163.0918 70.0651, 135.0605, 109.0448, 123.0605, 56.0495 
Penicillin V  C16H18N2O5S 350.0936 13.90 351.1009 373.0829  160.0427, 114.0372, 192.0655, 229.0641, 142.0321   114.0372, 160.0427, 142.0321, 116.0342, 107.0491  
Perindopril  C19H32N2O5 368.2311 15.23 369.2384   172.1332, 98.0964, 170.1176, 295.2016, 72.0808 98.0964, 72.0808, 56.0495, 172.1332, 124.1121 
Phenytoin  C15H12N2O2 252.0899 13.83 253.0972 275.0791  182.0964, 104.0495, 225.1022, 105.0335, 132.0444 104.0495, 77.0386, 182.0964, 132.0444, 79.0542 
Piroxicam C15H13N3O4S 331.0627 14.15 332.0700   95.0604, 121.0396, 164.0818, 78.0338, 210.0213 95.0604, 121.0396, 78.0338, 153.0005, 105.0421 
Prednisolone C21H28O5 360.1937 15.21 361.2010 383.1829  147.0804, 343.1904, 173.0961, 307.1693, 325.1798  147.0804, 121.0648, 173.0961, 159.0804, 135.0804 
Procyclidine  C19H29NO 287.2249 14.48 288.2322   84.0808, 270.2216  84.0808, 55.0542, 56.0495, 91.0542 
Progesterone C21H30O2 314.2246 20.30 315.2319   97.0648, 109.0648, 297.2213, 123.0804, 279.2107 109.0648, 97.0648, 81.0699, 79.0542, 123.0804 
Promethazine  C17H20N2S 284.1347 14.03 285.1420   86.0964, 198.0372, 240.0842, 71.0730, 56.0495 86.0964, 198.0372, 71.0730, 56.0495, 154.0651 
Propranolol C16H21NO2 259.1572 12.01 260.1645   116.1070, 183.0804, 74.0600, 72.0808, 56.0495 56.0495, 58.0651, 127.0542, 129.0699, 74.0600 
Quinine  C20H24N2O2 324.1838 10.87 325.1911   307.1805, 160.0757, 184.0757, 253.1335, 81.0699 81.0699, 79.0542, 172.0757, 160.0757, 184.0757 
Ramipril C23H32N2O5 416.2311 16.87 417.2384   234.1489, 343.2016, 130.0863, 160.1121, 156.1019 117.0699, 130.0863, 160.1121, 91.0542, 56.0495 
Ranitidine  C13H22N4O3S 314.1413 4.25 315.1485   176.0488, 130.0559, 125.0056, 98.0839, 102.0372 102.0372, 125.0056, 81.0335, 97.0760, 130.0559 
Risperidone C23H27FN4O2 410.2118 11.45 411.2191   191.11789  191.1179, 110.0598, 69.0335, 82.0651 
Ropinirole  C16H24N2O 260.1889 6.90 261.1961   114.1277, 160.0757, 86.0964, 132.0808, 72.0808 132.0808, 86.0964, 114.1277, 72.0808, 117.0573 
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Salbutamol C13H21NO3 239.1521 4.06 240.1594   148.0757, 57.0699, 121.0648, 166.0863, 130.0651 91.0542, 121.0648, 77.0386, 133.0522, 130.0651 
Salmeterol  C25H37NO4 415.2723 16.24 416.2795   380.2584, 398.2690, 232.1696, 91.0542, 248.1645 91.0542, 55.0542, 133.0648, 135.0804, 230.1539 
Scopolamine  C17H21NO4 303.1471 5.42 304.1543 326.1363  138.0913, 156.1019, 121.0648, 110.0964, 304.1543 103.0542, 138.0913, 79.0542, 110.0964, 77.0386 
Sertraline  C17H17Cl2N 305.0738 16.29 306.0811   158.9763, 275.0389, 129.0699, 91.0542, 196.9919 158.9763, 129.0699, 122.9996, 128.0621, 91.0542 
Sildenafil  C22H30N6O4S 474.2049 15.04 475.2122   58.0651, 100.0995, 99.0917, 311.1496, 283.1190 58.0651, 100.0995, 99.0917, 283.1183, 70.0651                                               
Simvastatin C25H38O5 418.2719 22.42 419.2792 441.2611  199.1481, 173.1325, 225.1638, 201.1121, 243.1743 Fragmentation too extensive 
Sotalol  C12H20N2O3S 272.1195 3.61 273.1267   213.0692, 133.0760, 255.1162, 134.0839, 176.1308 133.0760, 106.0651, 107.0730, 116.0495, 134.0839 
Spironolactone C24H32O4S 416.2021 17.68 Absent 439.1914 455.1653 341.2111, 187.1117 341.2111, 187.1117, 205.1223, 107.0855, 323.2006 
Sulfasalazine C18H14N4O5S 398.0685 13.59 399.0758   381.0652, 317.1033, 223.0496, 213.0652, 241.0635 119.0128, 94.0526, 223.0496, 147.0189, 91.0178 
Sumatriptan  C14H21N3O2S 295.1355 5.03 296.1427   58.0651, 251.0849, 157.0886, 158.0964, 201.1386 58.0651, 157.0886, 156.0808, 130.0685, 158.0964 
Tamoxifen C26H29NO 371.2249 19.56 372.2322   72.0808, 129.0699, 58.0651, 91.0542, 70.0651 72.0808, 70.0651, 129.0699, 91.0542, 57.0573 
Tamsulosin  C20H28N2O5S 408.1719 10.25 409.1792   228.0689, 271.1111, 200.0376, 148.0883, 147.0804 200.0376, 148.0883, 147.0804, 228.0682, 120.0444 
Telmisartan C33H30N4O2 514.2369 19.79 515.2442   497.2336, 305.1761, 276.1370  497.2336, 276.1370, 289.1448, 211.0754, 305.1761 
Terbinafine  C21H25N 291.1987 18.54 292.2060   141.0699, 93.0699, 91.0542, 105.0699, 79.0542 141.0699, 115.0542, 77.0386, 91.0542, 79.0542 
Terbutaline  C12H19NO3 225.1365 3.87 226.1438   152.0706, 125.0597, 107.0491, 57.0699, 135.0441 107.0491, 77.0386, 79.0542, 57.0699, 125.0597 
Theophylline C7H8N4O2 180.0647 5.96 181.0720   124.0505, 96.0556, 69.0447, 137.0822, 108.0556 Fragmentation too extensive 
Timolol  C13H24N4O3S 316.1569 8.89 317.1642   74.0600, 261.1016, 244.0750, 188.0488, 57.0699 74.0600, 56.0495, 57.0699, 144.0226, 188.0488 
Tramadol  C16H25NO2 263.1885 8.79 264.1958   58.06513  58.06513 
Trazodone  C19H22ClN5O 371.1513 11.84 372.1586   176.0818, 148.0524, 78.0338, 237.1135  148.0524, 176.0818, 78.0338, 133.0760, 93.0447 
Trimethoprim C14H18N4O3 290.1379 6.60 291.1452   230.1162, 261.0982, 123.0665, 275.1139, 258.1111 123.0665, 110.0587, 81.0447, 229.1084, 257.1033 
Valsartan C24H29N5O3 435.2270 17.79 436.2343 458.2163  207.0917, 235.0951, 291.1479, 306.1686, 180.0781 207.0917, 180.0808, 190.0651, 206.0839, 192.0768 
Varenicline  C13H13N3 211.1109 5.59 212.1182   212.1182, 169.0760, 183.0917, 195.0917, 168.0682  168.0682, 169.0760, 183.0917, 180.0682, 195.0917  
Venlafaxine C17H27NO2 277.2042 11.55 278.2115   58.0651, 121.0648, 215.1430, 147.0804, 260.2009 58.0651, 121.0648, 91.0542, 147.0804, 79.0542 
Verapamil C27H38N2O4 454.2832 14.06 455.2904   165.0910, 303.2067, 150.0675, 260.1645, 166.0948 165.0910, 150.0675, 105.0699, 133.0648, 303.2067 
Warfarin C19H16O4 308.1049 17.57 309.1121   251.0703, 163.0390, 147.0804, 173.0233, 183.0804 121.0284, 163.0390, 173.0233, 155.0855, 77.0386 
                                                         
 
Key  
Masses in bold and underlined are strong and ≥ 10-30 % of the base ion(s) 
* Strong precursor ion in 40eV CE spectrum 
 
 
 
 3.4.13 LC Q-TOF-MS analysis 
Chromatographic separation of compounds was carried out using an Agilent 1290 
Infinity ultra-high performance liquid chromatography (UHPLC) system consisting 
of a vacuum degasser, binary pump, high performance auto-sampler and thermostated 
column compartment. The chromatographic column used was an Atlantis T3 Column 
2.1 mm (i.d.) × 150 mm, 3.5 μm particle size (Waters, Elstree, UK). 
 
The UHPLC system was coupled to an Agilent G6540A quadrupole time-of-flight  
mass spectrometer (Q-TOF-MS) equipped with a dual sprayer Agilent Jet Stream 
electrospray source. A reference mass solution was delivered to the reference sprayer 
via a pressurised glass bottle (nitrogen gas at 5 psi) containing the reference mass 
solution. The flow rate was approximately 10 µL/min. The second sprayer was used 
to deliver the column eluent to the ESI source. 
 
The Q-TOF was operated in 2 GHz extended dynamic range mode and data was 
acquired in two different modes. Firstly, sample extracts were analysed using positive 
and negative electrospray ionisation in MS only mode and secondly in ‘all ions’ 
MS/MS mode using positive electrospray ionisation only. The use of the ‘all ions’ 
acquisition resulted in alternating spectra comprised of a low energy channel (0eV) 
containing the precursor ion, and two high energy channels (20eV and 40eV) which 
contained the product ions. The entire chromatographic system was controlled using 
Agilent Mass Hunter acquisition software (rev. B.06.01). Table 3.5 shows the 
chromatographic conditions and major MS settings. 
 
 
  
 
 
  Table 3.5       Chromatographic conditions and mass spectrometer settings. 
 
 
 
 
 
Analytical column  Waters, Atlantis T3 Column 2.1 × 150 mm, 3.5 μm                              
Column temperature  40 °C 
 
Mobile phase   A) 2 mM ammonium acetate + 0.01% formic acid in water 
B) 2 mM ammonium acetate + 0.01% formic acid in methanol 
 
 
 
 
 
 
 
 
 
 
 
  
  
  
  
  
 
Gradient programme   
 
Time (min)  % B  
00.0              5  
25.0                 100  
30.0                 100  
30.1                 5  
 
Stop time  30.0 min 
Post time  10.0 min 
Injection volume   20 μL 
 
 
Mass spectrometer settings 
 
Nebulizer (psi)  
                  
 
                 50                                                    45 
Sheath gas temperature (°C)                  350                                                  300 
Sheath gas flow (L/min)                  12                                                    11 
Capillary voltage (V)                3,000                                               2,000  
                                                                                                                               continued 
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Table 3.5 continued 
 
Nozzle voltage (V) 
                
 
                
 
 
 
               1,000                                     750  
Fragmentor 
Skimmer 1 
                135                                                  110 
                 65                                                    55 
Octopole RF Peak                 750                                                  750 
                  
 
  
MS only mode 
 
 
Data acquisition scan rate (Hz)                   1                                                       1 
Mass range (Da)             50-1,100                                            50-1,100 
  
 
 
All Ions MS/MS mode 
 
  
Data acquisition scan rate (Hz)                   3                                                        3 
Mass range (Da)             50- 1,100                                           50-1,100 
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3.4.14     Data Analysis  
The sample data was evaluated using Mass Hunter Qualitative Analysis software 
(B.07.00). A retention time window of ±1 min was specified for each target 
compound against the experimentally derived retention times. This was required to 
compensate for potential retention time shifts due to matrix variability and any target 
compound that fell outside this window was deemed to be absent. Positive 
identification of pharmaceutical compounds was established by using the find-by-
formula data mining algorithm with a mass error setting of no greater than 10 ppm 
for the molecular ion adduct with additional confirmation obtained from comparing 
the isotope abundance pattern and isotope spacing mass accuracy. A minimum peak 
area threshold of 1,000 was set for the detection of the molecular ion (adduct) in MS 
scan only mode. Weightings were set for the individual criteria used to generate an 
overall score for identified compounds, these were 100, 60, 50 and 100 for mass 
accuracy, isotope abundance score, isotope spacing and retention time respectively. 
An overall score of 60 was set as a threshold for the the positive identification of a 
compounds molecular adduct ion in the extract, this threshold together with fragment 
ion confirmation ensured that the potential for false positive reporting was remote. 
 
Fragment ion confirmation utilised a maximum of five of the most abundant ions 
(when available) from the personal compound database library with a minimum of 
one required for compound identification. A minimum threshold of five was set for 
the signal-to-noise ratio for each of the confirmatory ions and all had to be within 6 s 
of the precursor’s retention time to achieve the minimum co-elution score of 80 
required for peak compound confirmation. A mass error setting of no greater than 10 
ppm was also set for the fragment ions obtained from the precursor ion.  
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3.4.15    Waste water treatment plants chosen for the deployments 
Three WWTPs were chosen for the deployments with all three sites situated in South 
West Wales serving the areas of Carmarthen, Gowerton (west Swansea) and Llanelli. 
These were: 
 
i) Carmarthen sewage works, Parc-y-Splott, Llansteffan Road, Carmarthen, 
latitude 51.835780 longitude -4.3267572. The population equivalent of the 
works as of 2013 was approximately 22,000 but receives waste water from 
Glangwili General Hospital, Carmarthen located approximately 2.8 miles 
north of the works.  
 
ii) Gowerton sewage works, Victoria Road, Gowerton, Swansea, latitude 
51.6545 longitude -4.0323. The population equivalent of the works as of 2013 
was approximately 50,000. 
 
iii) Llanelli sewage works, Bynea, Llanelli, latitude 51.6636 longitude -4.1098. 
The population equivalent of the works as of 2013 was approximately 55,000. 
 
All three WWTPs employ identical treatment processes including bar screens to filter 
solids, fats, greases and large objects, before primary treatment which is a based on 
conventional activated sludge. Population equivalent data for the three waste water 
treatment plants was obtained from the operators, Dwr Cymru Welsh Water 
(DCWW). 
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3.5   Results and discussion 
3.5.1 Identification of pharmaceuticals in MS scan mode 
Of the 164 pharmaceuticals targeted using MS scan mode a total of 72 were identified 
with a mass accuracy of better than 10 ppm with additional confirmation coming from 
isotope pattern and spacing matching. The retention times of all compounds were 
within ± 0.2 min of the library retention time. Of the 47 pharmaceutical compound 
classes listed in Table 3.1, 30 were identified in the extracts of both samplers and, of 
the classes not found, the majority only contained one compound thereby limiting the 
possibility of detecting compounds within that class. The number of detections at 
each site were 71, 68 and 69 for Carmarthen, Gowerton and Llanelli respectively with 
an identical number identified for both samplers but not all were found at all three 
sites. Atorvastatin, terbinafine and naproxen were found only at the Carmarthen site 
whilst Piroxicam was found only at the Llanelli site.  
 
Of the 72 pharmaceuticals identified, 71 were found using positive ionisation and 19 
using negative ionisation with 57 and 5 detected in positive ion and negative ion 
modes only respectively. Of the five pharmaceuticals (ibuprofen, indapamide, 
naproxen mefenamic acid and salicylic acid) identified in negative ion mode only, all 
are acidic and, with the exception of indapamide, do not ionise efficiently in positive 
ion mode due to their very low proton affinities. Ibuprofen, naproxen, mefenamic 
acid and salicylic acid form strong anions due to the dissociation of a hydrogen atom 
resulting in a strong response with negative ion electrospray. Indapamide contains 
two ionisation sites, the sulfamoyl group and the amide functionality, and hydrogen 
abstraction at both groups is possible with the former process more likely to form a 
strong anion at a mobile phase pH of 4 under negative ion electrospray conditions. 
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Indapamide, however, was not observed in positive ion mode despite it containing a 
primary amine group that, for most compounds, would result in a strong response 
using positive ion electrospray ionisation. Two possibilities for its non-detection in 
positive ionisation mode are that indapamide was subject to interference from another 
compound of similar mass in positive ion mode or its concentration was too low in 
the passive sample extract to be detected. According to Salgado et al., indapamide 
has a removal rate of almost 100% during waste water treatment over 6 days so this 
is the most likely reason for its absence from the positive ion chromatogram (333). 
 
An unexpected observation was that a larger peak area response was obtained for 
salicylic acid with the Chemcatcher® sampler. A probable explanation for this 
observation is that salicylic acid, being an anion, adsorbs onto the positively charged 
groups on the surface of the glass fibre matrix (of the HLB-L disk) through an ion 
exchange mechanism which is absent from the POCIS sampler. A summary of the 
results obtained from MS scan mode are shown in Table 3.6. 
 
 
3.5.2 Peak area responses for cardiovascular drugs at the Carmarthen and 
Llanelli waste water treatment plants 
 
The peak area response for Valsartan at the Carmarthen site was approximately 20 
times higher than for the Gowerton site and twice the response observed at the 
Llanelli site. Also, the peak area response for dipyridamole, furosemide, verapamil 
and losartan at Carmarthen were approximately 5–6 times higher than observed at 
Gowerton and twice that of Llanelli. Both the Carmarthen and Llanelli treatment 
works receive effluents from hospitals with Carmarthen being the largest and having 
a specialist cardiac unit serving west Wales; Gowerton, however, does not receive 
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any hospital effluent. As all of the above drugs are used in cardiovascular treatment 
the most likely reason for their higher peak area response, especially at Carmarthen, 
is that the treatment works receive significant inputs of these pharmaceuticals from 
nearby hospitals. 
 
 
3.5.3 Identification of pharmaceuticals using the ‘all ions’ MS/MS technique 
Analysis of data files acquired using the ‘all ions’ MS/MS technique involved 
correlating the elution profile of the targets precursor ion in the low energy channel 
(0 eV) with those of the fragments generated under higher energy conditions (20 eV 
and 40 eV). The fragments within the searchable pharmaceutical compound database 
were used to form individual extracted ion chromatograms that were then overlaid 
with those of the precursors. A co-elution score was calculated for each fragment ion 
based on abundance, peak shape (symmetry), peak width and retention time. In 
addition, signal-to-noise ratios and mass accuracy calculations for the peak spectra 
for both molecular ions and fragment ions were performed and assessed against the 
criteria set in the data analysis software. 
 
Fifty of the 72 pharmaceuticals identified using the MS scan only were unequivocally 
identified (qualified) using the ‘all ions’ MS/MS technique, but differences in the 
number of compounds qualified were observed between the samplers and between 
sites. The individual number of compounds identified by each sampler at each site 
are shown in Table 3.7 with the highest number of qualified pharmaceuticals present 
at the Llanelli site (45) and the lowest at Gowerton (33). A lower number of 
pharmaceuticals were qualified with the Chemcatcher® sampler and this observation 
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was strongly correlated with lower signal-to-noise ratios for those compounds that 
returned scores of less than the set threshold of 60 in the data analysis workflow. The 
difference in the number of pharmaceuticals identified between sampler types at each 
site varied between 6 and 8 but only one more compound was identified in the POCIS 
sampler over the Chemcatcher® for the Gowerton 2 co-deployment.  
 
Unlike selective reaction monitoring on triple quadrupole mass spectrometers, no 
mass filtering (i.e. selection of precursor ion) takes place ahead of the collision cell 
with the ‘all ions’ MS/MS acquisition method. Therefore, other non-target precursor 
ions in the collision cell will also form fragment ions which may have very similar 
masses to those of the target compounds leading to a reduction in signal-to-noise ratio 
as well as a reduction in mass accuracy. The consequence of this is that there is a net 
loss in the signal-to-noise ratio when fragment ions are formed from the precursor 
ion potentially decreasing the rate of detection for compounds present in sample 
extracts at low concentrations. As the Chemcatcher® has a lower uptake rate, a lower 
mass of compound would be adsorbed onto the HLB-L disk and hence a lower signal-
to-noise ratio was obtained using the ‘all ions’ MS/MS method. Concentrating the 
Chemcatcher® extract to a lower volume, or making a smaller dilution of the extract, 
before analysis would improve peak height (or area) and therefore signal-to-noise 
ratio and detectability.  
 
Figure 3.11(a) shows the overlaid extracted ion chromatograms for the precursor and 
fragment ions obtained for irbesartan present in the Chemcatcher® deployed at the 
Llanelli site. Figure 3.11(b) shows the fragment ion mass spectra obtained from the 
high-energy channels for irbesrtan (shown in green) as well as for other co-eluting 
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compounds, whilst in Figure 3.11(c) the background fragment ions have been 
removed thus allowing for the mass accuracy and signal-to-noise ratio calculations 
to be performed for the irbesrtan fragment ions which were searched for within the 
compound database. The co-elution score corresponding to each of the fragment ions 
of irbesartan, under collision energies of 20 eV and 40 eV, are shown in Table 3.8 
and all are above the minimum threshold value of 80.  In addition, the signal-to-noise 
ratios for the qualified fragment ions are above the minimum threshold value of 10 
and the mass accuracy for the peak spectra for both molecular ions and fragment ions 
was better than 10 ppm as set in the data analysis software. The extracted ion 
chromatograms obtained for the compounds fexofenadine and clarithromycin, also 
present in the Chemcatcher® deployed at the Llanelli site, are shown in Figures 3.12 
and 3.13 respectively. The co-elution scores, signal-to-noise ratio values and mass 
accuracy information for the two compounds are shown in Tables 3.9 and 3.10 
respectively. For most of the qualified targeted compounds, at least one and up to 
five specific fragment ions within the compound database library were observed as 
qualifier ions.  
 
A further seven pharmaceuticals were identified using the ‘all ions’ MS/MS method 
over the MS scan only method. Four of the seven compounds, amiloride, felodipine, 
mebeverine and scopolamine were identified in the 20 eV collision energy channel 
together with qualifying fragment ions in at least one of the three sites. The most 
likely reason for their identification in the 20 eV channel is that the higher collision 
energy resulted in the fragmentation or reduction in the intensity of compounds of 
similar mass which prevented their identification when using the MS scan only 
method. The remaining three compounds, dosulepin, meloxicam and sildenafil were 
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identified only in the low energy channel but as a higher accelerating voltage is 
applied to the ions leaving the ion source, when using the ‘all ions’ MS/MS method, 
it is thought this was sufficient to increase the number of ionised molecules reaching 
the detector. Of the 72 compounds identified in MS scan mode, only betamethasone 
and trazadone, were not identified. Ibuprofen, indapamide, mefenamic acid, 
naproxen and saliyclic acid were not qualified using the negative ion ‘all ions’ 
MS/MS method due to an instrument fault which was traced to one of the amplifier 
boards.  
 
The results obtained from the screening of pharmaceuticals using the ‘all ions’ 
MS/MS technique are summarised in Table 3.7. 
 
 
3.5.4 Mass accuracy 
Mass accuracy calculations were undertaken on the molecular adduct ions in the low 
energy channel of the ‘all ions’ MS/MS method for each compound identified, and 
at each site including the co-deployment at Gowerton. The results including the 
average for each site are presented in Table 3.11. The mass accuracy of the molecular 
adducts ions for all identified compounds was generally better than 5 ppm (85 %), 
with 39 % and 75 % better than 1 ppm and 3 ppm respectively. The average across 
the three sites varied from 1.85 ppm for Carmarthen (POCIS) to 2.53 ppm at 
Gowerton (Chemcatcher®). A summary of the mass accuracy statistics obtained for 
each site is shown in Table 3.12 and a Welch’s t-test established that the means (of 
the mass accuracy) for the Chemcatcher® was not significantly different from the 
mean of the POCIS (t = 1.47, pr = 0.141) at the 0.05 level of significance.  
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Table 3.6   Pharmaceuticals identified in extracts at the three sites using the MS scan method (positive and negative ion modes). 
Compound Carmarthen 
Chemcatcher® 
Carmarthen 
POCIS 
Gowerton 1 
Chemcatcher® 
Gowerton 1 
POCIS 
Gowerton 2 
Chemcatcher® 
Gowerton 2 
POCIS 
Llanelli 
Chemcatcher® 
Llanelli         
POCIS 
Alfuzosin                 
Alverine                 
Amisulpride                 
Amitriptyline                 
Atenolol                 
Atorvastatin                 
Betamethasone 17 
valerate 
                
Bezafibrate                 
Bisoprolol                 
Carbamazepine                 
Cefalexin                 
Celiprolol                 
Cetirizine                 
Chlorpheniramine                 
Citalopram                 
Clarithromycin                 
Clopidogrel                 
Cyclizine                 
Diclofenac                 
Diltiazem (Cis)                 
                     Continued 
Key 
 Compound present Compound  absent,   a      Analysed in negative ion MS scan  
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Dipyridamole                 
Doxazosin                 
Erythromycin                 
Fexofenadine                 
Flecainide                 
Fluconazole                  
Furosemide                 
Gliclazide                 
Irbesartan                 
Ketoconazole                 
Ketoprofen                 
Labetalol                 
Lamotrigine                 
Lansoprazole                 
Lidocaine                  
Loperamide                 
Loratadine                 
Losartan                 
Metoclopramide                 
Metoprolol                 
Mirtazapine                 
Nifedipine                 
Omeprazole                 
Oxprenolol                 
                     Continued 
Key 
 Compound present Compound  absent,   a      Analysed in negative ion MS scan  
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Pantoprazole                 
Phenytoin                 
Piroxicam                 
Procyclidine                 
Propranolol                 
Quinine                 
Ranitidine                 
Sulfasalazine                 
Salbutamol                  
Sertraline                 
Sotalol                 
Sumatriptan                 
Tamsulosin                 
Telmisartan                 
Terbinafine                 
Timolol                 
Tramadol                 
Trazodone                 
Trimethoprim                 
Valsartan                 
Venlafaxine                 
Verapamil                 
Warfarin                 
Ibuprofena                 
       Continued 
 
Key 
 Compound present Compound  absent,   a      Analysed in negative ion MS scan  
   
215 
 
 
 
 
Indapamidea                 
Naproxena                 
Mefenamic acida                 
Salicylic acida                 
 
 
Key 
 Compound present Compound  absent,   a      Analysed in negative ion MS scan  
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Table 3.7 Pharmaceuticals identified in extracts at the three sites using the ‘all ions’ MS/MS technique.  
Compound Carmarthen 
Chemcatcher® 
Carmarthen 
POCIS 
Gowerton 1 
Chemcatcher® 
Gowerton 1 
POCIS 
Gowerton 2 
Chemcatcher® 
Gowerton 2 
POCIS 
Llanelli 
Chemcatcher® 
Llanelli         
POCIS 
Alfuzosin                 
Alverine                 
Amiloride                 
Amisulpride                 
Amitriptyline                 
Atenolol                 
Atorvastatin                 
Bezafibrate                 
Bisoprolol                 
Carbamazepine                 
Cefalexin                 
Celiprolol                 
Cetirizine                 
Chlorpheniramine                 
Citalopram                 
Clarithromycin                 
Clopidogrel                 
Cyclizine                 
continued 
Key 
Compound present in low energy MS channel of ‘all ions MS/MS’ method, Compound identified in the 20eV CE channel of ‘all ions MS/MS’ method 
 
Qualifying fragment ions present from ‘all ions MS/MS’ method,         Molecular adduct ion identified in the 20eV CE channel with qualifying fragment ions 
 
Adduct ion of compound absent                                                                                 a       Not identified in MS Scan only analysis    
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Diclofenac                 
Diltiazem (Cis)                 
Dipyridamole                 
Doxazosin                 
Dosulepina                 
Erythromycin                 
Felodipine                 
Fexofenadine                 
Flecainide                 
Fluconazole                  
Furosemide                 
Gliclazide                 
Irbesartan                 
Ketoconazole                 
Ketoprofen                 
Labetalol                 
Lamotrigine                 
Lansoprazole                 
Lidocaine                  
Loperamide                 
                      continued 
Key 
Compound present in low energy MS channel of ‘all ions MS/MS’ method, Compound identified in the 20eV CE channel of ‘all ions MS/MS’ method 
 
Qualifying fragment ions present from ‘all ions MS/MS’ method,         Molecular adduct ion identified in the 20eV CE channel with qualifying fragment ions 
 
Adduct ion of compound absent                                                                                 a       Not identified in MS Scan only analysis    
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Loratadine                 
Losartan                 
Mebeverine                 
Meloxicama                 
Metoclopramide                 
Metoprolol                 
Mirtazapine                 
Nifedipine                 
Omeprazole                 
Oxprenolol                 
Pantoprazole                 
Phenytoin                 
Piroxicam                 
Procyclidine                 
Propranolol                 
Quinine                 
Ranitidine                 
Sulfasalazine                 
Salbutamol                  
Scopolamine                 
                      continued 
 
Key 
Compound present in low energy MS channel of ‘all ions MS/MS’ method, Compound identified in the 20eV CE channel of ‘all ions MS/MS’ method 
 
Qualifying fragment ions present from ‘all ions MS/MS’ method,         Molecular adduct ion identified in the 20eV CE channel with qualifying fragment ions 
 
Adduct ion of compound absent                                                                                 a       Not identified in MS Scan only analysis    
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Sertraline                 
Sildenafila                 
Sotalol                 
Sumatriptan                 
Tamsulosin                 
Telmisartan                 
Terbinafine                 
Timolol                 
Tramadol                 
Trimethoprim                 
Valsartan                 
Venlafaxine                 
Verapamil                 
Warfarin                 
No. of compounds 
identified using ‘all 
ions’ MS/MS method 
 33 39  30  38  33  34  39  45  
 
 
Key 
Compound present in low energy MS channel of ‘all ions MS/MS’ method, Compound identified in the 20eV CE channel of ‘all ions MS/MS’ method 
 
Qualifying fragment ions present from ‘all ions MS/MS’ method,         Molecular adduct ion identified in the 20eV CE channel with qualifying fragment ions 
 
Adduct ion of compound absent                                                                                 a       Not identified in MS Scan only analysis    
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12 Overlay of precursor and fragment ion extracted ion 
chromatograms for irbesartan in a Chemcatcher® from Llanelli WWTW (a), 
high collision energy scan displaying all fragment ions (b) and cleaned high 
collision energy scan displaying only irbesartan fragment ions (c).
a 
b 
c 
  
 
Table 3.8      Co-elution scores for the individual irbesartan fragment ions, together with scores for the precursor mass accuracy, 
mass and retention time differences. 
 
 
Name Formula m/z Mass Mass (Tgt) Diff (ppm) Score (Tgt) RT RT (Tgt) RT Diff Score (RT) Species 
Irbesartan C25 H28 N6 O 
429.2399 
451.2216 
428.2326 428.2325 -0.29 99.61 18.203 18.2 0.003 99.94 
(M+H)+ 
(M+Na)+ 
            
Coelution 
Score 
CE Flags(FIs) Height m/z     Name RT RT Diff SNR    
98.9 20 Qualified 18802.7 195.1492 Irbesartan 18.211 0.009 44.4    
99.5 40 Qualified 120821 207.0917 Irbesartan 18.211 0.009 37.3    
97 20 Qualified 3011 386.2213 Irbesartan 18.194 0.009 12.9    
96.7 40 Qualified 7705.2 180.0808 Irbesartan 18.211 0.009 11.7    
98.1 40 Qualified 6189.7 206.0838 Irbesartan 18.194 0.009 11.5    
            
Score (iso. 
abund) 
Score (mass) 
Score 
(MS) 
Score (iso. 
spacing) 
Height Species m/z      
98.33 99.87 99.46 99.98 69055.4 (M+H)+ 429.2399      
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13     Overlay of precursor and fragment ion extracted ion 
chromatograms for fexofenadine in a Chemcatcher® from Llanelli WWTW 
(a), high collision energy scan displaying all fragment ions (b) and cleaned high 
collision energy scan displaying only fexofenadine fragment ions (c).
a 
b 
c 
  
 
Table 3.9      Co-elution scores for the individual fexofenadine fragment ions, together with scores for the precursor mass accuracy, 
mass and retention time differences. 
 
 
Name Formula m/z Mass Mass (Tgt) Diff (ppm) Score (Tgt) RT RT (Tgt) Score (RT)      Species 
Fexofenadine C32 H39 N O4 
502.2959 
524.2784 
501.2885 501.2879 -1.11 97.5 14.851 14.87 97.44 
(M+H)+ 
(M+Na)+ 
           
Coelution Score CE Flags(FIs) Height m/z Name RT RT Diff SNR 
 
  
99.6 20 Qualified 53886.5 484.2846 Fexofenadine 14.86 0.009 139.6 
 
  
99.5 40 Qualified 99160.2 466.2741 Fexofenadine 14.843 0.009 156.2 
 
  
99.1 40 Qualified 72359.9 171.1168 Fexofenadine 14.86 0.009 34.1 
 
  
98.9 40 Qualified 13738.1 262.159 Fexofenadine 14.843 0.009 30.5 
 
  
98.9 40 Qualified 23843.8 131.0855 Fexofenadine 14.843 0.009 7.3 
 
  
            
Score (iso. 
abund) 
Score (mass) Score (MS) 
Score (iso. 
spacing) 
Height Species m/z 
     
94.67 98.67 97.53 98.68 209463.1 (M+H)+ 502.2959      
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.14 Overlay of precursor and fragment ion extracted ion 
chromatograms for clarithromycin in a Chemcatcher® from Llanelli WWTW 
(a), high collision energy scan displaying all fragment ions (b) and cleaned high 
collision energy scan displaying only clarithromycin fragment ions (c).
a 
b 
c 
  
 
Table 3.10   Co-elution scores for the individual clarithromycin fragment ions, together with scores for the precursor mass accuracy, 
mass and retention time differences. 
 
 
Name Formula m/z Mass Mass (Tgt) Diff (ppm) Score (Tgt) RT RT (Tgt) Score (RT) Species 
Clarithromycin C38 H69 N O13 748.4846 747.4771 747.4769 -0.34 99.72 17.068 17.068 100 (M+H)+ 
 
          
Coelution Score CE Flags(FIs) Height m/z Name RT RT Diff SNR    
99.5 20 Qualified 30344 590.3899 Clarithromycin 17.06 0.009 131.9    
99.3 40 Qualified 113402 158.1176 Clarithromycin 17.06 0.009 44    
98.2 40 Qualified 17603 116.107 Clarithromycin 17.043 0.026 21.5    
92.5 40 Qualified 30561 83.0491 Clarithromycin 17.043 0.026 10.7    
 
 Low S/N 
ratio 
5060 116.0706 Clarithromycin 17.077 0.009 4    
 
           
Score (iso. abund) Score (mass) Score (MS) 
Score 
(iso. 
spacing) 
Height Species m/z 
 
    
99.45 99.84 99.58 99.23 56577 (M+H)+ 748.4846 
 
    
 
 
 
 
  
 
                              Table 3.11 Mass accuracy (in ppm) for compounds identified using the ‘all ions’ MS/MS method. 
 
Compound 
 
Carmarthen 
Chemcatcher® 
 
Carmarthen 
POCIS 
 
Gowerton 1 
Chemcatcher® 
 
Gowerton 1 
POCIS 
 
Gowerton 2 
Chemcatcher® 
 
Gowerton 2 
POCIS 
 
Llanelli 
Chemcatcher® 
 
Llanelli         
POCIS 
 
Alfuzosin -2.90 -3.00 -3.10 -2.93 -6.96 -4.53 -7.95 -2.89 
Alverine -2.71 -1.63 -9.65 -2.77 -8.42 -6.65 -2.57 -2.73 
Amiloride 3.74 -0.08 -1.55 -5.95 nd -5.80 1.81 -1.63 
Amisulpride 1.97 1.68 1.09 1.12 0.78 1.34 0.55 1.07 
Amitriptyline 0.42 -0.32 -0.41 -0.75 -0.74 -0.28 -0.45 -0.91 
Atenolol 1.23 1.23 0.71 0.32 0.83 0.55 0.35 1.11 
Atorvastatin 1.46 1.76 nd nd nd nd nd nd 
Bezafibrate 3.47 1.25 5.08 1.27 2.22 1.18 0.49 -2.08 
Bisoprolol -2.05 -3.37 -1.09 -1.51 -1.24 -1.00 -0.83 -2.21 
Carbamazepine 1.41 -1.27 1.02 0.63 1.00 0.41 1.68 0.02 
Cefalexin 6.79 5.90 nd 6.20 6.49 4.70 4.95 3.08 
Celiprolol -0.26 -1.03 -0.21 -0.60 -0.14 -0.24 0.32 0.11 
Cetirizine 0.94 0.18 1.01 0.78 0.95 0.25 1.00 0.60 
Chlorpheniramine 8.00 5.66 3.97 9.12 2.33 5.54 nd 4.64 
Citalopram 0.86 0.25 1.15 1.47 0.81 1.35 0.97 1.10 
Clarithromycin 1.00 1.41 0.19 0.38 0.50 0.35 0.34 1.07 
Clopidogrel 0.51 0.21 1.08 -0.25 0.48 0.03 0.49 0.26 
Cyclizine -2.29 -1.85 -2.75 -1.29 -2.96 -1.99 -1.55 -1.50 
Diclofenac -1.44 -2.35 -0.05 -0.42 -0.60 -0.95 -0.85 -2.25 
Diltiazem (Cis) 5.57 4.29 6.30 0.96 8.09 3.50 8.81 0.75 
Dipyridamole -1.15 -1.99 -1.54 -2.31 -5.59 -3.03 -1.80 -2.49 
Dosulepin nd nd nd nd nd 2.62 nd 5.34 
        continued 
  
 
 
 
Doxazosin nd nd nd nd nd -0.22 nd -3.96   
Erythromycin 0.29 0.03 -0.09 0.38 0.52 0.26 0.23 0.23 
Felodipine -3.37 nd nd nd nd nd nd nd 
Fexofenadine 1.07 0.98 1.42 1.17 1.18 1.11 1.11 0.77 
Flecainide -0.01 -0.03 -0.20 0.18 -0.30 -0.09 1.26 -0.33 
Fluconazole  0.62 1.59 0.61 1.09 3.35 1.74 1.30 -0.21 
Furosemide 7.28 -0.49 nd 2.19 1.07 nd 1.61 nd 
Gliclazide 2.01 1.64 1.57 1.93 1.98 2.30 2.14 0.99 
Irbesartan 0.17 -0.10 0.56 0.64 0.41 0.66 0.29 0.45 
Ketoconazole 0.19 1.54 1.79 -0.16 1.46 1.35 0.21 1.02 
Ketoprofen 2.26 4.34 6.11 7.31 nd 2.66 1.97 5.53 
Labetalol -0.08 0.41 nd 0.08 1.82 0.98 0.75 0.89 
Lamotrigine 1.24 1.47 1.49 1.86 1.02 2.21 1.67 1.56 
Lansoprazole 5.38 5.77 6.53 5.55 4.16 4.90 4.13 2.74 
Lidocaine  -0.01 0.30 -0.72 -1.47 -1.63 -1.27 -0.47 -0.28 
Loperamide 3.05 2.20 0.08 0.03 3.28 2.33 5.90 0.84 
Loratadine 2.61 3.31 3.95 1.01 1.59 1.54 7.12 4.24 
Losartan 1.87 0.26 3.95 2.86 7.47 7.48 5.64 5.55 
Mebeverine nd nd -7.03 nd -0.38 nd -3.45 -3.88 
Meloxicam 0.74 0.62 0.30 8.13 -0.42 -2.55 3.11 7.23 
Metoclopramide 1.24 0.86 2.34 1.81 2.01 2.25 1.78 1.22 
Metoprolol 0.46 -0.76 -0.81 -0.40 -0.34 -0.18 -0.27 0.59 
Mirtazapine -0.50 -1.02 -0.51 -0.48 -0.56 -0.56 -0.99 -0.01 
Nifedipine 0.25 nd nd nd nd nd 0.50 2.29 
Omeprazole -4.37 -1.22 -0.18 1.33 5.09 2.41 9.75 6.29 
Oxprenolol 9.98 0.90 1.65 0.37 0.75 0.71 0.76 0.90 
Pantoprazole nd 2.06 6.04 nd nd 2.30 9.12 1.61 
        continued 
  
 
 
 
Phenytoin 0.67 -1.36 -0.51 -1.42 -0.48 -0.47 -0.55 -1.00 
Piroxicam nd nd nd nd nd nd 1.51 -0.04 
Procyclidine -0.29 6.15 7.60 7.86 7.42 7.79 7.09 6.06 
Propranolol 9.75 0.23 0.65 1.43 0.82 1.47 0.09 0.85 
Quinine 0.16 -1.36 -8.30 -4.38 -9.63 nd -1.77 -1.59 
Ranitidine -1.05 3.62 2.09 0.84 4.61 3.71 2.32 4.79 
Salbutamol  4.74 -0.84 -1.15 -0.04 0.18 -2.64 0.54 0.99 
Scopolamine nd 0.49 nd 0.38 -2.07 -0.63 nd nd 
Sertraline -0.71 -0.75 0.67 0.49 0.51 0.04 0.75 -0.97 
Sildenafil 9.81 7.89 5.35 2.97 5.16 nd 6.14 5.85 
Sotalol 1.39 1.52 1.87 1.35 1.39 1.78 1.46 0.96 
Sulfasalazine 1.73 -1.35 -0.07 0.70 -0.36 0.43 1.18 -0.69 
Sumatriptan -0.59 0.21 1.29 0.22 0.79 1.07 1.05 0.81 
Tamsulosin nd nd 1.03 4.85 1.83 1.02 nd 9.97 
Telmisartan -0.30 0.01 0.50 -0.15 0.37 -0.55 0.69 -0.11 
Terbinafine nd -5.65 nd nd nd nd nd nd 
Timolol nd 1.09 nd nd 4.56 -9.83 nd nd 
Tramadol 0.34 -5.27 -3.43 -3.18 -4.10 0.17 -3.53 -5.94 
Trimethoprim -7.67 1.64 2.42 2.08 2.32 2.56 2.32 2.08 
Valsartan 2.34 0.09 9.17 6.66 nd nd 3.72 2.00 
Venlafaxine 1.09 -4.10 -9.46 -9.97 -9.89 -9.99 -9.11 -9.01 
Verapamil 9.87 -2.45 -1.50 nd -4.94 -2.44 -0.71 -1.16 
Warfarin -0.18 -1.18 3.28 1.07 1.16 -2.94 0.38 -4.69 
 
Key 
nd not detected 
 
 
  
 
      Table 3.12      Summary of the mass accuracy statistics (in ppm) obtained for each site. 
 
 
Compound 
 
Carmarthen 
Chemcatcher® 
 
Carmarthen 
POCIS 
 
Gowerton 1 
Chemcatcher® 
 
Gowerton 1 
POCIS 
 
Gowerton 2 
Chemcatcher® 
 
Gowerton 2 
POCIS 
 
Llanelli 
Chemcatcher® 
 
Llanelli         
POCIS 
 
Mean 2.41 1.85 2.50 2.16 2.53 2.22 2.35 2.29 
Standard Error 0.35 0.22 0.34 0.32 0.34 0.29 0.33 0.28 
Standard Deviation 2.76 1.81 2.66 2.48 2.62 2.31 2.60 2.26 
Sample Variance 7.63 3.28 7.09 6.17 6.86 5.32 6.75 5.13 
Number of compounds 
detected 
63 66 60 61 61 63 63 67 
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3.6 Conclusions 
A searchable accurate mass compound database containing all relevant ion species 
and selective qualifier ions for 164 pharmaceuticals was developed for the screening 
of pharmaceuticals in extracts of polar passive samplers using an UHPLC coupled to 
a Q-TOF-MS system. Chemcatcher® and POCIS passive samplers were deployed for 
a period of almost four weeks at three sewage treatment works in west Wales in 2014. 
Following retrieval and subsequent processing of the passive samplers the extracts 
obtained were screened using the newly developed ‘all ions’ MS/MS technique and 
a total of 79 pharmaceuticals were identified with high confidence. Fifty were 
unequivocally confirmed through the use of selective qualifier ions using the accurate 
mass compound database as the fragment ion source, and evaluating the five most 
specific ions from the MS/MS spectral library.  
 
Differences in the number of pharmaceuticals identified were observed between the 
MS scan only method and the ‘all ions’ MS/MS technique with seven additional 
pharmaceuticals identified using the new method but two compounds missed which 
were present in the MS scan data. Excellent mass accuracy was obtained from the 
analysis and was strongly correlated with chromatographic peak area or height. 75 
and 85% of compounds were identified with errors of less than 3 and 5 ppm 
respectively. Clean-up of the extracts using selective sorbents to remove potential 
interfering compounds, which lead to large mass measurement errors, would be 
highly beneficial. Further optimisation of the Q-TOF-MS methods may also result in 
a higher number of compounds being detected. 
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The method takes full advantage of UHPLC separations to increase the 
chromatographic resolution and benefits from the sensitivity and selectivity of a 
modern Q-TOF-MS instrument. The developed technique is an ideal complement for 
existing target and suspect screening methods. Applying both MS scan and the ‘all 
ions’ MS/MS methods resulted in a highly efficient workflow for the analysis of the 
passive sampling extracts. The ‘all ions’ MS/MS acquisition method is very fast and 
the acquired data can be re-interrogated at a later time for compounds that were 
outside the scope of the analysis during measurement allowing for retrospective data 
analysis for new emerging contaminants such as pharmaceutical metabolites, their 
transformation products plus personal care products without the need to reacquire 
data from old samples. It may also be possible to transfer the method to other 
instrument vendor systems which employ high resolution accurate mass detection. 
The results obtained clearly show the value of the approach developed and when 
combined with an efficient data analysis workflow should prove invaluable for 
investigative monitoring purposes within the remit of the WFD.  
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Chapter 4 
 
Comparison of the sampling efficiency of two passive 
samplers for organic compounds in effluents: Polar 
Chemcatcher® versus the polar organic chemical 
integrative sampler (POCIS) 
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4.1 Introduction 
The purpose of this chapter was to compare the sampling efficiency of two passive 
samplers, namely the polar Chemcatcher® and the polar organic chemical integrative 
sampler (POCIS), for organic compounds in effluents using an identical solid phase 
extraction sorbent commonly used in sample preparation.  
 
The use of quality-controlled, commercially available receiving phases within the 
Chemcatcher® device allows for high reproducibility and ease of use when compared 
with some other passive sampling devices. Both Chemcatcher® and POCIS samplers 
employ a solid sorbent sandwiched between polyethersulphone membranes which 
expose a sampling area of 45.8 cm2 for the POCIS sampler and 15.2 cm2 for the 
Chemcatcher, a factor of 3.01. With regards to the Chemcatcher® the immobilised 
receiving phase, within a disk of PTFE fibrils or glass fibre, ensures that the active 
sampling area of the device remains constant during field deployments and laboratory 
calibration uptake experiments. The sorbent in the POCIS sampler is in the form of a 
free-flowing powder and may not therefore have the same effective sampling area 
throughout the deployment period. In addition, unless care is taken during assembly 
of POCIS devices, losses of sorbent from POCIS devices can occur which, if 
significant, could lead to irreproducible results (334-336).  
 
Until recently the sorbent used by the POCIS sampler (Waters Oasis® HLB) was 
unavailable in the 47mm disk format used in the Chemcatcher®. However, the recent 
introduction of a commercially available SPE disk (Horizon Technology Atlantic 
range), which incorporates the same phase in the 47mm format, has allowed the 
Chemcatcher® to be used with one of the most commonly used and versatile solid 
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phase extraction sorbent phases used in environmental analysis. It was hypothesised 
that both polar passive samplers would behave in a similar manner.  
 
4.2 Aims and objectives 
i) Determine, via a combination of LC Q-TOF-MS analysis and statistical tools, 
the reproducibility of chromatographic peak areas of targeted pharmaceuticals 
identified in extracts obtained from two passive samplers deployed in a waste 
water effluent stream.  
 
ii)        Determine statistically, using compound peak areas obtained from LC Q-TOF-
MS analysis, whether the relative uptake rates of the targeted pharmaceuticals 
and ‘unknown’ peaks (features) differed between samplers at different sites 
and between co-deployed samplers at one site. 
 
 
iii)       Determine through the use of mass profiling and statistical software, whether 
the range of molecular masses for ‘unknown’ compounds adsorbed by both 
samplers was similar. 
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4.3 Experimental 
4.3.1 Data acquisition and analysis 
The following workflow, typically used in LC-MS based metabolomics, was used to 
acquire and process the known and ‘unknowns’ data and involved the following steps 
(337). 
 
i. Data acquisition using high resolution accurate mass LC-MS in MS only 
mode. 
ii. Compound and feature extraction from targeted and untargeted analysis. 
iii. Retention time alignment. 
iv. Integration of peak area. 
v. Export of data for statistical evaluation using Agilent Mass Profinder and 
Mass Profiler software in conjunction with Microsoft Excel and Minitab 
statistical software.  
 
4.3.2 LC Q-TOF-MS analysis 
Chromatographic separation of compounds present in the passive sampler extracts 
was carried out using an identical set-up as described in Chapter 3. In summary, an 
Agilent 1290 Infinity UHPLC system was coupled to an Agilent G6540A Quadrupole 
Time-of-Flight LC/MS System equipped with a dual sprayer Agilent Jet Stream 
electrospray source and operated using Agilent Mass Hunter acquisition software 
(rev. B.06.01). The Q-TOF MS instrument acquired data in 2 GHz extended dynamic 
range mode using positive and negative ion electrospray for the targeted 
pharmaceuticals and also for the ‘unknowns’ analysis. Sample data was acquired 
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using MS (scan mode) only at an acquisition rate of 1 Hz and corrected using 
reference lock mass correction with all data stored in profile mode. A mass axis 
calibration was undertaken at the beginning of every chromatogram using a dedicated 
tuning solution of known masses spanning the mass range of 118–922 Da. The ‘all 
ions’ feature used in Chapter 3 was not used in this chapter as only the molecular 
adduct ions and their isotopes were required with a metabolomics based workflow. 
All 24 sample extracts from the deployments (12 Chemcatcher® and 12 POCIS as 
described in Chapter 3) were analysed along with a standard mix of pharmaceuticals 
as used in Chapter 3. 
 
 
4.3.3 Peak extraction of targeted pharmaceuticals 
The personal compound database library developed of 164 pharmaceuticals in 
Chapter 3 was used in conjunction with Agilent Mass Hunter Profinder software to 
identify pharmaceuticals in the Chemcatcher® and POCIS extracts. A process within 
the software called ‘Batch Targeted Feature Extraction’ was used to extract 
compounds from the within the PCDL based on their chemical formulae. The 
approach is similar to the find by formula process described in Chapter 3 but as no 
fragment ion confirmation was employed a narrower retention time window of 0.2 
min was used for accurate retention alignment of peaks across all data files. A higher 
score threshold of 90 was also used to ensure that only high quality data would be 
obtained. Isotope ions were also used for confirming the presence of the targeted 
pharmaceuticals in the extracts. The parameters used are listed in Table 4.1. 
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 Table 4.1 Batch Targeted Feature Extraction parameters. 
 
Source of formulas to confirm 
 
Database:  Pharmaceuticals 
Values to match:  Mass and retention time 
  
Charge carriers (adducts) 
 
Positive Ions Negative Ions 
H+     (protonated) H-                (deprotonated) 
Na+  (sodiated) HCOO-           (formate) 
 
CH3COO
-   (acetate) 
  
Isotope grouping 
 
Peak spacing tolerance: 0.0025 m/z, plus 7 ppm 
Isotope model: Common organic molecules 
Charge state maximum: 1 
  
Matching tolerances and scoring 
 
Mass match tolerance:  +/- 10 ppm 
Retention time tolerance:  +/- 0.2 min 
  
Contribution to overall score 
 
Mass score:  100 
Isotope abundance score:  60 
Isotope spacing score:  50 
Retention time score:  100 
  
Matching criteria 
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Do not match if score is less than:  90 
Spectra to include 
 
Average scans: At 25% of peak height 
Peak spectrum background:  Average of spectra at peak start and end 
  
Post processing filters 
 
Minimum height: 1000 counts 
Minimum filter matches: Compound must be present across all 
data files 
  
  
  
  
  
  
  
  
  
  
  
 
 
 
 
 
 
 
239 
 
4.3.4 Feature finding and peak extraction of untargeted features 
Untargeted data acquisition on the LC Q-TOF MS was performed using the set up as 
described in section 3.4.13 in Chapter 3 (LC Q-TOF-MS analysis). Feature extraction, 
combined with chromatographic alignment across multiple data files, is a critical step 
in the peak finding and data reduction workflow that minimizes the possibility of both 
false positive and false negative features by ‘binning’ the features in the 
chromatographic time domain (337).  In this chapter the term feature is used to 
describe chemical entities or peaks that are found as a result of using an untargeted 
(unbiased) peak finding algorithm. Features only become compounds when a 
molecular formula is assigned to the feature either using a molecular formula 
generator or via a database search.  
 
A process within the Agilent MassHunter Profinder software called ‘Batch Recursive 
Feature Extraction’ (BRFE) was used to de-convolute (or extract) the data. This 
utilises an in-built molecular feature extractor which is an untargeted data mining 
algorithm which removes constant background ions and locates the co-variant ions in 
a chromatogram. It then tests for chemically logical relationships and looks for user 
specified adducts, specifically the protonated and sodiated adduct ions in this work, 
and groups together isotopes to form a single feature or peak with unique neutral mass 
and retention time values. Batch recursive feature extraction provides for missing 
feature recovery and is achieved by ‘binning’ and aligning compound features in the 
first-pass molecular feature extractor, after which a composite spectrum for all found 
ions is created for each consensus feature. The composite compound feature list is 
then used as a target list for the second-pass ‘find by ion’ feature extraction. By 
implementing two-pass batch feature extraction the number of false negatives is 
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reduced significantly resulting in decreased variability within sample group 
replicates. The find by ion algorithm therefore has a significant positive impact on 
statistics derived from the mass spectrometric data. Figure 4.1 shows the results of 
Profinder BRFE for data acquired from Chemcatcher® and POCIS extracts. The 
compound group table (Figure 4.1a) displays the compound information grouped and 
summarised across multiple data files. The individual file details of a selected 
compound group are shown in the compound details table (Figure 4.1b), integrated 
extracted ion chromatogram (Figure 4.1c), and MS spectrum (Figure 4.1d) windows. 
The parameters used by the find by ion algorithm for this work are listed in Table 4.2. 
 
The data outputs from both targeted batch feature extraction and batch recursive 
feature extraction contained features that were only found in all 24 sample extracts 
and were in the form of comma separated variable files which were further processed 
using Microsoft Excel and Minitab® statistical analysis software. 
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Table 4.2 Profinder Batch Recursive Feature Extraction parameters. 
Charge carriers (adducts) 
 
Positive Ions Negative Ions 
H+    (protonated) H-                (deprotonated) 
Na+  (sodiated) HCOO-        (formate) 
 
CH3COO
-   (acetate) 
  
Isotope grouping 
 
Peak spacing tolerance: 0.0025 m/z, plus 7 ppm 
Isotope model: Common organic molecules 
Charge state maximum: 1 
  
Compound ion count threshold 
 
Two or more ions 
 
  
‘Binning’ and alignment tolerances 
 
Retention time window:  +/- 0.2 min 
Mass window:  10ppm  
  
Contribution to overall score 
 
Mass score:  100 
Isotope abundance score:  60 
Isotope spacing score:  50 
Retention time score:  100 
  
Matching criteria 
 
Do not match if score is less than:  90 
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Spectra to include 
 
Average scans: At 50% of peak height 
Peak spectrum background:  Average of spectra at peak start  
and end   
MFE post processing filters 
 
Minimum height: 1000 counts 
Score MFE: 90 
Minimum filter matches:  Compound must be present  
across all data files   
Find by Ion -Matching tolerances and scoring 
 
Expansion of values for chromatographic 
extraction:  
Symmetric +/- 20 ppm 
Limit extracted ion chromatogram extraction 
range:  
+/- 5 min 
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4.3.5 Correction of peak areas obtained from POCIS devices  
 
Losses of sorbent occurred during deployment and/or when disassembling the POCIS 
devices at the laboratory and varied considerably between devices across all sites. 
The literature review which accompanies this thesis did not identify any published 
papers which mention the loss of sorbent when disassembling POCIS samplers or 
weighing the sorbent following retrieval to check for sorbent loss. A few authors 
mention the use of stainless-steel rings to sandwich the two membranes together to 
prevent the loss of sorbent prior to deployment (334, 336) and others have mentioned 
placing the samplers in the horizontal plane to prevent potential loss of sorbent (338). 
From the author’s own significant experience with POCIS, loss of sorbent does occur 
during deployment as the steel rings seldom form a perfect seal when fully tightened. 
The POCIS sorbent is also electrostatic when dry and precautions are required to 
prevent static build up which, as far as the author of this thesis is aware, are not 
mentioned in any published papers.  
 
It is generally recommended that the PES membrane from POCIS deployments be 
placed in glass funnels and methanol used to wash the sorbent off into a suitable glass 
receptacle (96). This may, however, result in the desorption of compounds which 
have been adsorbed onto the PES membrane during deployment (117). As POCIS is 
considered to be a monophasic sampler, equations for the calculation of uptake rates 
consider only what is adsorbed onto the sorbent. Inaccurate results could therefore be 
obtained if compounds adsorbed onto the membrane are also measured and included 
in any calculations. In contrast, the Chemcatcher® considers only compounds that 
have passed through the membrane and subsequently adsorbed onto the sorbent and 
glass fibre matrix of the disk. 
244 
 
The mass of sorbent recovered, after overnight drying to remove moisture, from each 
device was recorded using an analytical balance and appear in Table 4.3. An overall 
average of 69.6% of sorbent was recovered out of the original 200 mg added to each 
device with an RSD of 15.4%. Significantly lower amounts of sorbent, 103.8 mg and 
97.0 mg, were recovered from the Carmarthen (i) and Llanelli (ii) POCIS devices 
respectively. As POCIS sorbent is electrostatic when dried, precautions were taken to 
minimise these losses by discharging any static build up by ‘earthing’ a large sheet of 
aluminium foil that was used for holding any glass vials, containing the dried sorbent, 
and other equipment prior to weighing. As losses occurred from POCIS devices, peak 
areas obtained from peak (feature) integration in sections 4.3.4 were corrected for by 
applying the factors shown in Table 4.3. The corrected peak areas obtained would 
allow for the comparison of the compound uptake in both samplers. It was assumed 
that losses would not occur with the disks during deployments as the sorbent is 
immobilised within the glass fibre matrix. 
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Table 4.3 Mass of Oasis HLB sorbent recovered from POCIS devices from all 
replicates at all sites.  
 
 
Site Mass of 
sorbent added 
(mg) A 
Mass of sorbent 
recovered     
(mg) B 
% of 
sorbent 
recovered 
Recovery 
factor 
A/B 
Carmarthen A 200 ± 2 103.8 52.0 1.927 
Carmarthen B 200 ± 2 140.9 70.5 1.419 
Carmarthen C 200 ± 2 146.0 73.0 1.370 
Gowerton 1A 200 ± 2 144.0 72.0 1.390 
Gowerton 1B 200 ± 2 145.5 72.8 1.375 
Gowerton 1C 200 ± 2 126.2 63.1 1.585 
Gowerton 2A 200 ± 2 147.0 73.5 1.361 
Gowerton 2B 200 ± 2 151.4 75.7 1.320 
Gowerton 2C 200 ± 2 142.7 71.4 1.127 
Llanelli A 200 ± 2 177.5 88.8 1.127 
Llanelli B 200 ± 2 97.0 48.5 2.062 
Llanelli C 200 ± 2 146.7 73.4 1.363 
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Figure 4.1 Results obtained from batch recursive feature extraction.  [a] compound group table, [b] compound details table, [c(i) 
and c(ii)] overlaid extracted ion chromatograms for Chemcatcher® and POCIS respectively, (d) Mass spectra for POCIS. 
 
d c(i) a 
b c(ii
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4.3.6    Mass profiling of ‘unknowns’ present in Chemcatcher® and POCIS 
samplers 
 
Mass profiling of ‘unknown’ features present in both samplers was undertaken to 
determine whether the range of compounds sequestered by both samplers was similar. 
Feature plots of ‘unknown’ compounds detected in Chemcatcher® and POCIS 
samplers were produced from the UHPLC Q-TOF-MS data files using Agilent Mass 
Profiler software. The settings used were identical to those used with Mass Profinder 
(Table 4.2) with the exception that for a feature to be confirmed it had to be found in 
at least two of the three replicates in any one sampler type but independent of any 
deployment site. This allowed for an unbiased approach to establishing the molecular 
mass range of the features detected in each sampler type and determination of any 
differences between sampler types and between sites. 
 
Histograms of mass against frequency of detection were created, using the data 
analysis function incorporated within Microsoft Excel, for the Carmarthen, Llanelli 
and Gowerton sites; the latter site used to determine any differences obtained between 
the co-deployments at this site. The form of the histograms was obtained by splitting 
the range of the data obtained into 47 equal-sized, non-overlapping mass intervals (20 
Da wide) along the horizontal axis and the number of points from the data set that fell 
into each interval represented on the vertical axis. In addition, histograms of feature 
detection against retention time were made using 40 distinct non-overlapping time 
intervals of 30 s. The form of the histograms initially used were based on Scott’s 
normal reference rule (339) (the automatic option with Excel) which resulted in mass 
bin widths of approximately 55 Da and retention time bin widths of approximately 
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1.6 min. These were considered as too wide as it was felt that the underlying trend in 
the data would be missed.  
 
 
4.4   Results and discussion 
A total of 72 pharmaceuticals were identified in the extracts and 68 pharmaceuticals 
were identified at all three sites and in both types of sampler. Of these 72 
pharmaceuticals atorvastatin, naproxen and terbinafine were found only at the 
Carmarthen site whilst piroxicam was found only at the Llanelli site. Sixty-seven and 
19 pharmaceuticals were identified in positive ion and negative ion modes with 53 
and 5 pharmaceuticals identified only in positive and negative ion modes respectively. 
Of the five pharmaceuticals identified in negative ion mode only, four are acidic and 
do not ionise efficiently in positive ion mode due to their very low proton affinities. 
Peak areas obtained from positive ion mode were generally higher than obtained from 
negative ion mode for both samplers and were therefore chosen for statistical analysis. 
 
The peak areas obtained for each pharmaceutical that were common to all replicate 
samplers (both Chemcatcher® and POCIS) and at all sites were averaged, percentage 
relative standard deviations (% RSD) were calculated and are presented in Table 4.4. 
Percentage RSD’s varied significantly between compounds and between samplers 
with less variation observed between sites for the individual compounds. Percentage 
RSD’s obtained from positive ion analysis were generally higher for the 
Chemcatcher® sampler at two sites (Carmarthen and Gowerton) but considerably 
lower than POCIS for the Llanelli site. Lower recoveries of the sorbent obtained from 
the POCIS samplers for the Llanelli site may have contributed to the higher RSD’s 
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for POCIS but this would seem an unlikely reason as larger peak area responses were 
nevertheless obtained from the POCIS sampler because of its larger sampling area.  
 
Fixty-six and 32 compounds exceeded 15 % RSD in the Chemcatcher® and POCIS 
extracts respectively, the higher RSD’s in the Chemcatcher® strongly correlated with 
peak area response which were approximately 3 times lower in the Chemcatcher. 
Only 10 compounds exceeded 30% RSD in both samplers with the largest error 
observed for the POCIS sampler at 165% RSD for the compound loratadine.  The 
highest RSD observed for loratadine in the Chemcatcher® was only 23%.  
 
RSD’s obtained from negative ion analysis were generally lower for the 
Chemcatcher® sampler across all sites with five and three compounds exceeding 15 
% RSD in the Chemcatcher® and POCIS extracts respectively. Only one compound, 
naproxen in the POCIS sampler, exceeded 30% RSD in negative ion mode.  
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Table 4.4 % RSD’s obtained for 68 pharmaceutical compounds identified in Chemcatcher® and POCIS samplers.  
Compound 
 
Carmarthen 
Chemcatcher® 
 
Carmarthen 
POCIS 
Gowerton 1 
Chemcatcher® 
Gowerton 
1 POCIS 
Gowerton 2 
Chemcatcher® 
Gowerton 
2 POCIS 
Llanelli 
Chemcatcher® 
Llanelli         
POCIS 
Salicylic acida 8.7 15.1 13.3 2.9 12.6 11.4 3.9 14.1 
Ibuprofena 6.2 10.4 4.8 7.5 5.0 7.8 6.2 11.7 
Naproxena 10.7 34.6 nd nd nd nd nd nd 
Mefenamic acida 11.0 2.9 8.6 5.7 7.3 3.2 2.4 5.1 
Indapamidea 4.9 9.0 3.2 7.1 3.1 4.5 2.7 1.3 
Alfuzosin 27.9 12.5 1.8 6.4 16.2 5.7 17.4 1.5 
Alverine 12.9 7.4 11.6 5.1 5.6 3.8 27.2 8.1 
Amisulprideb 12.8 5.7 9.1 5.8 6.5 2.6 3.9 3.4 
Amitriptyline 15.8 18.7 9.0 3.5 6.2 4.9 4.8 14.2 
Atenolol 7.5 7.2 8.4 3.4 4.6 1.9 3.5 3.1 
Atorvastatin 21.8 32.4 nd nd nd nd nd nd 
Betamethasone 17 valerate 23.1 32.7 14.6 19.2 15.2 31.5 12.4 8.1 
Bezafibrate 18.3 6.9 8.0 6.6 6.9 3.1 3.2 10.1 
Bisoprolol 13.9 4.2 9.3 3.7 10.2 3.3 3.6 4.0 
Carbamazepine 13.3 6.9 8.9 4.1 7.3 1.8 3.0 3.0 
Cefalexin 14.2 4.9 9.9 4.8 11.0 6.1 3.5 9.4 
Celiprololb 16.9 6.8 7.6 4.6 7.9 1.5 1.3 2.1 
Cetirizine 13.0 4.0 6.2 3.1 7.8 2.5 3.0 4.5 
Chlorpheniramine 19.2 8.6 25.3 15.1 5.9 33.2 32.1 20.9 
Citalopram 14.1 8.2 7.8 3.8 6.8 4.2 3.8 11.8 
 
       
continued 
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Clarithromycinb 37.5 5.8 5.2 2.7 4.9 4.7 4.9 15.7 
Clopidogrel 12.3 19.2 6.3 3.3 7.2 1.5 9.5 9.5 
Cyclizine 13.2 4.5 6.8 1.7 9.1 2.3 3.6 5.8 
Diclofenac 11.0 5.9 7.9 4.6 3.8 3.3 2.9 2.0 
Diltiazem (Cis) 24.6 7.4 7.1 3.0 8.8 4.2 4.0 12.4 
Dipyridamole 24.0 5.0 9.1 6.5 6.2 5.4 5.0 3.7 
Doxazosin 49.5 30.2 28.3 14.3 24.0 20.6 2.7 8.3 
Erythromycinb 27.1 5.4 6.9 3.3 8.3 4.1 0.8 13.5 
Fexofenadineb 15.1 5.0 8.2 3.8 8.1 3.4 3.4 7.0 
Flecainideb 25.7 3.9 6.8 4.9 22.5 3.2 5.4 8.2 
Fluconazoleb 8.5 10.7 5.0 7.4 7.4 3.1 9.0 3.5 
Furosemide 3.8 15.6 0.6 6.6 7.9 9.4 6.2 12.5 
Gliclazide 12.9 9.9 24.5 3.4 6.1 4.5 2.5 2.1 
Irbesartanb 14.1 3.2 7.0 3.5 7.7 2.7 4.1 4.9 
Ketoconazole 26.3 5.8 11.4 3.3 8.3 2.7 3.5 14.2 
Ketoprofen 12.4 17.6 6.7 2.4 24.2 14.9 24.6 7.3 
Labetalol 12.0 1.1 10.1 3.7 7.1 1.2 0.5 11.0 
Lamotrigine 9.5 9.6 10.5 3.6 5.5 1.1 2.0 2.0 
Lansoprazole 10.1 8.2 10.4 3.9 8.8 2.2 3.1 9.8 
Lidocaine  12.3 7.0 6.8 1.8 8.6 1.8 3.8 3.2 
Loperamide 18.3 6.7 14.2 2.5 3.2 5.7 11.7 13.7 
Loratadine 23.0 97.7 22.0 164.7 18.2 5.1 15.0 22.1 
Losartan 14.4 4.0 10.8 5.4 1.0 6.3 7.0 3.8 
Metoclopramide 12.8 8.4 10.3 2.1 4.6 1.8 2.7 3.7 
Metoprolol 13.4 10.6 7.5 5.5 9.5 1.2 3.5 3.7 
Mirtazapine 11.7 3.6 10.0 4.4 8.5 3.0 3.1 3.6 
        continued 
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Nifedipine 32.0 45.7 47.8 18.2 24.0 13.4 9.3 28.5 
Omeprazole 16.4 1.8 6.9 3.9 7.4 6.6 6.0 10.3 
Oxprenololb 2.5 7.9 6.7 7.1 4.8 4.0 3.1 4.4 
Pantoprazole 11.7 12.8 26.6 6.3 20.3 5.1 7.1 8.8 
Phenytoin 13.1 13.9 6.5 6.6 8.6 1.2 4.6 4.4 
Piroxicam nd nd nd nd nd nd 3.7 3.2 
Procyclidine 20.2 8.1 6.0 3.9 7.8 6.5 6.5 7.9 
Propranolol 13.6 3.3 7.7 3.8 6.9 2.4 4.4 6.5 
Quinine 15.6 4.7 11.3 3.4 14.6 3.7 3.3 5.5 
Ranitidine 20.7 32.2 31.2 19.2 16.5 15.8 1.9 21.8 
Sulfasalazine 10.9 4.7 6.7 5.7 5.3 0.9 3.8 5.6 
Salbutamol  4.2 10.7 9.2 1.4 43.1 4.6 4.7 5.8 
Sertraline 20.6 22.1 11.8 3.4 1.7 4.1 6.2 11.2 
Sotalolb 9.2 8.5 7.9 4.0 5.7 2.5 3.1 2.5 
Sumatriptanb 11.6 9.0 14.4 5.3 5.2 3.9 2.5 5.9 
Tamsulosin 28.4 5.0 29.1 5.7 11.1 15.9 23.5 27.6 
Telmisartan 14.9 11.1 7.6 5.2 4.9 1.2 6.0 8.9 
Terbinafine 35.8 17.0 nd nd nd nd nd nd 
Timolol 32.2 19.5 18.5 12.3 22.2 15.8 8.3 10.2 
Tramadolb 12.8 5.9 8.2 4.4 8.0 1.5 3.5 0.2 
Trazodone 27.5 25.0 6.6 3.8 10.3 0.6 6.3 7.0 
Trimethoprim 13.4 8.4 7.5 3.6 8.1 0.9 3.8 0.2 
Valsartanb 23.6 4.5 18.1 17.2 6.2 8.4 5.0 13.1 
Venlafaxine 13.5 6.8 7.8 4.3 7.4 2.5 3.4 0.3 
Verapamil 31.0 12.2 2.2 2.7 7.4 5.1 3.0 12.7 
Warfarin 16.8 9.0 10.1 5.6 6.6 2.5 14.8 8.7 
        continued 
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Table 4.4 (continued) 
 
Key 
RSDs expressed as a percentage 
a obtained from negative ion data 
bidentified in both positive and negative ionisation 
nd - not identified in extract 
 
 
 
 
 
 
 
 
 
 
 
 
254 
 
4.4.1    Comparison of uptakes of 68 pharmaceuticals by Chemcatcher® and 
POCIS 
 
The uptake of the range of pharmaceuticals identified at all sites was similar in both 
samplers and a simple scatter plot of the averaged data, as shown in Figure 4.2, shows 
that the variance is not constant but increases with the amount of compound 
accumulated. Individual regression fits for the 3 sites, including the co-deployment at 
the Gowerton site, are shown below and there appears to be little variation between 
the sites. 
 
Carmarthen; POCIS (average) = - 115,259 + 2.843 Chemcatcher® (average),r2 = 97.2 % 
Gowerton 1; POCIS (average) = 20,715 + 2.457 Chemcatcher® (average), r2  = 95.8% 
Gowerton 2; POCIS (average) = - 57,104 + 2.288 Chemcatcher® (average), r2= 98.4%  
Llanelli; POCIS (average) = 217,632 + 2.462 Chemcatcher® (average), r2 = 90.6% 
 
Log transforming the data to Log base10 indicated a much smaller deviation from 
normality as seen in Figure 4.3, with the exception of one unusual value for the 
compound Loratadine in the POCIS sampler deployed at the Carmarthen site. 
 
A principal component analysis, using standardised variables, (340) for all replicates 
at all sites indicated that one major component accounted for 98.3% of the total 
variation. This is what the two samplers have in common whilst the second 
component shows the contrast between the two samplers and this accounted for only 
1.7% of the total variation and was probably based on random variation (see Table 
4.5).  
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4.4.2     Analysis of variance of pharmaceuticals identified in co-deployments 
undertaken at the Gowerton site 
 
A two-way ANOVA, with sample repeat and passive sampler type was undertaken 
on the areas obtained for the 68 pharmaceuticals identified in the two sets of passive 
samplers co-deployed in the final effluent stream at Gowerton.  An interaction 
between sample repeat and sampler type was also calculated.  A significant difference 
was observed between sampler types (f = 29.71, p = <0.001) but not between the 
locations (f = 0.33, p = 0.565) and there was no significant interaction (f = 0.29, p = 
0.591) as shown in Table 4.6. 
 
The ratio of the summed peak areas for the 68 pharmaceuticals obtained from both 
sets of samplers was approximately 2.53. The ratio of the mean peak areas for the 68 
pharmaceuticals from both sets of samplers at the two deployment locations was 2.48 
and 2.23 for Gowerton 1 and 2 respectively with an average value of 2.35. Therefore, 
the sampling rate of POCIS was approximately 2.4 times that of the Chemcatcher® as 
shown in Table 4.6. 
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Figure 4.2 Overlaid scatter plots with regression lines of the averaged peak 
areas for pharmaceuticals identified in POCIS and Chemcatcher® at all sites 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 Overlaid scatter plots with regression lines of the averaged Log10 
peak areas for pharmaceuticals identified in POCIS and Chemcatcher® at all 
sites. 
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Table 4.5 Principal component analysis for pharmaceuticals identified in the 
co-deployments undertaken at the Gowerton site. 
 
 
Eigenanalysis of the correlation matrix 
 
Eigenvalue 1.9166 0.0834 
Proportion 0.958 0.042 
Cumulative        0.958 1 
 
Variable PC1 PC2 
POCIS 0.707 0.707 
Chemcatcher® 0.707 -0.707 
 
 
 
Table 4.6 Two-way ANOVA with sample repeat and passive sampler type for 
pharmaceuticals identified in the co-deployments undertaken at the Gowerton 
site. 
 
Analysis of Variance 
 
Source DF Adj SS Adj MS F-Value   P-Value 
Samplera 1 3.05E+14   3.05E+14 29.71     < 0.001 
Locationb           1 3.40E+12   3.40E+12      0.33 0.565 
Sampler * 
Site           
1 2.97E+12   2.97E+12      0.29 0.591 
Error   812 8.35E+15   1.03E+13   
Total   815 8.66E+15    
aSampler = Chemcatcher® or POCIS 
bLocation ‘1’ or ‘2’ at Gowerton 
 
Total summed peak areas  
POCIS  1816277943 
Chemcatcher®  716559868 
Ratio 2.53 
 
 
Tables of means 
Location Chemcatcher® POCIS Ratio 
Gowerton  1                   908781 2253177 2.48 
Gowerton 2 900407 2003324 2.23 
  
Mean 2.35 
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4.4.3     Least squares and orthogonal regression analysis of the averaged 
pharmaceutical Chemcatcher® and POCIS data 
 
Orthogonal regression or Deming regression (341) is used where two variables each 
have an independent error distribution. This is in contrast with ordinary least squares 
regression where the predictor (x variable) is a fixed variable with no error and all of 
the error is associated with the dependent variable (y). In least squares regression, the 
fitted line gives the minimum deviation of the y-values from the fitted line. In 
orthogonal regression, the fitted line corresponds to the minimum deviations at right 
angles to the fitted line and is equivalent to the first principal component (341). The 
interpretation of the regression parameters of an orthogonal regression is similar to 
that for least squares. 
 
The output from the least squares regression, with the Chemcatcher® data as the 
predictor, is shown in Table 4.7 with the plot of residuals shown in Figure 4.4. The 
variation accounted for by the regression (r2) is 94.7% with a slope of 2.50 (t = 69.33, 
p = <0.001) and an intercept of 35,028 (t = 0.52, p = 0.61) which was not significantly 
different from zero since it falls within the confidence range (-98,625, 168,680) that 
contains zero. This indicates that the sampling rate of POCIS is approximately 2.5 
times higher than for the Chemcatcher®. The output from orthogonal regression is 
shown in Table 4.8, with the plot of residuals shown in Figure 4.5. The slope obtained 
from orthogonal regression was 2.62 which is significantly different from zero since 
the approximate 95 % confidence range is 2.7 to 3. The value of 2.62 does, however, 
fall just outside this range which reflects the lack of normality and homogeneity in 
the variance. However, since it is close, and the intercept -71,700 is not significantly 
different from zero it can be taken that the two samplers are behaving in a similar 
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manner, but with the sampling rate of POCIS being 2.6 times that of the 
Chemcatcher®. The plots of standardised residuals from the least squares and 
orthogonal regression plots show 9 large values greater than 3, which are for the 
compounds fexofenadine, lamotrigine and tramadol at all sites. These large residuals 
had little influence on the slope as removing them from the data set and performing a 
least squares regression on the remaining data produced a change in slope of only 
0.03 and the intercept was almost unchanged at 34,273. 
 
Least squares and orthogonal regression regression analysis was performed on the 
averaged Log10 transformed Chemcatcher
® and POCIS pharmaceutical data. The 
outputs are discussed in A1.1 and shown in Tables A1 & A2 plus Figures A1 & A2 
in Appendix A.  
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Table 4.7 Output from least squares regression analysis of the averaged 
pharmaceutical Chemcatcher® and POCIS data. 
 
 
Regression Equation 
POCIS (average) = 35028 + 2.4948 Chemcatcher® (average) 
 
Model Summary 
S R-sq R-sq(adj) PRESS R-sq(pred) 
990905 94.68% 94.66% 2.90E+14 94.17% 
 
Analysis of Variance 
Source DF Seq SS Contrib Adj SS Adj MS F-Value P-Value 
Regression 1 4.72E+15 94.68% 4.72E+15 4.72E+15 4806.6 < 0.001 
Chemcatcher® 
(average) 
1 4.72E+15 94.68% 4.72E+15 4.72E+15 4806.6 < 0.001 
Error 270 2.65E+14 5.32% 2.65E+14 9.82E+11 
  
Total 271 4.98E+15 100.00% 
    
 
Coefficients 
Term Coef SE Coef 95% CI T-Value P-Value VIF 
Constant 35028 67886 (-98625, 168680)   0.52 0.606 
 
Chemcatcher® 
(average) 
2.4948 0.036 (2.4240, 2.5657) 69.33 < 0.001 1.00 
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Figure 4.4 Fitted line regression and plots of standardised residuals obtained 
from least squares regression analysis of the averaged pharmaceutical 
Chemcatcher® and POCIS data. 
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Table 4.8 Output from the orthogonal regression analysis of the averaged 
pharmaceutical Chemcatcher® and POCIS data. 
 
 
Error Variance Ratio: POCIS (average)/Chemcatcher® (average): 1 
 
Regression Equation 
 
POCIS (average) = -71688 + 2.616 Chemcatcher® (average) 
 
Coefficients 
 
Predictor Coef SE Coef Z P Approx 95% CI 
Constant -7.17E+04 69719.2  -1.0282 0.304 (-208335, 64959.1) 
Chemcatcher® 
(average) 
2.61636         0.0 69.3239 < 0.001 (           3,         2.7) 
 
 
Error Variances   
     
 Variable Variance 
POCIS (average) 1.29962E+11 
Chemcatcher® (average) 1.29962E+11 
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Figure 4.5 Fitted line regression and plots of standardised residuals obtained 
from the orthogonal regression analysis of the averaged pharmaceutical 
Chemcatcher® and POCIS data. 
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4.4.4    Statistical analysis of ‘unknown’ features or peaks  
 
As stated in 4.1, the POCIS sampler uses the Waters OASIS HLB sorbent which has 
been used extensively for the determination of pollutants in the aqueous environment 
with typical Log10 Kow values up to 4. The choice of compounds to represent a Log10 
Kow cut-off of 4 for the data obtained was accomplished by choosing six pH neutral 
compounds, at the mobile phase pH value of 4.05, contained within the personal 
compound database library in Chapter 3. Six hormones (five synthetic and one 
natural); betamethasone-17-valerate, clobetasol propionate, fluticasone propionate, 
medroxyprogesterone-17-acetate, mometasone furoate and progesterone have 
calculated Log10 Kow values of 3.78, 3.98, 3.73, 4.11, 4.27 and 4.04 as determined 
using the ACD Labs Percepta Platform PhysChem module available on the Royal 
Society of Chemistry’s Chemspider website (http://www.chemspider.com/) and 
experimentally determined retention times of 20.77, 19.70, 19.74, 20.13, 19.78 and 
20.30 min respectively. Average values of 3.99 and 20.07 min for Log10 Kow and 
retention time respectively represent an appropriate retention time cut-off of 20 min 
for the evaluation of ‘unknowns’ data. 
 
Non-targeted metabolomics type studies, such as this work, seek to analyse as wide a 
range of compounds as possible. The use of LC-MS for this purpose has found a wide 
range of applications, including drug discovery, disease biomarker discovery, 
pesticide and wastewater analysis (342). LC-MS, however, suffers from lower 
reproducibility in comparison to other analytical techniques (e.g. nuclear magnetic 
resonance (NMR) spectroscopy) for the analysis of ‘unknowns’, therefore peak areas 
obtained from features identified in replicate sampler types at each site were averaged 
and, together with replicate data, subjected to statistical evaluation.  
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Negative ion data was not used for statistical evaluation as the instrument’s high-gain 
amplifier developed a fault leading to saturation of peaks at low peak area counts with 
significant mass errors rendering the data unusable.    
 
 
4.4.5    Comparison of uptakes of ‘unknown’ compounds by Chemcatcher® and 
POCIS 
 
The uptake of the range of 2,204 ‘unknowns’ identified at all sites, in positive ion 
mode, is similar in both samplers and a simple scatter plot with fitted lines was made 
from averaged data from all sites. The variance is not constant but increases with the 
amount of compound accumulated as shown in Figure 4.6. Individual least squares 
regression fits for the three sites, including the co-deployment at the Gowerton site, 
are shown below and there appears to be little variation between two sites (Gowerton 
and Llanelli) but a larger variation is observed for the Carmarthen site. Log 
transforming the data to Log base10 indicated a much smaller deviation from 
normality as seen in Figure 4.7.  
 
Carmarthen, POCIS (average) = 86,481 + 2.116 Chemcatcher® (average), r2 = 92.2% 
 
Gowerton 1, POCIS (average) = 144,291 + 1.626 Chemcatcher® (average), r2 = 85.3% 
 
Gowerton 2, POCIS (average) = 89,766 + 1.763 Chemcatcher® (average), r2 = 93.7% 
 
Llanelli, POCIS (average) = 107,084 + 1.824 Chemcatcher® (average),r2 = 80.7% 
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Figure 4.6 Overlaid scatter plots with regression lines of the averaged peak 
areas for ‘unknowns’ obtained from POCIS and Chemcatcher® for all WWTPs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7 Overlaid scatter plots with regression lines of the averaged Log10 
peak areas for ‘unknowns’ obtained from POCIS and Chemcatcher® for all 
WWTPs. 
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4.4.6    Analysis of variance of ‘unknowns’ identified in co-deployments 
undertaken at the Gowerton WWTP 
 
A principal component analysis (using standardised variables) for all replicates at all 
sites, indicated that one major component accounted for 95.8% of the total variation 
(Table 4.9), this is what the two samplers have in common whilst the second 
component shows the contrast between the two samplers and this accounted for only 
4.2% of the total variation and was probably based on random variation. 
 
A two-way ANOVA (Table 4.10), with sample repeat and passive sampler type was 
undertaken on the areas obtained for the 2204 features identified in the two sets of 
passive samplers co-deployed in the final effluent stream at Gowerton.  An interaction 
between sample repeat and sampler type was also calculated.  A significant difference 
was observed between sampler types but not between samples and there was no 
significant interaction. The ratio of the summed peak areas obtained from both sets 
of samplers was approximately 2.05. The ratio of the mean peak areas from both sets 
of samplers at the two deployment locations was 1.96 and 1.91 for Gowerton 1 and 2 
respectively with an average value of 1.93. Therefore, the sampling rate of POCIS is 
approximately 1.93 times that of the Chemcatcher®. 
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Table 4.9 Principal component analysis of ‘unknowns’ identified in co-
deployments undertaken at the Gowerton WWTP. 
 
Eigenanalysis of the correlation matrix 
 
Eigenvalue 1.9166 0.0834 
Proportion 0.958 0.042 
Cumulative 0.958 1 
 
Variable PC1 PC2 
POCIS 0.707 0.707 
Chemcatcher® 0.707 -0.707 
 
 
 
Table 4.10 Two-way ANOVA with sample repeat and passive sampler type for 
co-deployments undertaken at the Gowerton WWTP. 
 
 
Analysis of variance 
Source DF Adj SS Adj MS F-Value P-Value 
Samplera 1 5.20E+14 5.20E+14 85.88 < 0.001 
Siteb 1 5.87E+10 5.87E+10 0.01 0.922 
Sampler*Site 1 2.97E+11 2.97E+11 0.05 0.825 
Error 13220 8.01E+16 6.06E+12 
  
Total 13223 8.06E+16 
   
 aSampler = Chemcatcher® or POCIS 
 bSite = Location ‘1’ or ‘2’ at Gowerton 
 
Total summed peak areas 
 
POCIS  10891662241 
Chemcatcher®  5317346067 
Ratio 2.05 
 
Tables of means 
 
Location Chemcatcher® POCIS Ratio 
Gowerton  1                   422152 828402 1.96 
Gowerton  2 427417 814710 1.91 
  
Mean 1.93 
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4.4.7    Least squares and orthogonal regression analysis of the ‘unknowns’ data 
obtained from all replicates of Chemcatcher® and POCIS 
 
The output from the least squares regression is shown in Table 4.11. The variation 
accounted for by the regression (r2) is 84.0%. The slope of the regression is 1.76 (t = 
263.54, pr = < 0.001) which is significantly different from zero since the approximate 
95% confidence interval is 1.75 to 1.78. The intercept of 114,473 (t = 11.1, pr = < 
0.001) is not significantly different from zero as it falls within the 95% confidence 
range of 94,257 to 134,688, it can be taken that the two samplers are behaving in a 
similar manner, but with the sampling rate of POCIS being 1.76 times that of the 
Chemcatcher®. The plots of residuals in Figure 4.8 displays significant 
heteroscedasticity (non-homogeneity) with a few extreme standardised residual 
values in the range 5–25. The variance is not constant but increases with the amount 
of compound accumulated. 
 
The output from the orthogonal regression is shown in Table 4.12. The slope of the 
regression is 2.03 which is significantly different from zero since the approximate 
95% confidence interval is 2.0. The intercept of 8,986 is not significantly different 
from zero since it falls within the 95% confidence range that contains zero, therefore 
it can be taken that the two samplers are behaving in a similar manner, but with the 
sampling rate of POCIS being 2.03 times that of the Chemcatcher®. The plots of 
residuals in Figure 4.9 also displays significant heteroscedasticity with a few extreme 
standardised residual values in the range 5–35 and the variance is not constant but 
increases with the amount of compound accumulated. 
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Table 4.11  Output from least squares regression analysis of ‘unknowns’ in all replicates of POCIS and Chemcatcher®. 
 
Analysis of Variance  
Source DF Seq SS Contribution Adj SS Adj MS F-Value P-Value 
Regression 1 9.10E+16 84.01% 9.10E+16 9.10E+16 69451.16 < 0.001 
Chemcatcher® 1 9.10E+16 84.01% 9.10E+16 9.10E+16 69451.16 < 0.001 
Error 13222 1.73E+16 15.99% 1.73E+16 1.31E+12 
  
Lack-of-Fit 12898 1.70E+16 15.70% 1.70E+16 1.32E+12 1.35 < 0.001 
Pure Error 324 3.18E+14 0.29% 3.18E+14 9.80E+11 
  
Total 13223 1.08E+17 100.00% 
    
 
   Model Summary 
S R-sq R-sq(adj) PRESS R-sq(pred) 
1144897 84.01% 84.01% 1.77E+16 83.66% 
 
Coefficients 
Term Coef SE Coef 95% CI T-Value P-Value VIF 
Constant 114473 10313 (  94257,  134688)   11.1 < 0.001 
 
Chemcatcher® 1.76364 0.00669 (1.75052, 1.77676) 263.54 < 0.001 1.00 
 
Regression Equation 
POCIS = 114473 + 1.76364 Chemcatcher® 
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Figure 4.8 Fitted line and plots of standardised residuals obtained from least 
squares regression analysis of ‘unknowns’ in all replicates of POCIS and 
Chemcatcher®. 
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Table 4.12 Output from orthogonal regression analysis of ‘unknowns’ in all 
replicates of POCIS and Chemcatcher®.  
 
 
Error Variance Ratio (POCIS/Chemcatcher®): 1 
 
Regression Equation 
POCIS = 8987 + 2.026 Chemcatcher® 
 
Coefficients 
Predictor Coef SE Coef Z P Approx 95% CI 
Constant 8986.923 10963.5     0.8197 0.412 (-12501.1, 30474.9) 
Chemcatcher® 2.02598         0.0 263.5347 < 0.001 (         2.0,         2.0) 
 
 
Error Variances 
Variable Variance 
POCIS 2.87E+11 
Chemcatcher® 2.87E+11 
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Figure 4.9 Fitted line and plots of standardised residuals obtained from 
orthogonal regression analysis of ‘unknowns’ in all replicates of POCIS and 
Chemcatcher®. 
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4.4.8 Least squares and orthogonal regression analysis of the averaged 
‘unknowns’ data obtained from Chemcatcher® and POCIS 
 
The output from the least squares regression is shown in Table 4.13. The variation 
accounted for by the regression (r2) is 84.8% and the slope of the regression is 1.77 (t 
= 157.01, pr = < 0.001) which is significantly different from zero since the 
approximate 95% confidence interval is 1.75-1.79. The intercept of 111,421 (t = 6.42, 
pr = < 0.001) falls within the 95% confidence range of 77,403 to 145,438 which does 
not include zero. As it is close to zero it can be taken that the two samplers are 
behaving in a similar manner, but with the sampling rate of POCIS being 1.77 times 
that of the Chemcatcher®. The values for the slope and intercept based on the 
averaged data are very similar to those obtained from the least squares regression for 
all replicates which indicates that the replicate data does not show significant 
variability. The plots of residuals in Figure 4.10 displays heteroscedasticity but as 
expected with fewer extreme standardised residual values. The variance is not 
constant but increases with the amount of compound accumulated. 
 
The output from the orthogonal regression is shown in Table 4.14. The slope of the 
regression is 2.02 which is significantly different from zero since the approximate 
95% confidence interval is 2.0. The intercept of 11,951 is not significantly different 
from zero since it falls within the 95% confidence range that contains zero (-24,073.9, 
47,975.4), therefore it can be taken that the two samplers are behaving in a similar 
manner, but with the sampling rate of POCIS being 2.02 times that of the 
Chemcatcher®. The plots of residuals in Figure 4.11 also displays significant 
heteroscedasticity but with few extreme standardised residual values in the range 5–
30.  
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To assess the overall impact of the extreme residual values on the least squares 
regression, a statistical measure called DFITS was used to determine whether an 
observation was unusual. DFITS uses the leverage and deleted (studentised) residual 
to calculate the difference between the fitted value calculated with and without the ith 
observation. DFITS represents roughly the number of estimated standard deviations 
that the fitted value changes when the ith observation is removed from the data. 
According to Belsley, Kuh and Welsch (343), observations with DFITS value greater 
than 2√
𝒌
𝒏
 deserve attention where k is the number of estimated coefficients and n is 
the sample size. Based on the number of data points (4,408) obtained after averaging, 
a DFITS value of between -0.031 and 0.031 was calculated and any data points 
outside this range were removed (a total of 140 or 3.8% of the data set) as they were 
considered to exhibit significant leverage. The remaining data, within the range -
0.031 and 0.031, was re-plotted using least squares regression and the slope obtained 
compared to the original.  
 
The output from the least squares regression is shown in Table B1 (Appendix B). The 
variation accounted for by the regression (r2) is 89.4% and the slope of the regression 
is 1.9 (t = 7.46, pr = <0.001) which is significantly different from zero since the 
approximate 95% confidence interval is 1.87-1.91. The intercept of 33154 (t = 6.42, 
pr = <0.001) falls within the 95% confidence range of 24,440 to 41,868 which does 
not include zero. As it is close to zero it can be taken that the two samplers are 
behaving in a similar manner, but with the sampling rate of POCIS being 1.9 times 
that of the Chemcatcher®. The value for the slope is very similar to that obtained 
(1.77) from the least squares regression for the averaged data prior to application of 
DFITS, indicating that the extreme residuals had very little influence on the slope. 
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The plots of residuals in Figure B1 (Appendix B) displays lower extreme residual 
values (all less than 8) and almost equally distributed above and below zero. To assess 
the overall impact of the extreme residual values on the orthogonal regression, 
standardised residuals were used to assess the regression model. If the normal linear 
model holds, the standardised residuals have approximately standard normal 
distributions. Therefore, approximately 95% of them will be between -2 and +2. 
Standardised residuals greater than 2 were removed (a total of 72 or 1.6% of the data 
set) and the remaining data re-plotted using orthogonal regression. 
 
The output from the orthogonal regression is shown in Table B2 (Appendix B). The 
slope of the regression is 2.11 which is significantly different from zero since the 
approximate 95% confidence interval is between 2.10 and 2.13. The intercept of -
16,572 falls within the 95% confidence range of (-27,759 and -5,386) and almost 
includes zero. It can therefore be taken that the two samplers are behaving in a similar 
manner, but with the sampling rate of POCIS being 2.1 times that of the 
Chemcatcher®. The value for the slope is very similar to that obtained (2.02) from the 
orthogonal regression for the averaged data prior to application of standardised 
residuals filter, indicating that the extreme residuals had very little influence on the 
slope. The plots of residuals in Figure B2 (Appendix B) displays lower extreme 
residual values (all less than 8.5) and almost equally distributed above and below 
zero.  
Least squares and orthogonal regression regression analysis was performed on the 
averaged Log10 transformed Chemcatcher
® and POCIS ‘unknowns’ data. The outputs 
are discussed in C1.1 and shown in Tables C1 & C2 plus Figures C1 & C2 in 
Appendix C.  
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Table 4.13     Output from least squares regression analysis of the averaged Chemcatcher® and POCIS ‘unknowns’ data. 
 
Analysis of Variance 
Source DF Seq SS Contrib. Adj SS Adj MS F-Value P-Value 
Regression 1 3.05E+16 84.84% 3.05E+16 3.05E+16 24652.21 < 0.001 
Chemcatcher® 
(average) 
1 3.05E+16 84.84% 3.05E+16 3.05E+16 24652.21 < 0.001 
Error 4406 5.45E+15 15.16% 5.45E+15 1.24E+12 
  
Total 4407 3.59E+16 100.00% 
    
 
Model Summary 
S R-sq R-sq(adj) PRESS R-sq(pred) 
1111946 84.84% 84.83% 5.85E+15 83.71% 
 
Coefficients 
Term Coef SE Coef 95% CI T-Value P-Value VIF 
Constant 111421 17351 ( 77403, 145438) 6.42 < 0.001 
 
Chemcatcher® 
(average) 
1.7712 0.0113 (1.7491, 1.7933) 157.01 < 0.001 1.00 
 
Regression Equation 
POCIS (average) = 111421 + 1.7712 Chemcatcher® (average) 
278 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10 Fitted line and plots of standardised residuals obtained from least 
squares regression analysis of the averaged Chemcatcher® and POCIS 
‘unknowns’ data. 
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Table 4.14 Output from orthogonal regression analysis of the averaged 
Chemcatcher® and POCIS ‘unknowns’ data. 
 
 
Error Variance Ratio POCIS (average) / Chemcatcher® (average): 1 
 
Regression Equation 
POCIS (average) = 11951 + 2.019 Chemcatcher® (average) 
 
Coefficients 
Predictor Coef SE Coef Z P Approx 95% CI 
Constant 11950.75 18380.3     0.6502 0.516 (-24073.9, 47975.4) 
Chemcatcher® 
(average) 
2.01861         0.0 157.0083 < 0.001 (         2.0,         2.0) 
 
Error Variances 
Variable Variance 
POCIS (average) 2.70E+11 
Chemcatcher® (average) 2.70E+11 
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Figure 4.11 Fitted line and plots of standardised residuals obtained from 
orthogonal regression analysis of the averaged Chemcatcher® and POCIS 
‘unknowns’ data. 
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4.4.9 Mass and retention time profiling of passive sampling extracts 
 
The mass/retention time profiling plots obtained from the Chemcatcher® and POCIS 
extracts for the Carmarthen site were almost identical (Figure 4.12) with 4,695 and 
4,967 features detected for the Chemcatcher® and POCIS samplers respectively, 
amounting to 6% more features detected in the POCIS. The mass/feature and 
retention time/feature histograms in Figure 4.18 clearly shows the similarity obtained 
from both samplers at the Carmarthen site. This observation was unexpected as the 
larger surface sampling area of the POCIS was anticipated to sequester more 
compounds present at lower concentrations in the effluent stream which may have 
gone undetected in the Chemcatcher® extract. Both samplers can therefore be shown 
to be behaving in an identical manner at the Carmarthen site.  
 
The overall mass/retention time profiles for the Gowerton site was again almost 
identical for both samplers (Figures 4.13 and 4.14) with a negligible difference in the 
number of features found in the co-deployed samplers. The number of features 
detected were 4,570/4,952 in the Gowerton ‘1’ deployment with 4572/4944 features 
detected in the Gowerton ‘2’ deployment for the Chemcatcher® and POCIS samplers 
respectively. This amounted to an average of 8% more features detected in the POCIS 
samplers. The mass/feature and retention time/feature histograms in Figure 4.19 and 
4.20 show the similarity obtained from both samplers site and they can therefore be 
shown to be behaving in a very similar manner at the Gowerton site. 
 
The mass/retention time profile obtained for the Llanelli site were significantly 
different between samplers (Figure 4.15). The number of features detected were 3,690 
and 4,872 for the Chemcatcher® and POCIS samplers respectively amounting to 32% 
282 
 
more features detected in the POCIS sampler. A clear distinction is seen in the mass 
histogram/feature histogram in Figure 4.21 and specifically so for features with 
molecular masses above 500 Da where the number of features detected in the 
Chemcatcher® was 35% of the number found in the POCIS. This is in stark contrast 
for features with molecular masses below 500 Da where the number of features found 
in the Chemcatcher® was 85% of the number found in the POCIS.  
 
The histograms in Figure 4.21 indicate that most of the features with molecular 
masses above 500 Da elute between 16 and 20 min. A zoomed in section of the 
mass/retention time profile plot (Figure 4.16) for both samplers in this time range 
show a very distinct pattern of features which exhibited mass differences of 14 and 
44 Da. These are, in all probability, homologous series of polyethoxylated 
compounds with differing alkyl chain lengths such as those found in domestic and 
industrial surfactants (344). These compounds readily degrade in waste water 
treatment plants to lower molecular mass compounds although sufficient 
concentrations remain intact and are readily detected in spot samples and passive 
sampling extracts (73, 345). Upon examining the summed peak areas, for features 
above 500 Da in all the Chemcatcher® extracts, the Llanelli site had the lowest value 
and was approximately 48% less than the Carmarthen site which had the largest 
summed peak area. Upon examining the individual peak areas, for features above 500 
Da in all the Llanelli Chemcatcher® extracts, many were close to the threshold value 
set for peak detection and integration. Therefore, the most likely reason for the 
difference in the molecular mass profiles of the Chemcatcher® and POCIS extracts 
for the Llanelli site, is that many features in the Chemcatcher® extract, which eluted 
between 16 and 20 min were below the detection limit of the Q-TOF-MS instrument. 
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The mass/retention time profiling plots obtained from the Chemcatcher® and POCIS 
field blank extracts for the Carmarthen site are shown in Figure 4.17 which show the 
presence of a low number of polyethoxylated compounds but which elute much 
earlier in the chromatogram than those observed in the actual deployments. In all 
likelihood, these originated from the polyethersulphone membrane and were not 
completely removed during the organic solvent cleaning step for the membranes as 
described in Chapter 3. 
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Figure 4.12   Plot of mass versus retention time for features identified in the Chemcatcher® (a) and POCIS (b) samplers 
deployed at the Carmarthen WWTP. 
a 
b 
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Figure 4.13   Plot of mass versus retention time for features identified in the Chemcatcher® (a) and POCIS (b) samplers deployed 
at the Gowerton ‘1’ WWTP. 
a 
b 
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Figure 4.14  Plot of mass versus retention time for features detected in the Chemcatcher® (a) and POCIS (b) samplers 
deployed at the Gowerton ‘2’ WWTP. 
a 
b 
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Figure 4.15 Plot of mass versus retention time for features detected in the Chemcatcher® (a) and POCIS (b) samplers deployed 
at the Llanelli WWTP. 
a 
b 
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Figure 4.16 ‘Zoomed-in’ section of the mass versus retention time plot (14.5–20 min, 420–900 Da) for the Chemcatcher® (a) and POCIS 
(b) samplers deployed at the Llanelli WWTP. 
a 
b 
Feature pattern typical of the presence of 
polyethoxylated compounds such as surfactants and 
their degradation products displaying mass differences 
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Figure 4.17 Plot of mass versus retention time for features detected in the Chemcatcher® (a) and POCIS (b) field blanks 
used at the Carmarthen WWTP.
a 
b 
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Figure 4.18    Retention time/feature (a) and mass/feature (b) histograms for the 
Chemcatcher® and POCIS samplers deployed at the Carmarthen WWTP. 
  
b 
a 
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Figure 4.19 Retention time/feature (a) and mass/feature (b) histograms 
for the Chemcatcher® and POCIS samplers deployed at the Gowerton ‘1’ 
WWTP. 
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Figure 4.20 Retention time/feature (a) and mass/feature (b) histograms 
for the Chemcatcher® and POCIS samplers deployed at the Gowerton ‘2’ 
WWTP. 
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Figure 4.21 Retention time/feature (a) and mass/feature (b) histograms 
for the Chemcatcher® and POCIS samplers deployed at the Llanelli WWTP. 
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4.5   Conclusions 
Fixty-six and 32 compounds exceeded 15 % RSD in the Chemcatcher® and POCIS 
extracts respectively, the higher RSD’s in the Chemcatcher® strongly correlated with 
peak area response which were approximately 3 times lower in the Chemcatcher. Only 
10 compounds exceeded 30% RSD in both samplers with the largest error observed for 
the POCIS sampler at 165% RSD for the compound loratadine.  The highest RSD 
observed for loratadine in the Chemcatcher® was only 23%. RSD’s obtained from 
negative ion analysis were generally lower for the Chemcatcher® sampler across all sites 
with five and three compounds exceeding 15 % RSD in the Chemcatcher® and POCIS 
extracts respectively. Only one compound, naproxen in the POCIS sampler, exceeded 
30% RSD in negative ion mode. 
 
Two-way ANOVA analysis of the pharmaceutical data indicated a significant 
difference between sampler types for the Gowerton co-deployments but not between 
location and there was no significant interaction between location and sampler. 
Principal component analysis for the Gowerton co-deployments indicated that one 
major component (i.e. the uptake rate) accounted for 98.3% of the total variation. Least 
squares regression of the data from each site produced slopes between 2.3 (Gowerton 
‘2’) and 2.8 (Carmarthen), the differences possibly due to the varying flow rates at each 
site which may have influenced one sampler more than the other. The slopes obtained 
from least squares and orthogonal regression of the entire averaged pharmaceutical data 
set suggests that the Chemcatcher® uptake rate is approximately 2.4 to 2.6 times lower 
than that for the POCIS. 
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Two-way ANOVA analysis of the features detected in the ‘unknowns’ data also 
indicated a significant difference between sampler types for the Gowerton co-
deployments but not between location and there was no significant interaction between 
location and sampler. Principal component analysis for the Gowerton co-deployments 
indicated that one major component (i.e. the uptake rate) accounted for 95.8% of the 
total variation. Individual least squares regression of the averaged data from each site 
show little variation between the slopes for two sites (1.6, 1.8 and 1.8 for Gowerton ‘1’, 
Gowerton ‘2’ and Llanelli respectively) but a larger variation was observed for the 
Carmarthen site with a slope of 2.1. The slopes obtained from least squares and 
orthogonal regression of the entire averaged ‘unknowns’ data set suggests that the 
Chemcatcher® uptake rate is approximately 1.9 to 2.1 times lower than that for the 
POCIS. The differences in the uptake rates for the pharmaceuticals and the ‘unknowns’ 
data is, in all probability, due to the larger sampling area of 45.8 cm2 for the POCIS 
sampler compared to 15.2 cm2 for the Chemcatcher®, a factor of 3.01.  
 
The mass profiling plots obtained for both samplers were almost identical for the 
Carmarthen site and very similar for the co-deployments at the Gowerton site. 
However, significant differences were observed between the samplers at the Llanelli 
site for features with masses above 500 Da. This was attributed to many features, 
eluting between 16–20 min, in the Llanelli Chemcatcher® sampler extract being just 
below the limit of detection of the Q-TOF-MS instrument.  
 
It can be concluded from the LC Q-TOF-MS analysis of the extracts from the 
Chemcatcher® and POCIS extracts and the extensive statistical analysis that the 
performance of the polar Chemcatcher® is very similar to that of the POCIS.  
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Chapter 5 
 
In-silico prediction of liquid chromatographic 
retention times to aid in the identification of unknown 
or suspect compounds  
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5.1      Introduction 
 
The purpose of this chapter was to address the analytical challenges associated with 
the tentative identification of ‘suspect’ or ‘known unknowns’ pollutants present in 
polar passive samplers deployed in the aquatic environment.  
 
Hyphenated LC/MS techniques allow for the fast and highly sensitive generation of 
detailed and information rich analytical data on the compounds studied in various 
environmental matrices. Despite the introduction of large MS/MS libraries and on-
line searchable MS/MS databases, a major shortcoming in suspect or screening 
approaches is the lack of chromatographic retention times which is essential for 
tentative compound identification. The lack of reference standards for new 
pharmaceuticals, metabolites, pesticides and the plethora of industrial chemicals, 
however, forces the analyst to find alternative tools for tentative compound 
identification.  
 
This chapter therefore focuses on the use of a software package to predict the retention 
times of compounds based on their structure and physicochemical properties and is 
evaluated with respect to accuracy and practical application.  
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5.2 Aims and objectives 
 
i) To develop a complementary approach, based on retention time prediction, 
for the analysis of suspect pollutants in polar passive sampling extracts.  
 
ii) To build a large comprehensive database of over 1550 compounds for use 
with liquid chromatographic retention time prediction software. The database 
would include known environmental pollutants including pharmaceuticals, 
pesticides, drugs of abuse and their metabolites. 
 
iii) To assess the ability of the liquid chromatographic retention time prediction 
software to accurately calculate retention times for pharmaceutical residues 
 
 
5.3 Experimental 
 
5.3.1     Reagents and standards 
 
All reagents and solvents were HPLC, LC/MS or analytical reagent grade. 
Ammonium formate, formic acid and methanol were purchased from Fisher Scientific 
UK (Loughborough, Leicestershire, UK) or Sigma-Aldrich (Gillingham, Dorset, 
UK). Ultrapure water was obtained from an in-house source (ELGA Purelab Ultra) 
and was used in all laboratory procedures (Elga Process Water, Marlow, 
Buckinghamshire, UK).  The ultrapure water system was equipped with a UV lamp, 
carbon and membrane filter to remove trace organic compounds, ionic species and 
particulates. Stock standard solutions, intermediate and working solutions used were 
prepared as in Chapter 3. 
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5.3.2 LC Q-TOF-MS analysis 
Chromatographic separation of compounds was carried out using a Dionex Ultimate 
3000 UHPLC system consisting of a vacuum degasser, binary Pump, high 
performance auto-sampler and thermostated column compartment. (Thermo Fisher 
Scientific, Bremen, Germany). 
 
The UHPLC system was interfaced to a Bruker Maxis Impact II Q-TOF mass 
spectrometer (Bruker Daltonics, Bremen, Germany). Chromatographic separation 
was performed on a Dionex Acclaim RSLC 120 C18 analytical column (2.1 i.d. × 100 
mm length, 2.2 μm particle size, Thermo Fisher Scientific, Dreieich, Germany). A 
guard column, Waters VanGuard, Acquity UPLC BEH C18 1.7 μm, (Dublin, Ireland), 
was placed ahead of the analytical column and both columns thermostated at 30˚C.  
The entire system was operated with Bruker HyStar acquisition software (rev. 3.2). 
 
The Q-TOF-MS was equipped with an electrospray ionisation source, operating in 
positive ionisation mode only. The mobile phase was (A) methanol with 5 mM 
ammonium formate and 0.01 % v/v formic acid and (B) an aqueous solution 
comprised of 10 % of methanol, 5 mM ammonium formate and 0.01 % formic acid. 
The gradient and flow elution programme was: 0 min,1 % B, 0.2 mL/min; 3 min, 39 
% B, 0.2 mL/min; 14 min, 99.9 % B, 0.4 mL/min; 16 min, 99.9 % B, 0.480 mL/min; 
16.1 min, 1% B, 0.480 mL/min; 19 min, 1 % B, 0.480 mL/min; 19.1, 1 % B, 0.2 
mL/min; 20 min, 1 % B, 0.2 mL/min. 
 
The Q-TOF-MS operation parameters were: capillary voltage, 2500 V; end plate 
offset, 500 V; nebulizer pressure, 2 bar (N2); drying gas, 8 L/min (N2); and drying 
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temperature, 200 °C. The injection volume was 20 µL. The Q-TOF-MS system was 
used in broadband collision-induced dissociation (bbCID) acquisition mode and 
recorded spectra over the range 30−1000 Da at a scan rate of 2 Hz. The Bruker 
‘bbCID’ mode provides MS and MS/MS spectra at the same time, while it works at 
two different collision energies. A low collision energy of 6 eV was used to acquire 
MS spectra, and a higher energy setting of 30 eV was used to obtain MS/MS spectra. 
The higher energy setting was ramped from 80–120 % of its value (i.e from 24-36 
eV). Data was collected by the mass spectrometer between 0.1 and 15.0 min. 
 
A mass axis calibration was undertaken at the beginning of every chromatogram by 
infusing a mixture of 1 mM sodium formate in water/isopropanol/formic acid 
(1:1:0.01 v/v/v) with a syringe pump into the mass spectrometer ahead of the elution 
of the first target compound from the analytical column.  
 
 
5.3.3 Formation of database 
An in-house customised database for use with the ACD Labs ‘Chrom Genius’LC 
method development software was compiled from a commercial database 
‘ToxScreener’ (Bruker Daltonics, Bremen, Germany) which contained accurate 
mass, retention time and fragment ion information for 1556 compounds including 
pharmaceuticals, pesticides, drugs of abuse and their metabolites. The ‘ToxScreener’ 
database was curated by toxicologists at the forensic institutes at the Universities of 
Freiburg, Germany and Helsinki, Finland. The fragment ions for each compound 
were obtained from two different collision energies as stated in 7.4. The full list of 
compounds appears in the Table D2 (Appendix D). 
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Of the 165 pharmaceuticals that were screened for in Chapter 3, 103 of these appeared 
in the ‘ToxScreener’ database. The 103 compounds were removed from the database 
to avoid any potential bias, and would be used as the ‘testing set’ of compounds for 
the determination of the accuracy of the retention time prediction model. Canonical 
simplified molecular line entry system strings (SMILES) were obtained from the 
ChemSpider website (Royal Society of Chemistry, UK) or created using ACD Labs 
ChemSketch (Advanced Chemistry Development, Inc., Toronto, Canada) for the 
remaining 1453 compounds in the database. These compounds were representative 
of the ‘training set’ that would be used to build the retention time prediction model. 
 
The SMILES notations generated for the ‘training set’ were then imported into ACD 
Labs ChromGenius software. ChromGenius software bases retention time prediction 
on physicochemical parameters that are calculated for the ‘training set’ compounds 
whose retention times had been measured previously. The parameters used to create 
a chromatographic model for a reverse phase liquid chromatographic method were: 
LogP, LogD, molecular weight (MW), molecular volume (MV), molar refractivity 
(MR), polar surface area (PSA), number of proton donors (NDon) and number of 
proton acceptors (NAcc). LogD values calculated from the chemical structure using 
pKa and LogKow values, were used to estimate the pH-dependent chromatographic 
behaviour of each compound under the chromatographic conditions used (mobile 
phase is approximately pH 4.1). The calculated physicochemical parameters were 
then used to model the chromatographic method (346).  
Multiple linear regression is then used to build a predictive quantitative structure-
retention relationship (QSRR) model using a ‘training set’ database that is most 
similar to the suspect compound. To find the most similar compounds in the ‘training 
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set’ database ChromGenius generates 2D ‘fingerprints’ and from these ‘fingerprints’ 
the software calculates a structural similarity value, with ‘1’ being identical, using the 
Tanimoto similarity index (347). The accuracy of the resulting QSRR model is 
dependent on the size of the database and the compounds in the ‘training set’, with 
similar structure, are used to build the QSRR model (346). A prediction equation was 
created and calculated retention times were stored in a method file. 
 
5.4 Results and discussion 
5.4.1 The correlation plot obtained from the ‘training set’ of compounds 
 
The correlation plot between the predicted and measured retention times for the 1453 
compounds obtained from the ‘training set’ is shown in Figure 5.1. A linear fit was 
used and the equation of the line with the intercept set at zero was y = 0.9781x. A 
mean absolute error of 0.95 min with a standard deviation of 1.25 min and a 
coefficient of determination, R2, of 0.8052 obtained. 
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Figure 5.1 Correlation between experimental and calculated retention times of 
1453 compounds in the ‘training set’ database.  
 
 
5.4.2 Retention time prediction from testing set of compounds 
The retention time predictions for each of the 103 compounds in the ‘testing set’ were 
obtained using two approaches. The first used the model based on the entire ‘training 
set’ (all compounds fit) and the second was performed using 50 of the most similar 
compounds (best 50 compounds fit) obtained by the Tanimoto coefficient similarity 
search which is based on chemical structure. As can be observed from the distribution 
of retention time errors both prediction fits produced similar error values for retention 
time prediction (Figure 5.2). A larger maximum absolute error value and a higher 
mean absolute error was obtained using the all compounds fit but this was only due 
to 4 compounds out of a total of 103 or < 4 % of the entire ‘testing set’ of compounds.  
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Figure 5.2  Distribution of retention time errors from both prediction models. 
 
The maximum measured retention time for the liquid chromatographic system was 
14.5 min (fenbutatin oxide) and the minimum 1.2 min (histidine). For all compounds 
within the retention time window of 13.3 min, the percenatge mean error in retention 
time prediction was 6.6 % and 6.2 % for the all compounds fit and best 50 compounds 
fit respectively. The mean absolute errors and standard deviations obtained were 0.88 
± 0.73 min and 0.82  ±  0.68 min for the all compounds fit and best 50 compounds fit 
respectively. When looking specifically at the all compounds fit 70 % of the 
compounds were within one minute and 93 % were within two minutes of their 
measured retention times with a maximum absolute error of 3.58 min for mebeverine. 
A very similar set of error values was obtained for the best 50 compounds fit option 
with 65 % of the compounds within one minute and 92 % within two minutes of their 
measured retention times with a maximum absolute error of 2.69 min again for 
mebeverine. The maximum error recorded for the training set was 6.95 min for the 
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Benzoxonium cation with a calculated retention time of 4.32 min and a measured 
retention time of 11.27 min. This large error is probably due to the predicted LogKow 
value of 1.39 not accurately reflecting the compound’s hydrophobicity under the 
acididc experimental conditions.   
 
Prediction errors were investigated for any apparent trends and predicted retention 
times for polar compounds eluting in the first 5 min were generally overestimated but 
the converse was not observed for less polar compounds eluting after 5 min. The all 
compounds fit and best 50 compounds fit options overestimated the retention time for 
21 and 24 compounds respectively within the -1 to -4 min window with only 11 and 
12 compounds respectively being underestimated within the same retention time 
window. With the exception of mebeverine, percentage retention time prediction 
errors improved after 5 min. 
 
Only eight compounds accounted for retention time prediction errors in excess of 2.0 
min for both fits. In retention time order these were; ropinirole, donepezil, 
mebeverine, erythromycin, cetirizine, salmeterol, irbesartan and telmisartan. A 
minimum match factor of 0.670 was set within the software which typically allowed 
for the calculation of similarity coefficient fits for over 30 compounds. The structure 
for each of the returned compounds was also displayed which allowed for a visual 
comparison with the compound’s structure whose prediction time was being 
calculated. Similarity coefficient fit values obtained for the best 10 matching 
structures were on average lower than 0.8 for the eight compounds mentioned above. 
The lower match values were reflected in the considerable differences between the 
chemical structures. A fundamental premise of using QSRR models on those 
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compounds in the ‘training set’ database, whose prediction time were being 
calculated, is that they will yield more accurate predictions. This was indeed observed 
for compounds where retention time differences of considerably less than 1 minute 
were observed between the calculated and measured retention times. Ibuprofen, 
labetalol, diclofenac, propranolol, flecainide, naproxen, enalapril, atenolol, 
trimethoprim, progesterone, oxybutynin, hydrocortisone-21-acetate, clomipramine, 
terbinafine and loratadine all had retention time errors less than 0.10 minute with a 
minimum of five similar structures within the ‘training set’ database and high 
similarity coefficient fit values of between 0.95 and 0.85. 
 
Guidelines for compound identification criteria intended for environmental screening 
analysis by liquid chromatographic retention time are not available. However, a 
technical document for identification criteria for qualitative assays in doping analysis 
by the World Anti-doping Agency (WADA) states that the liquid chromatographic 
retention time of the compound and reference standard should not differ by more than 
2 % or ± 0.1 min in the same analysis (348). The Society of Toxicological and 
Forensic Chemistry guidelines specify an acceptable tolerance of 5 % for relative 
retention time repeatability as one criterion for positive compound identification 
(349). Considering that the retention time criteria are for methods where reference 
materials must be used, a retention time repeatability limit of 10 % should be 
considered as acceptable for liquid chromatographic analysis where reference 
materials are unavailable or too expensive to source. In this work the retention times 
calculated by ChromGenius, using the best 50 compounds fit, were within ± 2 % for 
16 % (16), by ± 5 % for 28 % (29) and by ± 10 % for 54 % (56) of the compounds in 
the ‘testing set’ database. When using the all compounds fit, calculated retention 
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times were within ± 2 % for 13 % (13), by ± 5 % for 29 % (30) and by ± 10 % for 44 
% (45) of the compounds in the ‘testing set’ database. (Number of compounds appear 
in brackets). 
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Table 5.1  Distribution of retention time errors from both prediction models. 
 
No. Compound Experimental 
RTa 
Calculated RT from 
all compounds fita 
Calculated RT from 
best 50 compounds fita 
RT error from all 
compounds fita 
RT error from best 
50 compounds fita 
% error from all 
compounds fit 
% error from best 
50 compounds fit 
1 Sotalol 2.96 3.29 2.58 -0.33 0.38 11 -13 
2 Terbutaline 3.06 3.01 2.81 0.05 0.25 -2 -8 
3 Atenolol 3.09 2.95 3.01 0.14 0.08 -5 -3 
4 Salbutamol 3.11 2.84 2.48 0.27 0.63 -9 -20 
5 Ranitidine 3.14 4.37 3.72 -1.23 -0.58 39 18 
6 Moxonidine 3.26 4.39 4.78 -1.13 -1.52 35 47 
7 Sumatriptan 3.43 3.93 3.17 -0.5 0.26 15 -8 
8 Acetaminophen 3.48 5.11 4.16 -1.63 -0.68 47 20 
9 Varenicline 3.63 3.94 3.9 -0.31 -0.27 9 7 
10 Amiloride 3.68 2.97 5.27 0.71 -1.59 -19 43 
11 Scopolamine 3.83 4.3 3.44 -0.47 0.39 12 -10 
12 Clonidine 3.83 4.81 5.03 -0.98 -1.2 26 31 
13 Thephylline 3.84 5.1 5.48 -1.26 -1.64 33 43 
14 Amisulpride 3.88 4.5 4.17 -0.62 -0.29 16 7 
15 Lisinopril 3.98 4.13 5.55 -0.15 -1.57 4 39 
16 Hydroxychloroquine 3.98 5.83 5.78 -1.85 -1.8 46 45 
17 Ropinirole 3.98 6.11 5.53 -2.13 -1.55 54 39 
18 Trimethoprim 3.99 3.87 4.02 0.12 -0.03 -3 1 
19 Ipratropium 4.17 4.63 3.34 -0.46 0.83 11 -20 
20 Ofloxacin 4.27 4.75 5.21 -0.48 -0.94 11 22 
21 Metoclopramide 4.36 4.66 5.05 -0.3 -0.69 7 16 
             continued 
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22 Lidocaine 4.59 5.35 5.09 -0.76 -0.5 17 11 
23 Tramadol 4.81 5.52 5.93 -0.71 -1.12 15 23 
24 Metoprolol 4.86 4.58 4.48 0.28 0.38 -6 -8 
25 Timolol 4.88 3.93 3.79 0.95 1.09 -19 -22 
26 Fluconazole 5.06 6.36 6.37 -1.3 -1.31 26 26 
27 Celiprolol 5.24 4.93 5.06 0.31 0.18 -6 -3 
28 Lamotrigine 5.28 3.63 4.12 1.65 1.16 -31 -22 
29 Mirtazapine 5.31 6.12 6.77 -0.81 -1.46 15 27 
30 Quinine 5.49 6.21 6.09 -0.72 -0.6 13 11 
31 Oxprenolol 5.61 4.94 5.45 0.67 0.16 -12 -3 
32 Risperidone 5.69 7.05 7.25 -1.36 -1.56 24 27 
33 Labetalol 5.74 4.3 5.82 1.44 -0.08 -25 1 
34 Donepezil        5.81 8.98 8.39 -3.17 -2.58 55 44 
35 Bisoprolol 5.91 5.15 5.14 0.76 0.77 -13 -13 
36 Venlafaxine 6.11 5.97 6.58 0.14 -0.47 -2 8 
37 Chlorpheniramine 6.25 6.36 6.87 -0.11 -0.62 2 10 
38 Flecainide 6.44 5.67 6.46 0.77 -0.02 -12 0 
39 Propranolol 6.48 5.64 6.5 0.84 -0.02 -13 0 
40 Trazodone 6.48 6.1 6.21 0.38 0.27 -6 -4 
41 Citalopram 6.48 6.24 6.71 0.24 -0.23 -4 4 
42 Sulfasalazine 6.61 6.81 7.24 -0.2 -0.63 3 10 
43 Indapamide 6.61 7.49 7.67 -0.88 -1.06 13 16 
44 Mebeverine 6.79 10.37 9.48 -3.58 -2.69 53 40 
45 Bendroflumethiazide 6.82 6.99 7.18 -0.17 -0.36 2 5 
46 Enalapril 6.83 6.66 6.87 0.17 -0.04 -2 1 
47 Piroxicam 6.84 7.05 6.41 -0.21 0.43 3 -6 
48 Carvedilol 6.91 7.16 8.23 -0.25 -1.32 4 19 
                  continued 
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49 Cyclizine 6.94 6.07 6.28 0.87 0.66 -13 -10 
50 Haloperidol 6.94 6.53 6.66 0.41 0.28 -6 -4 
51 Verapamil 7.03 6.62 7.88 0.41 -0.85 -6 12 
52 Phenytoin 7.08 7.77 7.57 -0.69 -0.49 10 7 
53 Meloxicam 7.09 8.23 7.78 -1.14 -0.69 16 10 
54 Diltiazem-Cis 7.18 7.95 7.77 -0.77 -0.59 11 8 
55 Carbamazepine 7.35 7.93 8.37 -0.58 -1.02 8 14 
56 Omeprazole 7.49 7.84 8.21 -0.35 -0.72 5 10 
57 Promethazine 7.53 8.4 8.85 -0.87 -1.32 12 18 
58 Dosulepin 7.61 8.12 8.02 -0.51 -0.41 7 5 
59 Paroxetine 7.68 6.99 6.77 0.69 0.91 -9 -12 
60 Fexofenadine 7.68 8.91 9.36 -1.23 -1.68 16 22 
61 Procyclidine 7.8 7.01 7.3 0.79 0.5 -10 -6 
62 Hydrocortisone 7.82 6.9 7.35 0.92 0.47 -12 -6 
63 Erythromycin 7.83 6.84 5.61 0.99 2.22 -13 -28 
64 Bumetanide 7.83 7.04 6.77 0.79 1.06 -10 -14 
65 Sildenafil 7.88 7.6 8.82 0.28 -0.94 -4 12 
66 Losartan 8.19 9.57 10.67 -1.38 -2.48 17 30 
67 Amitriptyline 8.23 8.65 8.78 -0.42 -0.55 5 7 
68 Hydroxyzine 8.25 6.28 6.63 1.97 1.62 -24 -20 
69 Nebivolol 8.28 6.3 7.19 1.98 1.09 -24 -13 
70 Ketoprofen 8.28 8.38 8.72 -0.1 -0.44 1 5 
71 Nifedipine 8.31 9.27 9.75 -0.96 -1.44 12 17 
72 Amlodipine 8.36 6.81 7.6 1.55 0.76 -19 -9 
73 Dexamethasone 8.38 7.47 8 0.91 0.38 -11 -5 
74 Fluoxetine 8.43 7 7.78 1.43 0.65 -17 -8 
                        continued 
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75 Ramipril 8.56 7.96 8.81 0.6 -0.25 -7 3 
76 Bezafibrate 8.77 8.59 9.37 0.18 -0.6 -2 7 
77 Cetirizine 8.79 6.38 6.78 2.41 2.01 -27 -23 
78 Hydrocortisone-21-
acetate 
8.8 8.79 8.8 0.01 0 0 0 
79 Salmeterol 8.83 5.81 7.05 3.02 1.78 -34 -20 
80 Sertraline 8.85 7.87 8.58 0.98 0.27 -11 -3 
81 Chlorpromazine  8.89 9 9.54 -0.11 -0.65 1 7 
82 Oxybutynin 8.92 8.81 8.9 0.11 0.02 -1 0 
83 Naproxen 8.99 8.61 8.97 0.38 0.02 -4 0 
84 Valsartan 9 10.38 10.62 -1.38 -1.62 15 18 
85 Clomipramine 9.03 9.24 9.04 -0.21 -0.01 2 0 
86 Warfarin 9.08 9.53 9.44 -0.45 -0.36 5 4 
87 Irbesartan 9.44 11.82 11.95 -2.38 -2.51 25 27 
88 Cinnarizine 9.86 9.56 8.65 0.3 1.21 -3 -12 
89 Atorvastatin 9.96 10.77 10.6 -0.81 -0.64 8 6 
90 Diclofenac 10.28 9.36 10.37 0.91 -0.09 -9 1 
91 Telmisartan 10.31 13.42 12.43 -3.11 -2.12 30 21 
92 Ibuprofen 10.68 9.13 10.61 1.55 0.07 -15 -1 
93 Terbinafine 10.97 11.22 11.03 -0.25 -0.06 2 1 
94 Felodipine 11.01 11.59 11.94 -0.58 -0.93 5 8 
95 Tamoxifen 11.02 12.6 10.86 -1.58 0.16 14 -1 
96 Progesterone 11.22 11.11 11.23 0.11 -0.01 -1 0 
97 Clobetasone-17-
butyrate 
11.33 12.68 12.4 -1.35 -1.07 12 9 
98 Loratadine 11.49 12.95 11.49 -1.46 0 13 0 
99 Mefenamic acid 11.55 10.56 11.59 0.99 -0.04 -9 0 
100 Clopidogrel 11.78 10.51 10.01 1.27 1.77 -11 -15 
                      continued 
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101 Amiodarone 12.1 13.44 11.4 -1.34 0.7 11 -6 
102 Fenofibrate 12.55 12.09 11.44 0.46 1.11 -4 -9 
103 Miconazole 12.97 11.15 10.59 1.82 2.38 -14 -18 
 
a values are listed in min 
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5.4.3 Comparison of chromatographic similarity between regression plots 
According to Tropsha et al., (350) for a QSRR model to be considered predictive 
the slope of the regression through the origin should be within the range 0.85–
1.15 and the normalised difference between the coefficients of determination, R2, 
(equation 5.1) should be less than 0.1: 
 
                                                    ΔR = (R2 – R02)/R02   -                  (5.1) 
 
where R0
2 is the coefficient of determination between the observed and predicted 
retention times where the regression is forced through the origin. An average slope 
of 0.9428 and a normalised difference between the coefficients of determination 
of 0.0386 for the best 50 compounds fit was well within the proposed values of 
0.85–1.15 and < 0.1; see Figure 5.3. Values of 0.9243 and 0.0999 were obtained 
for average slope and difference between the coefficients of determinations, 
respectively using the all compounds fit. These fall just within the proposed values 
as shown in Figure 5.4. The above data demonstrates that the use of a QSRR 
model derived from the best 50 compound fit is superior in its ability to accurately 
predict a suspect’s retention time. When ACD Labs ChromGenius is used with 
the all compounds fit, it can incorporate compound structures with lower 
similarity coefficient values in the calculation of retention time thereby reducing 
the accuracy of prediction. 
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Figure 5.3 Regression plots of calculated versus measured retention times 
using the best 50 compounds fit. a) = forced through the origin, b) = origin 
not included. 
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Figure 5.4    Regression plots of calculated versus measured retention 
times using the all compounds fit. a) = forced through the origin, b) = origin 
not included. 
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5.4.4 The effects of matrix on measured retention times in passive 
sampling extracts 
The retention time prediction model developed in this chapter was derived from 
reference materials prepared in organic solvents and then diluted to appropriate 
concentrations in mobile phase. In the context of a quantitative targeted method 
this can be considered as suitable as many method employ clean-up techniques to 
remove a large proportion of matrix components thereby reducing matrix 
interferences such as retention time shifting, ion suppression and ion 
enhancement. Cleaning the sample would also be expected to improve accurate 
mass measurements and isotope pattern matching. 
 
The use of a passive sampler with a polar polyethersulphone membrane would 
effectively eliminate any interfering effects from high molecular mass compounds 
such as lipids as these molecules are too large to pass through the pores of the 
membrane which is typically 0.1 µm for POCIS and 0.2 µm for the polar 
Chemcatcher®. Compounds such as the antibiotics, erythromycin, clarithromycin 
and azithromycin have molecular masses greater than 700 Da but these pass 
through the membrane unhindered. Bacteria would be prevented from passing 
through the polar membrane due to their large size. In effect, the polar polyether 
sulphone membrane acts as a clean-up step, allowing the passage of most known 
and emerging contaminants onto the sorbent beyond. 
 
Compounds in the testing set, i.e. those listed in Table 5.1, did not appear to be 
influenced by the presence of matrix from the polar passive sampling extract. 
Differences between the retention times obtained in mobile phase and the extracts 
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did not differ by more than 0.05–0.10 min and were therefore not corrected. 
Retention time differences observed between successive injections on the LC Q-
TOF-MS system were on average typically in the range 0.025–0.050 min so any 
differences obtained from the passive sampling extracts was therefore considered 
as insignificant.  
 
5.4.5 Tentative identification of three metabolites of the 
pharmaceutical irbesartan without reference standards 
 
The identification of suspect compounds is very challenging especially in 
environmental matrices such as waste water effluents where many thousands of 
compounds are present and reference materials are not available. While ultra-high 
resolution and accurate mass have gone some way to reduce false positive and 
false negatives, matrix interferences can have a significant effect on compound 
identification. The research so far in this thesis has concentrated on parent 
pharmaceutical compounds, however, many pharmaceuticals are metabolised in 
humans or degraded within waste water treatment plants. In this respect, the 
tentative identification of three metabolites of the pharmaceutical irbesartan (M4, 
M5 and M6) were explored using predictive retention time prediction together 
with accurate mass and a fragment ion common to irbesartan and its metabolites. 
As a result of human metabolism, irbesartan has at least nine metabolites and 
several metabolites have been reported recently in waste waters (264, 351). The 
structure and chemical formulae for irbesartan and three of its most common 
metabolites, that arise from human metabolism, are shown in Figure 5.5. The 
chemical formula for two the metabolites, M4 and M5, are identical and the 
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structures for the metabolites M4 and M5, differ only in the position of the 
hydroxyl group.  
A polar Chemcatcher® sample extract from the Carmarthen WWTP, previously 
screened and known to contain irbesartan (Chapter 3), was re-analysed using the 
UHPLC Q-TOF-MS instrument set up as described in section 7.4. As with the Q-
TOF-MS instrument in Chapter 3, the Bruker Maxis Impact instrument employs 
two collision energies, one at low (6 eV) and the second at a higher ramped energy 
of 25 eV. The presence of additional chromatographic peaks in the extracted ion 
chromatograms from the ramped higher energy setting of 25 eV, for a parent 
compound) may be indicative of the presence of potential metabolites. This 
strategy assumes that many metabolites share the same fragmentation pathway 
with the parent compound (352, 353). 
 
Two chromatographic peaks, for each of the metabolite chemical formulae, were 
observed at the exact mass of each protonated molecule, m/z 445.2347 for M4 
and M5 and m/z 443.2190 for M6. A single but strong irbesartan fragment ion 
(m/z 207.1907) shown in Figure 5.7 was also observed for the four other peaks 
which suggested a common skeletal structure. Irbesartan was therefore included 
in the all compound database as it was expected to improve the accuracy of 
prediction. Only one precursor and one fragment ion was used but this approach 
satisfies the requirement for a minimum of three identification points required for 
authorised and four identification points for banned substances in products of 
animal origin according to EU Council Directive 96/23/EC (354). For high 
resolution mass spectrometry two identification points are earned for the 
precursor ion and 2.5 identification points for each fragment ion. Assuming that 
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this approach can be adopted for environmental samples, a total of 4.5 
identification points was achieved fully meeting the requirement. 
 
ACD Labs ChromGenius was then used to try and predict the retention times and 
order of the four suspected metabolite peaks of irbesartan. The predicted retention 
time for the metabolites M4, M5 and M6 were 9.77, 9.88 and 9.90 min 
respectively using the best 50 compounds fit. For the peaks corresponding to 
metabolites M4 and M5 (retention times of 7.92 and 8.08 min respectively) both 
had prediction errors of less than 2.0 min. For the two peaks corresponding to the 
metabolite M6 (retention times of 7.84 and 8.16 min respectively) a prediction 
error of 2.06 min was obtained for the first peak and the second peak was within 
2.0 min of the predicted value. It was observed that a very low number of 
structures (maximum of four) had similarity coefficients above 0.70 which may 
have significantly influenced the accuracy of prediction. The retention time 
prediction settings were therefore adjusted and a best 10 compounds fit evaluated. 
Predicted retention times of 8.28, 8.60 and 8.27 min were obtained which 
corresponded to maximum prediction errors of 0.36, 0.68 and 0.43 min for the 
M4, M5 and M6 metabolites. The results clearly demonstrate that for accurate 
retention time prediction, using a QSRR model, a sufficient number of structures, 
with high similarity to the suspect compound under investigation, must be present 
within the retention prediction database. This may not always be possible 
especially when dealing with unknowns. Greater importance must therefore be 
placed on the use of very large databases of compounds where the probability of 
a compound with a similar structure is that much higher. 
 
320 
 
 
 
 
             
O
N
N
N
N
NH
CH3
N
CH3
N
N
N
N
H
N
N
OH
O
 
                       Irbesartan (C25H28ON6)   Irbesartan M4 (C25H28O2N6) 
 
 
 
 
 
 
CH3
N
NN
N
H
N
N
OH
O
CH3
N
N
N
N
H
N
N
O
O
 
                      Irbesartan M5 (C25H28O2N6)               Irbesartan M6 (C25H26O2N6) 
 
 
Figure 5.5 Structures and chemical formula for Irbesartan and three of its 
metabolites (M4, M5 and M6) tentatively identified in a Chemcatcher® 
passive sampler extract. 
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Figure 5.6 Accurate mass extracted ion chromatograms for 
Irbesartan and three of its common metabolites (Irbesartan M4, M5 
and M6). 
 
 
 
 
 
 
 
Figure 5.7    Structure and chemical formula for the common 
fragment ion of Irbesartan and three of its metabolites.  
 
 
 
m/z 207.0917 (C14H11N2) 
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5.5 Conclusions 
This work demonstrates the development and use of a retention time prediction 
tool based on commercially available software employing QSRR principles. 
Overall, retention times for 93% of compounds were within 2.0 min of the 
predicted values using the all compounds fit. Slightly lower accuracy of 92% was 
obtained using the best 50 compounds fit. Only eight compounds accounted for 
retention time prediction errors in excess of 2 min for both fits. Fifteen compounds 
had retention time errors equal to or less than 0.1 min when using the best 50 
compounds fit. This fit chooses the best 50 structurally similar compounds, 
compared to the suspect and forms the basis for the calculation of the predicted 
retention time.  
 
The database model was successfully applied to suspect compound identification 
in a Chemcatcher® passive sampler extract, previously deployed in a final effluent 
stream of a waste water treatment plant. While the examples explained in this 
chapter show the successful assignment of retention times, 100% confidence with 
retention time prediction is not possible. Notwithstanding this limitation, 
significant time can be saved by cutting down the number of chromatographic 
peaks requiring investigation when prior knowledge of molecular formulae, 
compound structures and fragment ions are available. 
 
It is recommended that when undertaking large scale screening of samples for 
unknowns or known unknowns (e.g. with a database of over 1500 compounds as 
used in this work) it would be sensible to include accurate retention time 
prediction in the strategy used for identification. This approach could also offer 
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significant cost advantages when reference standards are either unavailable or 
may have to be custom synthesised for unequivocal identification. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
324 
 
Chapter 6 
 
Conclusions and recommendations for further work 
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6.1     Overall conclusions 
The work undertaken in this study has demonstrated that the various analytical 
techniques developed over the course of this study can enhance the inherent 
advantages of passive sampling of watercourses over more traditional techniques 
currently employed. The key areas of novelty and its main contributions to 
knowledge are: 
 
 
i) The development and successful application of a GCxGC technique in-
conjunction with a new and highly innovative variable-energy ionisation 
source for the screening of target and non-target compounds in an SPMD 
passive sampler deployed in a river downstream of a WWTP discharge point.  
 
ii) The development and successful application of a LC Q-TOF-MS data-
independent acquisition technique for the identification of pharmaceuticals 
with high confidence and unequivocal compound confirmation using selective 
qualifier ions. 
 
 
iii) The introduction of a new SPE disk for use with the Chemcatcher® passive 
sampler enhancing its ability to sample highly polar compounds and deliver 
performance very similar to that of the established POCIS sampler.  
 
iv) The development and successful application of a new in-silico retention time 
prediction model based on a commercial LC method development software 
package.   
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The use of GCxGC together with the variable-energy ionisation source can be seen 
as increasing the ‘dimensionality’ of the analysis thereby increasing confidence in 
the identification of pollutants when undertaking investigations into emerging 
contaminants or target lists monitoring programmes under the auspices of the WFD.  
Furthermore, the reduced fragmentation of analytes, matrix interferences and carrier 
gases significantly improves signal-to-noise ratios for target substances, and should 
allow lower limits of detection to be achieved. The variable-energy ionisation 
technology described in this work has been shown to be a rugged technique that 
provided significant increases in the intensity of the molecular ion and produced 
considerably higher signal-to-noise ratios for all classes of pollutants including the 
emerging contaminants in the SPMD extract at lower ionisation energies. The ability 
to collect both regular 70 eV spectra for library matching alongside lower-energy 
spectra provides complementary information on the molecular ion and structurally 
significant fragment ions. 
 
The development of a suitably broad and reliable ‘all ions’ LC Q-TOF-MS technique 
for the analysis of extracts obtained from two polar passive samplers proved 
successful for the identification of 79 pharmaceuticals with 50 being unequivocally 
confirmed using selective qualifier ions. The developed technique is an ideal 
complement for existing target and suspect screening methods and the acquired data 
can be re-interrogated at a later time allowing for retrospective data analysis for new 
emerging contaminants such as pharmaceutical metabolites, their transformation 
products plus personal care products. The results obtained show the value of the 
approach taken and when combined with an efficient data analysis workflow should 
prove invaluable for investigative monitoring purposes. It may also be possible to 
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transfer the method to other instrument vendor systems which employ high resolution 
accurate mass detection.  
 
It can be concluded from the LC Q-TOF-MS analysis of the extracts from the 
Chemcatcher® and POCIS extracts and the extensive statistical analysis that the 
performance of the polar Chemcatcher® is very similar to that of the POCIS sampler. 
The polar Chemcatcher®  samplers themselves have proven to be robust, easy to 
prepare and the subsequent extraction has proven equally simple to undertake 
avoiding the difficulties associated with the POCIS sampler.  The slopes obtained 
from least squares and orthogonal regression of the entire averaged pharmaceutical 
data set suggests that the Chemcatcher® uptake rate is approximately 2.4 to 2.6 times 
lower than that for the POCIS whereas the slopes obtained from least squares and 
orthogonal regression of the entire averaged ‘unknowns’ data set suggests that the 
Chemcatcher® uptake rate is approximately 1.9 to 2.1 times lower than that for the 
POCIS. The differences in the uptake rates for the pharmaceuticals and the 
‘unknowns’ data is, in all probability, due to the larger sampling area of 45.8 cm2 for 
the POCIS sampler compared to 15.2 cm2 for the Chemcatcher®, a factor of 3.01. 
The statistical evidence therefore suggests that the Chemcatcher is more efficient at 
sampling polar compounds than the POCIS sampler when the surface sampling areas 
of both samplers are normalised.   
 
The development of a predictive chromatographic retention time model, employing 
QSRR principles, was shown to be a suitable complimentary tool to facilitate the 
identification of pharmaceutical residues in polar passive sampling Overall, retention 
times for 93% of the 164 test compounds were within 2.0 min of the predicted values 
using the all compounds fit. Slightly lower accuracy of 92% was obtained using the 
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best 50 compounds fit. Fifteen compounds had retention time errors equal to or less 
than 0.1 min when using the best 50 compounds fit. The database model was 
successfully applied to the identification of three metabolites of the pharmaceutical 
irbesartan in a Chemcatcher® passive sampler extract. It is expected that significant 
time can be saved by cutting down the number of chromatographic peaks requiring 
investigation when prior knowledge of molecular formulae, compound structures and 
fragment ions are available. This approach could also offer significant cost 
advantages when reference standards are either unavailable or when tentatively 
identified compounds must be custom synthesised for unequivocal identification. 
 
Overall, this study has furthered the knowledge of the analysis of known and 
unknown and especially regarding the use of multi-dimensional chromatography, 
high resolution mass spectrometric techniques and passive sampling for investigative 
monitoring.  
 
6.2    Recommendations for further work 
 
Ongoing research and development of passive sampling (and particularly for polar 
devices) will greatly support and further validate the technique for the purposes of 
future environmental monitoring. Further work to fully evaluate the performance of 
the polar Chemcatcher® against the POCIS by verifying uptake rates through 
quantitative analysis is considered as highly beneficial to the passive sampling 
community. Furthermore, the relevance of passive sampling as a monitoring tool in 
regulatory applications will be enhanced by future development of a proficiency 
testing schemes whereby laboratories can further develop their techniques and then 
use the derived analytical information for wider quality purposes. 
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Appendix A 
 
A 1.1   Least squares and orthogonal regression analysis of the averaged Log10 
transformed Chemcatcher® and POCIS pharmaceutical data  
 
 
The least squares and orthogonal regression plots obtained from the averaged Log10 
transformed data indicate a much smaller deviation from normality, and homogeneity 
of the variances. The variation accounted for by the least squares regression (r2), as 
shown in Table A1, is 95.1% and the slope of 1.00 (t = 71.98, pr = <0.001) is 
significantly different from zero since it falls within the approximate 95% confidence 
intervals of 0.98 to 1.03. The intercept of 0.37 falls within the approximate 95% 
confidence intervals of 0.22 to 0.52 and is significantly different from zero (t=4.90, 
pr = < 0.001). The antilog of 0.37 (2.33) is the value of POCIS when Chemcatcher® 
is 1.  The slope of 1 shows an approximate linear relationship in the unlogged data, 
and so this indicates that the sampling rate of POCIS is approximately 2.3 times that 
of the Chemcatcher®. The least squares regression plot is shown in Figure A1. 
 
The slope of 1.03 obtained from the orthogonal regression plot (Table A2) is 
significantly different from zero and falls within the approximate 95% confidence 
intervals of 1.00 to 1.06. The intercept of 0.23 falls within the approximate 95% 
confidence intervals (0.08, 0.38) but zero does not and is therefore significantly 
different from zero. Since the data are on a Log scale, the intercept corresponds to the 
Log10 POCIS value when the Chemcatcher
® value is one, and is equivalent to a 
POCIS value of 1.68 (the anti-log of 0.23). The plots of standardised residuals from 
the least squares and orthogonal regression plots show only two large values (greater 
than three) which are the compounds loratidine and oxprenolol at the Carmarthen and 
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Gowerton sites and appear to have little influence on the slope. The orthogonal 
regression plot is shown in Figure A2. 
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Table A1 Output from least squares regression analysis of the averaged Log10 
transformed Chemcatcher® and POCIS pharmaceutical data. 
 
 
 
Regression Equation 
 
Log10 POCIS (average) = 0.3678 + 1.0027 Log10 Chemcatcher
® (average) 
 
 
Analysis of Variance 
 
Source DF Seq SS Contrib. Adj SS Adj MS F-Value P-Value 
Regression 1 1.50E+02 95.05% 1.50E+02 1.50E+02 5181.05 < 0.001 
Log10  
Chemcatcher® 
(average) 
1 1.50E+02 95.05% 1.50E+02 1.50E+02 5181.05 < 0.001 
Error 270 7.803 4.95% 7.803 0.029 
  
Total 271 1.58E+02 100.00% 
    
 
 
Model Summary 
 
S R-sq R-sq(adj) PRESS R-sq(pred) 
0.170004 95.05% 95.03% 7.92E+00 94.97% 
 
 
Coefficients 
 
Term Coef SE Coef 95% CI T-Value P-Value VIF 
Constant 0.3678 0.0751 (0.2199, 0.5157)   4.90 < 0.001 
 
Log10 
Chemcatcher® 
(average) 
1.0027 0.0139 (0.9752, 1.0301) 71.98 < 0.001 1.00 
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Figure A1 Fitted line regression and plots of standardised residuals obtained 
from least squares regression analysis of the averaged Log10 transformed 
Chemcatcher® and POCIS pharmaceutical data. 
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Table A2 Output from the orthogonal regression analysis of the averaged 
Log10 transformed Chemcatcher® and POCIS pharmaceutical data. 
 
 
 
Error Variance Ratio: Log10 POCIS (average) / Log10 Chemcatcher
® (average): 1 
 
 
Regression Equation 
 
Log10 POCIS (average) = 0.226 + 1.029 Log10 Chemcatcher
® (average) 
 
 
Coefficients 
 
Predictor Coef SE Coef Z P Approx 95% CI 
Constant 0.22608 0.077079  2.9331 0.003 (0.07501, 
0.37716) 
Log10 
Chemcatcher® 
(average) 
1.02920 0.014299 71.9777 < 0.001 (1.00117, 
1.05723) 
 
 
Error Variances   
     
 Variable Variance 
Log10 POCIS (average) 0.0141710 
Log10 Chemcatcher® (average) 0.0141710 
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Figure A2 Fitted line regression and plots of standardised residuals obtained 
from the orthogonal regression analysis of the averaged Log10 transformed 
Chemcatcher® and POCIS pharmaceutical data. 
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Appendix B 
 
Table B1    Output from least squares regression analysis of the averaged Chemcatcher® and POCIS ‘unknowns’ data after 
application of DFITS.  
 
 Analysis of Variance 
Source DF Seq SS Contrib. Adj SS Adj MS F-Value P-Value 
Regression 1 2.28E+15 89.38% 2.28E+15 2.28E+15 35903.66 < 0.001 
Chemcatcher® (average) 1 2.28E+15 89.38% 2.28E+15 2.28E+15 35903.66 < 0.001 
Error 4266 2.71E+14 10.62% 2.71E+14 6.35E+10 
  
Total 4267 2.55E+15 100.00% 
    
 
Model Summary  
S R-sq R-sq(adj) PRESS R-sq(pred) 
251956 89.38% 89.38% 2.72E+14 89.33% 
 
Coefficients  
Term Coef SE Coef 95% CI T-Value P-Value VIF 
Constant 33154 4445  (24440,    41868) 7.46 < 0.001 
 
Chemcatcher® (average) 1.886 0.00995 (1.86649, 1.90552) 189.48 < 0.001 1 
 
Regression Equation 
 
POCIS (average) = 33154 + 1.88600 Chemcatcher® (average) 
402 
 
 
 
 
 
 
 
 
 
Figure B1 Fitted line and plots of standardised residuals obtained from least 
squares regression analysis of the averaged Chemcatcher® and POCIS 
‘unknowns’ data after application of DFITS. 
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Table B2  Output from orthogonal regression analysis of the averaged 
Chemcatcher® and POCIS ‘unknowns’ data after standardised residuals 
filtering.  
 
 
Error Variance Ratio  POCIS (average)/Chemcatcher® (average): 1 
 
Coefficients 
Predictor Coef SE Coef Z P Approx 95% CI 
Constant -1.66E+04 5707.39 -2.9037 0.004 (-27758.6, -5386.06) 
Chemcatcher® 
(average) 
2.11306 0.01 268.0219 < 0.001 (     2.1,     2.13) 
 
Regression Equation 
POCIS (average) = - 16572 + 2.113 Chemcatcher® (average) 
 
Error Variances 
Variable Variance 
POCIS (average) 2.19E+10 
Chemcatcher® (average) 2.19E+10 
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Figure B2 Fitted line and plots of standardised residuals obtained from 
orthogonal regression analysis of the averaged Chemcatcher® and POCIS 
‘unknowns’ data after standardised residuals filtering. 
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Appendix C 
 
C1.1  Least squares and orthogonal regression analysis of the Log10 
transformed data for ‘unknowns’ in all POCIS and Chemcatcher® replicates  
 
 
The variation accounted for by the least squares regression (r2), as shown in Table 
C1, is 85.8% and the slope of 0.94 (t = 282.33, pr = <0.001) is significantly different 
from zero and falls within the approximate 95% confidence intervals of 0.93 to 0.95. 
The intercept of 0.60 (t = 35.03, pr = <0.001) falls within the approximate 95% 
confidence intervals of 0.57 to 0.63 but zero does not and is therefore significantly 
different from zero. The least squares regression plot is shown in Figure C1. The 
antilog of 0.60 (3.98) is the value of POCIS when Chemcatcher® is 1.  The slope of 
approximately one shows an approximate linear relationship in the unlogged data. 
The plots of residuals in Figure C1 shows some heteroscedasticity with a few 
standardised residual values in the range 5–8. The variance is not constant but 
decreases with the amount of compound accumulated, the histogram of residuals, 
however, closely matches that of a normal distribution. 
 
The output from the orthogonal regression is shown in Table C2. The slope of 1.02 is 
significantly different from zero and falls within the approximate 95% confidence 
intervals of 1.01 to 1.02. The intercept of 0.21 falls within the approximate 95% 
confidence intervals (0.17, 0.25) but zero does not and is thus significantly different 
from zero. Since the data are on a Log scale, the intercept corresponds to the Log10 
POCIS value when the Chemcatcher® value is one, and is equivalent to a POCIS value 
of 1.62 (the anti-log of 0.21). The variance is not constant but decreases with the 
amount of compound accumulated, the histogram of residuals (Figure C2), however, 
closely matches that of a normal distribution. 
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Table C1 Output from least squares regression analysis of Log10 transformed data for ‘unknowns’ in all 
POCIS and Chemcatcher® replicates. 
 
Analysis of Variance 
Source DF Seq SS Contrib. Adj SS Adj MS F-Value P-Value 
Regression 1 3533.62 85.77% 3533.62 3533.62 79708.24 < 0.001 
Log10 Chemcatcher® 1 3533.62 85.77% 3533.62 3533.62 79708.24 < 0.001 
Error 13222   586.16 14.23%   586.16       0.04 
  
Lack-of-Fit 12898   572.06 13.89%   572.06       0.04         1.02 0.413 
Pure Error 324     14.09   0.34%     14.09       0.04 
  
Total 13223 4119.78 100.00% 
    
 
Model Summary 
S R-sq R-sq(adj) PRESS R-sq(pred) 
0.210551 85.77% 85.77% 586.334 85.77% 
 
Coefficients 
Term Coef SE Coef 95% CI T-Value P-Value VIF 
Constant 0.5986 0.0171 (0.5651,   0.6321)   35.03 < 0.001 
 
Log10 
Chemcatcher® 
0.94128 0.00333 (0.93475, 0.94782) 282.33 < 0.001 1.00 
 
Regression Equation 
Log10 POCIS = 0.5986 + 0.94128 Log10 Chemcatcher
® 
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Figure C1 Fitted line and plots of standardised residuals obtained from 
least squares regression analysis of Log10 transformed data for ‘unknowns’ in 
all POCIS and Chemcatcher® replicates. 
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  Table C2   Output from orthogonal regression analysis of Log10 transformed 
  data for ‘unknowns’ in all POCIS and Chemcatcher® replicates. 
 
 
  Error Variance Ratio Log10 POCIS/Log10 Chemcatcher
®: 1 
 
  Regression Equation 
  Log10 POCIS = 0.209 + 1.018 Log10 Chemcatcher
® 
 
  Coefficients 
Predictor Coef SE Coef Z P Approx 95% CI 
Constant 0.20929 0.018466   11.334 < 0.001 (0.17310, 0.24549) 
Log10 
Chemcatcher® 
1.01768 0.003605 282.3261 < 0.001 (1.01061, 1.02474) 
 
  Error Variances 
Variable Variance 
Log10 POCIS 0.022641 
Log10 Chemcatcher® 0.022641 
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Figure C2 Fitted line and plots of standardised residuals obtained from 
orthogonal regression analysis of Log10 transformed data for ‘unknowns’ in 
all POCIS and Chemcatcher® replicates. 
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C1.2    Least squares and orthogonal regression analysis of the averaged Log10    
transformed Chemcatcher® and POCIS ‘unknowns’ data 
 
The variation accounted for by the least squares regression (r2), as shown in Table C3, 
is 87.2% and the slope of 0.95 (t = 173.36, pr = < 0.001) is significantly different from 
zero and falls within the approximate 95% confidence intervals of 0.94 to 0.96. The 
intercept of 0.55 (t = 19.53, pr = < 0.001) falls within the approximate 95% confidence 
intervals of 0.49-0.60 but is significantly different from zero. The antilog of 0.55 (3.55) 
is the value of POCIS when Chemcatcher® is 1.  The slope of approximately one shows 
an approximate linear relationship in the unlogged data, and so this indicates that the 
sampling rate of POCIS is approximately 2.3 times that of the Chemcatcher®. The 
variance is not constant but decreases with the amount of compound accumulated, the 
histogram of residuals, however, is close to that of a normal distribution (Figure C3). 
 
The slope of 1.02 obtained from orthogonal regression is significantly different from 
zero and falls within the approximate 95% confidence intervals of 1.01 to 1.03. The 
intercept of 0.20 falls within the approximate 95% confidence intervals of 0.14 to 0.26 
but zero does not and is thus significantly different from zero. Since the data are on a 
Log scale, the intercept corresponds to the Log10 POCIS value when the Chemcatcher
® 
value is one, and is equivalent to a POCIS value of 1.58 (the anti-log of 0.20). See Table 
C4. The variance is not constant but decreases with the amount of compound 
accumulated, the histogram of residuals (Figure C4), however, is close to that of a 
normal distribution. 
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Table C3   Output from least squares regression analysis of the averaged Log10 
transformed Chemcatcher® and POCIS ‘unknowns’ data. 
 
 
Analysis of Variance  
Source DF Seq SS Contrib. Adj SS Adj MS F-Value P-Value 
Regression 1 1188.98 87.21% 1188.98 1188.98 30052.45 < 0.001 
Log10 
Chemcatcher® 
(average) 
1 1188.98 87.21% 1188.98 1188.98 30052.45 < 0.001 
Error 4406  174.32 12.79%   174.32       0.04 
  
Total 4407 1363.3 100.00% 
    
 
Model Summary 
S R-sq R-sq(adj) PRESS R-sq(pred) 
0.198906 87.21% 87.21% 174.472 87.20% 
 
Coefficients 
Term Coef SE Coef 95%CI T-Value P-Value VIF 
Constant 0.5493 0.0281  (0.4942,  0.6045)   19.53 < 0.001 
 
Log10 
Chemcatcher® 
(average) 
0.95082 0.00548 (0.94006, 0.96157) 173.36 < 0.001 1.00 
 
Regression Equation 
Log10 POCIS (average) = 0.5493 + 0.95082 Log10 Chemcatcher
® (average) 
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Figure C3 Fitted line and plots of standardised residuals obtained from least 
squares regression analysis of the averaged Log10 transformed Chemcatcher® and 
POCIS ‘unknowns’ data. 
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Table C4 Output from orthogonal regression analysis of the averaged Log10 
transformed Chemcatcher® and POCIS ‘unknowns’ data. 
 
 
Error Variance Ratio Log10 POCIS (average) / Log10 Chemcatcher
® (average): 1 
 
Regression Equation 
Log10 POCIS (average) = 0.199 + 1.019 Log10 Chemcatcher
® (average) 
 
Coefficients 
Predictor Coef SECoef Z P Approx95%CI 
Constant 0.19941 0.030144     6.6153 < 0.001 (0.14033, 0.25850) 
Log10 
Chemcatcher® 
(average) 
1.01943 0.005881 173.3557 < 0.001 (1.00790, 1.03095) 
 
Error variances 
Variable Variance 
Log10 POCIS (average) 0.020086 
Log10 Chemcatcher® (average) 0.020086 
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Figure C4 Fitted line and plots of standardised residuals obtained from 
orthogonal regression analysis of the averaged Log10 transformed Chemcatcher® 
and POCIS ‘unknowns’ data. 
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Appendix D 
 
Table D1 List of prescribed items by British National Formulary Chemical 
(BNF) name exceeding 25,000 items dispensed by GPs in Wales during 2014. 
 
 
No. British National Formulary Chemical Name Number of 
prescribed items 
1 Simvastatin 2875131 
2 Omeprazole 2502345 
3 Aspirin/Salicylic acid 2283925 
4 Levothyroxine Sodium 2281606 
5 Ramipril 2079882 
6 Co-Codamol (Codeine Phosphate/Paracetamol) 1798399 
7 Amlodipine 1792202 
8 Salbutamol 1739342 
9 Atorvastatin 1619116 
10 Lansoprazole 1566649 
11 Paracetamol 1506464 
12 Bisoprolol Fumarate 1439376 
13 Citalopram Hydrobromide 1324650 
14 Metformin Hydrochloride 1313226 
15 Bendroflumethiazide 1216015 
16 Furosemide 1038516 
17 Warfarin Sodium 965874 
18 Fluticasone Furoate/Propionate 934356 
19 Amitriptyline Hydrochloride 866025 
20 Amoxicillin 831646 
21 Lisinopril 819281 
22 Ibuprofen 676924 
23 Atenolol 674909 
24 Sertraline Hydrochloride 597904 
25 Tramadol Hydrochloride 592678 
26 Losartan Potassium 588148 
27 Diazepam 587903 
28 Prednisolone Acetate/Sodium Metasulphobenzoate 557255 
29 Naproxen 552789 
30 Gliclazide 533018 
  continued 
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31 Mirtazapine 531878 
32 Alendronic Acid 521663 
33 Fluoxetine Hydrochloride 516680 
34 Hydrocortisone Sodium Succinate/Phosphate/Acetate/Butyrate 512454 
35 Perindopril Erbumine/Arginine (Diuretic) 507244 
36 Clopidogrel 488036 
37 Zopiclone 454336 
38 Tamsulosin Hydrochloride 437346 
39 Tiotropium 433337 
40 Cetirizine Hydrochloride 421527 
41 Doxazosin Mesilate 421144 
42 Budesonide 418084 
43 Allopurinol 411959 
44 Alginic Acid  401114 
45 Gabapentin 395109 
46 Morphine Sulphate 345808 
47 Ranitidine Hydrochloride 329153 
48 Loratadine 305813 
49 Candesartan Cilexetil 290698 
50 Flucloxacillin Sodium 289770 
51 Pregabalin 289725 
52 Trimethoprim 286945 
53 Diltiazem Hydrochloride 284136 
54 Propranolol Hydrochloride 278877 
55 Felodipine 278116 
56 Betamethasone Dipropionate/Phosphate/Valerate 270426 
57 Co-Dydramol (Dihydrocodeine/Paracetamol) 253839 
58 Venlafaxine  250625 
59 Digoxin 249280 
60 Quinine Sulphate 239683 
61 Pravastatin Sodium 228578 
62 Combined Ethinylestradiol  227480 
63 Indapamide 221788 
64 Quetiapine 219003 
65 Finasteride 203334 
66 Temazepam 201342 
  continued 
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67 Latanoprost 200396 
68 Thiamine Hydrochloride 200347 
69 Duloxetine Hydrochloride 197748 
70 Nifedipine 197485 
71 Mometasone Furoate 193727 
72 Doxycycline Hyclate 190600 
73 Sodium Valproate 189815 
74 Hypromellose 188870 
75 Solifenacin Succinate 188592 
76 Spironolactone 187662 
77 Colecalciferol 187340 
78 Betahistine Hydrochloride 178983 
79 Diclofenac Sodium/Potassium 173686 
80 Phenoxymethylpenicillin (Penicillin V) 171520 
81 Montelukast 171190 
82 Mebeverine Hydrochloride 170087 
83 Hydroxocobalamin 168837 
84 Sildenafil 168799 
85 Erythromycin/Ethylsuccinate/Stearate 166866 
86 Clobetasone Butyrate/Propionate 165089 
87 Buprenorphine 163490 
88 Carbamazepine 162220 
89 Fexofenadine Hydrochloride 160418 
90 Clotrimazole 158855 
91 Olanzapine 158534 
92 Sitagliptin 158298 
93 Rosuvastatin Calcium 154124 
94 Clarithromycin 153445 
95 Lamotrigine 152070 
96 Glyceryl Trinitrate 151246 
97 Irbesartan 146398 
98 Methotrexate 144034 
99 Metronidazole 141415 
100 Paroxetine Hydrochloride 141335 
101 Codeine Phosphate 140314 
102 Dihydrocodeine Tartrate 140277 
  continued 
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103 Nicorandil 137978 
104 Loperamide Hydrochloride 137875 
105 Dexamethasone Phosphate/Sodium Metasulphobenzoate  134246 
106 Chloramphenicol 133536 
107 Nitrofurantoin 132764 
108 Enalapril Maleate 126081 
109 Carbocisteine 125672 
110 Co-Amoxiclav (Amoxicillin/ clavulanic acid) 122675 
111 Prochlorperazine Maleate 122600 
112 Estradiol/Valerate with Progestogen 118878 
113 Desogestrel 116469 
114 Methadone Hydrochloride 114742 
115 Ezetimibe 112920 
116 Hyoscine  Hydrobromide/Butylbromide 112485 
117 Valsartan 111786 
118 Oxybutynin Hydrochloride 108441 
119 Lercanidipine Hydrochloride 106936 
120 Sumatriptan Succinate 106745 
121 Levetiracetam 106420 
122 Cefalexin 104033 
123 Chlorpheniramine Maleate 101372 
124 Risperidone 100482 
125 Timolol Maleate 95370 
126 Domperidone 95335 
127 Sodium Cromoglicate 95012 
128 Oxycodone Hydrochloride 93901 
129 Bumetanide 91105 
130 Piroxicam 90659 
131 Trazodone Hydrochloride 89401 
132 Fusidic Acid 88682 
133 Mesalazine  88146 
134 Medroxyprogesterone Acetate 86892 
135 Lorazepam 86507 
136 Brinzolamide 84035 
137 Chlorhexidine Gluconate 83894 
138 Tadalafil 83242 
  continued 
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139 Lymecycline 80530 
140 Promethazine Hydrochloride 79920 
141 Beclometasone Dipropionate 79100 
142 Aciclovir 78402 
143 Bimatoprost 78324 
144 Dipyridamole 76807 
145 Donepezil Hydrochloride 76522 
146 Metoclopramide Hydrochloride 76343 
147 Terbutaline Sulphate 76247 
148 Fentanyl 75391 
149 Tolterodine Tartrate 74497 
150 Pioglitazone Hydrochloride 74065 
151 Esomeprazole 73307 
152 Nitrazepam 72840 
153 Letrozole 71250 
154 Nicotine/Nicotinates 70224 
155 Calcipotriol 69585 
156 Benzydamine Hydrochloride 68827 
157 Dorzolamide 67170 
158 Salmeterol 66670 
159 Terbinafine Hydrochloride 63996 
160 Methylphenidate Hydrochloride 63867 
161 Sulfasalazine 63710 
162 Pantoprazole 63157 
163 Verapamil Hydrochloride 63150 
164 Ipratropium Bromide 62781 
165 Procyclidine Hydrochloride 62307 
166 Lidocaine/Lidocaine hydrochloride 61941 
167 Dosulepin Hydrochloride 61773 
168 Cyclizine Hydrochloride 61636 
169 Baclofen 60175 
170 Fenofibrate 59595 
171 Clindamycin Phosphate/Hydrochloride 59578 
172 Norethisterone 58961 
173 Ciprofloxacin 58339 
174 Ketoconazole 58280 
  continued 
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175 Co-Careldopa (Carbidopa/Levodopa) 58094 
176 Fluconazole 57124 
177 Azathioprine 56886 
178 Aripiprazole 56813 
179 Phenytoin Sodium 55561 
180 Co-Amilofruse (Amiloride Hydrochloride/Frusemide) 54505 
181 Saxagliptin 54329 
182 Hydroxychloroquine Sulphate 54129 
183 Heparinoid 52325 
184 Nystatin 51750 
185 Clonazepam 51351 
186 Meloxicam 50960 
187 Liraglutide 50790 
188 Alfacalcidol 49430 
189 Zolpidem Tartrate 48805 
190 Bisacodyl 47784 
191 Co-Beneldopa (Benserazide/Levodopa) 47370 
192 Carmellose Sodium 46744 
193 Risedronate Sodium 45796 
194 Theophylline 45448 
195 Moxonidine 45335 
196 Pizotifen Malate 44827 
197 Oxytetracycline 44697 
198 Azithromycin 44154 
199 Methylprednisolone Acetate 43247 
200 Valproic Acid 42755 
201 Carvedilol 42032 
202 Dutasteride & Tamsulosin Hydrochloride 41970 
203 Miconazole Nitrate  /Miconazole 41781 
204 Alfuzosin Hydrochloride 41446 
205 Nebivolol 40742 
206 Alverine Citrate 40332 
207 Bezafibrate 39761 
208 Linagliptin 39741 
209 Colchicine 38993 
210 Sotalol Hydrochloride 38762 
  continued 
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211 Topiramate 38317 
212 Amisulpride 38067 
213 Telmisartan 37645 
214 Ropinirole 37252 
215 Cyanocobalamin 36345 
216 Olmesartan Medoxomil/Hydrochlorothiazide/Amlodipine 36252 
217 Lacidipine 35811 
218 Metoprolol Tartrate 35387 
219 Orlistat 34809 
220 Escitalopram 34403 
221 Cinnarizine 33955 
222 Carbimazole 33907 
223 Trospium Chloride 33759 
224 Tranexamic Acid 33378 
225 Glimepiride 33099 
226 Tamoxifen Citrate 33001 
227 Capsaicin 32154 
228 Dimethicone 30862 
229 Hydroxyzine Hydrochloride 30813 
230 Urea 30649 
231 Amiodarone Hydrochloride 30276 
232 Estriol 29466 
233 Etoricoxib 29288 
234 Ivabradine 29217 
235 Pneumococcal 29141 
236 Travoprost 28603 
237 Pancreatin 28225 
238 Clonidine Hydrochloride 27400 
239 Nortriptyline 27153 
240 Anastrozole 26590 
241 Mefenamic Acid 26404 
242 Co-Amilozide (Amiloride Hydrochloride & Hydrochlorothiazide) 26384 
243 Haloperidol Decanoate 26200 
244 Flecainide Acetate 25857 
245 Neomycin Sulphate 25512 
246 Lofepramine Hydrochloride 25266 
  continued 
422 
 
247 Eplerenone 25011 
248 Clomipramine Hydrochloride 25000 
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Table D2 Compounds for the entire ‘training set’ database 
 
No. RT (min) Name CAS Chemspider ID SMILES Notation 
1 1.23 Histidine (4998-57-6) 752 c1c(nc[nH]1)CC(C(=O)O)N 
2 1.23 Diquat (Ion 2+) (2764-72-9) 6537 c1cc[n+]2c(c1)-c3cccc[n+]3CC2 
3 1.24 Carbachol (51-83-2) 2454 C[N+](C)(C)CCOC(=N)O 
4 1.31 Calteridol (132722-73-7) 54720 CC(CN1CCN(CCN(CCN(CC1)CC(=O)O)CC(=O)O)CC(=O)O)O 
5 1.38 Ecgonine methyl ester (7143-09-1) 220696 CN1C2CCC1C(C(C2)O)C(=O)OC 
6 1.39 Metformin (657-24-9) 3949 CN(C)C(=N)NC(=N)N 
7 1.44 Glufosinate (51276-47-2) 4630 CP(=O)(CCC(C(=O)O)N)O 
8 1.44 Vigabatrin (60643-86-9) 5463 C=CC(CCC(=O)O)N 
9 1.44 Amitrole (61-82-5) 1577 c1[nH][nH]c(=N)n1 
10 1.45 Melamine (108-78-1) 7667 c1(nc(nc(n1)N)N)N 
11 1.58 Histamine (51-45-6) 753 c1c([nH]cn1)CCN 
12 1.63 Morphine-3-beta-D-glucuronide (20290-09-9) 3523765 CN1CCC23c4c5ccc(c4OC2C(C=CC3C1C5)O)OC6C(C(C(C(O6)C(=O)O)O)O)O 
13 1.67 Chlormequat (7003-89-6) 13237 C[N+](C)(C)CCCl 
14 1.74 Arecoline (63-75-2) 13872064 CN1CCC=C(C1)C(=O)OC 
15 1.79 Tranexamic acid (1197-18-8) 5325 C1CC(CCC1CN)C(=O)O 
16 1.81 Norfenefrine (536-21-0) 4379 c1cc(cc(c1)O)C(CN)O 
17 1.93 Ethambutol (74-55-5) 3164 CCC(CO)NCCNC(CC)CO 
18 1.99 Dioxethedrin (497-75-6) 64697 CCNC(C)C(c1ccc(c(c1)O)O)O 
19 2.01 Sulfaguanidine (57-67-0) 5133 c1cc(ccc1N)S(=O)(=O)NC(=N)N 
20 2.18 Isoniazide (54-85-3) 3635 c1cnccc1C(=O)NN 
21 2.18 Pyridoxine (65-23-6) 1025 Cc1c(c(c(cn1)CO)CO)O 
22 2.28 Tyramine (51-67-2) 5408 c1cc(ccc1CCN)O 
23 2.28 Hordenine (539-15-1) 61609 CN(C)CCc1ccc(cc1)O 
24 2.34 Aciclovir (59277-89-3) 1945 c1nc2c(n1COCCO)[nH]c(=N)nc2O 
 
                                                                                                                                             continued 
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25 2.37 4-Methoxy-1,3-phenylenediamine (615-05-4) 11481 COc1ccc(cc1N)N 
26 2.41 Nicotine (13890-81-8) 917 CN1CCCC1c2cccnc2 
27 2.43 Adenine (73-24-5) 185 c1[nH]c-2ncnc2c(n1)N 
28 2.48 Morphine-6-beta-D-glucuronide (50444-03-6) 2757229 CN1CCC23c4c5ccc(c4OC2C(C=CC3C1C5)OC6C(C(C(C(O6)C(=O)O)O)O)O)O 
29 2.53 Thioguanine (154-42-7) 2005804 c1[nH]c2c(n1)c(nc(=N)[nH]2)S 
30 2.54 Amidephrine (3354-67-4) 14288 CNCC(c1cccc(c1)NS(=O)(=O)C)O 
31 2.59 HHMA (3,4-Dihydroxymethamphetamine) (15398-87-5) 141547 CC(Cc1ccc(c(c1)O)O)NC 
32 2.61 Morphine (57-27-2) 4103 CN1CCC23c4c5ccc(c4OC2C(C=CC3C1C5)O)O 
33 2.61 6-Mercaptopurine (50-44-2) 580869 c1[nH]c2c(n1)c(ncn2)S 
34 2.64 Pramipexole (104632-26-0) 4716 CCCNC1CCc2c(sc(n2)N)C1 
35 2.66 Etilefrine (Etiladrianol) (709-55-7) 3190 CCNCC(c1cccc(c1)O)O 
36 2.66 Dihydromorphine (509-60-4) 240226 CN1CCC23c4c5ccc(c4OC2C(CCC3C1C5)O)O 
37 2.68 Anatabine (581-49-7) 229558 c1cc(cnc1)C2CC=CCN2 
38 2.71 Normorphine (466-97-7) 380506 c1cc(c2c3c1CC4C5C3(CCN4)C(O2)C(C=C5)O)O 
39 2.73 Pholcodine (509-67-1) 454729 CN1CCC23c4c5ccc(c4OC2C(C=CC3C1C5)O)OCCN6CCOCC6 
40 2.73 Nicotinamide (98-92-0) 911 c1cc(cnc1)C(=N)O 
41 2.74 Pilocarpine (92-13-7) 4653 CCC1C(COC1=O)Cc2cncn2C 
42 2.75 Oxymorphone (76-41-5) 4478 CN1CCC23c4c5ccc(c4OC2C(=O)CCC3(C1C5)O)O 
43 2.76 Methamidophos (10265-92-6) 3954 COP(=O)(N)SC 
44 2.78 Cyromazine (66215-27-8) 43550 C1CC1Nc2nc(nc(n2)N)N 
45 2.83 Procainamide (51-06-9) 4744 CCN(CC)CCNC(=O)c1ccc(cc1)N 
46 2.84 Apophedrin  (Phenylethanolamine) (7568-93-6) 975 c1ccc(cc1)C(CN)O 
47 2.88 Amrinone (60719-84-8) 3570 c1cnccc1c2cc(c(=O)[nH]c2)N 
48 2.89 Carbuterol (34866-47-2) 33928 CC(C)(C)NCC(c1ccc(c(c1)NC(=O)N)O)O 
49 2.91 Hydromorphone (466-99-9) 3522 CN1CCC23c4c5ccc(c4OC2C(=O)CCC3C1C5)O 
50 2.91 Pholedrine (370-14-9) 4494 CC(Cc1ccc(cc1)O)NC 
51 2.92 Monocrotaline (315-22-0) 4097 CC1C(=O)OC2CCN3C2C(=CC3)COC(=O)C(C1(C)O)(C)O 
52 2.94 Anabasine (13078-04-1) 21106257 c1cc(cnc1)C2CCCCN2 
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53 2.96 Sotalol (3930-20-9) 5063 CC(C)NCC(c1ccc(cc1)NS(=O)(=O)C)O 
54 2.96 Nizatidine (76963-41-2) 2298266 CNC(=C[N+](=O)[O-])NCCSCc1csc(n1)CN(C)C 
55 2.98 Sulpiride (15676-16-1) 5162 CCN1CCCC1CNC(=O)c2cc(ccc2OC)S(=O)(=O)N 
56 2.98 P-hydroxyamphetamine [(+)-Paredrine] (1693-66-9) 3525 CC(Cc1ccc(cc1)O)N 
57 2.98 P-Hydroxymethamphetamine (Pholedrine) (370-14-9) 4494 CC(Cc1ccc(cc1)O)NC 
58 2.99 Galanthamine (357-70-0) 3331 CN1CCC23C=CC(CC2Oc4c3c(ccc4OC)C1)O 
59 2.99 Xanthinol (2530-97-4) 9526 Cn1c2c(c(=O)n(c1=O)C)n(cn2)CC(CN(C)CCO)O 
60 3.03 Obidoxime (7683-36-5) 4588647 c1c(cc[n+](c1)COC[n+]2ccc(cc2)/C=N\O)/C=N\O 
61 3.06 Terbutaline (23031-25-6) 5210 CC(C)(C)NCC(c1cc(cc(c1)O)O)O 
62 3.06 Clopyralid (1702-17-6) 14797 c1cc(nc(c1Cl)C(=O)O)Cl 
63 3.09 Atenolol (29122-68-7) 2162 CC(C)NCC(COc1ccc(cc1)CC(=O)N)O 
64 3.09 Apraclonidine (66711-21-5) 2130 c1c(cc(c(c1Cl)NC2=NCCN2)Cl)N 
65 3.11 Salbutamol (18559-94-9) 1999 CC(C)(C)NCC(c1ccc(c(c1)CO)O)O 
66 3.11 Acephate (30560-19-1) 1905 CC(=O)NP(=O)(OC)SC 
67 3.13 Hydroxycotinine (34834-67-8) 401 CN1C(CC(C1=O)O)c2cccnc2 
68 3.14 Ranitidine (66357-35-5) 4863 CNC(=C[N+](=O)[O-])NCCSCc1ccc(o1)CN(C)C 
69 3.14 Formetanate (22259-30-9) 15150933 CNC(=O)Oc1cccc(c1)/N=C/N(C)C 
70 3.14 Adenosine (58-61-7) 21241906 C1=NC3=C([N]1C2OC(CO)C(C2O)O)N=CN=C3N 
71 3.16 Diethylcarbamazine (90-89-1) 2944 CCN(CC)C(=O)N1CCN(CC1)C 
72 3.16 Thiocyclam (Evisekt) (31895-21-3) 33084 CN(C1CSSSC1)C 
73 3.18 O-Desmethylsulpiride (67381-52-6) 27523917 CCN1CCCC1CNC(=O)c2cc(ccc2O)S(=O)(=O)N 
74 3.19 Dorzolamide (120279-96-1) 3042 CCNC1CC(S(=O)(=O)c2c1cc(s2)S(=O)(=O)N)C 
75 3.19 HMMA (4-Hydroxy-3-methoxymethamphetamine) (117652-28-5) 2338803 CC(Cc1ccc(c(c1)OC)O)NC 
76 3.19 Monocrotaline-N-oxide (35337-98-5) 170755 CC1C(=O)OC2CC[N+]3(C2C(=CC3)COC(=O)C(C1(C)O)(C)O)[O-] 
77 3.2 Endothal Peak 1&2 (28874-46-6) 3112 C1CC2C(C(C1O2)C(=O)O)C(=O)O 
78 3.21 Procaine (59-46-1) 4745 CCN(CC)CCOC(=O)c1ccc(cc1)N 
79 3.23 HMA (HMA-5) 1428-95-1 1728 C1CCCN(CC1)c2c(nc(c(n2)N)C(=O)NC(=N)N)Cl 
80 3.24 Famotidine (76824-35-6) 3208 c1c(nc(s1)N=C(N)N)CSCC/C(=N/S(=O)(=O)N)/N 
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81 3.24 Cimetidine (51481-61-9) 2654 Cc1c([nH]cn1)CSCCN/C(=N/C)/NC#N 
82 3.26 Moxonidine (75438-57-2) 4645 Cc1nc(c(c(n1)Cl)NC2=NCCN2)OC 
83 3.28 Tolazoline (59-98-3) 5303 c1ccc(cc1)CC2=NCCN2 
84 3.28 Theobromine (83-67-0) 5236 Cn1cnc2c1c(nc(=O)n2C)O 
85 3.29 Psilocin (520-53-6) 4807 CN(C)CCc1c[nH]c2c1c(ccc2)O 
86 3.34 Practolol (6673-35-4) 4715 CC(C)NCC(COc1ccc(cc1)NC(=O)C)O 
87 3.35 Omethoate (1113-02-6) 13574 CNC(=O)CSP(=O)(OC)OC 
88 3.35 Butocarboxim-sulfoxide (34681-24-8) 7851180 O=S(C(\C(=N\OC(=O)NC)C)C)C 
89 3.36 Dihydrocodeine (125-28-0) (N/A) CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(CC4)O 
90 3.37 Sulfadiazine (68-35-9) 5026 c1cnc(nc1)NS(=O)(=O)c2ccc(cc2)N 
91 3.39 Nalorphine (62-67-9) 4270 C=CCN1CCC23c4c5ccc(c4OC2C(C=CC3C1C5)O)O 
92 3.4 Codeine (76-57-3) 2726 CN1CCC23c4c5ccc(c4OC2C(C=CC3C1C5)O)OC 
93 3.41 Asulam (3337-71-1) 17707 CO/C(=N/S(=O)(=O)c1ccc(cc1)N)/O 
94 3.41 Tiapride (51012-32-9) 5268 CCN(CC)CC/N=C(/c1cc(ccc1OC)S(=O)(=O)C)\O 
95 3.43 Sumatriptan (103628-46-2) 5165 CNS(=O)(=O)Cc1ccc2c(c1)c(c[nH]2)CCN(C)C 
96 3.43 Acetazolamide (59-66-5) 1909 CC(=O)Nc1nnc(s1)S(=O)(=O)N 
97 3.44 Naloxone (465-65-6) (N/A) C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O 
98 3.48 Paracetamol (Acetaminophen) (103-90-2) 1906 C/C(=N\c1ccc(cc1)O)/O 
99 3.49 Heliotrine-N-oxide (6209-65-0) 2985574 CC(C)C(C(C)OC)(C(=O)OCC1=CC[N+]2(C1C(CC2)O)[O-])O 
100 3.49 Rizatriptan (144034-80-0) 4900 CN(C)CCc1c[nH]c2c1cc(cc2)Cn3cncn3 
101 3.5 Norcodeine (467-15-2) (N/A) COC1=C2C3=C(CC4C5C3(CCN4)C(O2)C(C=C5)O)C=C1 
102 3.5 Propamocarb (24579-73-5) 30114 CCCO/C(=N/CCCN(C)C)/O 
103 3.5 Aldicarb-sulfoxide (1646-87-3) 7843407 CC(C)(/C=N/OC(=O)NC)[S+](C)[O-] 
104 3.53 DMPEA (3,4-Dimethoxy phenethylamine) (120-20-7) 8114 COc1ccc(cc1OC)CCN 
105 3.53 Sulfathiazole (72-14-0) 5148 c1cc(ccc1N)S(=O)(=O)Nc2nccs2 
106 3.54 Norephedrine  (14838-15-4) 4622 CC(C(c1ccccc1)O)N 
107 3.56 Oxycodone (76-42-6) 4474 CN1CCC23c4c5ccc(c4OC2C(=O)CCC3(C1C5)O)OC 
108 3.56 Reproterol (54063-54-6) 23898 Cn1c2c(c(=O)n(c1=O)C)n(cn2)CCCNCC(c3cc(cc(c3)O)O)O 
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109 3.56 Actinoquinol (15301-40-3) 22136 CCOc1ccc(c2c1nccc2)S(=O)(=O)O 
110 3.57 2-Phenethylamine (64-04-0) 13856352 c1ccc(cc1)CCN 
111 3.58 Naltrexone (16590-41-3) 4275 c1cc(c2c3c1CC4C5(C3(CCN4CC6CC6)C(O2)C(=O)CC5)O)O 
112 3.58 Metronidazole (443-48-1) 4029 Cc1ncc(n1CCO)[N+](=O)[O-] 
113 3.59 Cathinone (71031-15-7) 96940 CC(C(=O)c1ccccc1)N 
114 3.59 Dinotefuran (165252-70-0) 171124 CN/C(=N/[N+](=O)[O-])/NCC1CCOC1 
115 3.61 Zolmitriptan (139264-17-8) 5529 CN(C)CCc1c[nH]c2c1cc(cc2)CC3COC(=O)N3 
116 3.62 Alizapride (59338-93-1) 39202 COc1cc2c(cc1C(=O)NCC3CCCN3CC=C)nn[nH]2 
117 3.63 Varenicline (249296-44-4) 148958 c1cnc2cc3c(cc2n1)C4CC3CNC4 
118 3.64 Tizanidine (51322-75-9) 5287 c1cc(c(c2c1nsn2)NC3=NCCN3)Cl 
119 3.64 Dimethylcathinone (Metamfepramone) (15351-09-4) 64889 CC(C(=O)c1ccccc1)N(C)C 
120 3.65 Lycopsamine (10285-07-1) 21009 CC(C)C(C(C)O)(C(=O)OCC1=CCN2C1C(CC2)O)O 
121 3.66 Levetiracetam (102767-28-2) 53863 CCC(C(=O)N)N1CCCC1=O 
122 3.66 Butoxycarboxim (34681-23-7) 55798 CC(/C(=N/OC(=O)NC)/C)S(=O)(=O)C 
123 3.68 Cathine (492-39-7) 4622 CC(C(c1ccccc1)O)N 
124 3.68 Amiloride (2016-88-8) 15403 c1(c(nc(c(n1)Cl)N)N)/C(=N/C(=N)N)/O 
125 3.68 Methcathinone (Ephedrone) (5650-44-2) 1519 CC(C(=O)c1ccccc1)NC 
126 3.69 Hydrocodone (125-29-1) 364475 CN1CCC23c4c5ccc(c4OC2C(=O)CCC3C1C5)OC 
127 3.69 Esculin (Aesculin) (531-75-9) 4508522 c1cc(=O)oc2c1cc(c(c2)O)OC3C(C(C(C(O3)CO)O)O)O 
128 3.69 Methiopropamine (801156-47-8) 385727 CC(Cc1cccs1)NC 
129 3.71 Noroxycodone (57664-96-7) 544866 COc1ccc2c3c1OC4C35CCNC(C2)C5(CCC4=O)O 
130 3.71 Gabapentin (60142-96-3) 3328 C1CCC(CC1)(CC(=O)O)CN 
131 3.71 Phenelzine (51-71-8) 3547 c1ccc(cc1)CCNN 
132 3.71 Sulfapyridine (144-83-2) 5145 c1ccnc(c1)NS(=O)(=O)c2ccc(cc2)N 
133 3.73 Methylephedrine (552-79-4) 4221 CC(C(c1ccccc1)O)N(C)C 
134 3.73 Homatropine (87-00-3) 3497 CN1C2CCC1CC(C2)OC(=O)C(c3ccccc3)O 
135 3.73 Dimethipin (Na adduct in MS spectrum) (55290-64-7) 37765 CC1=C([S](=O)(=O)CC[S]1(=O)=O)C 
136 3.74 Pseudoephedrine (90-82-4) 4856 CC(C(c1ccccc1)O)NC 
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137 3.75 6-O-Monoacetylmorphine (MAM) (2784-73-8) 21537497 CC(=O)OC1C=CC2C3Cc4ccc(c5c4C2(C1O5)CCN3C)O 
138 3.75 Cotinine (75202-09-4) 395 CN1C(CCC1=O)c2cccnc2 
139 3.75 Aldicarb-sulfone (Aldoxycarb) (1646-88-4) 7844561 CC(C)(/C=N/OC(=O)NC)S(=O)(=O)C 
140 3.76 Ephedrine (299-42-3) 4856 CC(C(c1ccccc1)O)NC 
141 3.76 Diprophylline (479-18-5) 3070 Cn1c2c(c(=O)n(c1=O)C)n(cn2)CC(CO)O 
142 3.77 Oxamyl (23135-22-0) 7869433 CNC(=O)O/N=C(/C(=O)N(C)C)\SC 
143 3.78 bk-MDDMA (Dimethylone) No CAS available 7970239 O=C(c1ccc2OCOc2c1)C(N(C)C)C 
144 3.79 Dropropizine (Dopropizin) (17692-31-8) 3057 c1ccc(cc1)N2CCN(CC2)CC(CO)O 
145 3.81 MDAI (132741-81-2) 111694 c1c2c(cc3c1OCO3)CC(C2)N 
146 3.81 Methylone (MDMC) (186028-79-5) 21106350 CC(C(=O)c1ccc2c(c1)OCO2)NC 
147 3.83 Scopolamine (51-34-3) 4997 CN1C2CC(CC1C3C2O3)OC(=O)C(CO)c4ccccc4 
148 3.83 Clonidine (4205-90-7) 2701 c1cc(c(c(c1)Cl)NC2=NCCN2)Cl 
149 3.84 Theophylline (58-55-9) 2068 Cn1c2c(c(=O)n(c1=O)C)nc[nH]2 
150 3.86 Tinidazole (19387-91-8) 5279 CCS(=O)(=O)CCn1c(ncc1[N+](=O)[O-])C 
151 3.86 Sulfamerazine (127-79-7) 5134 Cc1ccnc(n1)NS(=O)(=O)c2ccc(cc2)N 
152 3.87 Oxitropium No CAS available 4466 CC[N+]1(C2CC(CC1C3C2O3)OC(=O)C(CO)c4ccccc4)C 
153 3.88 Pregabalin (148553-50-8) 3902475 CC(C)CC(CC(=O)O)CN 
154 3.88 Methylscopolamine (13265-10-6) 3977 C[N+]1(C2CC(CC1C3C2O3)OC(=O)C(CO)c4ccccc4)C 
155 3.88 Amisulpiride (71675-85-9) 2074 CCN1CCCC1CNC(=O)c2cc(c(cc2OC)N)S(=O)(=O)CC 
156 3.88 Mescaline (54-04-6) 3934 COc1cc(cc(c1OC)OC)CCN 
157 3.88 Desethylhydroxychloroquine (Cletoquine) (4298-15-1) 64850 CC(CCCNCCO)Nc1ccnc2c1ccc(c2)Cl 
158 3.89 Physostigmine (57-47-6) 4646 CC12CCN(C1N(c3c2cc(cc3)OC(=O)NC)C)C 
159 3.89 Pindolol (13523-86-9) 4662 CC(C)NCC(COc1cccc2c1cc[nH]2)O 
160 3.9 Nitenpyram (150824-47-8) 2298774 CCN(Cc1ccc(nc1)Cl)/C(=C/[N+](=O)[O-])/NC 
161 3.91 Oxydemeton-methyl (301-12-2) 4457 CCS(=O)CCSP(=O)(OC)OC 
162 3.91 Carteolol (51781-06-7) 2485 CC(C)(C)NCC(COc1cccc2c1CCC(=O)N2)O 
163 3.91 Flephedrone (447-40-5) 21477355 CC(C(=O)c1ccc(cc1)F)NC 
164 3.92 Diaveridine (5355-16-8) 20162 COc1ccc(cc1OC)Cc2cnc(nc2N)N 
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165 3.93 Ethylcathinone (18259-37-5) 403504 CCNC(C)C(=O)c1ccccc1 
166 3.94 3-4-DMA (3,4-Dimethoxyamphetamine) (120-26-3) 8116 CC(Cc1ccc(c(c1)OC)OC)N 
167 3.94 DMT (Dimethyltryptamine) (61-50-7) 5864 CN(C)CCc1c[nH]c2c1cccc2 
168 3.94 3-F-Methcathinone (1049677-77-1) 24958236 CC(C(=O)c1cccc(c1)F)NC 
169 3.94 Lycopsamine-N-oxide (41708-76-3) 35633 CC(C)C(C(C)O)(C(=O)OCC1=CC[N+]2(C1C(CC2)O)[O-])O 
170 3.96 Methotrexate (59-05-2) 3969 CN(Cc1cnc2c(n1)c(nc(n2)N)N)c3ccc(cc3)C(=O)NC(CCC(=O)O)C(=O)O 
171 3.96 Sulfaclomide (4015-18-3) 64308 Cc1c(c(nc(n1)C)NS(=O)(=O)c2ccc(cc2)N)Cl 
172 3.97 Bethanidine (55-73-2) 2278 CNC(=NCc1ccccc1)NC 
173 3.97 Dazomet (533-74-4) 10332 CN1CN(C(=S)SC1)C 
174 3.98 Lisinopril (76547-98-3) 3800 c1ccc(cc1)CCC(C(=O)O)NC(CCCCN)C(=O)N2CCCC2C(=O)O 
175 3.98 Ropinirole (91374-21-9) 4916 CCCN(CCC)CCc1cccc2c1CC(=O)N2 
176 3.98 Demeton-S-methylsulfoxide (Oxydemeton-methyl) (301-12-2) 4457 CCS(=O)CCSP(=O)(OC)OC 
177 3.98 5-MeO-DMT (5-Methoxydimethyltryptamine) (1019-45-0) 1766 CN(C)CCc1c[nH]c2c1cc(cc2)OC 
178 3.98 Hydroxychloroquine (118-42-3) 3526 CCN(CCCC(C)Nc1ccnc2c1ccc(c2)Cl)CCO 
179 3.99 Trimethoprim (738-70-5) 5376 COc1cc(cc(c1OC)OC)Cc2c[nH]c(=N)[nH]c2=N 
180 4.01 Retrorsine (480-54-6) 4509313 C/C=C/1\CC(C(C(=O)OCC2=CCN3C2C(CC3)OC1=O)(CO)O)C 
181 4.01 alpha-PPP (alpha-Pyrrolidinopropiophenone) (19134-50-0) 181124 CC(C(=O)c1ccccc1)N2CCCC2 
182 4.01 Pymetrozine (123312-89-0) 7850487 CC1=NN=C(N(C1)/N=C/c2cccnc2)O 
183 4.01 5-MeOT (5-Methoxytryptamine) (608-07-1) 1767 COc1ccc2c(c1)c(c[nH]2)CCN 
184 4.04 Ethylone (1112937-64-0) 21106271 CCNC(C)C(=O)c1ccc2c(c1)OCO2 
185 4.06 O-Desmethyltramadol (73986-53-5) 115703 CN(C)CC1CCCCC1(c2cccc(c2)O)O 
186 4.08 Ethylmorphine (76-58-4) 3187 CCOc1ccc2c3c1OC4C35CCN(C(C2)C5C=CC4O)C 
187 4.08 MDDMA (N,N Dimethyl-3,4-
methylenedioxyamphetamine) 
(74698-50-3) 479880 CC(Cc1ccc2c(c1)OCO2)N(C)C 
188 4.09 Nimorazole (6506-37-2) 21533 c1c(n(cn1)CCN2CCOCC2)[N+](=O)[O-] 
189 4.09 Etofylline (519-37-9) 1820 Cn1c2c(c(=O)n(c1=O)C)n(cn2)CCO 
190 4.1 Imazapyr (81334-34-1) 49445 CC(C)C1(C(=O)N=C(N1)c2c(cccn2)C(=O)O)C 
191 4.11 Amfepramone (134-80-5) 6762 CCN(CC)C(C)C(=O)c1ccccc1 
192 4.11 Sulfamethizole (144-82-1) 5137 Cc1nnc(s1)NS(=O)(=O)c2ccc(cc2)N 
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193 4.11 Sulthiame (61-56-3) 5163 c1cc(ccc1N2CCCCS2(=O)=O)S(=O)(=O)N 
194 4.11 Pirenzepine (28797-61-7) 4682 CN1CCN(CC1)CC(=O)N2c3ccccc3C(=O)Nc4c2nccc4 
195 4.13 MDPPP (3',4'-Methylenedioxy-alpha-
pyrrolidinopropiophenone) 
(783241-66-7) 4936183 CC(C(=O)c1ccc2c(c1)OCO2)N3CCCC3 
196 4.14 N-MBZP (1-Benzyl-4-methylpiperazine) (62226-74-8) 667589 CN1CCN(CC1)Cc2ccccc2 
197 4.14 Fenproporex (NARL) (15686-61-0) 55690 CC(Cc1ccccc1)NCCC#N 
198 4.14 Phenmetrazine (134-49-6) 4598 CC1C(OCCN1)c2ccccc2 
199 4.15 Demeton-S-methylsulfone (17040-19-6) 26248 CCS(=O)(=O)CCSP(=O)(OC)OC 
200 4.16 Strychnine (57-24-9) 21428631 c1ccc2c(c1)C34CCN5C3CC6C7C4N2C(=O)CC7OCC=C6C5 
201 4.16 Methomyl (16752-77-5) 3966 C/C(=N\OC(=O)NC)/SC 
202 4.16 TMA (trimethoxyamphetamine) (1082-23-1) 28771 CC(Cc1ccc(c(c1OC)OC)OC)N 
203 4.16 Amphetamine (300-62-9) 13852819 CC(Cc1ccccc1)N 
204 4.16 Chloroquine (54-05-7) 2618 CCN(CC)CCCC(C)Nc1ccnc2c1ccc(c2)Cl 
205 4.16 Methedrone (530-54-1) 187475 CC(C(=O)c1ccc(cc1)OC)NC 
206 4.17 Nalbuphine (20594-83-6) 4266 c1cc(c2c3c1CC4C5(C3(CCN4CC6CCC6)C(O2)C(CC5)O)O)O 
207 4.17 Ipratropium (22254-24-6) 3615 CC(C)[N+]1(C2CCC1CC(C2)OC(=O)C(CO)c3ccccc3)C 
208 4.17 Seneciphylline (480-81-9) 16093177 C/C=C\1/CC(=C)C(C(=O)OCC2=CCN3C2C(CC3)OC1=O)(C)O 
209 4.18 MDMA (Ecstacy) (42542-10-9) 1556 CC(Cc1ccc2c(c1)OCO2)NC 
210 4.19 Methamphetamine (537-46-2) 1169 CC(Cc1ccccc1)NC 
211 4.19 MDA (3,4-Methylenedioxyamphetamine) (4764-17-4) 1555 CC(Cc1ccc2c(c1)OCO2)N 
212 4.19 Furazolidone (67-45-8) 3317 c1cc(oc1C=NN2CCOC2=O)[N+](=O)[O-] 
213 4.19 5-MeO-TMT (67292-68-6) 45143 Cc1c(c2cc(ccc2[nH]1)OC)CCN(C)C 
214 4.21 Brucine (357-57-3) 191250 COc1cc2c(cc1OC)N3C4C25CCN6C5CC7C4C(CC3=O)OCC=C7C6 
215 4.21 Dobutamine (34368-04-2) 33786 CC(CCc1ccc(cc1)O)NCCc2ccc(c(c2)O)O 
216 4.21 Simazine 2-Hydroxy (2599-11-3) 16505 CC/N=c\1/[nH]/c(=N\CC)/nc([nH]1)O 
217 4.22 1-Piperonylpiperazine (32231-06-4) 85214 c1cc2c(cc1CN3CCNCC3)OCO2 
218 4.22 Flonicamid (158062-67-0) 8010234 c1cncc(c1C(F)(F)F)/C(=N/CC#N)/O 
219 4.23 Caffeine (58-08-2) 2424 Cn1cnc2c1c(=O)n(c(=O)n2C)C 
220 4.23 Benzylpiperazine (2759-28-6) 68493 c1ccc(cc1)CN2CCNCC2 
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221 4.24 Dimethocaine (94-15-5) 6909 CCN(CC)CC(C)(C)COC(=O)c1ccc(cc1)N 
222 4.24 Tetroxoprim (53808-87-0) 58910 COCCOc1c(cc(cc1OC)Cc2cnc(nc2N)N)OC 
223 4.24 2-Fluoramphetamine (1716-60-5) 108441 CC(Cc1ccccc1F)N 
224 4.25 Thiamethoxam (153719-23-4) 96828 CN1COCN(C1=N[N+](=O)[O-])Cc2cnc(s2)Cl 
225 4.26 Ketobemidone (Ketogan) (469-79-4) 9697 CCC(=O)C1(CCN(CC1)C)c2cccc(c2)O 
226 4.26 Buphedrone (408332-79-6) 26286946 CCC(C(=O)c1ccccc1)NC 
227 4.27 Heliotrine (303-33-3) 8977 CC(C)C(C(C)OC)(C(=O)OCC1=CCN2C1C(CC2)O)O 
228 4.27 Tranylcypromine (155-09-9) 5329 c1ccc(cc1)C2CC2N 
229 4.27 Dimetridazole (551-92-8) 2980 Cc1ncc(n1C)[N+](=O)[O-] 
230 4.27 Ofloxacin (82419-36-1) 4422 CC1COc2c3n1cc(c(=O)c3cc(c2N4CCN(CC4)C)F)C(=O)O 
231 4.27 Baclofen (1134-47-0) 2197 c1cc(ccc1C(CC(=O)O)CN)Cl 
232 4.28 O-Desmethylnortramadol (N/A) (N/A) OC1(CCCCC1CNC)c2ccc(O)cc2 
233 4.28 Methazolamide (554-57-4) 3958 CC(=O)/N=c\1/n(nc(s1)S(=O)(=O)N)C 
234 4.28 Apomorphine (58-00-4) 2129 CN1CCc2cccc-3c2C1Cc4c3c(c(cc4)O)O 
235 4.29 Nadolol (42200-33-9) 4258 CC(C)(C)NCC(COc1cccc2c1CC(C(C2)O)O)O 
236 4.3 PMMA (p-Methoxymethamphetamine) (22331-70-0) 81951 CC(Cc1ccc(cc1)OC)NC 
237 4.31 Mefexamide (1227-61-8) 3905 CCN(CC)CC/N=C(/COc1ccc(cc1)OC)\O 
238 4.32 MDAT (6,7-(Methylenedioxy)-2-aminotetralin) (101625-35-8) 33531 c1c2c(cc3c1OCO3)CC(CC2)N 
239 4.33 Retrorsine-N-oxide (Isatidine)) (15503-86-3) 3317818 CC=C1CC(C(C(=O)OCC2=CC[N+]3(C2C(CC3)OC1=O)[O-])(CO)O)C 
240 4.33 2-Fluoromethamphetamine (1017176-48-5) 23900072 CC(Cc1ccccc1F)NC 
241 4.34 PMA (4-methoxyamphetamine) (64-13-1) 29417 CC(Cc1ccc(cc1)OC)N 
242 4.34 Pemoline (2152-34-3) 4561 c1ccc(cc1)C2C(=O)N=C(O2)N 
243 4.34 Proxyphylline (603-00-9) 4806 CC(Cn1cnc2c1c(=O)n(c(=O)n2C)C)O 
244 4.34 4-OH-DIPT (4-Hydroxy-N,N-diisopropyltryptamine) (63065-90-7) 10579819 CC(C)N(CCc2cnc1cccc(O)c12)C(C)C 
245 4.34 Butylone (bk-MBDB) (802575-11-7) 21106270 CCC(C(=O)c1ccc2c(c1)OCO2)NC 
246 4.34 DET (Diethyltryptamine) (61-51-8) 5865 CCN(CC)CCc1c[nH]c2c1cccc2 
247 4.36 Bulbocapnine (298-45-3) 8919 CN1CCc2cc3c(c-4c2C1Cc5c4c(c(cc5)OC)O)OCO3 
248 4.36 Metoclopramide (364-62-5) 4024 CCN(CC)CC/N=C(/c1cc(c(cc1OC)N)Cl)\O 
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249 4.36 5-MeO-AMT (5-Methoxy-alpha-methyltryptamine) (1137-04-8) 33864 CC(Cc1c[nH]c2c1cc(cc2)OC)N 
250 4.36 O-Desmethyldinortramadol (N/A) (N/A) OC1(CCCCC1CN)c2ccc(O)cc2 
251 4.36 Monocrotophos (6923-22-4) 4522053 CC(=CC(=O)NC)OP(=O)(OC)OC 
252 4.36 Atropine (51-55-8) 3534 CN1C2CCC1CC(C2)OC(=O)C(CO)c3ccccc3 
253 4.37 cis-1,2,3,6-Tetrahydrophthalimide  (1469-48-3) 6549 C1C=CCC2C1C(=O)NC2=O 
254 4.38 Dibutylone (802286-83-5) (N/A) CN(C)C(CC)C(=O)c1ccc2OCOc2c1 
255 4.39 4-Fluoroamphetamine (459-02-9) 9592 CC(Cc1ccc(cc1)F)N 
256 4.39 MDEA (N-Ethyl-3,4-methylenedioxyamphetamine) (82801-81-8) 10723892 CC(NCC)Cc1ccc2COOc2c1 
257 4.39 3-Fluoroamphetamine (1626-71-7) 108417 CC(Cc1cccc(c1)F)N 
258 4.39 Debrisoquine (1131-64-2) 2860 c1ccc2c(c1)CCN(C2)C(=N)N 
259 4.39 3-Fluoromethamphetamine (1182818-14-9) 27050449 CC(Cc1cccc(c1)F)NC 
260 4.4 N-Ethylamphetamine (457-87-4) 9588 CCNC(C)Cc1ccccc1 
261 4.42 Ciprofloxacin (85721-33-1) 2662 c1c2c(cc(c1F)N3CCNCC3)n(cc(c2=O)C(=O)O)C4CC4 
262 4.43 2C-H (2,5-Dimethoxyphenethylamine) (3600-86-0) 28541669 COc1ccc(cc1CCN)CO 
263 4.43 4-Fluoromethamphetamine (351-03-1) 9919721 Fc1ccc(cc1)CC(NC)C 
264 4.44 Biotin (58-85-5) 248 C1C2C(C(S1)CCCCC(=O)O)NC(=O)N2 
265 4.44 Sulfalene (152-47-6) 8695 COc1c(nccn1)NS(=O)(=O)c2ccc(cc2)N 
266 4.44 Alpha-Methyltryptamine (AMT) (299-26-3) 8930 CC(Cc1c[nH]c2c1cccc2)N 
267 4.44 Sulfamethoxypyridazine (80-35-3) 5139 COc1ccc(nn1)NS(=O)(=O)c2ccc(cc2)N 
268 4.44 Mepindolol (23694-81-7) 64750 Cc1cc2c([nH]1)cccc2OCC(CNC(C)C)O 
269 4.46 Acetiamine (trans) (299-89-8) 4677905 Cc1ncc(c(n1)N)CN(C=O)/C(=C(\CCOC(=O)C)/SC(=O)C)/C 
270 4.46 Norfloxacin (70458-96-7) 4380 CCn1cc(c(=O)c2c1cc(c(c2)F)N3CCNCC3)C(=O)O 
271 4.47 Thebacon (466-90-0) (N/A) CC(=O)OC1=CCC2C3CC4=C5C2(C1OC5=C(C=C4)OC)CCN3C 
272 4.47 Tetryzoline (Tetrahydrozoline) (84-22-0) 5226 c1ccc2c(c1)CCCC2C3=NCCN3 
273 4.48 2,6-Dichlorobenzamide (2008-58-4) 15359 c1cc(c(c(c1)Cl)C(=N)O)Cl 
274 4.49 MDPBP (3',4'-Methylenedioxy-alpha-
pyrrolidinobutyrophenone) 
(24622-60-4) (N/A) CCC(C(=O)C1=CC2=C(C=C1)OCO2)N3CCCC3 
275 4.5 Seneciphylline-N-oxide (38710-26-8) (N/A) CC=C1CC(=C)C(C(=O)OCC2=CC[N+]3(C2C(CC3)OC1=O)[O-])(C)O 
276 4.5 Dicrotophos (141-66-2) 4522051 C/C(=C\C(=O)N(C)C)/OP(=O)(OC)OC 
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277 4.53 Zonisamide (68291-97-4) 5532 c1ccc2c(c1)c(no2)CS(=O)(=O)N 
278 4.53 Mephedrone (1189805-46-6) 21485694 Cc1ccc(cc1)C(=O)C(C)NC 
279 4.54 Sulfamethoxazole (723-46-6) 5138 Cc1cc(no1)NS(=O)(=O)c2ccc(cc2)N 
280 4.56 Nifenazone (2139-47-1) 4332 Cc1c(c(=O)n(n1C)c2ccccc2)NC(=O)c3cccnc3 
281 4.57 Guanoxan (2165-19-7) 15704 c1ccc2c(c1)OCC(O2)CNC(=N)N 
282 4.59 Captopril (62571-86-2) 2453 CC(CS)C(=O)N1CCCC1C(=O)O 
283 4.59 Lidocaine (137-58-6) 3548 CCN(CC)C/C(=N\c1c(cccc1C)C)/O 
284 4.59 Tolycaine (3686-58-6) 65111 CCN(CC)CC(=O)Nc1c(cccc1C(=O)OC)C 
285 4.61 Ritalinic acid (19395-41-6) 78360 c1ccc(cc1)C(C2CCCCN2)C(=O)O 
286 4.61 Triamterene (396-01-0) 5345 c1ccc(cc1)c2c(=N)nc-3[nH]c(=N)[nH]c(c3n2)N 
287 4.62 Senecionine (130-01-8) 223408 CC=C1CC(C(C(=O)OCC2=CCN3C2C(CC3)OC1=O)(C)O)C 
288 4.62 7-Aminodesmethylflunitrazepam (894-76-8) 141082 c1ccc(c(c1)C2=NCC(=O)Nc3c2cc(cc3)N)F 
289 4.62 Detajmium (1+) (47719-70-0) (N/A) CCC1C2CC3C4C5(CC(C2C5O)[N+]3(C1O)CC(CN(CC)CC)O)C6=CC=CC=C6N4C 
290 4.63 Imazamox (114311-32-9) 77711 CC(C)C1(C(=O)NC(=N1)c2c(cc(cn2)COC)C(=O)O)C 
291 4.63 Ethiofencarb-sulfone (53380-23-7) 106713 CCS(=O)(=O)Cc1ccccc1OC(=O)NC 
292 4.63 Phenazone (antipyrine) (60-80-0) 2121 Cc1cc(=O)n(n1C)c2ccccc2 
293 4.64 Chlordimeform (6164-98-3) 10468746 CC1=C(C=CC(=C1)Cl)N=CN(C)C 
294 4.64 Phentermine (122-09-8) 4607 CC(C)(Cc1ccccc1)N 
295 4.64 Nikethamide (59-26-7) 5296 CCN(CC)C(=O)c1cccnc1 
296 4.66 Heroin (561-27-3) (N/A) CC(=O)OC1C=CC2C3CC4=C5C2(C1OC5=C(C=C4)OC(=O)C)CCN3C 
297 4.66 Bunitrolol (34915-68-9) 2379 CC(C)(C)NCC(COC1=CC=CC=C1C#N)O 
298 4.66 MBDB (103818-46-8) 111153 CCC(Cc1ccc2c(c1)OCO2)NC 
299 4.66 Mepivacaine (22801-44-1) 3922 Cc1cccc(c1NC(=O)C2CCCCN2C)C 
300 4.66 Phthalylsulfathiazole (85-73-4) 4641 c1ccc(c(c1)C(=O)Nc2ccc(cc2)S(=O)(=O)Nc3nccs3)C(=O)O 
301 4.67 Clenbuterol (50306-03-1) 2681 CC(C)(C)NCC(c1cc(c(c(c1)Cl)N)Cl)O 
302 4.68 Benzoylecgonine (519-09-5) 2250 CN1C2CCC1C(C(C2)OC(=O)c3ccccc3)C(=O)O 
303 4.68 Methylhexanamine (1,3-DMAA) (105-41-9) 7467 CCC(C)CC(C)N 
304 4.68 Ketamine (100477-72-3) 3689 CNC1(CCCCC1=O)c2ccccc2Cl 
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305 4.68 Norfentanyl (1609-66-1) 227671 CCC(=O)N(c1ccccc1)C2CCNCC2 
306 4.69 Methoxyphenamine (93-30-1) 3974 CC(Cc1ccccc1OC)NC 
307 4.69 Carticaine (Articaine) (23964-58-1) 29837 CCCNC(C)C(=O)Nc1c(csc1C(=O)OC)C 
308 4.69 Prilocaine (721-50-6) 4737 CCCNC(C)C(=O)Nc1ccccc1C 
309 4.69 Sulfadoxine (2447-57-6) 16218 COc1c(ncnc1OC)NS(=O)(=O)c2ccc(cc2)N 
310 4.7 Ethiofencarb Sulfoxide (53380-22-6) 2299504 CCS(=O)Cc1ccccc1OC(=O)NC 
311 4.71 Laudanosine (20412-65-1) 14792 CN1CCc2cc(c(cc2C1Cc3ccc(c(c3)OC)OC)OC)OC 
312 4.72 Sulfabenzamide (127-71-9) 5128 c1ccc(cc1)C(=O)NS(=O)(=O)c2ccc(cc2)N 
313 4.73 BDB (1,3-Benzodioxolylbutanamine) (107447-03-0) 114963 CCC(Cc1ccc2c(c1)OCO2)N 
314 4.74 Rivastigmine (123441-03-2) 4899 CCN(C)C(=O)Oc1cccc(c1)C(C)N(C)C 
315 4.74 Meptazinol (54340-58-8) 37469 CCC1(CCCCN(C1)C)c2cccc(c2)O 
316 4.74 4-Methylaminophenazone (519-98-2) 10173 Cc1c(c(=O)n(n1C)c2ccccc2)NC 
317 4.74 4-MEC (4-Methylethcathinone) (1225617-18-4) 25630091 CCNC(C)C(=O)c1ccc(cc1)C 
318 4.74 Disopyramide (3737-09-5) 3002 CC(C)N(CCC(c1ccccc1)(c2ccccn2)C(=O)N)C(C)C 
319 4.75 Atrazine-desisopropyl (Deisopropylatrazine) (1007-28-9) 13278 CC/N=c\1/[nH]c(=N)nc([nH]1)Cl 
320 4.75 Quinmerac (90717-03-6) 82847 Cc1cc2ccc(c(c2nc1)C(=O)O)Cl 
321 4.76 Selegiline (14611-51-9) 5007 CC(Cc1ccccc1)N(C)CC#C 
322 4.76 Indanazoline (40507-78-6) 59376 c1cc2c(c(c1)NC3=NCCN3)CCC2 
323 4.76 Desvenlafaxine (O-Desmethylvenlafaxine) (93413-62-8) 111300 CN(C)CC(c1ccc(cc1)O)C2(CCCCC2)O 
324 4.76 Imidacloprid (138261-41-3) 77934 c1cc(ncc1CN2CCN=C2N[N+](=O)[O-])Cl 
325 4.76 Salicylamide (65-45-2) 4963 c1ccc(c(c1)C(=N)O)O 
326 4.76 Dikegulac (18467-77-1) 65070 CC1(OCC2C(O1)C3C(O2)(OC(O3)(C)C)C(=O)O)C 
327 4.76 4-MePPP (28117-80-8) 4936084 Cc1ccc(cc1)C(=O)C(C)N2CCCC2 
328 4.77 3,5-Diiodotyrosine (66-02-4) 5946 c1c(cc(c(c1I)O)I)CC(C(=O)O)N 
329 4.77 Tacrine (321-64-2) 1859 c1ccc2c(c1)c(=N)c3c([nH]2)CCCC3 
330 4.78 2-5-DMA (2,5-Dimethoxyamphetamine ) (2801-68-5) 56526 CC(Cc1cc(ccc1OC)OC)N 
331 4.78 Acebutolol (37517-30-9) 1901 CCCC(=O)Nc1ccc(c(c1)C(=O)C)OCC(CNC(C)C)O 
332 4.78 7-Aminonitrazepam (4928-02-3) 70996 c1ccc(cc1)C2=NCC(=Nc3c2cc(cc3)N)O 
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333 4.79 5-APB (5-(2-aminopropyl)benzofuran) (286834-80-8) as HCl 8012953 o2c1ccc(cc1cc2)CC(N)C 
334 4.81 Tramadol (27203-92-5) 5322 CN(C)CC1CCCCC1(c2cccc(c2)OC)O 
335 4.81 Sulfaethidole (94-19-9) 6913 CCc1nnc(s1)NS(=O)(=O)c2ccc(cc2)N 
336 4.81 5-MeO-DIPT (5-Methoxy-N,N-diisopropyltryptamine) (4021-34-5) 133247 CC(C)N(CCc1c[nH]c2c1cc(cc2)OC)C(C)C 
337 4.81 6-APB [6-(2-Aminopropyl)benzofuran] (286834-85-3) 7970110 o2c1cc(ccc1cc2)CC(N)C 
338 4.83 N-Propylamphetamine (51799-32-7) 93484 CCCNC(C)Cc1ccccc1 
339 4.83 Flumetsulam (98967-40-9) 82857 Cc1ccn2c(n1)nc(n2)S(=O)(=O)Nc3c(cccc3F)F 
340 4.84 Levobunolol (47141-42-4) 3777 CC(C)(C)NCC(COc1cccc2c1CCCC2=O)O 
341 4.84 Naphazoline (835-31-4) 4283 c1ccc2c(c1)cccc2CC3=NCCN3 
342 4.84 Ornidazole (16773-42-5) 26102 Cc1ncc(n1CC(CCl)O)[N+](=O)[O-] 
343 4.86 Metoprolol (37350-58-6) 4027 CC(C)NCC(COc1ccc(cc1)CCOC)O 
344 4.86 Trimethobenzamide (138-56-7) 5375 CN(C)CCOc1ccc(cc1)CNC(=O)c2cc(c(c(c2)OC)OC)OC 
345 4.86 7-Aminoclonazepam (4959-17-5) 163665 c1ccc(c(c1)C2=NCC(=Nc3c2cc(cc3)N)O)Cl 
346 4.86 Amantadine (768-94-5) 2045 C1C2CC3CC1CC(C2)(C3)N 
347 4.86 Cocaine (50-36-2) 2724 CN1C2CCC1C(C(C2)OC(=O)c3ccccc3)C(=O)OC 
348 4.86 Methiocarb-sulfoxide (2635-10-1) 16568 Cc1cc(cc(c1S(=O)C)C)OC(=O)NC 
349 4.87 DiPT (N,N-Diisopropyltryptamine) (14780-24-6) 25060 CC(C)N(CCc1c[nH]c2c1cccc2)C(C)C 
350 4.87 Aceclidine (827-61-2) 1902 CC(=O)OC1CN2CCC1CC2 
351 4.88 Timolol (26839-75-8) 5278 CC(C)(C)NCC(COc1c(nsn1)N2CCOCC2)O 
352 4.88 4-AcO-DIPT (4-Acetoxy-diisopropyltryptamine) (na) 29760176 CC(C)N(CCc1c[nH]c2c1ccc(c2)OC(=O)C)C(C)C 
353 4.88 Minoxidil (38304-91-5) 4056 [H]/N=c/1\nc(cc(n1O)N)N2CCCCC2 
354 4.89 Molindone (7416-34-4) 22342 CCc1c([nH]c2c1C(=O)C(CC2)CN3CCOCC3)C 
355 4.89 5-MeO-DALT (N,N-Diallyl-5-methoxytryptamine) (928822-98-4) 21106245 COc1ccc2c(c1)c(c[nH]2)CCN(CC=C)CC=C 
356 4.89 Pentedrone (879722-57-3) 26286729 CCCC(C(=O)c1ccccc1)NC 
357 4.9 Clothiandin (210880-92-5) 184723 C/N=C(/NCc1cnc(s1)Cl)\N[N+](=O)[O-] 
358 4.9 Quinclorac (84087-01-4) 82837 c1cc(c(c2c1cc(cn2)Cl)C(=O)O)Cl 
359 4.91 Gibberellic acid (77-06-5) (N/A) CC12C(C=CC3(C1C(C45C3CCC(C4)(C(=C)C5)O)C(=O)O)OC2=O)O 
360 4.91 Harmane (Harman) (486-84-0) 4444755 Cc1c2c(ccn1)c3ccccc3[nH]2 
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361 4.92 Terazosin (63590-64-7) 5208 COc1cc2c(cc1OC)nc(nc2N)N3CCN(CC3)C(=O)C4CCCO4 
362 4.93 Befunolol (39552-01-7) 2219 CC(C)NCC(COc1cccc2c1oc(c2)C(=O)C)O 
363 4.93 Zopiclone (43200-80-2) 5533 CN1CCN(CC1)C(=O)OC2c3c(nccn3)C(=O)N2c4ccc(cn4)Cl 
364 4.93 Methoxetamine (1239943-76-0) 24721792 CCNC1(CCCCC1=O)c2cccc(c2)OC 
365 4.94 Cafaminol (30924-31-3) 32824 Cn1c2c(nc1N(C)CCO)n(c(=O)n(c2=O)C)C 
366 4.96 Methylphenidate (113-45-1) 4015 COC(=O)C(c1ccccc1)C2CCCCN2 
367 4.97 Dicamba (1918-00-9) 2922 COc1c(ccc(c1C(=O)O)Cl)Cl 
368 4.98 Ondansetron (99614-02-5) 4434 Cc1nccn1CC2CCc3c(c4ccccc4n3C)C2=O 
369 4.98 Pheniramine (86-21-5) 4597 CN(C)CCC(c1ccccc1)c2ccccn2 
370 4.98 Moclobemide (71320-77-9) 4087 c1cc(ccc1C(=O)NCCN2CCOCC2)Cl 
371 4.99 Aminoglutethimide (125-84-8) 2060 CCC1(CCC(=O)NC1=O)c2ccc(cc2)N 
372 4.99 Hydroxyquetiapine (139079-39-3) 116771 c1ccc2c(c1)C(=Nc3ccc(cc3S2)O)N4CCN(CC4)CCOCCO 
373 4.99 Pentylone (bk-MBDP) (698963-77-8) 29786041 CCCC(C(=O)c1ccc2c(c1)OCO2)NC 
374 5 Sulcotrione (99105-77-8) 82858 CS(=O)(=O)c1ccc(c(c1)Cl)C(=O)C2C(=O)CCCC2=O 
375 5.01 3-Methylnorfentanyl (N-Methylfentanyl) (na) 459397 CCC(=O)N(c1ccccc1)C2CCN(CC2)C 
376 5.01 5-Carboxybupranolol (42242-69-3) 2284302 CC(C)(C)NCC(COc1cc(ccc1Cl)C(=O)O)O 
377 5.02 Vamidothion (2275-23-2) 486975 CC(C(=O)NC)SCCSP(=O)(OC)OC 
378 5.03 Atrazine 2-Hydroxy (Hydroxyatrazine) (2163-68-0) 15693 CC/N=c/1\[nH]/c(=N/C(C)C)/[nH]c(n1)O 
379 5.04 Vincamine (1617-90-9) 5466 CCC12CCCN3C1c4c(c5ccccc5n4C(C2)(C(=O)OC)O)CC3 
380 5.04 2,4-Dimethylaniline (Metabolite Amitraz) (95-68-1) 13869462 Cc1ccc(c(c1)C)N 
381 5.04 alpha-ET (Alpha-Ethyltryptamine) (2235-90-7) 8064 CCC(Cc1c[nH]c2c1cccc2)N 
382 5.04 4-Methylbuphedrone (1336911-98-8) as the HCl 
salt 
(N/A) CCC(C(=O)C1=CC=C(C=C1)C)NC  
383 5.05 Brefedrone (486459-03-4) 8597261 O=C(c1ccc(Br)cc1)C(NC)C 
384 5.06 Remoxipride (117591-79-4) 49611 CCN1CCCC1CNC(=O)c2c(ccc(c2OC)Br)OC 
385 5.06 Fenethylline (3736-08-1) 18398 CC(Cc1ccccc1)NCCn2cnc3c2c(=O)n(c(=O)n3C)C 
386 5.06 Tiemonium (1+) (6252-92-2) 5274 C[N+]1(CCOCC1)CCC(c2ccccc2)(c3cccs3)O 
387 5.06 Chlortalidone (77-36-1) 2631 c1ccc2c(c1)C(=O)NC2(c3ccc(c(c3)S(=O)(=O)N)Cl)O 
388 5.06 2-Benzyltetronic acid (3734-22-3) 21249083 c1ccc(cc1)CC2=C(COC2=O)O 
                                                                                                                                             continued 
437 
 
 
 
 
 
 
 
 
389 5.06 Fluconazole (86386-73-4) 3248 c1cc(c(cc1F)F)C(Cn2cncn2)(Cn3cncn3)O 
390 5.06 Harmaline (304-21-2) 4444444 CC1=C2C(=c3ccc(cc3=N2)OC)CCN1 
391 5.07 Senecionine-N-oxide (13268-67-2) 3617285 CC=C1CC(C(C(=O)OCC2=CC[N+]3(C2C(CC3)OC1=O)[O-])(C)O)C 
392 5.08 Yohimbine (146-48-5) 2763 COC(=O)C1C(CCC2C1CC3c4c(c5ccccc5[nH]4)CCN3C2)O 
393 5.08 Olanzapine (132539-06-1) 10442212 Cc1cc2c(s1)Nc3ccccc3N=C2N4CCN(CC4)C 
394 5.08 Ethylphenidate (57413-43-1) 2338571 CCOC(=O)C(c1ccccc1)C2CCCCN2 
395 5.08 Alpha-PVP (α-Pyrrolidinopentiophenone) (14530-33-7) 9324063 CCCC(C(=O)C1=CC=CC=C1)N2CCCC2 
396 5.08 Lacosamide (175481-36-4) 10266281 CC(=O)NC(COC)C(=O)NCc1ccccc1 
397 5.08 Sitagliptin (486460-32-6) 9481667 Fc1cc(c(F)cc1F)CC(N)CC(=O)N3Cc2nnc(n2CC3)C(F)(F)F 
398 5.09 Carbofuran-3-hydroxy (16655-82-6) 26024 CC1(C(c2cccc(c2O1)OC(=O)NC)O)C 
399 5.09 Tropisetron (89565-68-4) 5393 CN1C2CCC1CC(C2)OC(=O)c3c[nH]c4c3cccc4 
400 5.1 Tilidine (51931-66-9) 29969 CCOC(=O)C1(CCC=CC1N(C)C)c2ccccc2 
401 5.1 Mevinphos Peak 1 (Z or Trans isomer) (298-01-1) 4938358 C/C(=C/C(=O)OC)/OP(=O)(OC)OC 
402 5.11 Guaifenesin (93-14-1) 3396 COc1ccccc1OCC(CO)O 
403 5.12 Fenuron (101-42-8) 7279 CN(C)/C(=N\c1ccccc1)/O 
404 5.13 3-MBZP (1-benzyl-4-methylpiperazine) (62226-74-8) 667589 CN1CCN(CC1)Cc2ccccc2 
405 5.15 Aminocarb  (Metacil) (2032-59-9) 15416 Cc1cc(ccc1N(C)C)OC(=O)NC 
406 5.16 Senkirkine (2318-18-5) 4516153 C/C=C\1/CC(C(C(=O)OC/C/2=C/CN(CCC(C2=O)OC1=O)C)(C)O)C 
407 5.16 Bambuterol (81732-65-2) 49466 CC(C)(C)NCC(c1cc(cc(c1)OC(=O)N(C)C)OC(=O)N(C)C)O 
408 5.16 Dioxacarb (6988-21-2) 21901 CNC(=O)Oc1ccccc1C2OCCO2 
409 5.16 m-CPP (meta-Chlorophenylpiperazine) (6640-24-0) 1314 c1cc(cc(c1)Cl)N2CCNCC2 
410 5.17 Tulobuterol (41570-61-0) 5404 CC(C)(C)NCC(c1ccccc1Cl)O 
411 5.17 Acetamiprid (135410-20-7) 184719 C/C(=N\C#N)/N(C)Cc1ccc(nc1)Cl 
412 5.18 Esmolol (103598-03-4) 53916 CC(C)NCC(COc1ccc(cc1)CCC(=O)OC)O 
413 5.18 Doxylamine (469-21-6) 3050 CC(c1ccccc1)(c2ccccn2)OCCN(C)C 
414 5.18 MDPV (Methylenedioxypyrovalerone) (687603-66-3) 16788110 CCCC(C(=O)c1ccc2c(c1)OCO2)N3CCCC3 
415 5.19 Fenpipramide (77-01-0) 59016 c1ccc(cc1)C(CCN2CCCCC2)(c3ccccc3)C(=O)N 
416 5.19 Ajmaline (4360-12-7) 1989 CCC1C2CC3C4C5(CC(C2C5O)N3C1O)c6ccccc6N4C 
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417 5.21 Remifentanyl (132875-61-7) 54803 CCC(=O)N(c1ccccc1)C2(CCN(CC2)CCC(=O)OC)C(=O)OC 
418 5.21 Difenzoquat (Ion 1+) (49866-87-7) 36047 Cn1c(cc([n+]1C)c2ccccc2)c3ccccc3 
419 5.21 Methocarbamol (532-03-6) 3964 COc1ccccc1OCC(COC(=O)N)O 
420 5.21 Melperone (3575-80-2) 14646 CC1CCN(CC1)CCCC(=O)c2ccc(cc2)F 
421 5.21 Primidone (125-33-7) 4740 CCC1(C(=NCN=C1O)O)c2ccccc2 
422 5.21 Aminophenazone (Amidopyrine) (58-15-1) 5787 Cc1c(c(=O)n(n1C)c2ccccc2)N(C)C 
423 5.22 Bentazone (25057-89-0) 2238 CC(C)N1C(=O)c2ccccc2NS1(=O)=O 
424 5.22 Pethidine (57-42-1) 3918 CCOC(=O)C1(CCN(CC1)C)c2ccccc2 
425 5.23 Dimethoate (60-51-5) 2973 C/N=C(\CSP(=S)(OC)OC)/O 
426 5.23 Trichlorfon (Dylox) (52-68-6) 5644 COP(=O)(C(C(Cl)(Cl)Cl)O)OC 
427 5.23 3-4-DMMC (3,4-Dimethylmethcathinone) (1081772-06-6) 25630192 Cc1ccc(cc1C)C(=O)C(C)NC 
428 5.23 Pentoxifylline (6493-05-6) 4578 CC(=O)CCCCn1c(=O)c2c(ncn2C)n(c1=O)C 
429 5.24 Bamifylline (2016-63-9) 15401 CCN(CCn1c(nc2c1c(=O)n(c(=O)n2C)C)Cc3ccccc3)CCO 
430 5.24 4-MTA (4-Methylthioamphetamine) (14116-06-4) 133883 CC(Cc1ccc(cc1)SC)N 
431 5.24 Celiprolol (56980-93-9) 2563 CCN(CC)C(=O)Nc1ccc(c(c1)C(=O)C)OCC(CNC(C)(C)C)O 
432 5.24 Metamitron (41394-05-2) 35563 Cc1nnc(c(=O)n1N)c2ccccc2 
433 5.26 DPT (N,N-Dipropyltryptamine) (61-52-9) 5866 CCCN(CCC)CCc1c[nH]c2c1cccc2 
434 5.28 Nortilidine (38677-94-0) 459101 CCOC(=O)C1(CCC=CC1NC)c2ccccc2 
435 5.28 Methiocarb-sulfone (2179-25-1) 15729 Cc1cc(cc(c1S(=O)(=O)C)C)OC(=O)NC 
436 5.28 Isoxsuprine (395-28-8) 3651 CC(COc1ccccc1)NC(C)C(c2ccc(cc2)O)O 
437 5.28 Lamotrigine (84057-84-1) 3741 c1cc(c(c(c1)Cl)Cl)c2c([nH]c(=N)nn2)N 
438 5.28 2C-C (4-chloro-2,5-dimethoxyphenethylamine) (88441-14-9) 21106221 COc1cc(c(cc1Cl)OC)CCN 
439 5.29 Quinidine (56-54-2) 1036 COc1ccc2c(c1)c(ccn2)C(C3CC4CCN3CC4C=C)O 
440 5.29 Toliprolol (2933-94-0) 17050 Cc1cccc(c1)OCC(CNC(C)C)O 
441 5.31 Mefenorex (17243-57-1) 20467 CC(Cc1ccccc1)NCCCCl 
442 5.31 Mirtazapine (61337-67-5) 4060 CN1CCN2c3c(cccn3)Cc4ccccc4C2C1 
443 5.31 Desmethyl-Mirtazapine (61337-68-6) 8642761 n1cccc3c1N4C(c2c(cccc2)C3)CNCC4 
444 5.32 Cinoxacin (28657-80-9) 2660 CCn1c2cc3c(cc2c(=O)c(n1)C(=O)O)OCO3 
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445 5.33 Paliperidone (9-OH-Risperidone) (144598-75-4) 103109 Cc1c(c(=O)n2c(n1)C(CCC2)O)CCN3CCC(CC3)c4c5ccc(cc5on4)F 
446 5.34 2 C-D (2-(2,5-Dimethoxy-4-methylphenyl)ethanamine) (24333-19-5) 119559 Cc1cc(c(cc1OC)CCN)OC 
447 5.34 Prazosin (19216-56-9) 4724 COc1cc2c(cc1OC)nc([nH]c2=N)N3CCN(CC3)C(=O)c4ccco4 
448 5.34 Oxomemazine (3689-50-7) 18281 CC(CN1c2ccccc2S(=O)(=O)c3c1cccc3)CN(C)C 
449 5.34 Chloridazon (1698-60-8) 14790 c1ccc(cc1)n2c(=O)c(c(cn2)N)Cl 
450 5.34 Harmine (442-51-3) 4444445 Cc1c2c(ccn1)c3ccc(cc3[nH]2)OC 
451 5.36 Melatonin (73-31-4) 872 C/C(=N\CCc1c[nH]c2c1cc(cc2)OC)/O 
452 5.36 Carbutamide (339-43-5) 9189 CCCC/N=C(/NS(=O)(=O)c1ccc(cc1)N)\O 
453 5.36 Schradan (152-16-9) 8685 CN(C)P(=O)(N(C)C)OP(=O)(N(C)C)N(C)C 
454 5.37 Indoramin (26844-12-2) 31014 c1ccc(cc1)C(=O)NC2CCN(CC2)CCc3c[nH]c4c3cccc4 
455 5.39 Ropivacaine (84057-95-4) 21513357 CCCC1CCCCN1C(=O)Nc2c(cccc2C)C 
456 5.41 7-Aminoflunitrazepam (34084-50-9) 83325 CN1c2ccc(cc2C(=NCC1=O)c3ccccc3F)N 
457 5.42 Nomifensine (24526-64-5) 4371 CN1Cc2c(cccc2N)C(C1)c3ccccc3 
458 5.43 LSD (Lysergic acid diethylamide) (50-37-3) 3843 CCN(CC)C(=O)C1CN(C2Cc3c[nH]c4c3c(ccc4)C2=C1)C 
459 5.43 Fluroxypyr (69377-81-7) 45757 C(C(=O)O)Oc1c(c(c(c(n1)F)Cl)N)Cl 
460 5.44 Pitofenone (54063-52-4) 108096 COC(=O)c1ccccc1C(=O)c2ccc(cc2)OCCN3CCCCC3 
461 5.46 Pentazocine (359-83-1) 4574 CC1C2Cc3ccc(cc3C1(CCN2CC=C(C)C)C)O 
462 5.46 Cocaethylene (529-38-4) 2723 CCOC(=O)C1C2CCC(N2C)CC1OC(=O)c3ccccc3 
463 5.46 Carbendazim (10605-21-7) 23741 CO/C(=N/c1[nH]c2ccccc2n1)/O 
464 5.47 4-Benzamidosalicylic acid (13898-58-3) 10267 c1ccc(cc1)C(=O)Nc2ccc(c(c2)O)C(=O)O 
465 5.49 Carazolol (57775-29-8) 64783 CC(C)NCC(COc1cccc2c1c3ccccc3[nH]2)O 
466 5.49 Dibenzepin (4498-32-2) 9048 CN1c2ccccc2C(=O)N(c3c1cccc3)CCN(C)C 
467 5.49 Quinine (130-95-0) 1036 COc1ccc2c(c1)c(ccn2)C(C3CC4CCN3CC4C=C)O 
468 5.54 Pyritinol (1098-97-1) 13561 Cc1c(c(c(cn1)CSSCc2cnc(c(c2CO)O)C)CO)O 
469 5.54 Ketotifen (34580-13-7) 3695 CN1CCC(=C2c3ccccc3CC(=O)c4c2ccs4)CC1 
470 5.56 Prolintane (493-92-5) 13930 CCCC(Cc1ccccc1)N2CCCC2 
471 5.56 2C-B (2-(4-Bromo-2,5-dimethoxyphenyl)ethanamine) (66142-81-2) 88978 COc1cc(c(cc1Br)OC)CCN 
472 5.57 5-IAI (2-Amino-5-iodoindane) (132367-76-1) 116224 c1cc2c(cc1I)CC(C2)N 
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473 5.58 Benazolin (3813-05-6) 18521 c1cc2c(c(c1)Cl)n(c(=O)s2)CC(=O)O 
474 5.59 Iso-LSD (2126-78-5) 3843 CCN(CC)C(=O)C1CN(C2Cc3c[nH]c4c3c(ccc4)C2=C1)C 
475 5.59 Mexiletine (31828-71-4) 4034 Cc1cccc(c1OCC(C)N)C 
476 5.59 Oxycarboxin (5259-88-1) 20048 CC1=C(S(=O)(=O)CCO1)/C(=N\c2ccccc2)/O 
477 5.6 Cymoxanil (57966-95-7) 4514714 CCNC(=O)NC(=O)/C(=N\OC)/C#N 
478 5.6 Imazethapyr (81335-77-5) 49447 CCc1cc(c(nc1)C2=NC(C(=O)N2)(C)C(C)C)C(=O)O 
479 5.61 Oxprenolol (6452-71-7) 4470 CC(C)NCC(COc1ccccc1OCC=C)O 
480 5.61 Guanabenz (5051-62-7) 3397 c1cc(c(c(c1)Cl)C=NN=C(N)N)Cl 
481 5.62 Thiacloprid (111988-49-9) 103099 c1cc(ncc1CN\2CCS/C2=N\C#N)Cl 
482 5.63 Prohexadione (88805-35-0) 160745 CCC(=O)C1C(=O)CC(CC1=O)C(=O)O 
483 5.66 Dapiprazole (72822-12-9) 2298190 Cc1ccccc1N2CCN(CC2)CCc3nnc4n3CCCC4 
484 5.66 Olsalazine (15772-48-2) 10642377 C1=CC(=C(C=C1/N=N/C2=CC(=C(C=C2)O)C(=O)O)C(=O)O)O 
485 5.67 Acetaminodantrolene (Acetamide, N-[4-[5-[(E)-[(2,4-
dioxo-1-imidazolidinyl)imino]methyl]-2-furanyl]phenyl]-) 
F490 
(41515-09-7) 7845047 O=C(Nc3ccc(c2oc(\C=N\N1C(=O)NC(=O)C1)cc2)cc3)C 
486 5.67 Nefopam (13669-70-0) 4295 CN1CCOC(c2ccccc2C1)c3ccccc3 
487 5.67 DOC (4-chloro-2,5-dimethoxyamphetamine) (123431-31-2) 472008 CC(Cc1cc(c(cc1OC)Cl)OC)N 
488 5.68 Ethenzamide (938-73-8) 3167 CCOc1ccccc1C(=O)N 
489 5.69 Risperidone (106266-06-2) 4895 Cc1c(c(=O)n2c(n1)CCCC2)CCN3CCC(CC3)c4c5ccc(cc5on4)F 
490 5.69 Chlorothiamid (1918-13-4) 2016563 c1cc(c(c(c1)Cl)C(=N)S)Cl 
491 5.71 Sulfaquinoxaline (59-40-5) 5147 c1ccc2c(c1)[nH]/c(=N/S(=O)(=O)c3ccc(cc3)N)/cn2 
492 5.72 Ramifenazone (3615-24-5) 4861 Cc1c(c(=O)n(n1C)c2ccccc2)NC(C)C 
493 5.72 Relaspium (1+) [Trospium] (47608-32-2) 5394 c1ccc(cc1)C(c2ccccc2)(C(=O)OC3CC4CCC(C3)[N+]45CCCC5)O 
494 5.73 Milnacipran (92623-85-3) 9797657 CCN(CC)C(=O)C1(CC1CN)C2=CC=CC=C2 
495 5.73 Atrazine-desethyl (Deethylatrazine) (6190-65-4) 21157 CC(C)/N=c\1/[nH]c(=N)nc([nH]1)Cl 
496 5.74 Levopropylhexedrine (6192-97-8) 7277 CC(CC1CCCCC1)NC 
497 5.74 Isocarbamide (Azolamide) (30979-48-7) 32837 CC(C)CNC(=O)N1CCNC1=O 
498 5.74 Labetalol (36894-69-6) 3734 CC(CCc1ccccc1)NCC(c2ccc(c(c2)C(=O)N)O)O 
499 5.74 Phencyclidine (77-10-1) 6224 c1ccc(cc1)C2(CCCCC2)N3CCCCC3 
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500 5.75 Mevinphos Peak 2 (E-or Cis isomer) (7786-34-7) 4511751 O=P(OC)(OC)O\C(=C/C(=O)OC)C 
501 5.75 Florasulam (145701-23-1) 9875220 COc1ncc(c2n1nc(n2)S(=O)(=O)Nc3c(cccc3F)F)F 
502 5.76 Bupropion (34911-55-2) 431 CC(C(=O)c1cccc(c1)Cl)NC(C)(C)C 
503 5.76 Oxypertine (153-87-7) 4479 Cc1c(c2cc(c(cc2[nH]1)OC)OC)CCN3CCN(CC3)c4ccccc4 
504 5.76 TFMPP (15532-75-9) 4145 c1cc(cc(c1)N2CCNCC2)C(F)(F)F 
505 5.77 Azithromycin (83905-01-5) 2182 CCC1C(C(C(N(CC(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)
C)N(C)C)O)(C)O)C)C)C)O)(C)O 
506 5.78 Pipradrol (467-60-7) 9681 c1ccc(cc1)C(c2ccccc2)(C3CCCCN3)O 
507 5.78 Buspirone (36505-84-7) 2383 c1cnc(nc1)N2CCN(CC2)CCCCN3C(=O)CC4(CCCC4)CC3=O 
508 5.8 Zolpidem (82626-48-0) 5530 Cc1ccc(cc1)c2c(n3cc(ccc3n2)C)CC(=O)N(C)C 
509 5.81 Donepezil (120014-06-4) 3040 COc1cc2c(cc1OC)C(=O)C(C2)CC3CCN(CC3)Cc4ccccc4 
510 5.83 DOM (dl-2,5-Dimethoxy-4-methylamphetamine) (15588-95-1) 77462 Cc1cc(c(cc1OC)CC(C)N)OC 
511 5.84 Clidinium (1+) (7020-55-5) 2682 C[N+]12CCC(CC1)C(C2)OC(=O)C(c3ccccc3)(c4ccccc4)O 
512 5.86 Pyribenzamine (Tripelennamine / Azaron) (91-81-6) 5385 CN(C)CCN(Cc1ccccc1)c2ccccn2 
513 5.86 Phentolamine (50-60-2) 5571 Cc1ccc(cc1)N(CC2=NCCN2)c3cccc(c3)O 
514 5.88 2CT-2 (2,5-Dimethoxy-4-Ethylthiophenethylamine) (207740-24-7) 16787961 CCSc1cc(c(cc1OC)CCN)OC 
515 5.89 Mepyramine (Pyrilamine) (91-84-9) 4818 CN(C)CCN(Cc1ccc(cc1)OC)c2ccccn2 
516 5.89 Pirimicarb-desmethyl (30614-22-3) 84084 Cc1c(nc(nc1OC(=O)N(C)C)NC)C 
517 5.91 Bisoprolol (66722-44-9) 2312 CC(C)NCC(COc1ccc(cc1)COCCOC(C)C)O 
518 5.92 Lisuride (18016-80-3) 3801 CCN(CC)C(=O)NC1CN(C2Cc3c[nH]c4c3c(ccc4)C2=C1)C 
519 5.92 Pyrimethamine (58-14-0) 4819 CCc1c(c([nH]c(=N)n1)N)c2ccc(cc2)Cl 
520 5.93 DOB (2,5-Dimethoxy-4-bromoamphetamine) (64638-07-9) 55902 CC(Cc1cc(c(cc1OC)Br)OC)N 
521 5.93 Phenacetin (62-44-2) 4590 CCOc1ccc(cc1)/N=C(\C)/O 
522 5.93 Tricyclazole (41814-78-2) 35726 Cc1cccc2c1n3cnnc3s2 
523 5.94 Meprobamate (57-53-4) 3924 CCCC(C)(COC(=O)N)COC(=O)N 
524 5.94 Oxybuprocaine (99-43-4) 4472 CCCCOc1cc(ccc1N)C(=O)OCCN(CC)CC 
525 5.94 Chlormezanone (80-77-3) 2616 CN1C(S(=O)(=O)CCC1=O)c2ccc(cc2)Cl 
526 5.94 10-Hydroxycarbamazepine (29331-92-8) 102704 c1ccc2c(c1)CC(c3ccccc3N2C(=O)N)O 
527 5.96 Norbuprenorphine (78715-23-8) (N/A) CC(C)(C)C(C)(C1CC23CCC1(C4C25CCNC3CC6=C5C(=C(C=C6)O)O4)OC)O 
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528 5.96 Benperidol (2062-84-2) 15521 c1ccc2c(c1)[nH]c(=O)n2C3CCN(CC3)CCCC(=O)c4ccc(cc4)F 
529 5.98 Levomepromazinesulfoxide (7052-08-6) 145102 CC(CN1c2ccccc2S(=O)c3c1cc(cc3)OC)CN(C)C 
530 5.99 Fenfluramine (458-24-2) 3220 CCNC(C)Cc1cccc(c1)C(F)(F)F 
531 5.99 Azatadine (3964-81-6) 18709 CN1CCC(=C2c3ccccc3CCc4c2nccc4)CC1 
532 6 Isoaminile Peak 1 & 2 (77-51-0) 6236 CC(C)C(CC(C)N(C)C)(C#N)c1ccccc1 
533 6.01 Clopamide (636-54-4) 2702 CC1CCCC(N1NC(=O)c2ccc(c(c2)S(=O)(=O)N)Cl)C 
534 6.01 Pirmenol (68252-19-7) 4687 CC1CCCC(N1CCCC(c2ccccc2)(c3ccccn3)O)C 
535 6.01 Fentanyl (437-38-7) 3228 CCC(=O)N(c1ccccc1)C2CCN(CC2)CCc3ccccc3 
536 6.03 Pyrovalerone (3563-49-3) 13733 CCCC(C(=O)c1ccc(cc1)C)N2CCCC2 
537 6.03 Tropicamide (1508-75-4) 5391 CCN(Cc1ccncc1)C(=O)C(CO)c2ccccc2 
538 6.04 Ambroxol (18683-91-5) 2047 c1c(cc(c(c1CNC2CCC(CC2)O)N)Br)Br 
539 6.04 Dexfenfluramine (3239-44-9) 3220 CCNC(C)Cc1cccc(c1)C(F)(F)F 
540 6.04 Carbamazepine-10,11-epoxide (10,11-Dihydro-10,11-
epoxycarbamazepine) 
(36507-30-9) 2458 c1ccc2c(c1)C3C(O3)c4ccccc4N2C(=O)N 
541 6.04 Flumazenil (78755-81-4) 3256 CCOC(=O)c1c2n(cn1)-c3ccc(cc3C(=O)N(C2)C)F 
542 6.06 2C-I (2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine) (69587-11-7) 8442670 COC1=CC(=C(C=C1CCN)OC)I 
543 6.07 Butocarboxim (34681-10-2) 33840 CC(C(=NOC(=O)NC)C)SC 
544 6.07 Alypin (Amydricaine) (963-07-5) 11921 CCC(CN(C)C)(CN(C)C)OC(=O)c1ccccc1 
545 6.08 Phenazocine (127-35-5) 14031 CC1C2Cc3ccc(cc3C1(CCN2CCc4ccccc4)C)O 
546 6.08 Metolazone (17560-51-9) 4026 Cc1ccccc1N2C(Nc3cc(c(cc3C2=O)S(=O)(=O)N)Cl)C 
547 6.08 Benactyzine (302-40-9) 8966 CCN(CC)CCOC(=O)C(c1ccccc1)(c2ccccc2)O 
548 6.08 Carbinoxamine (486-16-8) 2466 CN(C)CCOC(c1ccc(cc1)Cl)c2ccccn2 
549 6.08 Fencamfamine (norcamphane) (2240-14-4) 13922 CCNC1C2CCC(C2)C1c3ccccc3 
550 6.09 Alpha-methylfentanyl (79704-88-4) 56081 CCC(=O)N(c1ccccc1)C2CCN(CC2)C(C)Cc3ccccc3 
551 6.1 Imazaquin (81335-37-7) 49446 CC(C)C1(C(=O)NC(=N1)c2c(cc3ccccc3n2)C(=O)O)C 
552 6.11 Venlafaxine (93413-69-5) 5454 CN(C)CC(c1ccc(cc1)OC)C2(CCCCC2)O 
553 6.11 Pipamperone (1893-33-0) 4664 c1cc(ccc1C(=O)CCCN2CCC(CC2)(C(=O)N)N3CCCCC3)F 
554 6.12 Fedrilate (23271-74-1) 29485 CC(CCN1CCOCC1)OC(=O)C2(CCOCC2)c3ccccc3 
 
continued 
443 
 
 
 
 
 
 
 
 
555 6.13 Para-fluorofentanyl (90736-23-5) 56096 CCC(=O)N(c1ccc(cc1)F)C2CCN(CC2)CCc3ccccc3 
556 6.14 Oxyfedrine (15687-41-9) 25548 CC(C(c1ccccc1)O)NCCC(=O)c2cccc(c2)OC 
557 6.14 Butizide (2043-38-1) 15442 CC(C)CC1Nc2cc(c(cc2S(=O)(=O)N1)S(=O)(=O)N)Cl 
558 6.16 Cyclopentolate (512-15-2) 2802 CN(C)CCOC(=O)C(c1ccccc1)C2(CCCC2)O 
559 6.17 Metoxuron (19937-59-8) 27749 CN(C)C(=O)Nc1ccc(c(c1)Cl)OC 
560 6.17 Bromisoval (Bromural) (496-67-3) 2353 CC(C)C(C(=O)NC(=O)N)Br 
561 6.17 Aldicarb (116-06-3) 7844539 CC(C)(/C=N/OC(=O)NC)SC 
562 6.18 Bupivacaine (38396-39-3) 2380 CCCCN1CCCCC1C(=O)Nc2c(cccc2C)C 
563 6.18 Droperidol (548-73-2) 3056 c1ccc2c(c1)nc(n2C3=CCN(CC3)CCCC(=O)c4ccc(cc4)F)O 
564 6.18 Norvenlafaxine (149289-30-5) 2741972 CNCC(c1ccc(cc1)OC)C2(CCCCC2)O 
565 6.19 Pergolide (66104-22-1) 4583 CCCN1CC(CC2C1Cc3c[nH]c4c3c2ccc4)CSC 
566 6.19 Azacyclonol (115-46-8) 14952 c1ccc(cc1)C(c2ccccc2)(C3CCNCC3)O 
567 6.19 Cythioate (115-93-5) 7992 COP(=S)(OC)Oc1ccc(cc1)S(=O)(=O)N 
568 6.2 Crimidine (535-89-7) 10356 Cc1cc(nc(n1)Cl)N(C)C 
569 6.2 Thiabendazole (148-79-8) 5237 c1ccc2c(c1)[nH]c(n2)c3cscn3 
570 6.21 Moxisylyte (54-32-0) 4110 Cc1cc(c(cc1OC(=O)C)C(C)C)OCCN(C)C 
571 6.21 Metyrapone (54-36-4) 4030 CC(C)(c1cccnc1)C(=O)c2cccnc2 
572 6.22 Diflufenzopyr (109293-97-2) 4816775 C/C(=N\NC(=O)NC1=CC(=CC(=C1)F)F)/C2=C(C=CC=N2)C(=O)O 
573 6.23 Doxapram (309-29-5) 3044 CCN1CC(C(C1=O)(c2ccccc2)c3ccccc3)CCN4CCOCC4 
574 6.24 Propipocaine (3670-68-6) 64027 CCCOc1ccc(cc1)C(=O)CCN2CCCCC2 
575 6.24 Thifensulfuron-methyl (79277-27-3) 66325 Cc1n/c(=N/C(=N/S(=O)(=O)c2ccsc2C(=O)OC)/O)/[nH]c(n1)OC 
576 6.25 Chlorpheniramine (132-22-9) 2624 CN(C)CCC(c1ccc(cc1)Cl)c2ccccn2 
577 6.26 Dimethylanilin (N,N-) (121-69-7) 924 CN(C)c1ccccc1 
578 6.33 Phosphamidon (Dimecron)  (13171-21-6) 2297538 CCN(CC)C(=O)/C(=C(\C)/OP(=O)(OC)OC)/Cl 
579 6.27 Benzocaine (94-09-7) 13854242 CCOC(=O)c1ccc(cc1)N 
580 6.27 Papaverine (58-74-2) 4518 COc1ccc(cc1OC)Cc2c3cc(c(cc3ccn2)OC)OC 
581 6.27 Clibucaine (15302-10-0) 59054 CC(CC(=O)Nc1ccc(cc1Cl)Cl)N2CCCCC2 
582 6.27 Bucetin (Bucetalon) (1083-57-4) 13507 CCOc1ccc(cc1)NC(=O)CC(C)O 
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583 6.27 Beclamide (501-68-8) 9962 c1ccc(cc1)C/N=C(/CCCl)\O 
584 6.28 Colchicine (64-86-8) 2731 CC(=O)NC1CCc2cc(c(c(c2-c3c1cc(=O)c(cc3)OC)OC)OC)OC 
585 6.28 Metipranolol (22664-55-7) 29193 Cc1cc(c(c(c1OC(=O)C)C)C)OCC(CNC(C)C)O 
586 6.28 Triprolidine (486-12-4) 4445597 Cc1ccc(cc1)/C(=C\CN2CCCC2)/c3ccccn3 
587 6.29 Oxadixyl (77732-09-3) 48518 Cc1cccc(c1N(C(=O)COC)N2CCOC2=O)C 
588 6.3 Desoxypipradol (519-74-4) 141045 c1ccc(cc1)C(c2ccccc2)C3CCCCN3 
589 6.31 Metsulfuron-methyl (74223-64-6) 47883 Cc1n/c(=N\C(=N/S(=O)(=O)c2ccccc2C(=O)OC)\O)/[nH]c(n1)OC 
590 6.31 Clobutinol (Pertoxil) (14860-49-2) 25085 CC(CN(C)C)C(C)(Cc1ccc(cc1)Cl)O 
591 6.32 Clobenzepam (1159-93-9) 13752 CN(C)CCN1c2ccc(cc2Nc3ccccc3C1=O)Cl 
592 6.32 Methaphenilene (493-78-7) 9884 CN(C)CCN(Cc1cccs1)c2ccccc2 
593 6.33 Letrozole (112809-51-5) 3765 c1cc(ccc1C#N)C(c2ccc(cc2)C#N)n3cncn3 
594 6.36 Cinosulfuron (94593-91-6) 83438 COCCOc1ccccc1S(=O)(=O)NC(=O)Nc2nc(nc(n2)OC)OC 
595 6.36 Protionamide (14222-60-7) 579891 CCCc1cc(ccn1)C(=S)N 
596 6.36 Paraoxon-methyl (950-35-6) 13114 COP(=O)(OC)Oc1ccc(cc1)[N+](=O)[O-] 
597 6.37 Allidochlor (93-71-0) 6890 C=CCN(CC=C)C(=O)CCl 
598 6.38 Triazamate (112143-82-5) 77849 CCOC(=O)CSc1nc(nn1C(=O)N(C)C)C(C)(C)C 
599 6.38 EDDP (2E)-2-ethylidene-1,5-dimethyl-3,3-
diphenylpyrrolidine) 
(30223-73-5) 4509491 C/C=C/1\C(CC(N1C)C)(c2ccccc2)c3ccccc3 
600 6.41 Deacetyldiltiazem (42399-40-6) 9243880 CN(C)CCN1C2=CC=CC=C2SC(C(C1=O)O)C3=CC=C(C=C3)OC 
601 6.41 Antazoline (91-75-8) 2115 c1ccc(cc1)CN(CC2=NCCN2)c3ccccc3 
602 6.41 Fluanisone (1480-19-9) 14410 COc1ccccc1N2CCN(CC2)CCCC(=O)c3ccc(cc3)F 
603 6.43 Tetracaine (94-24-6) 5218 CCCCNc1ccc(cc1)C(=O)OCCN(C)C 
604 6.44 Flecainide (54143-55-4) 3239 c1cc(c(cc1OCC(F)(F)F)C(=O)NCC2CCCCN2)OCC(F)(F)F 
605 6.46 Oxcarbazepine (28721-07-5) 31608 c1ccc2c(c1)CC(=O)c3ccccc3N2C(=O)N 
606 6.47 Isothipendyl (482-15-5) 3649 CC(CN1c2ccccc2Sc3c1nccc3)N(C)C 
607 6.48 Trazodone (19794-93-5) 5332 c1ccn2c(c1)nn(c2=O)CCCN3CCN(CC3)c4cccc(c4)Cl 
608 6.48 Citalopram (59729-33-8) 2669 CN(C)CCCC1(c2ccc(cc2CO1)C#N)c3ccc(cc3)F 
609 6.48 Propranolol (525-66-6) 4777 CC(C)NCC(COc1cccc2c1cccc2)O 
continued 
 
445 
 
 
 
 
 
 
 
 
610 6.48 Fuberidazole (3878-19-1) 18609 c1ccc2c(c1)[nH]c(n2)c3ccco3 
611 6.48 2C-E (2,5-Dimethoxy-4-ethylphenethylamine) (71539-34-9) 21106222 CCc1cc(c(cc1OC)CCN)OC 
612 6.49 TEPP (Tetraethyl pyrophosphate) (107-49-3) 7585 CCOP(=O)(OCC)OP(=O)(OCC)OCC 
613 6.51 Dextromethorphan (125-71-3) 2901 CN1CCC23CCCCC2C1Cc4c3cc(cc4)OC 
614 6.51 Norcitalopram (144025-14-9) 142424 CNCCCC1(c2ccc(cc2CO1)C#N)c3ccc(cc3)F 
615 6.52 Benzoctamine (17243-39-9) 26444 CNCC12CCC(c3c1cccc3)c4c2cccc4 
616 6.52 Oxasulfuron (144651-06-9) 77958 Cc1cc(nc(n1)NC(=O)NS(=O)(=O)c2ccccc2C(=O)OC3COC3)C 
617 6.54 Flurazepam (17617-23-1) 3276 CCN(CC)CCN1c2ccc(cc2C(=NCC1=O)c3ccccc3F)Cl 
618 6.54 Azapropazone (13539-59-8) 24310 CCCC1C(=O)N2c3cc(ccc3N=C(N2C1=O)N(C)C)C 
619 6.54 Chlorsulfuron (64902-72-3) 43209 Cc1nc(nc(n1)OC)NC(=O)NS(=O)(=O)c2ccccc2Cl 
620 6.55 Cyanazine (21725-46-2) 28552 CC/N=c/1\[nH]c(nc(n1)Cl)NC(C)(C)C#N 
621 6.56 Brompheniramine (86-22-6) 6573 CN(C)CCC(c1ccc(cc1)Br)c2ccccn2 
622 6.56 Mefruside (7195-27-9) 3907 CC1(CCCO1)CN(C)S(=O)(=O)c2ccc(c(c2)S(=O)(=O)N)Cl 
623 6.58 Carbetamide (16118-49-3) 25761 CCNC(=O)C(C)OC(=O)Nc1ccccc1 
624 6.58 Talinolol (57460-41-0) 62014 CC(C)(C)NCC(COc1ccc(cc1)NC(=O)NC2CCCCC2)O 
625 6.59 Metolcarb (1129-41-5) 13684 Cc1cccc(c1)OC(=O)NC 
626 6.59 Moperone (1050-79-9) 4100 Cc1ccc(cc1)C2(CCN(CC2)CCCC(=O)c3ccc(cc3)F)O 
627 6.6 Triasulfuron (82097-50-5) 66025 Cc1nc(nc(n1)OC)NC(=O)NS(=O)(=O)c2ccccc2OCCCl 
628 6.61 Indapamide (26807-65-8) 3574 CC1Cc2ccccc2N1NC(=O)c3ccc(c(c3)S(=O)(=O)N)Cl 
629 6.61 Sulfasalazine (599-79-1) 10481900 C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O 
630 6.61 Zaleplon (151319-34-5) 5517 CCN(c1cccc(c1)c2ccnc3n2ncc3C#N)C(=O)C 
631 6.62 Nicosulfuron (111991-09-4) 66024 CN(C)C(=O)c1cccnc1S(=O)(=O)N/C(=N/c2nc(cc(n2)OC)OC)/O 
632 6.63 Diphenhydramine (58-73-1) 2989 CN(C)CCOC(c1ccccc1)c2ccccc2 
633 6.63 Dimethylphthalate (131-11-3) 13837329 COC(=O)c1ccccc1C(=O)OC 
634 6.64 Tromantadine (53783-83-8) 57947 CN(C)CCOCC(=O)NC12CC3CC(C1)CC(C3)C2 
635 6.64 Trapidil (15421-84-8) 5330 CCN(CC)c1cc(nc2n1ncn2)C 
636 6.64 Thioridazine-5-sulfoxide (7776-05-8) 22902 CN1CCCCC1CCN2c3ccccc3S(=O)c4c2cc(cc4)SC 
637 6.66 Raubasine (Ajmalicine) (483-04-5) 220386 CC1C2CN3CCc4c5ccccc5[nH]c4C3CC2C(=CO1)C(=O)OC 
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638 6.66 Acrivastine (87848-99-5) 4447574 Cc1ccc(cc1)/C(=C\CN2CCCC2)/c3cccc(n3)/C=C/C(=O)O 
639 6.67 N-(2,4-Dimethylphenyl)formamide (Amitraz Metabolite) (60397-77-5) 83385 Cc1ccc(c(c1)C)NC=O 
640 6.67 Enoximon (77671-31-9) 48492 Cc1c([nH]c(=O)[nH]1)C(=O)c2ccc(cc2)SC 
641 6.67 Torasemide (56211-40-6) 38123 Cc1cccc(c1)Nc2ccncc2S(=O)(=O)NC(=O)NC(C)C 
642 6.68 Betaxolol (63659-18-7) 2279 CC(C)NCC(COc1ccc(cc1)CCOCC2CC2)O 
643 6.69 Clomethiazole (533-45-9) 10327 Cc1c(scn1)CCCl 
644 6.69 2C-T-4 (2,5-dimethoxy-4-isopropylthiophenethylamine) (207740-25-8) 21106232 CC(C)Sc1cc(c(cc1OC)CCN)OC 
645 6.71 Alprenolol (13655-52-2) 2035 CC(C)NCC(COc1ccccc1CC=C)O 
646 6.72 Budipine (57982-78-2) 62021 CC(C)(C)N1CCC(CC1)(c2ccccc2)c3ccccc3 
647 6.73 Cisapride (81098-60-4) 2667 COc1cc(c(cc1C(=O)NC2CCN(CC2OC)CCCOc3ccc(cc3)F)Cl)N 
648 6.74 Mesoridazine (5588-33-0) 3936 CN1CCCCC1CCN2c3ccccc3Sc4c2cc(cc4)S(=O)C 
649 6.75 Naptalam (N-1-Naphthylphthalamicacid) (132-66-1) 8275 c1ccc2c(c1)cccc2NC(=O)c3ccccc3C(=O)O 
650 6.76 Tertatolol (34784-64-0) 33875 CC(C)(C)NCC(COc1cccc2c1SCCC2)O 
651 6.76 Modafinil (68693-11-8) 4088 c1ccc(cc1)C(c2ccccc2)S(=O)CC(=O)N 
652 6.77 Amidosulfuron (120923-37-7) 82874 CN(S(=O)(=O)C)S(=O)(=O)NC(=O)Nc1nc(cc(n1)OC)OC 
653 6.79 Mebeverine (3625-06-7) 3891 CCN(CCCCOC(=O)c1ccc(c(c1)OC)OC)C(C)Cc2ccc(cc2)OC 
654 6.8 Oxfendazole (53716-50-0) 37316 COC(=O)Nc1[nH]c2ccc(cc2n1)S(=O)c3ccccc3 
655 6.8 Thiram [Tetramethylthiuramdisulfide] (137-26-8) 5256 CN(C)C(=S)SSC(=S)N(C)C 
656 6.81 Benzthiazide (91-33-8) 2253 c1ccc(cc1)CSCC2=Nc3cc(c(cc3S(=O)(=O)N2)S(=O)(=O)N)Cl 
657 6.82 Fenpiprane (3540-95-2) 171191 c1ccc(cc1)C(CCN2CCCCC2)c3ccccc3 
658 6.82 Bendroflumethiazide (73-48-3) 2225 c1ccc(cc1)CC2Nc3cc(c(cc3S(=O)(=O)N2)S(=O)(=O)N)C(F)(F)F 
659 6.82 Primaquine (90-34-6) 4739 CC(CCCN)Nc1cc(cc2c1nccc2)OC 
660 6.83 Enalapril (75847-73-3) 3109 CCOC(=O)C(CCc1ccccc1)NC(C)C(=O)N2CCCC2C(=O)O 
661 6.84 Piroxicam (36322-90-4) 10442653 CN1C(=C(c2ccccc2S1(=O)=O)O)/C(=N/c3ccccn3)/O 
662 6.85 Mefluidide (53780-34-0) 37346 Cc1cc(c(cc1NC(=O)C)NS(=O)(=O)C(F)(F)F)C 
663 6.86 Dimetindene (5636-83-9) 20541 CC(c1ccccn1)C2=C(Cc3c2cccc3)CCN(C)C 
664 6.86 Normianserine (71936-92-0) 103070 c1ccc2c(c1)Cc3ccccc3N4C2CNCC4 
665 6.88 DOET (22004-32-6) 25499 CCc1cc(c(cc1OC)CC(C)N)OC 
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666 6.88 Doxepin (1668-19-5) 3046 CN(C)CC/C=C\1/c2ccccc2COc3c1cccc3 
667 6.89 Entacapon (130929-57-6) 4444537 CCN(CC)C(=O)/C(=C/c1cc(c(c(c1)O)O)[N+](=O)[O-])/C#N 
668 6.89 2-Mercaptobenzothiazole (149-30-4) 608157 c1ccc2c(c1)[nH]c(=S)s2 
669 6.9 Monuron (150-68-5) 8470 CN(C)C(=O)Nc1ccc(cc1)Cl 
670 6.91 Carvedilol (72956-09-3) 2487 COc1ccccc1OCCNCC(COc2cccc3c2c4ccccc4[nH]3)O 
671 6.91 Memantine (19982-08-2) 3914 CC12CC3CC(C1)(CC(C3)(C2)N)C 
672 6.92 Sulfometuron-methyl (74222-97-2) 47881 Cc1cc(nc(n1)NC(=O)NS(=O)(=O)c2ccccc2C(=O)OC)C 
673 6.93 Thiophanate-methyl (23564-05-8) 2297683 COC(=O)NC(=S)Nc1ccccc1NC(=S)NC(=O)OC 
674 6.94 Mianserine (24219-97-4) 4040 CN1CCN2c3ccccc3Cc4ccccc4C2C1 
675 6.94 Apronalide (528-92-7) 10264 CC(C)C(CC=C)C(=O)NC(=O)N 
676 6.94 Cyclizine (82-92-8) 6470 CN1CCN(CC1)C(c2ccccc2)c3ccccc3 
677 6.94 Ketorolac (74103-06-3) 3694 c1ccc(cc1)C(=O)c2ccc3n2CCC3C(=O)O 
678 6.94 Propoxur (114-26-1) 4775 CC(C)Oc1ccccc1O/C(=N/C)/O 
679 6.94 Haloperidol (52-86-8) 3438 c1cc(ccc1C(=O)CCCN2CCC(CC2)(c3ccc(cc3)Cl)O)F 
680 6.95 Levocabastine (79516-68-0) 3778 CC1CN(CCC1(c2ccccc2)C(=O)O)C3CCC(CC3)(C#N)c4ccc(cc4)F 
681 6.96 Noscapine (128-62-1) 4385 CN1CCc2cc3c(c(c2C1C4c5ccc(c(c5C(=O)O4)OC)OC)OC)OCO3 
682 6.96 Norverapamil (67018-85-3) 94724 CC(C)C(CCCNCCc1ccc(c(c1)OC)OC)(C#N)c2ccc(c(c2)OC)OC 
683 6.98 DNOC (4,6-dinitro-o-cresol) (534-52-1) 10343 Cc1cc(cc(c1O)[N+](=O)[O-])[N+](=O)[O-] 
684 6.98 Proguanil (500-92-5) 4754 CC(C)NC(=N)NC(=N)Nc1ccc(cc1)Cl 
685 6.98 Rosiglitazone (122320-73-4) 70383 CN(CCOc1ccc(cc1)CC2C(=O)NC(=O)S2)c3ccccn3 
686 6.98 2C-T-7 (2,5-dimethoxy-4-n-propylthiophenethylamine) (207740-26-9) 21106233 CCCSc1cc(c(cc1OC)CCN)OC 
687 6.99 Oxymetazoline (1491-59-4) 4475 Cc1cc(c(c(c1CC2=NCCN2)C)O)C(C)(C)C 
688 6.99 Cyclamic acid (100-88-9) 7252 C1CCC(CC1)NS(=O)(=O)O 
689 6.99 Carboxyibuprofen (15935-54-3) 8619532 O=C(O)C(c1ccc(cc1)CC(C(=O)O)C)C 
690 7 Ofurace (58810-48-3) 39084 Cc1cccc(c1N(C2CCOC2=O)C(=O)CCl)C 
691 7 Dichlorvos (62-73-7) 2931 COP(=O)(OC)OC=C(Cl)Cl 
692 7.01 Malaoxon (1634-78-2) 14674 CCOC(=O)CC(C(=O)OCC)SP(=O)(OC)OC 
693 7.01 Melphalan (148-82-3) 3913 c1cc(ccc1CC(C(=O)O)N)N(CCCl)CCCl 
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694 7.01 Carbofuran (1563-66-2) 2468 CC1(Cc2cccc(c2O1)O/C(=N/C)/O)C 
695 7.01 Dimetotiazine (7456-24-8) 2979 CC(CN1c2ccccc2Sc3c1cc(cc3)S(=O)(=O)N(C)C)N(C)C 
696 7.02 Bendiocarb (22781-23-3) 2224 CC1(Oc2cccc(c2O1)OC(=O)NC)C 
697 7.03 Nordoxepin (1225-56-5) 4510230 CNCC/C=C\1/c2ccccc2COc3c1cccc3 
698 7.03 Verapamil (52-53-9) 2425 CC(C)C(CCCN(C)CCc1ccc(c(c1)OC)OC)(C#N)c2ccc(c(c2)OC)OC 
699 7.06 Nalidixic acid (389-08-2) 4268 CCn1cc(c(=O)c2c1nc(cc2)C)C(=O)O 
700 7.07 Bromacil (314-40-9) 9040 CCC(C)n1c(=O)c(c([nH]c1=O)C)Br 
701 7.07 Simazine (122-34-9) 5027 CC/N=c\1/[nH]/c(=N\CC)/nc([nH]1)Cl 
702 7.07 Bupranolol (14556-46-8) 2381 Cc1ccc(c(c1)OCC(CNC(C)(C)C)O)Cl 
703 7.07 Metribuzin (21087-64-9) 28287 CC(C)(C)c1c(=O)n(c(nn1)SC)N 
704 7.08 Phenytoin (57-41-0) 1710 c1ccc(cc1)C2(C(=NC(=N2)O)O)c3ccccc3 
705 7.08 2-Hydroxyibuprofen (51146-55-5) 8618954 O=C(O)C(c1ccc(cc1)CC(O)(C)C)C 
706 7.09 Aconitine (302-27-2) 1935 CCN1CC2(C(CC(C34C2C(C(C31)C5(C6C4CC(C6OC(=O)c7ccccc7)(C(C5O)OC)O)OC(=O)C)
OC)OC)O)COC 
707 7.09 N-Desmethylpropafenone (86383-21-3)  
as the maleate salt 
114154 c1ccc(cc1)CCC(=O)c2ccccc2OCC(CN)O 
708 7.09 Flupirtine (56995-20-1) 48119 CCOC(=O)Nc1ccc(nc1N)NCc2ccc(cc2)F 
709 7.09 Chloropyramine (59-32-5) 23628 CN(C)CCN(Cc1ccc(cc1)Cl)c2ccccn2 
710 7.09 Rimsulfuron (122931-48-0) 82876 CCS(=O)(=O)c1cccnc1S(=O)(=O)N/C(=N/c2nc(cc(n2)OC)OC)/O 
711 7.09 Meloxicam (71125-38-7) 10442740 Cc1cnc(s1)/N=C(/C2=C(c3ccccc3S(=O)(=O)N2C)O)\O 
712 7.09 Hexazinone (51235-04-2) 36542 Cn1c(nc(=O)n(c1=O)C2CCCCC2)N(C)C 
713 7.1 Metosulam (139528-85-1) 77938 Cc1ccc(c(c1Cl)NS(=O)(=O)c2nc3nc(cc(n3n2)OC)OC)Cl 
714 7.11 AM-2233 (444912-75-8) 8401830 CN1CCCCC1CN2C=C(C3=CC=CC=C32)C(=O)C4=CC=CC=C4I 
715 7.12 Bromperidol (10457-90-6) 2354 c1cc(ccc1C(=O)CCCN2CCC(CC2)(c3ccc(cc3)Br)O)F 
716 7.13 Norclozapine (6104-71-8) 14126465 c1ccc2c(c1)C(=Nc3cc(ccc3N2)Cl)N4CCNCC4 
717 7.13 Benzthiazuron (1929-88-0) 15208 CNC(=O)Nc1nc2ccccc2s1 
718 7.14 N-Isopropylsalicylamide (551-35-9) 61658 CC(C)NC(=O)c1ccccc1O 
719 7.14 Demoxepam (963-39-3) 10441314 C1C(=O)NC2=C(C=C(C=C2)Cl)C(=[N+]1[O-])C3=CC=CC=C3 
720 7.15 Ancymidol (12771-68-5) 23841 COc1ccc(cc1)C(c2cncnc2)(C3CC3)O 
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721 7.16 Methyl 2-dimethoxyphosphinothioylsulfanylacetate 
(formothion methanolyse) 
(1741-11-3) 62992 COC(=O)CSP(=S)(OC)OC 
722 7.16 Imazamethabenz-methyl (Imazamethabenz) (81405-85-8) 49450 Cc1ccc(c(c1)C2=NC(C(=O)N2)(C)C(C)C)C(=O)OC 
723 7.17 Piretanide (55837-27-9) 4683 c1ccc(cc1)Oc2c(cc(cc2S(=O)(=O)N)C(=O)O)N3CCCC3 
724 7.17 Thidiazuron (51707-55-2) 36635 c1ccc(cc1)/N=C(\Nc2cnns2)/O 
725 7.18 Diltiazem (42399-41-7) 2967 CC(=O)OC1C(Sc2ccccc2N(C1=O)CCN(C)C)c3ccc(cc3)OC 
726 7.18 Dichlormid (37764-25-3) 34686 C=CCN(CC=C)C(=O)C(Cl)Cl 
727 7.19 Prednisone (53-03-2) 4731 CC12CC(=O)C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C 
728 7.19 Histapyrrodine (493-80-1) 61430 c1ccc(cc1)CN(CCN2CCCC2)c3ccccc3 
729 7.19 Chlorpropamide (94-20-2) 2626 CCC/N=C(/NS(=O)(=O)c1ccc(cc1)Cl)\O 
730 7.19 Clozapine (5786-21-0) 10442628 CN1CCN(CC1)C2=Nc3cc(ccc3Nc4c2cccc4)Cl 
731 7.19 Gallopamil (16662-47-8) 1197 CC(C)C(CCCN(C)CCc1ccc(c(c1)OC)OC)(C#N)c2cc(c(c(c2)OC)OC)OC 
732 7.21 Prothipendyl (303-69-5) 14002 CN(C)CCCN1c2ccccc2Sc3c1nccc3 
733 7.21 Nordiltiazem (N-Desmethyldiltiazem) (85100-17-0) 14600890 CC(=O)OC1C(Sc2ccccc2N(C1=O)CCNC)c3ccc(cc3)OC 
734 7.21 Fenamiphos - sulfone (31972-44-8) 33142 CCOP(=O)(NC(C)C)Oc1ccc(c(c1)C)S(=O)(=O)C 
735 7.23 Propyphenazone (479-92-5) 3646 Cc1c(c(=O)n(n1C)c2ccccc2)C(C)C 
736 7.23 Diphenylpyraline (147-20-6) 2992 CN1CCC(CC1)OC(c2ccccc2)c3ccccc3 
737 7.24 P-Hydroxymesocarb (72460-70-9) (N/A) Oc1ccc(cc1)NC(=O)[N-]c2c[n+](no2)C(C)Cc3ccccc3 
738 7.25 N.N-Dimethyl-N'-p-tolylsulphamide (DMST) (66840-71-9) 645289 Cc1ccc(cc1)NS(=O)(=O)N(C)C 
739 7.25 Tebuthiuron (34014-18-1) 5190 CC(C)(C)c1nnc(s1)N(C)C(=O)NC 
740 7.26 Aceprometazine (13461-01-3) 24249 CC(CN1c2ccccc2Sc3c1cc(cc3)C(=O)C)N(C)C 
741 7.28 Reboxetine (98769-81-4) 2289101 CCOc1ccccc1OC(c2ccccc2)C3CNCCO3 
742 7.28 Bromazepam (1812-30-2) 2347 c1ccnc(c1)C2=NCC(=Nc3c2cc(cc3)Br)O 
743 7.28 Fenthion-sulfoxide (3761-41-9) 18444 Cc1cc(ccc1S(=O)C)OP(=S)(OC)OC 
744 7.29 Norsildenafil (N-Desmethyl Sildenafil) (139755-82-1) 4932278 CCCc1c2c(c(=O)nc([nH]2)c3cc(ccc3OCC)S(=O)(=O)N4CCNCC4)n(n1)C 
745 7.29 Phenyltoloxamine (92-12-6) 6810 CN(C)CCOc1ccccc1Cc2ccccc2 
746 7.31 Sufentanil (56030-54-7) 38043 CCC(=O)N(c1ccccc1)C2(CCN(CC2)CCc3cccs3)COC 
747 7.33 Terbacil  (5902-51-2) 20830 Cc1c(c(=O)n(c(=O)[nH]1)C(C)(C)C)Cl 
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748 7.33 Naphyrone (850352-53-3) 9418039 CCCC(C(=O)C1=CC2=CC=CC=C2C=C1)N3CCCC3 
749 7.34 2-C-C-NBoMe (2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-
methoxybenzyl)ethanamine) 
(1227608-02-7) 24583389 COc1ccccc1CNCCc2cc(c(cc2OC)Cl)OC 
750 7.35 N-Desmethylflunitrazepam (Norflunitrazepam) (2558-30-7) 453770 c1ccc(c(c1)C2=NCC(=O)Nc3c2cc(cc3)[N+](=O)[O-])F 
751 7.35 Propantheline (+) (298-50-0) 4765 CC(C)[N+](C)(CCOC(=O)C1c2ccccc2Oc3c1cccc3)C(C)C 
752 7.36 Quetiapine (111974-69-7) 4827 c1ccc2c(c1)C(=Nc3ccccc3S2)N4CCN(CC4)CCOCCO 
753 7.35 Carbamazepine (298-46-4) 2457 c1ccc2c(c1)C=Cc3ccccc3N2C(=O)N 
754 7.36 Xipamide (14293-44-8) 24795 Cc1cccc(c1NC(=O)c2cc(c(cc2O)Cl)S(=O)(=O)N)C 
755 7.37 Cortisone (53-06-5) 454849 CC12CCC(=O)C=C1CCC3C2C(=O)CC4(C3CCC4(C(=O)CO)O)C 
756 7.37 Valdecoxib (181695-72-7) 106796 Cc1c(c(no1)c2ccccc2)c3ccc(cc3)S(=O)(=O)N 
757 7.39 Asenapine (65576-45-6) 8079624 CN1CC2C(C1)C3=C(C=CC(=C3)Cl)OC4=CC=CC=C24 
758 7.39 Pipotiazine (39860-99-6) 56598 CN(C)S(=O)(=O)c1ccc2c(c1)N(c3ccccc3S2)CCCN4CCC(CC4)CCO 
759 7.41 Benorilate (5003-48-5) 19846 C/C(=N\c1ccc(cc1)OC(=O)c2ccccc2OC(=O)C)/O 
760 7.41 Bromodragonfly (502759-67-3) 8014776 CC(CC1=C2C=COC2=C(C3=C1OC=C3)Br)N 
761 7.42 Trifluperidol (749-13-3) 5366 c1cc(cc(c1)C(F)(F)F)C2(CCN(CC2)CCCC(=O)c3ccc(cc3)F)O 
762 7.44 Flumequine (42835-25-6) 3257 CC1CCc2cc(cc3c2n1cc(c3=O)C(=O)O)F 
763 7.44 Orphenadrine (83-98-7) 4440 Cc1ccccc1C(c2ccccc2)OCCN(C)C 
764 7.45 Periciazine (2622-26-6) 4585 c1ccc2c(c1)N(c3cc(ccc3S2)C#N)CCCN4CCC(CC4)O 
765 7.46 Carbaryl (63-25-2) 5899 C/N=C(\O)/Oc1cccc2c1cccc2 
766 7.46 Chlorazanil (500-42-5) 9946 c1cc(ccc1Nc2ncnc(n2)N)Cl 
767 7.46 Carboxin (5234-68-4) 20027 CC1=C(SCCO1)C(=O)Nc2ccccc2 
768 7.46 2C-P (2-(2,5-Dimethoxy-4-propylphenyl)ethanamine) (207740-22-5) 21106226 CCCc1cc(c(cc1OC)CCN)OC 
769 7.47 Tolpropamine (5632-44-0) 65115 Cc1ccc(cc1)C(CCN(C)C)c2ccccc2 
770 7.47 Acepromazine (61-00-7) 5852 CC(=O)c1ccc2c(c1)N(c3ccccc3S2)CCCN(C)C 
771 7.48 Desloratadine (100643-71-8) 110575 c1cc2c(nc1)C(=C3CCNCC3)c4ccc(cc4CC2)Cl 
772 7.49 Eprosartan (133040-01-4) 4444504 CCCCc1ncc(n1Cc2ccc(cc2)C(=O)O)C=C(Cc3cccs3)C(=O)O 
773 7.49 Omeprazole (73590-58-6) 4433 Cc1cnc(c(c1OC)C)CS(=O)c2[nH]c3ccc(cc3n2)OC 
774 7.52 Cyamemazine (3546-03-0) 56597 CC(CN1c2ccccc2Sc3c1cc(cc3)C#N)CN(C)C 
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775 7.53 Promethazine (60-87-7) 4758 CC(CN1c2ccccc2Sc3c1cccc3)N(C)C 
776 7.54 Nororphenadrine (Tofenacin or Elamol) (15301-93-6) 23647 Cc1ccccc1C(c2ccccc2)OCCNC 
777 7.54 Hexobendine (54-03-5) 5573 CN(CCCOC(=O)c1cc(c(c(c1)OC)OC)OC)CCN(C)CCCOC(=O)c2cc(c(c(c2)OC)OC)OC 
778 7.56 Azadirachtin (Na adduct in MS spectrum) (11141-17-6) 10619174 C/C=C(\C)/C(=O)OC1CC(C2(COC3C2C14COC(C4C(C3O)(C)C56C7CC(C5(O6)C)C8(C=COC
8O7)O)(C(=O)OC)O)C(=O)OC)OC(=O)C 
779 7.56 Clonazepam (1622-61-3) 2700 c1ccc(c(c1)C2=NCC(=O)Nc3c2cc(cc3)[N+](=O)[O-])Cl 
780 7.57 Oxypendyl (5585-93-3) 147734 c1ccc2c(c1)N(c3c(cccn3)S2)CCCN4CCN(CC4)CCO 
781 7.57 Fenthion-sulfone (3761-42-0) 18445 Cc1cc(ccc1S(=O)(=O)C)OP(=S)(OC)OC 
782 7.59 Azelastine (58581-89-8) 2180 CN1CCCC(CC1)n2c(=O)c3ccccc3c(n2)Cc4ccc(cc4)Cl 
783 7.59 Fenfuram (24691-80-3) 81792 Cc1c(cco1)C(=O)Nc2ccccc2 
784 7.59 Nitrazepam (146-22-5) 4350 c1ccc(cc1)C2=NCC(=Nc3c2cc(cc3)[N+](=O)[O-])O 
785 7.61 Dosulepin (113-53-1) 4447605 CN(C)CC/C=C/1\c2ccccc2CSc3c1cccc3 
786 7.62 Azimsulfuron (120162-55-2) 77873 Cn1c(c(cn1)c2nnn(n2)C)S(=O)(=O)NC(=O)Nc3nc(cc(n3)OC)OC 
787 7.63 Atomoxetine (83015-26-3) 49516 Cc1ccccc1O[C@H](CCNC)c2ccccc2 
788 7.63 Mianserine-N-oxide (62510-46-7) 2342189 C[N+]1(CCN2c3ccccc3Cc4ccccc4C2C1)[O-] 
789 7.63 Biperidene (514-65-8) 2289 c1ccc(cc1)C(CCN2CCCCC2)(C3CC4CC3C=C4)O 
790 7.64 Amoxapine (14028-44-5) 2085 c1ccc2c(c1)N=C(c3cc(ccc3O2)Cl)N4CCNCC4 
791 7.64 Barverin (1639-79-8) 175137 c1ccc(cc1)C2(C(=O)N(C(=O)N(C2=O)CCN3CCCCC3)CCN4CCCCC4)N5CCCCC5 
792 7.64 Thiodicarb (59669-26-0) 7875353 C/C(=N\OC(=O)N(SN(C(=O)O/N=C(/SC)\C)C)C)/SC 
793 7.65 1-Hydroxymethyltriazolam (alpha-Hydroxy-Triazolam) (37115-45-0) 1887 c1ccc(c(c1)C2=NCc3nnc(n3-c4c2cc(cc4)Cl)CO)Cl 
794 7.66 Fludrocortisone (127-31-1) 471225 CC12CCC(=O)C=C1CCC3C2(C(CC4(C3CCC4(C(=O)CO)O)C)O)F 
795 7.66 Cambendazole (26097-80-3) 30767 CC(C)OC(=O)Nc1ccc2c(c1)[nH]c(n2)c3cscn3 
796 7.68 Paroxetine (61869-08-7) 4529 c1cc(ccc1C2CCNCC2COc3ccc4c(c3)OCO4)F 
797 7.68 Tolbutamide (64-77-7) 5304 CCCC/N=C(/NS(=O)(=O)c1ccc(cc1)C)\O 
798 7.68 Fexofenadine (83799-24-0) 3231 CC(C)(c1ccc(cc1)C(CCCN2CCC(CC2)C(c3ccccc3)(c4ccccc4)O)O)C(=O)O 
799 7.68 Normethadone (467-85-6) 9687 CCC(=O)C(CCN(C)C)(c1ccccc1)c2ccccc2 
800 7.69 Alfentanyl (71195-58-9) 46451 CCC(=O)N(c1ccccc1)C2(CCN(CC2)CCn3c(=O)n(nn3)CC)COC 
801 7.69 Promazine (58-40-2) 4757 CN(C)CCCN1c2ccccc2Sc3c1cccc3 
802 7.7 Dimethirimol (5221-53-4) 20014 CCCCc1c(nc(nc1O)N(C)C)C 
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803 7.7 Ethiofencarb (29973-13-5) 31991 CCSCc1ccccc1OC(=O)NC 
804 7.73 Dextropropoxyphene (469-62-5) 14592 CCC(=O)OC(Cc1ccccc1)(c2ccccc2)C(C)CN(C)C 
805 7.73 Fosthiazate (98886-44-3) 82856 CCC(C)SP(=O)(N1CCSC1=O)OCC 
806 7.75 Xylometazoline (526-36-3) 5507 Cc1cc(cc(c1CC2=NCCN2)C)C(C)(C)C 
807 7.76 Diethazine (60-91-3) 58979 CCN(CC)CCN1c2ccccc2Sc3c1cccc3 
808 7.76 Monolinuron (1746-81-2) 14868 CN(C(=O)Nc1ccc(cc1)Cl)OC 
809 7.76 1-Naphthaleneacetic acid (NH4 adduct in MS spectrum) (86-87-3) 6601 c1ccc2c(c1)cccc2CC(=O)O 
810 7.77 Bamipine (4945-47-5) 65061 CN1CCC(CC1)N(Cc2ccccc2)c3ccccc3 
811 7.77 Pirimicarb (23103-98-2) 29348 Cc1c(nc(nc1OC(=O)N(C)C)N(C)C)C 
812 7.78 XMC (Group of peaks!) (2655-14-3) 16606 Cc1cc(cc(c1)OC(=O)NC)C 
813 7.8 Thiofanox (39196-18-4) 4517040 CC(C)(C)/C(=N\OC(=O)NC)/CSC 
814 7.8 Procyclidine (77-37-2) 4750 c1ccc(cc1)C(CCN2CCCC2)(C3CCCCC3)O 
815 7.81 Propafenone (54063-53-5) 4763 CCCNCC(COc1ccccc1C(=O)CCc2ccccc2)O 
816 7.81 Esomeprazole (119141-88-7) 4433 Cc1cnc(c(c1OC)C)CS(=O)c2[nH]c3ccc(cc3n2)OC 
817 7.81 Atraton (1610-17-9) 14620 CC/N=c/1\[nH]/c(=N/C(C)C)/[nH]c(n1)OC 
818 7.81 Hydroxyalprazolam (30896-57-2) 158315 Cc1nnc2n1-c3ccc(cc3C(=NC2O)c4ccccc4)Cl 
819 7.82 Hydrocortisone (50-23-7) 21240790 CC12CCC(=O)C=C1CCC3C2C(CC4(C3CCC4(C(=O)CO)O)C)O 
820 7.83 Opipramol (315-72-0) 9046 c1ccc2c(c1)C=Cc3ccccc3N2CCCN4CCN(CC4)CCO 
821 7.83 Flunitrazepam (1622-62-4) 3263 CN1c2ccc(cc2C(=NCC1=O)c3ccccc3F)[N+](=O)[O-] 
822 7.83 Bumetanide (28395-03-1) 2377 CCCCNc1cc(cc(c1Oc2ccccc2)S(=O)(=O)N)C(=O)O 
823 7.83 Methaqualone (72-44-6) 6055 Cc1ccccc1n2c(nc3ccccc3c2=O)C 
824 7.84 Nordextropropoxyphene (Norpropoxyphene) (3376-94-1) 17756 CCC(=O)OC(Cc1ccccc1)(c2ccccc2)C(C)CNC 
825 7.83 Erythromycin (114-07-8) 3140 CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O
3)C)N(C)C)O)(C)O)C)C)O)(C)O 
826 7.85 Triclopyr (55335-06-3) 37801 c1c(c(nc(c1Cl)Cl)OCC(=O)O)Cl 
827 7.85 Fluometuron (2164-17-2) 15702 CN(C)C(=O)Nc1cccc(c1)C(F)(F)F 
828 7.86 Trihexyphenidyl (Benzhexol) (144-11-6) 5371 c1ccc(cc1)C(CCN2CCCCC2)(C3CCCCC3)O 
829 7.86 Pizotifen (15574-96-6) 25497 CN1CCC(=C2c3ccccc3CCc4c2ccs4)CC1 
830 7.86 Disulfoton-sulfoxid (oxydisulfoton) (2497-07-6) 16321 CCOP(=S)(OCC)SCCS(=O)CC 
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831 7.87 Pentoxyverine (77-23-6) 2464 CCN(CC)CCOCCOC(=O)C1(CCCC1)c2ccccc2 
832 7.88 Sildenafil (139755-83-2) 5023 CCCc1c2c(c(=O)[nH]c(n2)c3cc(ccc3OCC)S(=O)(=O)N4CCN(CC4)C)n(n1)C 
833 7.89 Tolmetin (26171-23-3) 5308 Cc1ccc(cc1)C(=O)c2ccc(n2C)CC(=O)O 
834 7.89 Clobazam (22316-47-8) 2687 CN1c2ccc(cc2N(C(=O)CC1=O)c3ccccc3)Cl 
835 7.89 Cyproheptadine (129-03-3) 2810 CN1CCC(=C2c3ccccc3C=Cc4c2cccc4)CC1 
836 7.91 Terodiline (15793-40-5) 21952 CC(CC(c1ccccc1)c2ccccc2)NC(C)(C)C 
837 7.92 Furilazole (121776-33-8) 77743 CC1(N(CC(O1)c2ccco2)C(=O)C(Cl)Cl)C 
838 7.93 Imipramine (50-49-7) 3568 CN(C)CCCN1c2ccccc2CCc3c1cccc3 
839 7.93 Trimeprazine (84-96-8) 5373 CC(CN1c2ccccc2Sc3c1cccc3)CN(C)C 
840 7.94 Cilazapril (88768-40-5) 2649 CCOC(=O)C(CCc1ccccc1)NC2CCCN3CCCC(N3C2=O)C(=O)O 
841 7.94 Sulfinpyrazone (57-96-5) 5149 c1ccc(cc1)N2C(=O)C(C(=O)N2c3ccccc3)CCS(=O)c4ccccc4 
842 7.94 Tribenuron-methyl (101200-48-0) 135649 Cc1nc(nc(n1)OC)N(C)C(=O)NS(=O)(=O)c2ccccc2C(=O)OC 
843 7.95 Cyclobenzaprine (303-53-7) 2792 CN(C)CCC=C1c2ccccc2C=Cc3c1cccc3 
844 7.96 Buprenorphine (52485-79-7) 2382 CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3Cc6c5c(c(cc6)O)O4)CC7CC7)OC)O 
845 7.96 Methadone (76-99-3) 3953 CCC(=O)C(CC(C)N(C)C)(c1ccccc1)c2ccccc2 
846 7.97 Benzatropine (86-13-5) 2254 CN1C2CCC1CC(C2)OC(c3ccccc3)c4ccccc4 
847 7.98 Chlorotoluron (15545-48-9) 25472 Cc1ccc(cc1Cl)/N=C(\N(C)C)/O 
848 7.98 Oxyphencyclimine (125-53-1) 4481 CN1CCCN=C1COC(=O)C(c2ccccc2)(C3CCCCC3)O 
849 7.99 Carisoprodol (78-44-4) 2478 CCCC(C)(COC(=O)N)COC(=O)NC(C)C 
850 7.99 Famphur (52-85-7) 5650 CN(C)S(=O)(=O)c1ccc(cc1)OP(=S)(OC)OC 
851 7.99 Protriptyline (438-60-8) 4805 CNCCCC1c2ccccc2C=Cc3c1cccc3 
852 8 Ethirimol (23947-60-6) 29820 CCCCc1c(nc(nc1O)NCC)C 
853 8.01 Paraoxon (311-45-5) 9026 CCOP(=O)(OCC)Oc1ccc(cc1)[N+](=O)[O-] 
854 8.02 Benodanil (15310-01-7) 25310 c1ccc(cc1)NC(=O)c2ccccc2I 
855 8.02 Disulfoton-sulfone (2497-06-5) 16320 CCOP(=S)(OCC)SCCS(=O)(=O)CC 
856 8.03 Ziprasidone (146939-27-7) 54841 c1ccc2c(c1)c(ns2)N3CCN(CC3)CCc4cc5c(cc4Cl)NC(=O)C5 
857 8.03 Astemizole (68844-77-9) 2160 COc1ccc(cc1)CCN2CCC(CC2)Nc3nc4ccccc4n3Cc5ccc(cc5)F 
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858 8.03 25I-NBoMe [2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2-
methoxybenzyl)ethanamine] 
(919797-19-6) 8427392 COC1=CC=CC=C1CNCCC2=CC(=C(C=C2OC)I)OC 
859 8.04 Duloxetine (116539-59-4) 109024 CNCCC(c1cccs1)Oc2cccc3c2cccc3 
860 8.04 Oxeladin (468-61-1) 4458 CCC(CC)(c1ccccc1)C(=O)OCCOCCN(CC)CC 
861 8.05 Griseofulvin (126-07-8) 3392 CC1CC(=O)C=C(C12C(=O)c3c(cc(c(c3O2)Cl)OC)OC)OC 
862 8.05 Triazolam (28911-01-5) 5355 Cc1nnc2n1-c3ccc(cc3C(=NC2)c4ccccc4Cl)Cl 
863 8.06 Rosuvastatin (287714-41-4) 4859072 CC(C)c1c(c(nc(n1)N(C)S(=O)(=O)C)c2ccc(cc2)F)/C=C/C(CC(CC(=O)O)O)O 
864 8.08 Desipramine (50-47-5) 2888 CNCCCN1c2ccccc2CCc3c1cccc3 
865 8.08 Maprotiline (10262-69-8) 3871 CNCCCC12CCC(c3c1cccc3)c4c2cccc4 
866 8.08 Metominostrobin 1 (Z-Isomer) (133408-51-2) 7850488 O=C(NC)C(=N\OC)/c2ccccc2Oc1ccccc1 
867 8.09 Dienogest (65928-58-7) 10761296 O=C\2CC\C\3=C4/CCC1(C)C(CCC1(O)CC#N)C4CC\C/3=C/2 
868 8.09 Tolazamide (1156-19-0) 5302 Cc1ccc(cc1)S(=O)(=O)NC(=O)NN2CCCCCC2 
869 8.09 AM-1220 [(1-{[(2R)-1-Methyl-2-piperidinyl]methyl}-1H-
indol-3-yl)(1-naphthyl)methanone] 
(134959-64-1) 8105520 CN1CCCCC1CN2C=C(C3=CC=CC=C32)C(=O)C4=CC=CC5=CC=CC=C54 
870 8.1 Trimethacarb (3,4,5-) [Shell SD 8530] (2686-99-9) 16632 Cc1cc(cc(c1C)C)OC(=O)NC 
871 8.1 Alimemazine (84-96-8) 5373 CC(CN1c2ccccc2Sc3c1cccc3)CN(C)C 
872 8.11 Glipizide (29094-61-9) 3359 Cc1cnc(cn1)/C(=N\CCc2ccc(cc2)S(=O)(=O)N/C(=N\C3CCCCC3)/O)/O 
873 8.11 alpha-Hydroxy-Alprazolam (37115-43-8) 142474 c1ccc(cc1)C2=NCc3nnc(n3-c4c2cc(cc4)Cl)CO 
874 8.11 Metazachlor (67129-08-2) 44885 Cc1cccc(c1N(Cn2cccn2)C(=O)CCl)C 
875 8.11 Propham (IPC) (122-42-9) 23083 CC(C)OC(=O)Nc1ccccc1 
876 8.11 Vardenafil (224785-90-4) 99300 CCCc1nc(c2n1nc([nH]c2=O)c3cc(ccc3OCC)S(=O)(=O)N4CCN(CC4)CC)C 
877 8.11 Trifloxysulfuron (145099-21-4) 8131496 COC1=CC(=NC(=N1)NC(=O)NS(=O)(=O)C2=C(C=CC=N2)OCC(F)(F)F)OC 
878 8.12 Lethane 384 (112-56-1) 7904 CCCCOCCOCCSC#N 
879 8.12 Isoprocarb (2631-40-5) 16564 CC(C)c1ccccc1OC(=O)NC 
880 8.12 Flutriafol (76674-21-0) 82827 c1ccc(c(c1)C(Cn2cncn2)(c3ccc(cc3)F)O)F 
881 8.12 5-(p-Methylphenyl)-5-phenylhydantoin (MPPH) (51169-17-6) 83358 Cc1ccc(cc1)C2(C(=O)NC(=O)N2)c3ccccc3 
882 8.14 Levomepromazine (60-99-1) 3779 CC(CN1c2ccccc2Sc3c1cc(cc3)OC)CN(C)C 
883 8.14 Simetryn (1014-70-6) 13303 CC/N=c\1/[nH]/c(=N\CC)/nc([nH]1)SC 
884 8.14 Estazolam (29975-16-4) 3146 c1ccc(cc1)C2=NCc3nncn3-c4c2cc(cc4)Cl 
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885 8.15 Metobromuron (3060-89-7) 17276 CN(C(=O)Nc1ccc(cc1)Br)OC 
886 8.15 Thioproperazine (316-81-4) 9058 CN1CCN(CC1)CCCN2c3ccccc3Sc4c2cc(cc4)S(=O)(=O)N(C)C 
887 8.16 Atrazine (1912-24-9) 2169 CC/N=c/1\[nH]/c(=N/C(C)C)/[nH]c(n1)Cl 
888 8.17 Dihydroergocristine (17479-19-5) 2957 CC(C)C1(C(=O)N2C(C(=O)N3CCCC3C2(O1)O)Cc4ccccc4)NC(=O)C5CC6c7cccc8c7c(c[nH]8)
CC6N(C5)C 
889 8.17 Desmetryn (1014-69-3) 13302 CC(C)Nc1nc(nc(n1)SC)NC 
890 8.19 Lorazepam (846-49-1) 3821 c1ccc(c(c1)C2=NC(C(=O)Nc3c2cc(cc3)Cl)O)Cl 
891 8.19 Losartan (114798-26-4) 3824 CCCCc1nc(c(n1Cc2ccc(cc2)c3ccccc3c4n[nH]nn4)CO)Cl 
892 8.19 Piritramide (302-41-0) 8967 c1ccc(cc1)C(CCN2CCC(CC2)(C(=O)N)N3CCCCC3)(C#N)c4ccccc4 
893 8.2 Terconazole (67915-31-5) 5211 CC(C)N1CCN(CC1)c2ccc(cc2)OCC3COC(O3)(Cn4cncn4)c5ccc(cc5Cl)Cl 
894 8.2 N,N-Diethyl-m-toluamide (DEET) (134-62-3) 4133 CCN(CC)C(=O)c1cccc(c1)C 
895 8.22 Metalaxyl (57837-19-1) 38839 Cc1cccc(c1N(C(C)C(=O)OC)C(=O)COC)C 
896 8.22 Cyprazine (22936-86-3) 23128 CC(C)Nc1nc(nc(n1)Cl)NC2CC2 
897 8.23 Spirapril (83647-97-6) (N/A) CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N2CC3(CC2C(=O)O)SCCS3 
898 8.23 Amitriptyline (50-48-6) 2075 CN(C)CCC=C1c2ccccc2CCc3c1cccc3 
899 8.24 Sulindac (38194-50-2) 1265915 CC\1=C(c2cc(ccc2/C1=C\c3ccc(cc3)S(=O)C)F)CC(=O)O 
900 8.25 Harpagoside (19210-12-9) 3430705 CC1(CC(C2(C1C(OC=C2)OC3C(C(C(C(O3)CO)O)O)O)O)O)OC(=O)C=Cc4ccccc4 
901 8.25 Propachlor (1918-16-7) 4762 CC(C)N(c1ccccc1)C(=O)CCl 
902 8.26 Tadalafil (171596-29-5) 3875386 CN1CC(=O)N2C(C1=O)Cc3c4ccccc4[nH]c3C2c5ccc6c(c5)OCO6 
903 8.26 Oxazepam (604-75-1) 4455 c1ccc(cc1)C2=NC(C(=O)Nc3c2cc(cc3)Cl)O 
904 8.26 Methabenzthiazuron (18691-97-9) 27173 CNC(=O)N(C)c1nc2ccccc2s1 
905 8.27 N-Desmethyl-Chlordiazepoxide (7722-15-8) 10441296 Clc1ccc2\N=C(\N)C[N+](/[O-])=C(\c2c1)c3ccccc3 
906 8.27 Fensulfothion (115-90-2) 7991 CCOP(=S)(OCC)Oc1ccc(cc1)S(=O)C 
907 8.27 Cyanophos (2636-26-2) 16569 COP(=S)(OC)Oc1ccc(cc1)C#N 
908 8.27 Rabenzazole (40341-04-6) 35229 Cc1cc(n(n1)c2[nH]c3ccccc3n2)C 
909 8.27 Lenacil (2164-08-1) 15699 C1CCC(CC1)n2c(=O)c3c(nc2O)CCC3 
910 8.28 Brotizolam (57801-81-7) 2357 Cc1nnc2n1-c3c(cc(s3)Br)C(=NC2)c4ccccc4Cl 
911 8.28 Fluvoxamine (54739-18-3) 4481878 COCCCC/C(=N\OCCN)/c1ccc(cc1)C(F)(F)F 
912 8.28 Nebivolol (99200-09-6) 64421 c1cc2c(cc1F)CCC(O2)C(CNCC(C3CCc4cc(ccc4O3)F)O)O 
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913 8.28 Ketoprofen (22071-15-4) 3693 CC(c1cccc(c1)C(=O)c2ccccc2)C(=O)O 
914 8.28 Chlorcyclizine (82-93-9) 2609 CN1CCN(CC1)C(c2ccccc2)c3ccc(cc3)Cl 
915 8.25 Hydroxyzine (68-88-2) 3531 c1ccc(cc1)C(c2ccc(cc2)Cl)N3CCN(CC3)CCOCCO 
916 8.29 Moxaverine (10539-19-2) 64045 CCc1cc2cc(c(cc2c(n1)Cc3ccccc3)OC)OC 
917 8.29 Mequitazine (29216-28-2) 3926 c1ccc2c(c1)N(c3ccccc3S2)CC4CN5CCC4CC5 
918 8.31 Etizolam (40054-69-1) 3191 CCc1cc2c(s1)-n3c(nnc3CN=C2c4ccccc4Cl)C 
919 8.31 Nifedipine (21829-25-4) 4330 CC1=C(C(C(=C(N1)C)C(=O)OC)c2ccccc2[N+](=O)[O-])C(=O)OC 
920 8.31 Trimipramine (739-71-9) 5382 CC(CN1c2ccccc2CCc3c1cccc3)CN(C)C 
921 8.32 Benproperine (2156-27-6) 2236 CC(COc1ccccc1Cc2ccccc2)N3CCCCC3 
922 8.32 Isoproturon (34123-59-6) 33695 CC(C)c1ccc(cc1)NC(=O)N(C)C 
923 8.32 Isocarbophos (24353-61-5) 81690 CC(C)OC(=O)c1ccccc1OP(=S)(N)OC 
924 8.32 Kavain (500-64-1) 4520267 COC1=CC(=O)OC(C1)/C=C/c2ccccc2 
925 8.33 Etodroxizine (17692-34-1) 57011 c1ccc(cc1)C(c2ccc(cc2)Cl)N3CCN(CC3)CCOCCOCCO 
926 8.33 Norlevomepromazine (37819-98-0) 8511272 O(c2cc1N(c3c(Sc1cc2)cccc3)CC(C)CNC)C 
927 8.34 3-Hydroxyphenazepam (70030-11-4) 111897 c1ccc(c(c1)C2=NC(C(=O)Nc3c2cc(cc3)Br)O)Cl 
928 8.35 Buturon (3766-60-7) 18451 CC(C#C)N(C)C(=O)Nc1ccc(cc1)Cl 
929 8.35 Thionazin (Zinophos) (297-97-2) 8915 CCOP(=S)(OCC)Oc1cnccn1 
930 8.36 Alprazolam (28981-97-7) 2034 Cc1nnc2n1-c3ccc(cc3C(=NC2)c4ccccc4)Cl 
931 8.36 Amlodipine (88150-42-9) 2077 CCOC(=O)C1=C(NC(=C(C1c2ccccc2Cl)C(=O)OC)C)COCCN 
932 8.37 Triazoxide (72459-58-6) 84327 c1cc2c(cc1Cl)[n+](nc(n2)n3ccnc3)[O-] 
933 8.38 Dexamethasone (50-02-2) (N/A) CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C 
934 8.39 Tiagabine (115103-54-3) 5267 Cc1ccsc1C(=CCCN2CCCC(C2)C(=O)O)c3c(ccs3)C 
935 8.39 Nicardipine (55985-32-5) 4319 CC1=C(C(C(=C(N1)C)C(=O)OCCN(C)Cc2ccccc2)c3cccc(c3)[N+](=O)[O-])C(=O)OC 
936 8.4 Trimethacarb (2.3.5-) (2655-15-4) 23827 Cc1cc(c(c(c1)OC(=O)NC)C)C 
937 8.4 Nortriptyline (72-69-5) 4384 CNCCC=C1c2ccccc2CCc3c1cccc3 
938 8.41 Cinchocaine (85-79-0) 2917 CCCCOc1cc(c2ccccc2n1)/C(=N/CCN(CC)CC)/O 
939 8.42 Oxatomide (60607-34-3) 4454 c1ccc(cc1)C(c2ccccc2)N3CCN(CC3)CCCn4c5ccccc5[nH]c4=O 
940 8.43 Difenoxuron (14214-32-5) 24757 CN(C)C(=O)Nc1ccc(cc1)Oc2ccc(cc2)OC 
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941 8.43 Fluoxetine (54910-89-3) 3269 CNCCC(c1ccccc1)Oc2ccc(cc2)C(F)(F)F 
942 8.44 1-Hydroxymidazolam (59468-90-5) 97043 c1ccc(c(c1)C2=NCc3cnc(n3-c4c2cc(cc4)Cl)CO)F 
943 8.45 Trinexapac-ethyl (95266-40-3) 83439 CCOC(=O)C1CC(=O)C(=C(C2CC2)O)C(=O)C1 
944 8.47 Reserpine (50-55-5) 21428561 COc1ccc2c(c1)[nH]c3c2CCN4C3CC5C(C4)CC(C(C5C(=O)OC)OC)OC(=O)c6cc(c(c(c6)OC)OC
)OC 
945 8.47 Cycluron (2163-69-1) 15694 CN(C)C(=O)NC1CCCCCCC1 
946 8.48 Fensulfothion-sulfone (14255-72-2) 24774 CCOP(=S)(OCC)Oc1ccc(cc1)S(=O)(=O)C 
947 8.49 Propionylpromazine (3568-24-9) 22768 CCC(=O)c1ccc2c(c1)N(c3ccccc3S2)CCCN(C)C 
948 8.49 Chlorphenethazine (2095-24-1) 56593 CN(C)CCN1c2ccccc2Sc3c1cc(cc3)Cl 
949 8.49 Phenazopyridine (94-78-0) 4592 c1ccc(cc1)/N=N/c2ccc(=N)[nH]c2N 
950 8.49 Temazepam (846-50-4) 5198 CN1c2ccc(cc2C(=NC(C1=O)O)c3ccccc3)Cl 
951 8.49 Nortrimipramine (2293-21-2) 141149 CC(CNC)CN1c2ccccc2CCc3c1cccc3 
952 8.49 Heptenophos (23560-59-0) 56515 COP(=O)(OC)OC1=C(C2C1CC=C2)Cl 
953 8.51 Metixene (4969-02-2) 4023 CN1CCCC(C1)CC2c3ccccc3Sc4c2cccc4 
954 8.51 Norflurazon (27314-13-2) 31131 CNc1cnn(c(=O)c1Cl)c2cccc(c2)C(F)(F)F 
955 8.52 Naftifine (65472-88-0) 43344 CN(C/C=C/c1ccccc1)Cc2cccc3c2cccc3 
956 8.53 Metominostrobin 2 (E-Isomer) (133408-50-1) 4588319 CNC(=O)/C(=N/OC)/c1ccccc1Oc2ccccc2 
957 8.53 Forchlorfenuron (68157-60-8) 84301 c1ccc(cc1)/N=C(\Nc2ccnc(c2)Cl)/O 
958 8.54 Bornaprine (20448-86-6) 28011 CCN(CC)CCCOC(=O)C1(CC2CCC1C2)c3ccccc3 
959 8.54 Fendiline (13042-18-7) 3219 CC(c1ccccc1)NCCC(c2ccccc2)c3ccccc3 
960 8.54 Aminopromazine (58-37-7) 18278 CN(C)CC(CN1c2ccccc2Sc3c1cccc3)N(C)C 
961 8.55 Diuron (330-54-1) 3008 CN(C)/C(=N\c1ccc(c(c1)Cl)Cl)/O 
962 8.55 Naled (300-76-5) 4267 COP(=O)(OC)OC(C(Cl)(Cl)Br)Br 
963 8.56 Ramipril (87333-19-5) 4862 CCOC(=O)C(CCc1ccccc1)NC(C)C(=O)N2C3CCCC3CC2C(=O)O 
964 8.56 Flazasulfuron (104040-78-0) 84440 COc1cc(nc(n1)NC(=O)NS(=O)(=O)c2c(cccn2)C(F)(F)F)OC 
965 8.57 Prosulfuron (94125-34-5) 82849 Cc1nc(nc(n1)OC)NC(=O)NS(=O)(=O)c2ccccc2CCC(F)(F)F 
966 8.57 Diphenamid (957-51-7) 13133 CN(C)C(=O)C(c1ccccc1)c2ccccc2 
967 8.57 Desmedipham (13684-56-5) 23133 CCO/C(=N/c1cccc(c1)O/C(=N/c2ccccc2)/O)/O 
968 8.58 Dimethachlor (50563-36-5) 36319 Cc1cccc(c1N(CCOC)C(=O)CCl)C 
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969 8.59 Mefloquine (53230-10-7) 3906 c1cc2c(cc(nc2c(c1)C(F)(F)F)C(F)(F)F)C(C3CCCCN3)O 
970 8.6 Phorate-oxon (2600-69-3) 68291 CCOP(=O)(OCC)SCSCC 
971 8.6 Flamprop (58667-63-3) 39044 CC(C(=O)O)N(c1ccc(c(c1)Cl)F)C(=O)c2ccccc2 
972 8.6 Diphacinone (82-66-6) 6463 c1ccc(cc1)C(c2ccccc2)C(=O)C3C(=O)c4ccccc4C3=O 
973 8.61 Lormetazepam (848-75-9) 12750 CN1c2ccc(cc2C(=NC(C1=O)O)c3ccccc3Cl)Cl 
974 8.61 Thiophanat-ethyl (23564-06-9) 2297684 CCOC(=O)NC(=S)Nc1ccccc1NC(=S)NC(=O)OCC 
975 8.61 AM-1220-Azepane (1348081-04-8) 29341387 CN1CCCCC(C1)n2cc(c3c2cccc3)C(=O)c4cccc5c4cccc5 
976 8.62 Fenpropidin (67306-00-7) 82797 CC(Cc1ccc(cc1)C(C)(C)C)CN2CCCCC2 
977 8.63 Aripiprazole (129722-12-9) 54790 c1cc(c(c(c1)Cl)Cl)N2CCN(CC2)CCCCOc3ccc4c(c3)NC(=O)CC4 
978 8.65 Diazinon-O-analog (Diazoxon) (962-58-3) 13157 CCOP(=O)(OCC)Oc1cc(nc(n1)C(C)C)C 
979 8.66 Sibutramine (106650-56-0) 5021 CC(C)CC(C1(CCC1)c2ccc(cc2)Cl)N(C)C 
980 8.68 Norsibutramine (Desmethylsibutramine) (na) 8374698 Clc1ccc(cc1)C2(C(NC)CC(C)C)CCC2 
981 8.68 Agomelatine (138112-76-2) 74141 CC(=O)NCCc1cccc2c1cc(cc2)OC 
982 8.7 Methidathion (950-37-8) 13115 COc1nn(c(=O)s1)CSP(=S)(OC)OC 
983 8.7 Chlorantraniliprole (500008-45-7) 9446648 CC1=CC(=CC(=C1NC(=O)C2=CC(=NN2C3=C(C=CC=N3)Cl)Br)C(=O)NC)Cl 
984 8.73 Flumioxazin (103361-09-7) 83443 C#CCN1c2cc(c(cc2OCC1=O)F)N3C(=O)C4=C(C3=O)CCCC4 
985 8.73 Pimozide (2062-78-4) 15520 c1ccc2c(c1)nc(n2C3CCN(CC3)CCCC(c4ccc(cc4)F)c5ccc(cc5)F)O 
986 8.74 Corticosterone (50-22-6) 388799 CC12CCC(=O)C=C1CCC3C2C(CC4(C3CCC4C(=O)CO)C)O 
987 8.74 Desalkylflurazepam (Norfludiazepam) (2886-65-9) 4381 c1ccc(c(c1)C2=NCC(=Nc3c2cc(cc3)Cl)O)F 
988 8.75 Phenmedipham (13684-63-4) 23134 Cc1cccc(c1)/N=C(\O)/Oc2cccc(c2)/N=C(\O)/OC 
989 8.76 Dimefuron (34205-21-5) 82721 CC(C)(C)c1nn(c(=O)o1)c2ccc(cc2Cl)NC(=O)N(C)C 
990 8.77 Bensulfuron-methyl (83055-99-6) 49630 COc1cc(nc(n1)NC(=O)NS(=O)(=O)Cc2ccccc2C(=O)OC)OC 
991 8.77 Bicalutamide (90357-06-5) 2284 CC(CS(=O)(=O)c1ccc(cc1)F)(C(=O)Nc2ccc(c(c2)C(F)(F)F)C#N)O 
992 8.77 Bezafibrate (41859-67-0) 35728 CC(C)(C(=O)O)Oc1ccc(cc1)CCNC(=O)c2ccc(cc2)Cl 
993 8.77 Captan (133-06-2) 8287 C1C=CCC2C1C(=O)N(C2=O)SC(Cl)(Cl)Cl 
994 8.78 Imazosulfuron (122548-33-8) 83451 COc1cc(nc(n1)NC(=O)NS(=O)(=O)c2c(nc3n2cccc3)Cl)OC 
995 8.79 Melitracen (5118-29-6) 23697 CC1(c2ccccc2C(=CCCN(C)C)c3c1cccc3)C 
996 8.79 Secbumeton (26259-45-0) 30881 CCC(C)Nc1nc(nc(n1)OC)NCC 
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997 8.79 Cetirizine (83881-51-0) 2577 c1ccc(cc1)C(c2ccc(cc2)Cl)N3CCN(CC3)CCOCC(=O)O 
998 8.79 Methfuroxam (28730-17-8) 31609 Cc1c(oc(c1C(=O)Nc2ccccc2)C)C 
999 8.8 Hydrocortisone 21-acetate (50-03-3) 3515 CC(=O)OCC(=O)C1(CCC2C1(CC(C3C2CCC4=CC(=O)CCC34C)O)C)O 
1000 8.8 Perazine (84-97-9) 4582 CN1CCN(CC1)CCCN2c3ccccc3Sc4c2cccc4 
1001 8.81 5-[3-(4-Methoxybenzoyl)-1H-indol-1-yl]pentanoic acid  
(RCS-4-M-5-COOH-Pentyl) 
(1427521-39-8) 29341868 COc1ccc(cc1)C(=O)c2cn(c3c2cccc3)CCCCC(=O)O 
1002 8.82 Fenthion-oxon (6552-12-1) 21567 Cc1cc(ccc1SC)OP(=O)(OC)OC 
1003 8.82 Fluridone (59756-60-4) 39255 Cn1cc(c(=O)c(c1)c2cccc(c2)C(F)(F)F)c3ccccc3 
1004 8.83 Salmeterol (89365-50-4) 4968 c1ccc(cc1)CCCCOCCCCCCNCC(c2ccc(c(c2)CO)O)O 
1005 8.83 Midazolam (59467-70-8) 4047 Cc1ncc2n1-c3ccc(cc3C(=NC2)c4ccccc4F)Cl 
1006 8.84 Dicloran (99-30-9) 7152 c1c(cc(c(c1Cl)N)Cl)[N+](=O)[O-] 
1007 8.85 Aprindine (37640-71-4) 2132 CCN(CC)CCCN(c1ccccc1)C2Cc3ccccc3C2 
1008 8.86 Prometon (1610-18-0) 4759 CC(C)/N=c\1/[nH]/c(=N\C(C)C)/nc([nH]1)OC 
1009 8.86 Bispyribac (125401-75-4) 391332 COc1cc(nc(n1)Oc2cccc(c2C(=O)O)Oc3nc(cc(n3)OC)OC)OC 
1010 8.86 Cetirizine (Methyl ester) (83881-46-3) 528920 COC(=O)COCCN1CCN(CC1)C(c2ccccc2)c3ccc(cc3)Cl 
1011 8.87 Benoxacor (98730-04-2) 56101 CC1COc2ccccc2N1C(=O)C(Cl)Cl 
1012 8.85 Sertraline (79617-96-2) 5014 CNC1CCC(c2c1cccc2)c3ccc(c(c3)Cl)Cl 
1013 8.89 Chlorpromazine (50-53-3) 2625 CN(C)CCCN1c2ccccc2Sc3c1cc(cc3)Cl 
1014 8.89 Clomazone  (Command) (81777-89-1) 49469 CC1(CON(C1=O)Cc2ccccc2Cl)C 
1015 8.89 Azinphos-methyl (Guthion) (86-50-0) 2181 COP(=S)(OC)SCn1c(=O)c2ccccc2nn1 
1016 8.89 Prenylamine (390-64-7) 9418 CC(Cc1ccccc1)NCCC(c2ccccc2)c3ccccc3 
1017 8.91 Demeton-S (126-75-0) 23115 CCOP(=O)(OCC)SCCSCC 
1018 8.91 Fenpiclonil (74738-17-3) 82824 c1cc(c(c(c1)Cl)Cl)c2c[nH]cc2C#N 
1019 8.91 Nortramadol (N-Desmethyltramadol) (75377-45-6) 171856 CNCC1CCCCC1(c2cccc(c2)OC)O 
1020 8.92 Oxybutynin (5633-20-5) 4473 CCN(CC)CC#CCOC(=O)C(c1ccccc1)(C2CCCCC2)O 
1021 8.93 Phenazepam (51753-57-2) 36657 c1ccc(c(c1)C2=NCC(=O)Nc3c2cc(cc3)Br)Cl 
1022 8.94 Phosmet (732-11-6) 12367 COP(=S)(OC)SCN1C(=O)c2ccccc2C1=O 
1023 8.95 Acifluorfen (as the NH4 adduct) (50594-66-6) 40113 c1cc(c(cc1C(F)(F)F)Cl)Oc2ccc(c(c2)C(=O)O)[N+](=O)[O-] 
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1024 8.96 Clothiapine (2058-52-8) 15510 CN1CCN(CC1)C2=Nc3ccccc3Sc4c2cc(cc4)Cl 
1025 8.98 Embutramide (15687-14-6) 25547 CCC(CC)(CNC(=O)CCCO)c1cccc(c1)OC 
1026 8.98 Phenylbutazone (50-33-9) 4617 CCCCC1C(=O)N(N(C1=O)c2ccccc2)c3ccccc3 
1027 8.99 Furalaxyl (57646-30-7) 38763 Cc1cccc(c1N(C(C)C(=O)OC)C(=O)c2ccco2)C 
1028 8.99 Chlorprotixene (113-59-7) 580849 CN(C)CC/C=C\1/c2ccccc2Sc3c1cc(cc3)Cl 
1029 8.99 Naproxen (22204-53-1) 1262 CC(c1ccc2cc(ccc2c1)OC)C(=O)O 
1030 8.99 2-Amino-5-nitrobenzophenone (1775-95-7) 14916 c1ccc(cc1)C(=O)c2cc(ccc2N)[N+](=O)[O-] 
1031 9 Valsartan (137862-53-4) 5448 CCCCC(=O)N(Cc1ccc(cc1)c2ccccc2c3n[nH]nn3)C(C(C)C)C(=O)O 
1032 9 Terbufos-sulfoxid (10548-10-4) 23684 CCOP(=S)(OCC)SCS(=O)C(C)(C)C 
1033 9.01 Penbutolol (36507-48-9) 4562 CC(C)(C)NCC(COc1ccccc1C2CCCC2)O 
1034 9.01 Terbufossulfone (56070-16-7) 38067 CCOP(=S)(OCC)SCS(=O)(=O)C(C)(C)C 
1035 9.01 Fomesafen (72178-02-0) 46694 CS(=O)(=O)/N=C(/c1cc(ccc1[N+](=O)[O-])Oc2ccc(cc2Cl)C(F)(F)F)\O 
1036 9.02 Azoxystrobin (131860-33-8) 2298772 CO/C=C(\c1ccccc1Oc2cc(ncn2)Oc3ccccc3C#N)/C(=O)OC 
1037 9.03 Quinapril (85441-61-8) 4830 CCOC(=O)C(CCc1ccccc1)NC(C)C(=O)N2Cc3ccccc3CC2C(=O)O 
1038 9.03 Exemestane (107868-30-4) 3659700 CC12CCC3C(C1CCC2=O)CC(=C)C4=CC(=O)C=CC34C 
1039 9.03 Clomipramine (303-49-1) 2699 CN(C)CCCN1c2ccccc2CCc3c1cc(cc3)Cl 
1040 9.04 O.O.O-Triethylphosphorothioate (126-68-1) 29087 CCOP(=S)(OCC)OCC 
1041 9.04 Diethofencarb (87130-20-9) 82840 CCOc1ccc(cc1OCC)NC(=O)OC(C)C 
1042 9.04 Zotepine (26615-21-4) 5534 CN(C)CCOC1=Cc2ccccc2Sc3c1cc(cc3)Cl 
1043 9.05 Fenobucarb (3766-81-2) 18452 CCC(C)c1ccccc1OC(=O)NC 
1044 9.05 Phenprocoumon (435-97-2) 10441592 CCC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O 
1045 9.08 Dixyrazine (Esocalm) (2470-73-7) 16265 CC(CN1CCN(CC1)CCOCCO)CN2c3ccccc3Sc4c2cccc4 
1046 9.08 Warfarin (81-81-2) 10442445 CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O 
1047 9.09 Methohexital (151-83-7) 8683 CCC#CC(C)C1(C(=O)NC(=O)N(C1=O)C)CC=C 
1048 9.09 Sebuthylazine (7286-69-3) 22172 CCC(C)Nc1nc(nc(n1)Cl)NCC 
1049 9.09 Flunixin (38677-85-9) 34911 Cc1c(cccc1Nc2c(cccn2)C(=O)O)C(F)(F)F 
1050 9.09 Imazalil (Enilconazole) (35554-44-0) 34116 C=CCOC(Cn1ccnc1)c2ccc(cc2Cl)Cl 
1051 9.12 Riluzole (1744-22-5) 4892 c1cc2c(cc1OC(F)(F)F)sc(n2)N 
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1052 9.14 Methoprotryne (841-06-5) 12730 CC(C)Nc1nc(nc(n1)SC)NCCCOC 
1053 9.14 Ethofumesate (26225-79-6) 30816 CCOC1C(c2cc(ccc2O1)OS(=O)(=O)C)(C)C 
1054 9.14 Norclomipramine (Desmethylclomipramine) (303-48-0) as the HCl salt 540947 CNCCCN1c2ccccc2CCc3c1cc(cc3)Cl 
1055 9.14 Mizolastine (108612-45-9) 59315 CN(c1[nH]c(=O)ccn1)C2CCN(CC2)c3nc4ccccc4n3Cc5ccc(cc5)F 
1056 9.14 Flurtamone (96525-23-4) 82853 CNC1=C(C(=O)C(O1)c2ccccc2)c3cccc(c3)C(F)(F)F 
1057 9.16 Terbumeton (33693-04-8) 33617 CC/N=c/1\nc([nH]c(n1)OC)NC(C)(C)C 
1058 9.16 Ametryn (834-12-8) 12705 CC/N=c/1\[nH]/c(=N/C(C)C)/[nH]c(n1)SC 
1059 9.16 Propazine (139-40-2) 4768 CC(C)/N=c\1/[nH]/c(=N\C(C)C)/nc([nH]1)Cl 
1060 9.17 Acrinathrin (101007-06-1) 4859914 CC1(C(C1C(=O)OC(C#N)c2cccc(c2)Oc3ccccc3)/C=C/C(=O)OC(C(F)(F)F)C(F)(F)F)C 
1061 9.17 Nuarimol (63284-71-9) 82786 c1ccc(c(c1)C(c2ccc(cc2)F)(c3cncnc3)O)Cl 
1062 9.18 RCS-4-M-5-OH-Pentyl (1379604-66-6) 29341441 COc1ccc(cc1)C(=O)c2cn(c3c2cccc3)CCCCCO 
1063 9.19 Drofenine (1679-76-1) 3054 CCN(CC)CCOC(=O)C(c1ccccc1)C2CCCCC2 
1064 9.19 Albendazole (54965-21-8) 1998 CCCSc1ccc2c(c1)nc([nH]2)NC(=O)OC 
1065 9.19 Fluspirilene (1841-19-6) 3279 c1ccc(cc1)N2CNC(=O)C23CCN(CC3)CCCC(c4ccc(cc4)F)c5ccc(cc5)F 
1066 9.2 Diponium (58875-33-5) 64834 CC[N+](CC)(CC)CCOC(=O)C(C1CCCC1)C2CCCC2 
1067 9.22 Fenamidone (161326-34-7) 10701914 CS/C2=N/C(C)(C(=O)N2Nc1ccccc1)c3ccccc3 
1068 9.22 Triflusulfuron-methyl (126535-15-7) 83452 Cc1cccc(c1S(=O)(=O)N/C(=N/c2nc(nc(n2)OCC(F)(F)F)N(C)C)/O)C(=O)OC 
1069 9.23 Nordiazepam (Desmethyldiazepam) (1088-11-5) 2890 c1ccc(cc1)C2=NCC(=Nc3c2cc(cc3)Cl)O 
1070 9.23 Pioglitazone (111025-46-8) 4663 CCc1ccc(nc1)CCOc2ccc(cc2)CC3C(=O)NC(=O)S3 
1071 9.24 Parathion-methyl (298-00-0) 3987 COP(=S)(OC)Oc1ccc(cc1)[N+](=O)[O-] 
1072 9.25 TCMTB [(1,3-Benzothiazol-2-ylsulfanyl)methyl 
thiocyanate] 
(21564-17-0) 28480 c1ccc2c(c1)nc(s2)SCSC#N 
1073 9.25 Ticlopidine (55142-85-3) 5273 c1ccc(c(c1)CN2CCc3c(ccs3)C2)Cl 
1074 9.25 Halofenozide (112226-61-6) 102925 CC(C)(C)N(C(=O)c1ccccc1)NC(=O)c2ccc(cc2)Cl 
1075 9.26 Dimethenamid (87674-68-8) 82842 Cc1csc(c1N(C(C)COC)C(=O)CCl)C 
1076 9.26 Iprindol (5560-72-5) 20417 CN(C)CCCn1c2ccccc2c3c1CCCCCC3 
1077 9.26 Sertindole (106516-24-9) 54229 c1cc(ccc1n2cc(c3c2ccc(c3)Cl)C4CCN(CC4)CCN5CCNC5=O)F 
1078 9.27 Inabenfide (82211-24-3) 83423 c1ccc(cc1)C(c2cc(ccc2NC(=O)c3ccncc3)Cl)O 
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1079 9.27 Triflupromazine (146-54-3) 5367 CN(C)CCCN1c2ccccc2Sc3c1cc(cc3)C(F)(F)F 
1080 9.27 Chlorbufam (1967-16-4) 15261 CC(C#C)OC(=O)Nc1cccc(c1)Cl 
1081 9.29 Dabigatran etexilate (211915-06-9) 4948999 CCCCCCOC(=O)/N=C(\c1ccc(cc1)NCc2nc3cc(ccc3n2C)C(=O)N(CCC(=O)OCC)c4ccccn4)/N 
1082 9.3 Chlorimuronethyl (90982-32-4) 50690 CCOC(=O)c1ccccc1S(=O)(=O)NC(=O)Nc2nc(cc(n2)Cl)OC 
1083 9.3 Linuron (330-55-2) 9130 CN(/C(=N\c1ccc(c(c1)Cl)Cl)/O)OC 
1084 9.3 Mexacarbate (315-18-4) 9043 Cc1cc(cc(c1N(C)C)C)OC(=O)NC 
1085 9.31 Clemastine (15686-51-8) 2679 CC(c1ccccc1)(c2ccc(cc2)Cl)OCCC3CCCN3C 
1086 9.32 Ethiprole (181587-01-9) 8106298 CCS(=O)C1=C(N(N=C1C#N)C2=C(C=C(C=C2Cl)C(F)(F)F)Cl)N 
1087 9.32 Ethoxysulfuron (126801-58-9) 2858750 CCOc1ccccc1OS(=O)(=O)NC(=O)Nc2nc(cc(n2)OC)OC 
1088 9.33 JWH-073-M-N-Butanoic acid (1307803-52-6) 26458429 c1ccc2c(c1)cccc2C(=O)c3cn(c4c3cccc4)CCCC(=O)O 
1089 9.34 Methiocarb (Mercaptodimethur) (2032-65-7) 15417 Cc1cc(cc(c1SC)C)O/C(=N/C)/O 
1090 9.34 Thioridazine (50-52-2) 5253 CN1CCCCC1CCN2c3ccccc3Sc4c2cc(cc4)SC 
1091 9.35 Deflazacort (14484-47-0) 24883 CC1=NC2(C(O1)CC3C2(CC(C4C3CCC5=CC(=O)C=CC45C)O)C)C(=O)COC(=O)C 
1092 9.36 Terbuthylazine (5915-41-3) 20848 CC/N=c/1\[nH]c(nc(n1)Cl)NC(C)(C)C 
1093 9.36 Propiverine (60569-19-9) 4773 CCCOC(c1ccccc1)(c2ccccc2)C(=O)OC3CCN(CC3)C 
1094 9.37 Nandrolone (434-22-0) 191235 CC12CCC3C(C1CCC2O)CCC4=CC(=O)CCC34 
1095 9.38 Propanil (709-98-8) 4764 CCC(=O)Nc1ccc(c(c1)Cl)Cl 
1096 9.39 Crotoxyphos (7700-17-6) 4522061 CC(c1ccccc1)OC(=O)/C=C(\C)/OP(=O)(OC)OC 
1097 9.4 Boscalid (188425-85-6) 184713 c1ccc(c(c1)c2ccc(cc2)Cl)/N=C(\c3cccnc3Cl)/O 
1098 9.41 Proadifen (302-33-0) 4741 CCCC(c1ccccc1)(c2ccccc2)C(=O)OCCN(CC)CC 
1099 9.42 Isoxaben (82558-50-7) 66323 CCC(C)(CC)c1cc(on1)NC(=O)c2c(cccc2OC)OC 
1100 9.44 Pyrimethanil (53112-28-0) 82753 Cc1cc(nc(n1)Nc2ccccc2)C 
1101 9.44 Pentifylline (1028-33-7) 63738 CCCCCCn1c(=O)c2c(ncn2C)n(c1=O)C 
1102 9.44 Irbesartan (138402-11-6) 3618 CCCCC1=NC2(CCCC2)C(=O)N1Cc3ccc(cc3)c4ccccc4c5n[nH]nn5 
1103 9.48 Fludioxonil (131341-86-1) 77916 c1cc(c2c(c1)OC(O2)(F)F)c3c[nH]cc3C#N 
1104 9.48 Benthiavalicarb-isopropyl (177406-68-7) (N/A) CC(C)C(C(=O)NC(C)C1=NC2=C(S1)C=C(C=C2)F)NC(=O)OC(C)C 
1105 9.49 Paclobutrazole (76738-62-0) 536024 CC(C)(C)C(C(Cc1ccc(cc1)Cl)n2cncn2)O 
1106 9.51 Promecarb (2631-37-0) 16563 Cc1cc(cc(c1)OC(=O)NC)C(C)C 
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1107 9.52 Flutolanil (66332-96-5) 43579 CC(C)Oc1cccc(c1)/N=C(/c2ccccc2C(F)(F)F)\O 
1108 9.53 Diazepam (439-14-5) 2908 CN1c2ccc(cc2C(=NCC1=O)c3ccccc3)Cl 
1109 9.55 Perphenazine (58-39-9) 4586 c1ccc2c(c1)N(c3cc(ccc3S2)Cl)CCCN4CCN(CC4)CCO 
1110 9.55 Chlorbromuron (13360-45-7) 24141 CN(C(=O)Nc1ccc(c(c1)Cl)Br)OC 
1111 9.55 WIN-48-098 (Pravadoline) (92623-83-1) 50942 Cc1c(c2ccccc2n1CCN3CCOCC3)C(=O)c4ccc(cc4)OC 
1112 9.56 Methoxyfenozide (161050-58-4) 94755 Cc1cc(cc(c1)C(=O)N(C(C)(C)C)/N=C(/c2cccc(c2C)OC)\O)C 
1113 9.56 JWH-073-M-4-OH-Butyl [1-(4-Hydroxybutyl)-1H-indol-
3-yl)(naphthalen-1-yl)methanone] 
(335161-14-3) 26458428 c1ccc2c(c1)cccc2C(=O)c3cn(c4c3cccc4)CCCCO 
1114 9.59 Malathion (121-75-5) 3864 CCOC(=O)CC(C(=O)OCC)SP(=S)(OC)OC 
1115 9.59 Niflumic acid (4394-00-7) 4333 c1cc(cc(c1)Nc2c(cccn2)C(=O)O)C(F)(F)F 
1116 9.59 Cyclovalone (579-23-7) 1266902 COc1c(ccc(c1)/C=C\2/C(=O)/C(=C/c3cc(c(cc3)O)OC)/CCC2)O 
1117 9.6 Bensultap (17606-31-4) 78640 CN(C)C(CSS(=O)(=O)c1ccccc1)CSS(=O)(=O)c2ccccc2 
1118 9.61 Proquazone (22760-18-5) 29222 Cc1ccc2c(c1)n(c(=O)nc2c3ccccc3)C(C)C 
1119 9.61 Isradipine (75695-93-1) 3652 CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)c2cccc3c2non3)C(=O)OC 
1120 9.61 Suxibuzone (27470-51-5) 5169 CCCCC1(C(=O)N(N(C1=O)c2ccccc2)c3ccccc3)COC(=O)CCC(=O)O 
1121 9.62 Mepronil (55814-41-0) 37994 Cc1ccccc1/C(=N/c2cccc(c2)OC(C)C)/O 
1122 9.62 Flurprimidol (56425-91-3) 66319 CC(C)C(c1ccc(cc1)OC(F)(F)F)(c2cncnc2)O 
1123 9.64 Dicamba-methyl (6597-78-0) 73143 COc1c(ccc(c1C(=O)OC)Cl)Cl 
1124 9.65 Acibenzolar-S-Methyl (135158-54-2) 77928 CSC(=O)c1cccc2c1snn2 
1125 9.68 SWEP /MCC [Methyl (3,4-dichlorophenyl)carbamate] (1918-18-9) 15173 COC(=O)Nc1ccc(c(c1)Cl)Cl 
1126 9.68 Triadimefon (43121-43-3) 36029 CC(C)(C)C(=O)C(n1cncn1)Oc2ccc(cc2)Cl 
1127 9.68 Daimuron (Dymron) (42609-52-9) 35899 Cc1ccc(cc1)NC(=O)NC(C)(C)c2ccccc2 
1128 9.69 Propyzamide (Pronamide) (23950-58-5) 29822 CC(C)(C#C)/N=C(/c1cc(cc(c1)Cl)Cl)\O 
1129 9.69 Terfenadine (50679-08-8) 5212 CC(C)(C)c1ccc(cc1)C(CCCN2CCC(CC2)C(c3ccccc3)(c4ccccc4)O)O 
1130 9.71 Aziprotryne (4658-28-0) 2297441 CC(C)Nc1nc(nc(n1)SC)N=[N+]=[N-] 
1131 9.71 JWH-018-N-Pentanoic acid (1254475-87-0) 26458423 c1ccc2c(c1)cccc2C(=O)c3cn(c4c3cccc4)CCCCC(=O)O 
1132 9.74 Barban  (endo)  (isomerA) (101-27-9) 7270 c1cc(cc(c1)Cl)NC(=O)OCC#CCCl 
1133 9.74 Anilazine (Dyrene) (101-05-3) 7260 c1ccc(c(c1)Nc2nc(nc(n2)Cl)Cl)Cl 
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1134 9.74 Myclobutanil (88671-89-0) 6096 CCCCC(Cn1cncn1)(C#N)c2ccc(cc2)Cl 
1135 9.74 Chlorophacinone (3691-35-8) 18286 c1ccc(cc1)C(c2ccc(cc2)Cl)C(=O)C3C(=O)c4ccccc4C3=O 
1136 9.77 Canrenone (976-71-6) 282625 CC12CCC(=O)C=C1C=CC3C2CCC4(C3CCC45CCC(=O)O5)C 
1137 9.78 Chlorpropham (101-21-3) 2627 CC(C)OC(=O)Nc1cccc(c1)Cl 
1138 9.79 Indinavir (150378-17-9) 3577 CC(C)(C)NC(=O)C1CN(CCN1CC(CC(Cc2ccccc2)C(=O)NC3c4ccccc4CC3O)O)Cc5cccnc5 
1139 9.79 Propetamphos (31218-83-4) 4939080 CCNP(=S)(OC)O/C(=C\C(=O)OC(C)C)/C 
1140 9.79 Ketazolam (27223-35-4) 31110 CC1=CC(=O)N2CC(=O)N(c3ccc(cc3C2(O1)c4ccccc4)Cl)C 
1141 9.79 Zuclopenthixol (53772-83-1) 4470984 c1ccc2c(c1)/C(=C/CCN3CCN(CC3)CCO)/c4cc(ccc4S2)Cl 
1142 9.79 Glibornuride (26944-48-9) 31034 Cc1ccc(cc1)S(=O)(=O)NC(=O)NC2C3CCC(C2O)(C3(C)C)C 
1143 9.79 Pyridaphenthion (119-12-0) 8078 CCOP(=S)(OCC)Oc1ccc(=O)n(n1)c2ccccc2 
1144 9.82 Nabumetone (42924-53-8) 4256 CC(=O)CCc1ccc2cc(ccc2c1)OC 
1145 9.82 Iprovalicarb Peak 1 & 2  (140923-17-7) 5290696 CC1=CC=C(C=C1)C(C)NC(=O)C(C(C)C)NC(=O)OC(C)C 
1146 9.83 Capsaicin (404-86-4) 1265957 CC(C)/C=C/CCCC/C(=N/Cc1ccc(c(c1)OC)O)/O 
1147 9.83 Mefenacet (73250-68-7) 82816 CN(c1ccccc1)C(=O)COc2nc3ccccc3s2 
1148 9.84 Flurochloridone (61213-25-0) 82780 c1cc(cc(c1)N2CC(C(C2=O)Cl)CCl)C(F)(F)F 
1149 9.85 Piprozolin (17243-64-0) 4744588 CCN1C(=CC(=O)OCC)SC(C1=O)N2CCCCC2 
1150 9.86 Dimethylvinphos (2274-67-1) 4938499 COP(=O)(OC)O/C(=C\Cl)/c1ccc(cc1Cl)Cl 
1151 9.86 Cinnarizine (298-57-7) 1299022 c1ccc(cc1)/C=C\CN2CCN(CC2)C(c3ccccc3)c4ccccc4 
1152 9.87 Isazophos (42509-80-8) 35885 CCOP(=S)(OCC)Oc1nc(n(n1)C(C)C)Cl 
1153 9.87 Bifenazate (149877-41-8) 154052 CC(C)OC(=O)NNc1cc(ccc1OC)c2ccccc2 
1154 9.88 JWH-200 [{1-[2-(4-Morpholinyl)ethyl]-1H-indol-3-yl}(1-
naphthyl)methanone] 
(103610-04-4) 8221134 C1COCCN1CCN2C=C(C3=CC=CC=C32)C(=O)C4=CC=CC5=CC=CC=C54 
1155 9.89 Molinate (2212-67-1) 15790 CCSC(=O)N1CCCCCC1 
1156 9.89 Butafenacil (134605-64-4) 10001509 CC(C)(C(=O)OCC=C)OC(=O)c1cc(ccc1Cl)n2c(=O)cc(n(c2=O)C)C(F)(F)F 
1157 9.89 Prochlorperazine (58-38-8) 4748 CN1CCN(CC1)CCCN2c3ccccc3Sc4c2cc(cc4)Cl 
1158 9.9 Acemetacin (53164-05-9) 1904 Cc1c(c2cc(ccc2n1C(=O)c3ccc(cc3)Cl)OC)CC(=O)OCC(=O)O 
1159 9.9 Triazophos (24017-47-8) 29847 CCOP(=S)(OCC)Oc1ncn(n1)c2ccccc2 
1160 9.91 JWH-073-M-3-OH-Butyl [1-(3-Hydroxybutyl)-1H-indol-
3-yl](1-naphthyl)methanone 
1320363-48-1  29341402 CC(CCn1cc(c2c1cccc2)C(=O)c3cccc4c3cccc4)O 
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1161 9.92 Fenitrothion (122-14-5) 28941 Cc1cc(ccc1[N+](=O)[O-])OP(=S)(OC)OC 
1162 9.93 Fluphenazine (69-23-8) 3255 c1ccc2c(c1)N(c3cc(ccc3S2)C(F)(F)F)CCCN4CCN(CC4)CCO 
1163 9.93 Chromafenozide (143807-66-3) 8332992 Cc1cc(cc(c1)C(=O)N(C(C)(C)C)NC(=O)c2ccc3c(c2C)CCCO3)C 
1164 9.93 Triadimenol I &2 (55219-65-3) 37749 CC(C)(C)C(C(n1cncn1)Oc2ccc(cc2)Cl)O 
1165 9.95 Nefazodone (83366-66-9) 4294 CCc1nn(c(=O)n1CCOc2ccccc2)CCCN3CCN(CC3)c4cccc(c4)Cl 
1166 9.95 Fluoxastrobin (361377-29-9) 9223963 CO/N=C(\C1=CC=CC=C1OC2=C(C(=NC=N2)OC3=CC=CC=C3Cl)F)/C4=NOCCO4 
1167 9.96 Atorvastatin (134523-00-5) 2163 CC(C)c1c(c(c(n1CCC(CC(CC(=O)O)O)O)c2ccc(cc2)F)c3ccccc3)C(=O)Nc4ccccc4 
1168 9.97 Clopenthixol Peaks 1 & 2  (982-24-1) 11945 c1ccc2c(c1)/C(=C\CCN3CCN(CC3)CCO)/c4cc(ccc4S2)Cl 
1169 9.98 Glibenclamide (10238-21-8) 3368 COc1ccc(cc1/C(=N\CCc2ccc(cc2)S(=O)(=O)N/C(=N\C3CCCCC3)/O)/O)Cl 
1170 9.98 Captafol (2425-06-1) 16139 C1C=CCC2C1C(=O)N(C2=O)SC(C(Cl)Cl)(Cl)Cl 
1171 9.99 Dicycloverine (77-19-0) 2934 CCN(CC)CCOC(=O)C1(CCCCC1)C2CCCCC2 
1172 9.99 Chloroxuron  (1982-47-4) 15299 CN(C)C(=O)Nc1ccc(cc1)Oc2ccc(cc2)Cl 
1173 10.01 Bromhexine (3572-43-8) 2348 CN(Cc1cc(cc(c1N)Br)Br)C2CCCCC2 
1174 10.02 Thiopropazate (84-06-0) 6504 CC(=O)OCCN1CCN(CC1)CCCN2c3ccccc3Sc4c2cc(cc4)Cl 
1175 10.02 Camazepam (36104-80-0) 34285 CN1c2ccc(cc2C(=NC(C1=O)OC(=O)N(C)C)c3ccccc3)Cl 
1176 10.02 Dichlofluanid (1085-98-9) 13520 CN(C)S(=O)(=O)N(c1ccccc1)SC(F)(Cl)Cl 
1177 10.04 JWH-018-M-N-5-OH-Pentyl (335161-21-2) 26458422 c1ccc2c(c1)cccc2C(=O)c3cn(c4c3cccc4)CCCCCO 
1178 10.05 Fenhexamid (126833-17-8) 184726 CC1(CCCCC1)C(=O)Nc2ccc(c(c2Cl)Cl)O 
1179 10.05 Fluquinconazole (136426-54-5) 77933 c1cc2c(cc1F)c(=O)n(c(n2)n3cncn3)c4ccc(cc4Cl)Cl 
1180 10.06 Diphenylamine (122-39-4) 11003 c1ccc(cc1)Nc2ccccc2 
1181 10.06 Flufenacet (142459-58-3) 77944 CC(C)N(c1ccc(cc1)F)C(=O)COc2nnc(s2)C(F)(F)F 
1182 10.06 Prometryn (7287-19-6) 4760 CC(C)/N=c\1/[nH]/c(=N\C(C)C)/nc([nH]1)SC 
1183 10.07 Thenylchlor (96491-05-3) 391337 Cc1cccc(c1N(Cc2c(ccs2)OC)C(=O)CCl)C 
1184 10.07 Penfluridol (26864-56-2) 31017 c1cc(ccc1C(CCCN2CCC(CC2)(c3ccc(c(c3)C(F)(F)F)Cl)O)c4ccc(cc4)F)F 
1185 10.08 JWH-018-M-N-4-OH-Pentyl (1320363-47-0) 29341417 CC(CCCn1cc(c2c1cccc2)C(=O)c3cccc4c3cccc4)O 
1186 10.09 Pethoxamid (106700-29-2) 4953376 CCOCCN(C(=O)CCl)C(=C(C)C)c1ccccc1 
1187 10.11 Ethoxyquin (91-53-2) 3177 CCOc1ccc2c(c1)C(=CC(N2)(C)C)C 
1188 10.12 Climbazole (38083-17-9) 34752 CC(C)(C)C(=O)C(n1ccnc1)Oc2ccc(cc2)Cl 
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1189 10.12 Fenson (as sodium adduct) (80-38-6) 6384 c1ccc(cc1)S(=O)(=O)Oc2ccc(cc2)Cl 
1190 10.13 Triticonazole (131983-72-7) 4941086 CC1(CC/C(=C/c2ccc(cc2)Cl)/C1(Cn3cncn3)O)C 
1191 10.13 Nortetrazepam (10379-11-0) 145774 c1cc2c(cc1Cl)C(=NCC(=O)N2)C3=CCCCC3 
1192 10.13 Fenarimol (60168-88-9) 39394 c1ccc(c(c1)C(c2ccc(cc2)Cl)(c3cncnc3)O)Cl 
1193 10.13 CGA 321113 (Trifloxystrobin Metabolite) (252913-85-2) (N/A) FC(F)(F)c1cccc(c1)C(\C)=N\OCc2ccccc2C(=N\OC)/C(=O)O 
1194 10.13 JWH-200-M-4-OH-Ind ({4-Hydroxy-1-[2-(4-
morpholinyl)ethyl]-1H-indol-3-yl}(1-
naphthyl)methanone) 
(1427325-73-2) 29341839 c1ccc2c(c1)cccc2C(=O)c3cn(c4c3c(ccc4)O)CCN5CCOCC5 
1195 10.14 Tetraconazole (112281-77-3) 72518 c1cc(c(cc1Cl)Cl)C(Cn2cncn2)COC(C(F)F)(F)F 
1196 10.14 Altretamine (645-05-6) 2038 CN(C)c1nc(nc(n1)N(C)C)N(C)C 
1197 10.15 Trietazine (1912-26-1) 15157 CCNc1nc(nc(n1)Cl)N(CC)CC 
1198 10.16 Mecarbam (2595-54-2) 16491 CCOC(=O)N(C)C(=O)CSP(=S)(OCC)OCC 
1199 10.16 Ethoprophos (13194-48-4) 3173 CCCSP(=O)(OCC)SCCC 
1200 10.17 Clotiazepam (33671-46-4) 2709 CCc1cc2c(s1)N(C(=O)CN=C2c3ccccc3Cl)C 
1201 10.17 Azinphos-ethyl (2642-71-9) 16576 CCOP(=S)(OCC)SCn1c(=O)c2ccccc2nn1 
1202 10.17 Etaconazole Peak 1 & 2 (60207-93-4) 82776 CCC1COC(O1)(Cn2cncn2)c3ccc(cc3Cl)Cl 
1203 10.18 Chlorthion (500-28-7) 9944 COP(=S)(OC)Oc1ccc(c(c1)Cl)[N+](=O)[O-] 
1204 10.18 Napropamide (15299-99-7) 25304 CCN(CC)C(=O)C(C)Oc1cccc2c1cccc2 
1205 10.18 Ditalimfos (5131-24-8) 19939 CCOP(=S)(N1C(=O)c2ccccc2C1=O)OCC 
1206 10.19 Flupentixol (2709-56-0) 4445173 c1ccc2c(c1)/C(=C/CCN3CCN(CC3)CCO)/c4cc(ccc4S2)C(F)(F)F 
1207 10.19 Mepanipyrim (110235-47-7) 77839 CC#Cc1cc(nc(n1)Nc2ccccc2)C 
1208 10.2 Iopodic acid (5587-89-3) 5051 CN(C)/C=N/c1c(cc(c(c1I)CCC(=O)O)I)I 
1209 10.2 Coumachlor (81-82-3) 10443016 CC(=O)CC(C1=CC=C(C=C1)Cl)C2=C(C3=CC=CC=C3OC2=O)O 
1210 10.22 Chlorfenprop-methyl (14437-17-3) 24868 COC(=O)C(Cc1ccc(cc1)Cl)Cl 
1211 10.22 Procymidone (32809-16-8) 33326 CC12CC1(C(=O)N(C2=O)c3cc(cc(c3)Cl)Cl)C 
1212 10.22 Medazepam (2898-12-6) 3901 CN1CCN=C(c2c1ccc(c2)Cl)c3ccccc3 
1213 10.23 Terbutryn (886-50-0) 12874 CC/N=c/1\nc([nH]c(n1)SC)NC(C)(C)C 
1214 10.23 Thiometon (640-15-3) 12024 CCSCCSP(=S)(OC)OC 
1215 10.23 Acetochlor (34256-82-1) 1911 CCc1cccc(c1N(COCC)C(=O)CCl)C 
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1216 10.24 Trifluoperazine (117-89-5) 5365 CN1CCN(CC1)CCCN2c3ccccc3Sc4c2cc(cc4)C(F)(F)F 
1217 10.25 Tebutame (35256-85-0) 83330 CC(C)N(Cc1ccccc1)C(=O)C(C)(C)C 
1218 10.26 Epoxiconazole (133855-98-8) 2564795 c1ccc(c(c1)C2C(O2)(Cn3cncn3)c4ccc(cc4)F)Cl 
1219 10.28 Diclofenac (15307-86-5) 2925 c1ccc(c(c1)CC(=O)O)Nc2c(cccc2Cl)Cl 
1220 10.29 Nilvadipine (75530-68-6) 4338 CC1=C(C(C(=C(N1)C#N)C(=O)OC)c2cccc(c2)[N+](=O)[O-])C(=O)OC(C)C 
1221 10.29 Indomethacin (53-86-1) 3584 Cc1c(c2cc(ccc2n1C(=O)c3ccc(cc3)Cl)OC)CC(=O)O 
1222 10.29 Metolachlor (51218-45-2) 4025 CCc1cccc(c1N(C(C)COC)C(=O)CCl)C 
1223 10.31 Telmisartan (144701-48-4) 59391 CCCc1nc2c(cc(cc2n1Cc3ccc(cc3)c4ccccc4C(=O)O)c5nc6ccccc6n5C)C 
1224 10.32 Cyazofamid (120116-88-3) 8037772 Cc1ccc(cc1)c2c(nc(n2S(=O)(=O)N(C)C)C#N)Cl 
1225 10.33 Alachlor (15972-60-8) 1994 CCc1cccc(c1N(COC)C(=O)CCl)CC 
1226 10.34 Drazoxolon (5707-69-7) 7844674 CC\1=NOC(=O)/C1=N\NC2=CC=CC=C2Cl 
1227 10.35 Oryzalin (19044-88-3) 27326 CCCN(CCC)c1c(cc(cc1[N+](=O)[O-])S(=O)(=O)N)[N+](=O)[O-] 
1228 10.36 Nateglinide (105816-04-4) 4290 CC(C)C1CCC(CC1)C(=O)NC(Cc2ccccc2)C(=O)O 
1229 10.37 17-alpha-Methyltestosterone (58-18-4) (N/A) CC12CCC(=O)C=C1CCC3C2CCC4(C3CCC4(C)O)C 
1230 10.37 Lonazolac (53808-88-1) 61957 c1ccc(cc1)n2cc(c(n2)c3ccc(cc3)Cl)CC(=O)O 
1231 10.38 Fentin (as the cation triphenylstannylium) (1+) (668-34-8) 82606 c1ccc(cc1)[Sn+](c2ccccc2)c3ccccc3 
1232 10.38 Fenbuconazole (114369-43-6) 77712 c1ccc(cc1)C(CCc2ccc(cc2)Cl)(Cn3cncn3)C#N 
1233 10.39 Fipronil-desulfinyl (205650-65-3) 11542895 c1c(cc(c(c1Cl)n2c(c(c(n2)C#N)C(F)(F)F)N)Cl)C(F)(F)F 
1234 10.41 Thiethylperazine (1420-55-9) 5245 CCSc1ccc2c(c1)N(c3ccccc3S2)CCCN4CCN(CC4)C 
1235 10.43 Diphenoxylate (915-30-0) 12919 CCOC(=O)C1(CCN(CC1)CCC(C#N)(c2ccccc2)c3ccccc3)c4ccccc4 
1236 10.44 Triclopyr-methylester (60825-26-5) 85360 COC(=O)COc1c(cc(c(n1)Cl)Cl)Cl 
1237 10.45 Fenamiphos (22224-92-6) 28827 CCOP(=O)(NC(C)C)Oc1ccc(c(c1)C)SC 
1238 10.45 Tebufenozide (112410-23-8) 82870 CCc1ccc(cc1)C(=O)NN(C(=O)c2cc(cc(c2)C)C)C(C)(C)C 
1239 10.46 Tetrazepam (10379-14-3) 23551 CN1c2ccc(cc2C(=NCC1=O)C3=CCCCC3)Cl 
1240 10.46 Uniconazole (83657-22-1) 4941231 CC(C)(C)C(/C(=C\c1ccc(cc1)Cl)/n2cncn2)O 
1241 10.46 Iprodione  (36734-19-7) 34418 CC(C)/N=C(/N1CC(=O)N(C1=O)c2cc(cc(c2)Cl)Cl)\O 
1242 10.46 AM-694 (1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole) (335161-03-0) 8064843 Ic1ccccc1C(=O)c3c2ccccc2n(c3)CCCCCF 
1243 10.47 Rotenone (83-79-4) 6500 CC(=C)C1Cc2c(ccc3c2OC4COc5cc(c(cc5C4C3=O)OC)OC)O1 
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1244 10.48 Prazepam (2955-38-6) 4721 c1ccc(cc1)C2=NCC(=O)N(c3c2cc(cc3)Cl)CC4CC4 
1245 10.48 Flusilazole (85509-19-9) 66326 C[Si](Cn1cncn1)(c2ccc(cc2)F)c3ccc(cc3)F 
1246 10.49 Toremifene (89778-26-7) 2275722 CN(C)CCOc1ccc(cc1)/C(=C(/CCCl)\c2ccccc2)/c3ccccc3 
1247 10.5 Fipronil (120068-37-3) 3235 c1c(cc(c(c1Cl)n2c(c(c(n2)C#N)S(=O)C(F)(F)F)N)Cl)C(F)(F)F 
1248 10.5 2-Amino-5-chlorobenzophenone (719-59-5) 12339 c1ccc(cc1)C(=O)c2cc(ccc2N)Cl 
1249 10.5 Dicapthon (American Cyanamid 4124) (2463-84-5) 16252 COP(=S)(OC)Oc1ccc(cc1Cl)[N+](=O)[O-] 
1250 10.51 Bupirimate (41483-43-6) 35588 CCCCc1c(nc(nc1OS(=O)(=O)N(C)C)NCC)C 
1251 10.51 Bensulide (741-58-2) 12397 CC(C)OP(=S)(OC(C)C)SCCNS(=O)(=O)c1ccccc1 
1252 10.51 Crufomate (299-86-5) 8941 CC(C)(C)c1ccc(c(c1)Cl)OP(=O)(NC)OC 
1253 10.56 JWH-073-M-6-OH-Ind   [(1-butyl-6-hydroxy-1H-indol-3-
yl)(naphthalen-1-yl)-methanone)] 
(1307803-48-0) 26458426 CCCCn1cc(c2c1cc(cc2)O)C(=O)c3cccc4c3cccc4  
1254 10.58 Diflubenzuron (35367-38-5) 34065 c1cc(c(c(c1)F)C(=O)NC(=O)Nc2ccc(cc2)Cl)F 
1255 10.59 Tetrachlorvinphos (Stirofos) (22248-79-9) 4447527 COP(=O)(OC)O/C(=C\Cl)/c1cc(c(cc1Cl)Cl)Cl 
1256 10.59 Iprobenfos (26087-47-8) 30753 CC(C)OP(=O)(OC(C)C)SCc1ccccc1 
1257 10.59 Fenoxycarb (79127-80-3) 46739 CCO/C(=N\CCOc1ccc(cc1)Oc2ccccc2)/O 
1258 10.62 Nisoldipine (63675-72-9) 4343 CC1=C(C(C(=C(N1)C)C(=O)OCC(C)C)c2ccccc2[N+](=O)[O-])C(=O)OC 
1259 10.63 Pentanochlor (2307-68-8) 15945 CCCC(C)C(=O)Nc1ccc(c(c1)Cl)C 
1260 10.64 Vinclozolin (as Na adduct) (50471-44-8) 36278 CC1(C(=O)N(C(=O)O1)c2cc(cc(c2)Cl)Cl)C=C 
1261 10.64 Beflubutamid (113614-08-7) 4953638 CCC(C(=O)NCc1ccccc1)Oc2ccc(c(c2)C(F)(F)F)F 
1262 10.64 JWH-122-M-N-5-OH-Pentyl (1379604-68-8) 29341442 Cc1ccc(c2c1cccc2)C(=O)c3cn(c4c3cccc4)CCCCCO 
1263 10.66 Dimoxystrobin (149961-52-4) 9111528 CC1=CC(=C(C=C1)C)OCC2=CC=CC=C2/C(=N\OC)/C(=O)NC 
1264 10.67 Clodinafop-propargyl (105512-06-9) 5291880 CC(C(=O)OCC#C)OC1=CC=C(C=C1)OC2=C(C=C(C=N2)Cl)F 
1265 10.67 EPTC (S-Ethyl dipropylthiocarbamate) (759-94-4) 12428 CCCN(CCC)C(=O)SCC 
1266 10.67 Neburon (555-37-3) 10672 CCCCN(C)C(=O)Nc1ccc(c(c1)Cl)Cl 
1267 10.68 Ibuprofen (15687-27-1) 3544 CC(C)Cc1ccc(cc1)C(C)C(=O)O 
1268 10.68 Isoxadifen-ethyl (163520-33-0) 4953634 CCOC(=O)C1=NOC(C1)(c2ccccc2)c3ccccc3 
1269 10.68 Phenthoate (2597-03-7) 16492 CCOC(=O)C(c1ccccc1)SP(=S)(OC)OC 
1270 10.69 Glimepiride (93479-97-1) 3357 CCC1=C(CN(C1=O)C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)NC3CCC(CC3)C)C 
 
continued 
469 
 
 
 
 
 
 
 
 
1271 10.69 Carfentrazone-ethyl (128639-02-1) 77773 CCOC(=O)C(Cc1cc(c(cc1Cl)F)n2c(=O)n(c(n2)C)C(F)F)Cl 
1272 10.7 Fenpropimorph (67564-91-4) 82798 CC1CN(CC(O1)C)CC(C)Cc2ccc(cc2)C(C)(C)C 
1273 10.71 Parathion (56-38-2) 13844817 CCOP(=S)(OCC)Oc1ccc(cc1)[N+](=O)[O-] 
1274 10.71 Diclobutrazol (main peak) (75736-33-3) 48148 CC(C)(C)C(C(Cc1ccc(cc1Cl)Cl)n2cncn2)O 
1275 10.72 Thiazopyr (117718-60-2) 82873 CC(C)Cc1c(c(nc(c1C(=O)OC)C(F)F)C(F)(F)F)C2=NCCS2 
1276 10.73 Fenothiocarb (62850-32-2) 40198 CN(C)C(=O)SCCCCOc1ccccc1 
1277 10.74 Croconazole (77175-51-0) 2777 C=C(c1ccccc1OCc2cccc(c2)Cl)n3ccnc3 
1278 10.75 Fipronil-sulfide (120067-83-6) 8129550 c1c(cc(c(c1Cl)n2c(c(c(n2)C#N)SC(F)(F)F)N)Cl)C(F)(F)F 
1279 10.76 Kresoxim-methyl (143390-89-0) 4813314 Cc1ccccc1OCc2ccccc2/C(=N\OC)/C(=O)OC 
1280 10.76 Alanycarb (83130-01-2) 7850539 CCOC(=O)CCN(CC1=CC=CC=C1)SN(C)C(=O)O/N=C(/C)\SC 
1281 10.77 Sulfotepp (3689-24-5) 18280 CCOP(=S)(OCC)OP(=S)(OCC)OCC 
1282 10.78 Tolyfluanid (731-27-1) 12364 Cc1ccc(cc1)N(SC(F)(Cl)Cl)S(=O)(=O)N(C)C 
1283 10.78 Flufenzine (Diflovidazin) (162320-67-4) 135715 c1ccc(c(c1)c2nnc(nn2)c3c(cccc3F)F)Cl 
1284 10.79 Propaphos (7292-16-2) 22177 CCCOP(=O)(OCCC)Oc1ccc(cc1)SC 
1285 10.8 Edifenphos (17109-49-8) 26320 CCOP(=O)(Sc1ccccc1)Sc2ccccc2 
1286 10.8 Quinalphos (13593-03-8) 24335 CCOP(=S)(OCC)Oc1cnc2ccccc2n1 
1287 10.83 Penconazole (66246-88-6) 82796 CCCC(Cn1cncn1)c2ccc(cc2Cl)Cl 
1288 10.83 Chlorbenzoxamine (522-18-9) 64700 Cc1ccccc1CN2CCN(CC2)CCOC(c3ccccc3)c4ccccc4Cl 
1289 10.84 Flamprop-isopropyl (52756-22-6) 37022 CC(C)OC(=O)C(C)N(c1ccc(c(c1)Cl)F)C(=O)c2ccccc2 
1290 10.84 Anilofos (64249-01-0) 82790 CC(C)N(c1ccc(cc1)Cl)C(=O)CSP(=S)(OC)OC 
1291 10.85 Halcinonide (3093-35-4) 3432 CC1(OC2CC3C4CCC5=CC(=O)CCC5(C4(C(CC3(C2(O1)C(=O)CCl)C)O)F)C)C 
1292 10.85 Norethisterone acetate (51-98-9) 471291 CC(=O)OC1(CCC2C1(CCC3C2CCC4=CC(=O)CCC34)C)C#C 
1293 10.86 Aclonifen (74070-46-5) 83411 c1ccc(cc1)Oc2ccc(c(c2Cl)N)[N+](=O)[O-] 
1294 10.87 Tebuconazole (107534-96-3) 77680 CC(C)(C)C(CCc1ccc(cc1)Cl)(Cn2cncn2)O 
1295 10.87 Penfluron (35367-31-8) 96832 c1cc(c(c(c1)F)C(=O)NC(=O)Nc2ccc(cc2)C(F)(F)F)F 
1296 10.88 Cyanofenphos (13067-93-1) 23911 CCOP(=S)(c1ccccc1)Oc2ccc(cc2)C#N 
1297 10.88 Ebastine (90729-43-4) 3079 CC(C)(C)c1ccc(cc1)C(=O)CCCN2CCC(CC2)OC(c3ccccc3)c4ccccc4 
1298 10.89 Benalaxyl (71626-11-4) 46525 Cc1cccc(c1N(C(C)C(=O)OC)C(=O)Cc2ccccc2)C 
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1299 10.89 Oxetacaine (126-27-2) 4460 CC(C)(Cc1ccccc1)N(C)C(=O)CN(CCO)CC(=O)N(C)C(C)(C)Cc2ccccc2 
1300 10.9 Pyraflufen-ethyl (129630-19-9) 159109 CCOC(=O)COc1cc(c(cc1Cl)F)c2c(c(n(n2)C)OC(F)F)Cl 
1301 10.91 Pyrazoxyfen (71561-11-0) 83405 Cc1c(c(n(n1)C)OCC(=O)c2ccccc2)C(=O)c3ccc(cc3Cl)Cl 
1302 10.93 WIN-55-212-2 (131543-22-1) 5487 Cc1c(c2cccc3c2n1C(CO3)CN4CCOCC4)C(=O)c5cccc6c5cccc6 
1303 10.94 Fluvastatin (93957-54-1) 4510159 CC(C)n1c2ccccc2c(c1/C=C/C(CC(CC(=O)O)O)O)c3ccc(cc3)F 
1304 10.96 Etrimfos (38260-54-7) 34830 CCc1nc(cc(n1)OP(=S)(OC)OC)OCC 
1305 10.97 Terbinafine (91161-71-6) 1266005 CC(C)(C)C#C/C=C/CN(C)Cc1cccc2c1cccc2 
1306 10.98 Propiconazole Peak 1 & 2 (60207-90-1) 39402 CCCC1COC(O1)(Cn2cncn2)c3ccc(cc3Cl)Cl 
1307 10.99 Benzoylprop-ethyl (22212-55-1) 28825 CCOC(=O)C(C)N(c1ccc(c(c1)Cl)Cl)C(=O)c2ccccc2 
1308 11.01 Fipronilsulfone (120068-36-2) 2336427 c1c(cc(c(c1Cl)n2c(c(c(n2)C#N)S(=O)(=O)C(F)(F)F)N)Cl)C(F)(F)F 
1309 11.01 Felodipine (72509-76-3) 3216 CCOC(=O)C1=C(NC(=C(C1c2cccc(c2Cl)Cl)C(=O)OC)C)C 
1310 11.01 Triphenylphosphate (115-86-6) 7988 c1ccc(cc1)OP(=O)(Oc2ccccc2)Oc3ccccc3 
1311 11.02 Fenthion (55-38-9) 3229 Cc1cc(ccc1SC)OP(=S)(OC)OC 
1312 11.02 Coumaphos (56-72-4) 2768 CCOP(=S)(OCC)Oc1ccc2c(c(c(=O)oc2c1)Cl)C 
1313 11.02 Tamoxifen (10540-29-1) 2015313 CC/C(=C(\c1ccccc1)/c2ccc(cc2)OCCN(C)C)/c3ccccc3 
1314 11.03 Famoxadone (131807-57-3) 184727 CC1(C(=O)N(C(=O)O1)Nc2ccccc2)c3ccc(cc3)Oc4ccccc4 
1315 11.04 Diazinon (333-41-5) 2909 CCOP(=S)(OCC)Oc1cc(nc(n1)C(C)C)C 
1316 11.04 Cyprodinil (121552-61-2) 77885 Cc1cc(nc(n1)Nc2ccccc2)C3CC3 
1317 11.05 Lercanidipine (100427-26-7) 59276 CC1=C(C(C(=C(N1)C)C(=O)OC(C)(C)CN(C)CCC(c2ccccc2)c3ccccc3)c4cccc(c4)[N+](=O)[O-
])C(=O)OC 
1318 11.05 Vegadex (Sulfallate) (95-06-7) 6946 CCN(CC)C(=S)SCC(=C)Cl 
1319 11.07 Pyranocoumarin (518-20-7) 10161 CC1(CC(c2c(c3ccccc3oc2=O)O1)c4ccccc4)OC 
1320 11.08 Zoxamide (156052-68-5) 108892 CCC(C)(C(=O)CCl)NC(=O)c1cc(c(c(c1)Cl)C)Cl 
1321 11.1 Chlorfenson (80-33-1) 6383 c1cc(ccc1OS(=O)(=O)c2ccc(cc2)Cl)Cl 
1322 11.1 Mefenpyr-diethyl (135590-91-9) 9112846 CCOC(=O)C1=NN(C(C1)(C)C(=O)OCC)C2=C(C=C(C=C2)Cl)Cl 
1323 11.11 Endosulfan-sulfate (Na) (1031-07-8) 13338 C1C2C(COS(=O)(=O)O1)C3(C(=C(C2(C3(Cl)Cl)Cl)Cl)Cl)Cl 
1324 11.15 Oxadiargyl (39807-15-3) 85276 CC(C)(C)c1nn(c(=O)o1)c2cc(c(cc2Cl)Cl)OCC#C 
1325 11.16 Pyraclostrobin (175013-18-0) 4928348 COC(=O)N(c1ccccc1COc2ccn(n2)c3ccc(cc3)Cl)OC 
1326 11.18 JWH-018-M-6-OH-Ind (1307803-44-6) 26458420 CCCCCn1cc(c2c1cc(cc2)O)C(=O)c3cccc4c3cccc4 
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1327 11.19 Hexaconazole (79983-71-4) 59833 CCCCC(Cn1cncn1)(c2ccc(cc2Cl)Cl)O 
1328 11.19 Prothioconazole (178928-70-6) 4953623 c1ccc(c(c1)CC(Cn2c(=S)nc[nH]2)(C3(CC3)Cl)O)Cl 
1329 11.21 Phoxim (14816-18-3) 25076 CCOP(=S)(OCC)ON=C(C#N)c1ccccc1 
1330 11.21 Metconazole (125116-23-6) 77764 CC1(CCC(C1(Cn2cncn2)O)Cc3ccc(cc3)Cl)C 
1331 11.21 Endosulfan I / II (115-29-7) 3111 C1C2C(COS(=O)O1)C3(C(=C(C2(C3(Cl)Cl)Cl)Cl)Cl)Cl 
1332 11.21 JWH-073-M-7-OH-Ind [(1-Butyl-7-hydroxy-1H-indol-3-
yl)(1-naphthyl)methanone] 
(1307803-49-1) 26458427 CCCCn1cc(c2c1c(ccc2)O)C(=O)c3cccc4c3cccc4 
1333 11.22 Progesterone (57-83-0) 4751 CC(=O)C1CCC2C1(CCC3C2CCC4=CC(=O)CCC34C)C 
1334 11.22 Butamifos (36335-67-8) 34329 CCC(C)NP(=S)(OCC)Oc1cc(ccc1[N+](=O)[O-])C 
1335 11.22 Benzododecinium (Ion1+) 10328-35-5 8424 CCCCCCCCCCCC[N+](C)(C)Cc1ccccc1 
1336 11.22 Dodine [Dodecylguanidine] (Ion1+) 112-65-2 7912 CCCCCCCCCCCCNC(=N)N 
1337 11.23 Isofenphos (25311-71-1) 30459 CCOP(=S)(NC(C)C)Oc1ccccc1C(=O)OC(C)C 
1338 11.23 Triflumuron (64628-44-0) 43172 c1ccc(c(c1)C(=O)NC(=O)Nc2ccc(cc2)OC(F)(F)F)Cl 
1339 11.23 AM-2201 (335161-24-5) 24751884 c1ccc2c(c1)cccc2C(=O)c3cn(c4c3cccc4)CCCCCF 
1340 11.23 RCS-4-ortho [(2-Methoxyphenyl)(1-pentyl-1H-indol-3-
yl)methanone] 
(1345966-76-8) 29341490 CCCCCn1cc(c2c1cccc2)C(=O)c3ccccc3OC 
1341 11.25 Prochloraz (67747-09-5) 159925 CC(C)N(CCOc1c(cc(cc1Cl)Cl)Cl)C(=O)n2ccnc2 
1342 11.26 Isoxathion (18854-01-8) 27255 CCOP(=S)(OCC)Oc1cc(on1)c2ccccc2 
1343 11.26 JWH-018-M-5-OH-Ind [(5-Hydroxy-1-pentyl-1H-indol-3-
yl)(1-naphthyl)methanone] 
(1307803-43-5) 26458419 CCCCCn1cc(c2c1ccc(c2)O)C(=O)c3cccc4c3cccc4 
1344 11.27 Meclofenamic acid (644-62-2) 3897 Cc1ccc(c(c1Cl)Nc2ccccc2C(=O)O)Cl 
1345 11.27 Phosalone (2310-17-0) 4629 CCOP(=S)(OCC)SCn1c2ccc(cc2oc1=O)Cl 
1346 11.27 Benzoxonium (Ion1+) (23884-64-2) 27484 CCCCCCCCCCCC[N+](CCO)(CCO)Cc1ccccc1 
1347 11.27 Bitertanol (55179-31-2) 82759 CC(C)(C)C(C(n1cncn1)Oc2ccc(cc2)c3ccccc3)O 
1348 11.27 Butoxycaine (3772-43-8) 15997 CCCCOc1ccc(cc1)C(=O)OCCN(CC)CC 
1349 11.29 Benzoximate (29104-30-1) 496542 CCO/N=C(\c1c(ccc(c1OC)Cl)OC)/OC(=O)c2ccccc2 
1350 11.29 JWH-073-M-5-OH-Ind (1307803-47-9) 26458425 CCCCn1cc(c2c1ccc(c2)O)C(=O)c3cccc4c3cccc4 
1351 11.31 Meclozine (569-65-3) 3894 Cc1cccc(c1)CN2CCN(CC2)C(c3ccccc3)c4ccc(cc4)Cl 
1352 11.33 Clobetasone butyrate (25122-57-0) 2690 CCCC(=O)OC1(C(CC2C1(CC(=O)C3(C2CCC4=CC(=O)C=CC43C)F)C)C)C(=O)CCl 
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1353 11.34 Spinosad A (Spinosyn A) (168316-95-8) 3685331 CCC1CCCC(C(C(=O)C2=CC3C4CC(CC4C=CC3C2CC(=O)O1)OC5C(C(C(C(O5)C)OC)OC)O
C)C)OC6CCC(C(O6)C)N(C)C 
1354 11.34 Orbencarb (34622-58-7) 33829 CCN(CC)C(=O)SCc1ccccc1Cl 
1355 11.35 Pirimiphos-methyl (29232-93-7) 31773 CCN(CC)c1nc(cc(n1)OP(=S)(OC)OC)C 
1356 11.37 Phorate (298-02-2) 4626 CCOP(=S)(OCC)SCSCC 
1357 11.38 Pencycuron (66063-05-6) 82795 c1ccc(cc1)NC(=O)N(Cc2ccc(cc2)Cl)C3CCCC3 
1358 11.4 Pyrazophos (13457-18-6) 24247 CCOC(=O)c1cn2c(cc(n2)OP(=S)(OCC)OCC)nc1C 
1359 11.41 Metrafenone (220899-03-6) 4953549 Cc1cc(c(c(c1C(=O)c2c(c(ccc2OC)Br)C)OC)OC)OC 
1360 11.42 Tolclofos-methyl (57018-04-9) 82767 Cc1cc(c(c(c1)Cl)OP(=S)(OC)OC)Cl 
1361 11.44 Thiobencarb (28249-77-6) 31512 CCN(CC)C(=O)SCc1ccc(cc1)Cl 
1362 11.48 Vernolate (1929-77-7) 15204 CCCN(CCC)C(=O)SCCC 
1363 11.49 Cadusafos (95465-99-9) 82850 CCC(C)SP(=O)(OCC)SC(C)CC 
1364 11.49 Fluacrypyrim (229977-93-9) 8129795 CC(C)OC1=NC(=CC(=N1)OCC2=CC=CC=C2/C(=C\OC)/C(=O)OC)C(F)(F)F 
1365 11.49 Loratadine (79794-75-5) 3820 CCOC(=O)N1CCC(=C2c3ccc(cc3CCc4c2nccc4)Cl)CC1 
1366 11.49 Bifenox (42576-02-3) 35891 COC(=O)c1cc(ccc1[N+](=O)[O-])Oc2ccc(cc2Cl)Cl 
1367 11.51 Pebulate (1114-71-2) 13579 CCCCN(CC)C(=O)SCCC 
1368 11.51 Diniconazole (83657-24-3) 4941232 CC(C)(C)C(/C(=C\c1ccc(cc1Cl)Cl)/n2cncn2)O 
1369 11.51 Clofentezine (74115-24-5) 66321 c1ccc(c(c1)c2nnc(nn2)c3ccccc3Cl)Cl 
1370 11.51 JWH-015 (155471-08-2) 3480676 CCCn1c(c(c2c1cccc2)C(=O)c3cccc4c3cccc4)C 
1371 11.52 Disulfoton (298-04-4) 3006 CCOP(=S)(OCC)SCCSCC 
1372 11.52 Bromadiolone (28772-56-7) 10606098 C1=CC=C(C=C1)C(CC(C2=CC=C(C=C2)C3=CC=C(C=C3)Br)O)C4=C(C5=CC=CC=C5OC4=
O)O 
1373 11.53 Dialifos (10311-84-9) 23490 CCOP(=S)(OCC)SC(CCl)N1C(=O)c2ccccc2C1=O 
1374 11.55 Pyrethrins: Cinerin II (121-20-0) 4520910 C/C=C/CC1=C(C(CC1=O)OC(=O)C2C(C2(C)C)/C=C(\C)/C(=O)OC)C 
1375 11.55 Indoxacarb (173584-44-6) 8112367 COC(=O)C12CC3=C(C1=NN(CO2)C(=O)N(C4=CC=C(C=C4)OC(F)(F)F)C(=O)OC)C=CC(=C
3)Cl 
1376 11.55 Chlorthal-dimethyl (as the NH4 adduct) (1861-32-1) 2839 COC(=O)c1c(c(c(c(c1Cl)Cl)C(=O)OC)Cl)Cl 
1377 11.58 JWH-201 [2-(4-Methoxyphenyl)-1-(1-pentyl-1H-indol-3-
yl)ethanone] 
(864445-47-6) 23256220 CCCCCn1cc(c2c1cccc2)C(=O)Cc3ccc(cc3)OC 
1378 11.6 Cerivastatin (145599-86-6) 2575 CC(C)c1c(c(c(c(n1)C(C)C)C=CC(CC(CC(=O)O)O)O)c2ccc(cc2)F)COC 
1379 11.6 Metaclazepam (65517-27-3) 64398 CN1c2ccc(cc2C(=NCC1COC)c3ccccc3Cl)Br 
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1380 11.55 Mefenamic acid (61-68-7) 3904 Cc1cccc(c1C)Nc2ccccc2C(=O)O 
1381 11.6 Benzethonium (Ion1+) (10172-60-8) 2245 CC(C)(C)CC(C)(C)c1ccc(cc1)OCCOCC[N+](C)(C)Cc2ccccc2 
1382 11.6 Trifloxystrobin (141517-21-7) 9839700 C/C(=N\OCc1ccccc1/C(=N\OC)/C(=O)OC)/c2cccc(c2)C(F)(F)F 
1383 11.64 Denaverine (3579-62-2) 64278 CCC(CC)COC(c1ccccc1)(c2ccccc2)C(=O)OCCN(C)C 
1384 11.64 JWH-302 [2-(3-Methoxyphenyl)-1-(1-pentyl-1H-indol-3-
yl)ethanone] 
(864445-45-4) 9668546 CCCCCN1C=C(C2=CC=CC=C21)C(=O)CC3=CC(=CC=C3)OC 
1385 11.65 Cycloate (1134-23-2) 13698 CCN(C1CCCCC1)C(=O)SCC 
1386 11.65 Isofenphos-methyl (99675-03-3) 113043 CC(C)NP(=S)(OC)Oc1ccccc1C(=O)OC(C)C 
1387 11.68 Pyrethrin II (121-29-9) 4522309 CC1=C(C(=O)CC1OC(=O)C2C(C2(C)C)/C=C(\C)/C(=O)OC)C/C=C/C=C 
1388 11.7 Chlorpyriphos-methyl (5598-13-0) 20493 COP(=S)(OC)Oc1c(cc(c(n1)Cl)Cl)Cl 
1389 11.7 EPN [O-Ethyl O-(4-nitrophenyl) phenylphosphonothioate] (2104-64-5) 15571 CCOP(=S)(c1ccccc1)Oc2ccc(cc2)[N+](=O)[O-] 
1390 11.71 Fluoroglycofen-ethyl (77501-90-7) 48457 CCOC(=O)COC(=O)c1cc(ccc1[N+](=O)[O-])Oc2ccc(cc2Cl)C(F)(F)F 
1391 11.72 Diflufenican (83164-33-4) 82834 c1cc(cc(c1)Oc2c(cccn2)C(=O)Nc3ccc(cc3F)F)C(F)(F)F 
1392 11.74 Dithiopyr (97886-45-8) 82855 CC(C)Cc1c(c(nc(c1C(=O)SC)C(F)(F)F)C(F)F)C(=O)SC 
1393 11.74 JWH-122-F-Pentyl [[1-(5-Fluoropentyl)-1H-indol-3-yl](4-
methyl-1-naphthyl)methanone] 
(1354631-24-5) 28289977 Cc1ccc(c2c1cccc2)C(=O)c3cn(c4c3cccc4)CCCCCF 
1394 11.76 Hexaflumuron (86479-06-3) 82839 c1cc(c(c(c1)F)C(=O)NC(=O)Nc2cc(c(c(c2)Cl)OC(C(F)F)(F)F)Cl)F 
1395 11.78 Clopidogrel (113665-84-2) 2704 COC(=O)C(c1ccccc1Cl)N2CCc3c(ccs3)C2 
1396 11.78 Pretilachlor (51218-49-6) 82747 CCCOCCN(c1c(cccc1CC)CC)C(=O)CCl 
1397 11.78 JWH-018-M-7-OH-Ind (1307803-45-7) 26458421 CCCCCn1cc(c2c1c(ccc2)O)C(=O)c3cccc4c3cccc4 
1398 11.8 RCS-4 [(4-Methoxyphenyl)(1-pentyl-1H-indol-3-
yl)methanone] 
(1345966-78-0) 24769418 CCCCCn1cc(c2c1cccc2)C(=O)c3ccc(cc3)OC 
1399 11.81 Diallate (2303-16-4) 4447452 CC(C)N(C(C)C)C(=O)SC/C(=C/Cl)/Cl 
1400 11.82 Chlorfenapyr (as the Na adduct) (122453-73-0) 82875 CCOCn1c(c(c(c1C(F)(F)F)Br)C#N)c2ccc(cc2)Cl 
1401 11.83 Triflumizole (68694-11-1) 82801 CCCOC/C(=N\c1ccc(cc1C(F)(F)F)Cl)/n2ccnc2 
1402 11.83 JWH-250 (864445-43-2) 23256117 CCCCCn1cc(c2c1cccc2)C(=O)Cc3ccccc3OC 
1403 11.84 Spinosad D (131929-63-0) 3685333 CCC1CCCC(C(C(=O)C2=CC3C4CC(CC4C(=CC3C2CC(=O)O1)C)OC5C(C(C(C(O5)C)OC)OC
)OC)C)OC6CCC(C(O6)C)N(C)C 
1404 11.84 Dinobuton (as the Na adduct) (973-21-7) 13186 CCC(C)c1cc(cc(c1OC(=O)OC(C)C)[N+](=O)[O-])[N+](=O)[O-] 
1405 11.85 Dicofol Fragm 251 (115-32-2) 7970 c1cc(ccc1C(c2ccc(cc2)Cl)(C(Cl)(Cl)Cl)O)Cl 
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1406 11.87 p,p-Dichlorobenzophenone (90-98-2) 6767 c1cc(ccc1C(=O)c2ccc(cc2)Cl)Cl 
1407 11.88 JWH-073 [(1-Butyl-1H-indol-3-yl)(1-
naphthyl)methanone] 
(208987-48-8) 8647081 CCCCN1C=C(C2=CC=CC=C21)C(=O)C3=CC=CC4=CC=CC=C43 
1408 11.9 Novaluron (116714-46-6) 84442 c1cc(c(c(c1)F)C(=O)NC(=O)Nc2ccc(c(c2)Cl)OC(C(OC(F)(F)F)F)(F)F)F 
1409 11.92 Prosulfocarb (52888-80-9) 55867 CCCN(CCC)C(=O)SCc1ccccc1 
1410 11.92 Benfuracarb (82560-54-1) 49560 CCOC(=O)CCN(C(C)C)SN(C)C(=O)Oc1cccc2c1OC(C2)(C)C 
1411 11.95 Repaglinide (135062-02-1) 4388 CCOc1cc(ccc1C(=O)O)CC(=O)NC(CC(C)C)c2ccccc2N3CCCCC3 
1412 11.96 Butylate (2008-41-5) 15357 CCSC(=O)N(CC(C)C)CC(C)C 
1413 11.96 Triclocarban (101-20-2) 7266 c1cc(ccc1N/C(=N/c2ccc(c(c2)Cl)Cl)/O)Cl 
1414 11.96 JWH-073-M-4-OH-Ind (1307803-46-8) 26458424 CCCCn1cc(c2c1cccc2O)C(=O)c3cccc4c3cccc4 
1415 11.98 CP-55940 (83002-04-4) 3612960 CCCCCCC(C)(C)c1ccc(c(c1)O)C2CC(CCC2CCCO)O 
1416 11.98 Tritoqualine (14504-73-5) 65119 CCOc1c2c(c(c(c1OCC)OCC)N)C(=O)OC2C3c4c(cc5c(c4OC)OCO5)CCN3C 
1417 12.01 Emamectin B1b (121424-52-0) 8299197 O=C4OC7CC/1(OC(C(C)C)C(\C=C\1)C)OC(C/C=C(/C(OC3OC(C(OC2OC(C)C(NC)C(OC)C2)
C(OC)C3)C)C(\C=C\C=C5\C6(O)C4/C=C(/C)C(O)C6OC5)C)C)C7 
1418 12.02 Nitrothal-isopropyl (10552-74-6) 39827 CC(C)OC(=O)c1cc(cc(c1)[N+](=O)[O-])C(=O)OC(C)C 
1419 12.03 Lovastatin (74133-25-8) 3825 CCC(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC3CC(CC(=O)O3)O)C 
1420 12.03 Profenophos (41198-08-7) 35529 CCCSP(=O)(OCC)Oc1ccc(cc1Cl)Br 
1421 12.06 Nitrofen (as NH4 adduct) (1836-75-5) 15010 c1cc(ccc1[N+](=O)[O-])Oc2ccc(cc2Cl)Cl 
1422 12.09 Furathiocarb (65907-30-4) 43456 CCCCOC(=O)N(C)SN(C)C(=O)Oc1cccc2c1OC(C2)(C)C 
1423 12.1 Amiodarone (1951-25-3) 2072 CCCCc1c(c2ccccc2o1)C(=O)c3cc(c(c(c3)I)OCCN(CC)CC)I 
1424 12.11 Dioxathion (78-34-2) 6283 CCOP(=S)(OCC)SC1C(OCCO1)SP(=S)(OCC)OCC 
1425 12.11 Oxyfluorfen (42874-03-3) 35974 CCOc1cc(ccc1[N+](=O)[O-])Oc2ccc(cc2Cl)C(F)(F)F 
1426 12.15 Haloxyfop ethoxyethyl ester (87237-48-7) 82841 CCOCCOC(=O)C(C)Oc1ccc(cc1)Oc2c(cc(cn2)C(F)(F)F)Cl 
1427 12.15 Lactofen (77501-63-4) 56077 CCOC(=O)C(C)OC(=O)c1cc(ccc1[N+](=O)[O-])Oc2ccc(cc2Cl)C(F)(F)F 
1428 12.15 JWH-251 [2-(2-Methylphenyl)-1-(1-pentyl-1H-indol-3-
yl)ethanone] 
(864445-39-6) 9791472 CCCCCN1C=C(C2=CC=CC=C21)C(=O)CC3=CC=CC=C3C 
1429 12.16 Pyrethrins: Jasmolin II (1172-63-0) 4520896 CC/C=C/CC1=C(C(CC1=O)OC(=O)C2C(C2(C)C)/C=C(\C)/C(=O)OC)C 
1430 12.18 JWH-203 (2-(2-Chlorophenyl)-1-(1-pentyl-1H-indol-3-
yl)ethanone ) 
(864445-54-5) 23256082 CCCCCn1cc(c2c1cccc2)C(=O)Cc3ccccc3Cl 
1431 12.19 Tebufenpyrad (119168-77-3) 77872 CCc1c(c(n(n1)C)C(=O)NCc2ccc(cc2)C(C)(C)C)Cl 
1432 12.2 Tetradifon (as Na adduct) (116-29-0) 8004 c1cc(ccc1S(=O)(=O)c2cc(c(cc2Cl)Cl)Cl)Cl 
continued 
475 
 
 
 
 
 
 
 
 
1433 12.21 STS-135 (1354631-26-7) 28189067 c1ccc2c(c1)c(cn2CCCCCF)C(=O)NC34CC5CC(C3)CC(C5)C4 
1434 12.23 Esprocarb (85785-20-2) 82838 CCN(C(C)C(C)C)C(=O)SCc1ccccc1 
1435 12.25 Terbufos (13071-79-9) 23912 CCOP(=S)(OCC)SCSC(C)(C)C 
1436 12.25 Tolnaftate (2398-96-1) 5309 Cc1cccc(c1)N(C)C(=S)Oc2ccc3ccccc3c2 
1437 12.25 Buprofezin  (Z-isomer) (953030-84-7) 45678 CC(C)N1/C(=N/C(C)(C)C)/SCN(C1=O)c2ccccc2 
1438 12.28 Fluazinam (79622-59-6) 82831 c1c(cnc(c1Cl)Nc2c(cc(c(c2[N+](=O)[O-])Cl)C(F)(F)F)[N+](=O)[O-])C(F)(F)F 
1439 12.28 Isoconazole (27523-40-6) 3629 c1cc(c(c(c1)Cl)COC(Cn2ccnc2)c3ccc(cc3Cl)Cl)Cl 
1440 12.31 JWH-073-2-Methyl [(1-Butyl-1H-indol-3-yl)(2-methyl-1-
naphthyl)methanone] 
(1427325-61-8) 29341456 CCCCn1cc(c2c1cccc2)C(=O)c3c(ccc4c3cccc4)C 
1441 12.31 Picolinafen (137641-05-5) 2542991 c1cc(cc(c1)Oc2cccc(n2)/C(=N/c3ccc(cc3)F)/O)C(F)(F)F 
1442 12.32 Pirimiphos-ethyl (23505-41-1) 29635 CCN(CC)c1nc(cc(n1)OP(=S)(OCC)OCC)C 
1443 12.32 Tebupirimphos (96182-53-5) 84419 CCOP(=S)(Oc1cnc(nc1)C(C)(C)C)OC(C)C 
1444 12.35 Butachlor (23184-66-9) 29376 CCCCOCN(c1c(cccc1CC)CC)C(=O)CCl 
1445 12.35 Oxadiazon (19666-30-9) 27628 CC(C)Oc1cc(c(cc1Cl)Cl)n2c(=O)oc(n2)C(C)(C)C 
1446 12.36 Temephos (3383-96-8) 5199 COP(=S)(OC)Oc1ccc(cc1)Sc2ccc(cc2)OP(=S)(OC)OC 
1447 12.36 Tolfenpyrad (129558-76-5) 8286062 CCC1=NN(C(=C1Cl)C(=O)NCC2=CC=C(C=C2)OC3=CC=C(C=C3)C)C 
1448 12.36 Imibenconazole (86598-92-7) 84387 c1cc(ccc1CS/C(=N\c2ccc(cc2Cl)Cl)/Cn3cncn3)Cl 
1449 12.36 JWH-018-6-Methoxy-Ind [(6-Methoxy-1-pentyl-1H-indol-
3-yl)(1-naphthyl)methanone] 
(1427325-49-2) 26458653 CCCCCn1cc(c2c1cc(cc2)OC)C(=O)c3cccc4c3cccc4 
1450 12.37 Piperonylbutoxide (51-03-6) 5590 CCCCOCCOCCOCc1cc2c(cc1CCC)OCO2 
1451 12.39 JWH-073-3-Methyl    [1-(3-Methylbutyl)-1H-indol-3-
yl](1-naphthyl)methanone 
(1346604-93-0) 26458652 CC(C)CCn1cc(c2c1cccc2)C(=O)c3cccc4c3cccc4 
1452 12.4 Emamectin B1a (119791-41-2) 8410190 CCC(C)C1C(C=CC2(O1)CC3CC(O2)C/C=C(/C(C(/C=C/C=C/4\COC5C4(C(C=C(C5O)C)C(=O)
O3)O)C)OC6CC(C(C(O6)C)OC7CC(C(C(O7)C)NC)OC)OC)\C)C 
1453 12.41 JWH-018 (209414-07-3) 8558143 CCCCCN1C=C(C2=CC=CC=C21)C(=O)C3=CC=CC4=CC=CC=C43 
1454 12.42 Cinidon-ethyl (142891-20-1) 4722745 CCOC(=O)/C(=C/c1cc(ccc1Cl)N2C(=O)C3=C(C2=O)CCCC3)/Cl 
1455 12.43 Flocoumafen Peak 1 & 2 (90035-08-8) 10469214 C1C(CC2=CC=CC=C2C1C3=C(C4=CC=CC=C4OC3=O)O)C5=CC=C(C=C5)OCC6=CC=C(C=
C6)C(F)(F)F 
1456 12.45 Ethion (563-12-2) 3171 CCOP(=S)(OCC)SCSP(=S)(OCC)OCC 
1457 12.47 THC-OH  (11-OH-THC) (36557-05-8) 34385 CCCCCc1cc(c2c(c1)OC(C3C2C=C(CC3)CO)(C)C)O 
1458 12.48 Lufenuron (103055-07-8) 64813 c1cc(c(c(c1)F)C(=O)NC(=O)Nc2cc(c(cc2Cl)OC(C(C(F)(F)F)F)(F)F)Cl)F 
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1459 12.49 Metenolone acetate (434-05-9) 3946 CC1=CC(=O)CC2C1(C3CCC4(C(C3CC2)CCC4OC(=O)C)C)C 
1460 12.5 THC-COOH  (11-COOH-THC or 11-nor-9-Carboxy-THC) (56354-06-4) 97019 CCCCCc1cc(c2c(c1)OC(C3C2C=C(CC3)C(=O)O)(C)C)O 
1461 12.5 Pyrimidifen (105779-78-0) 4953620 CCc1c(c(ncn1)NCCOc2ccc(c(c2C)C)CCOCC)Cl 
1462 12.51 Teflubenzuron (83121-18-0) 82833 c1cc(c(c(c1)F)/C(=N/C(=N/c2cc(c(c(c2F)Cl)F)Cl)/O)/O)F 
1463 12.51 JWH-018-M-4-OH-Ind (1307803-42-4) 26458418 CCCCCn1cc(c2c1cccc2O)C(=O)c3cccc4c3cccc4 
1464 12.52 Fenclofos (Ronnel) (299-84-3) 8939 COP(=S)(OC)Oc1cc(c(cc1Cl)Cl)Cl 
1465 12.52 Pyributicarb (88678-67-5) 84390 CC(C)(C)c1cccc(c1)OC(=S)N(C)c2cccc(n2)OC 
1466 12.55 Dichlofenthion (97-17-6) 7051 CCOP(=S)(OCC)Oc1ccc(cc1Cl)Cl 
1467 12.55 Fenofibrate (49562-28-9) 3222 CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c2ccc(cc2)Cl 
1468 12.61 Pyriproxyfen (95737-68-1) 82851 CC(COc1ccc(cc1)Oc2ccccc2)Oc3ccccn3 
1469 12.62 Hexythiazox (78587-05-0) 3753586 CC1C(SC(=O)N1C(=O)NC2CCCCC2)c3ccc(cc3)Cl 
1470 12.64 JWH-007 (155471-10-6) 8536309 CCCCCN1C(=C(C2=CC=CC=C21)C(=O)C3=CC=CC4=CC=CC=C43)C 
1471 12.65 Iodofenphos (Jodfenphos) (18181-70-9) 26915 COP(=S)(OC)Oc1cc(c(cc1Cl)I)Cl 
1472 12.66 Bromophos (Bromophos-methyl) (2104-96-3) 15572 COP(=S)(OC)Oc1cc(c(cc1Cl)Br)Cl 
1473 12.66 Flucythrinate (70124-77-5) 46213 CC(C)C(c1ccc(cc1)OC(F)F)C(=O)OC(C#N)c2cccc(c2)Oc3ccccc3 
1474 12.67 Noviflumuron (121451-02-3) 8004099 C1=CC(=C(C(=C1)F)C(=O)NC(=O)NC2=CC(=C(C(=C2F)Cl)OC(C(C(F)(F)F)F)(F)F)Cl)F 
1475 12.68 Fluazuron (86811-58-7) 59088 c1cc(c(c(c1)F)C(=O)NC(=O)Nc2ccc(c(c2)Oc3c(cc(cn3)C(F)(F)F)Cl)Cl)F 
1476 12.68 JWH-081 (210179-46-7) 8722599 CCCCCN1C=C(C2=CC=CC=C21)C(=O)C3=CC=C(C4=CC=CC=C43)OC 
1477 12.68 ORG 27569 (868273-06-7) 22369629 CCc1c2cc(ccc2[nH]c1C(=O)NCCc3ccc(cc3)N4CCCCC4)Cl 
1478 12.7 Cannabidiol (13956-29-1) 454786 CCCCCc1cc(c(c(c1)O)C2C=C(CCC2C(=C)C)C)O 
1479 12.71 Chlorpyriphos (2921-88-2) 2629 CCOP(=S)(OCC)Oc1c(cc(c(n1)Cl)Cl)Cl 
1480 12.73 Triallate (2303-17-5) 5342 CC(C)N(C(C)C)C(=O)SCC(=C(Cl)Cl)Cl 
1481 12.77 Sulprofos (Bolstar) (35400-43-2) 34067 CCCSP(=S)(OCC)Oc1ccc(cc1)SC 
1482 12.77 Flucycloxuron (113036-88-7) 5020876 c1cc(c(c(c1)F)C(=O)NC(=O)Nc2ccc(cc2)CO/N=C(/c3ccc(cc3)Cl)\C4CC4)F 
1483 12.77 JWH-412 (1364933-59-4) 28647803 CCCCCn1cc(c2c1cccc2)C(=O)c3ccc(c4c3cccc4)F 
1484 12.78 Quinoxyfen (124495-18-7) 2635909 c1cc(ccc1Oc2ccnc3c2c(cc(c3)Cl)Cl)F 
1485 12.8 Pendimethalin (40487-42-1) 35265 CCC(CC)Nc1c(cc(c(c1[N+](=O)[O-])C)C)[N+](=O)[O-] 
1486 12.8 Spiromesifen (283594-90-1) 8083064 CC1=CC(=C(C(=C1)C)C2=C(C3(CCCC3)OC2=O)OC(=O)CC(C)(C)C)C 
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1487 12.83 Propargite (2312-35-8) 4767 CC(C)(C)c1ccc(cc1)OC2CCCCC2OS(=O)OCC#C 
1488 12.83 Etoxazole (153233-91-1) 135707 CCOc1cc(ccc1C2COC(=N2)c3c(cccc3F)F)C(C)(C)C 
1489 12.85 Tiocarbazil (36756-79-3) 34422 CCC(C)N(C(C)CC)C(=O)SCc1ccccc1 
1490 12.86 Flufenoxuron (101463-69-8) 82863 c1cc(c(c(c1)F)C(=O)NC(=O)Nc2ccc(cc2F)Oc3ccc(cc3Cl)C(F)(F)F)F 
1491 12.88 Amorolfine (78613-35-1) 2083 CCC(C)(C)c1ccc(cc1)CC(C)CN2CC(OC(C2)C)C 
1492 12.89 JWH-122 (619294-47-2) 24623066 CCCCCn1cc(c2c1cccc2)C(=O)c3ccc(c4c3cccc4)C 
1493 12.9 Pyrethrins: Cinerin I (25402-06-6) 4722677 C/C=C/CC1=C(C(CC1=O)OC(=O)C2C(C2(C)C)C=C(C)C)C 
1494 12.9 Carbophenothion (786-19-6) 12536 CCOP(=S)(OCC)SCSc1ccc(cc1)Cl 
1495 12.91 Aspon (3244-90-4) 17576 CCCOP(=S)(OCCC)OP(=S)(OCCC)OCCC 
1496 12.93 Fenpropathrin (39515-41-8) 43074 CC1(C(C1(C)C)C(=O)OC(C#N)c2cccc(c2)Oc3ccccc3)C 
1497 12.93 JWH-019 (209414-08-4) 24598813 CCCCCCn1cc(c2c1cccc2)C(=O)c3cccc4c3cccc4 
1498 12.93 UR-144 (1199943-44-6) 24634882 CCCCCn1cc(c2c1cccc2)C(=O)C3C(C3(C)C)(C)C 
1499 12.94 Diafenthiuron (80060-09-9) 2298854 CC(C)c1cc(cc(c1NC(=S)NC(C)(C)C)C(C)C)Oc2ccccc2 
1500 12.95 Pyrethrin I (121-21-1) 4521834 CC1=C(C(=O)CC1OC(=O)C2C(C2(C)C)C=C(C)C)C/C=C/C=C 
1501 12.97 Miconazole (22916-47-8) 4044 c1cc(c(cc1Cl)Cl)COC(Cn2ccnc2)c3ccc(cc3Cl)Cl 
1502 12.99 Cyhalothrin (lambda-) (91465-08-6) 8519181 Cl\C(=C\C3C(C(=O)OC(C#N)c2cccc(Oc1ccccc1)c2)C3(C)C)C(F)(F)F 
1503 12.99 Butralin (33629-47-9) 33600 CCC(C)Nc1c(cc(cc1[N+](=O)[O-])C(C)(C)C)[N+](=O)[O-] 
1504 13 Desoxycortone 21-(3-phenylpropionate) (14007-50-2) 77265 CC12CCC3C(C1CCC2C(=O)COC(=O)CCc4ccccc4)CCC5=CC(=O)CCC35C 
1505 13 Tiocarlide (910-86-1) 2272774 CC(C)CCOc1ccc(cc1)NC(=S)Nc2ccc(cc2)OCCC(C)C 
1506 13.01 Beta-Cyfluthrin (Baythroid)  (68359-37-5) 94690 CC1(C(C1C(=O)OC(C#N)c2ccc(c(c2)Oc3ccccc3)F)C=C(Cl)Cl)C 
1507 13.02 Brodifacoum Peak 1 & 2 (56073-10-0) 10444663 C1C(CC2=CC=CC=C2C1C3=C(C4=CC=CC=C4OC3=O)O)C5=CC=C(C=C5)C6=CC=C(C=C6)
Br 
1508 13.03 Spirodiclofen (148477-71-8) 17215909 CCC(C)(C)C(=O)OC1=C(C(=O)OC12CCCCC2)c3cc(cc(c3)Cl)Cl 
1509 13.03 RCS-8 (1345970-42-4) 24751863 COc1ccccc1CC(=O)c2cn(c3c2cccc3)CCC4CCCCC4 
1510 13.08 CP-47947 (2-(3-Hydroxycyclohexyl)-5-(2-methyl-2-
octanyl)phenol) 
(70434-82-1) 8171613 OC2CC(c1c(O)cc(cc1)C(C)(C)CCCCCC)CCC2 
1511 13.15 Fenpyroximate (134098-61-6) 7850857 CC1=NN(C(=C1/C=N/OCC2=CC=C(C=C2)C(=O)OC(C)(C)C)OC3=CC=CC=C3)C 
1512 13.21 Deltamethrin (NH4) (120710-23-8) 2876 CC1(C(C1C(=O)OC(C#N)c2cccc(c2)Oc3ccccc3)C=C(Br)Br)C 
1513 13.22 Chlorfluazuron (71422-67-8) 82810 c1cc(c(c(c1)F)C(=O)NC(=O)Nc2cc(c(c(c2)Cl)Oc3c(cc(cn3)C(F)(F)F)Cl)Cl)F 
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1514 13.24 JWH-210 (824959-81-1) 24617616 CCCCCn1cc(c2c1cccc2)C(=O)c3ccc(c4c3cccc4)CC 
1515 13.25 Isopropalin (33820-53-0) 33636 CCCN(CCC)c1c(cc(cc1[N+](=O)[O-])C(C)C)[N+](=O)[O-] 
1516 13.28 JWH-398 (1292765-18-4) 28647395 CCCCCn1cc(c2c1cccc2)C(=O)c3ccc(c4c3cccc4)Cl 
1517 13.3 Amitraz (33089-61-1) 33405 Cc1cc(c(cc1)/N=C/N(/C=N/c2c(cc(cc2)C)C)C)C 
1518 13.34 Pyrethrins: Jasmolin I (4466-14-2) 4521837 CC/C=C/CC1=C(C(CC1=O)OC(=O)C2C(C2(C)C)C=C(C)C)C 
1519 13.34 Fenvalerate (51630-58-1) 3230 CC(C)C(c1ccc(cc1)Cl)C(=O)OC(C#N)c2cccc(c2)Oc3ccccc3 
1520 13.34 JWH-147 (914458-20-1) 23277882 CCCCCCn1cc(cc1c2ccccc2)C(=O)c3cccc4c3cccc4 
1521 13.35 Proquinazid (189278-12-4) 9232930 Ic2ccc1\N=C(\OCCC)N(C(=O)c1c2)CCC 
1522 13.36 AvermectinB1b (Abamectin) (65195-56-4) 26456620 CC1/C=C/C=C/2\COC3C2(C(C=C(C3O)C)C(=O)OC4CC(C/C=C(/C1OC5CC(C(C(O5)C)OC6C
C(C(C(O6)C)O)OC)OC)\C)OC7(C4)C=CC(C(O7)C(C)C)C)O 
1523 13.38 Fenticonazole (72479-26-6) 46840 c1ccc(cc1)Sc2ccc(cc2)COC(Cn3ccnc3)c4ccc(cc4Cl)Cl 
1524 13.39 Tribufos (Merphos oxide or DEF) (78-48-8) 4944 CCCCSP(=O)(SCCCC)SCCCC 
1525 13.4 Pyridaben (96489-71-3) 82852 CC(C)(C)c1ccc(cc1)CSc2cnn(c(=O)c2Cl)C(C)(C)C 
1526 13.41 Tefluthrin (as the Na adduct) (79538-32-2) 8020661 Cl\C(=C\C2C(C(=O)OCc1c(F)c(F)c(c(F)c1F)C)C2(C)C)C(F)(F)F 
1527 13.43 JWH-370 (914458-22-3) 23277889 CCCCCn1cc(cc1c2ccccc2C)C(=O)c3cccc4c3cccc4 
1528 13.45 Almitrine (27469-53-0) 31235 C=CCNc1nc(nc(n1)N2CCN(CC2)C(c3ccc(cc3)F)c4ccc(cc4)F)NCC=C 
1529 13.49 Fluvalinate  (79472-91-6) 45805 CC(C)C(C(=O)OC(C#N)c1cccc(c1)Oc2ccccc2)Nc3ccc(cc3Cl)C(F)(F)F 
1530 13.51 (C8)-CP 47,497  (70434-92-3) 10442937 OC1CC(CCC1)c2ccc(cc2O)C(C)(C)CCCCCCC 
1531 13.53 Bromophos-ethyl (4824-78-6) 19722 CCOP(=S)(OCC)Oc1cc(c(cc1Cl)Br)Cl 
1532 13.53 HU-210 (112830-95-2) 3404012 CCCCCCC(C)(C)c1cc(c2c(c1)OC(C3C2CC(=CC3)CO)(C)C)O 
1533 13.53 JWH-073-M-2-OH-Ind (1427325-54-9) 26458112 CCCCn1c2ccccc2c(c1O)C(=O)c3cccc4c3cccc4 
1534 13.59 Bioresmethrin (or Resmethrin) (28434-01-7) 4877 CC(=CC1C(C1(C)C)C(=O)OCc2cc(oc2)Cc3ccccc3)C 
1535 13.6 Nandrolone phenylpropionate (62-90-8) 4282 CC12CCC3C(C1CCC2OC(=O)CCc4ccccc4)CCC5=CC(=O)CCC35 
1536 13.61 Prothiophos (Tokuthion) (34643-46-4) 33832 CCCSP(=S)(OCC)Oc1ccc(cc1Cl)Cl 
1537 13.63 Tralomethrin (66841-25-6) 7985670 CC1(C(C1C(=O)OC(C#N)C2=CC(=CC=C2)OC3=CC=CC=C3)C(C(Br)(Br)Br)Br)C 
1538 13.64 AvermectinB1a (Abamectin) (65195-55-3) 2175 CCC(C)C1C(C=CC2(O1)CC3CC(O2)CC=C(C(C(C=CC=C4COC5C4(C(C=C(C5O)C)C(=O)O3)
O)C)OC6CC(C(C(O6)C)OC7CC(C(C(O7)C)O)OC)OC)C)C 
1539 13.65 Cannabinol (521-35-7) 2447 CCCCCc1cc(c-2c(c1)OC(c3c2cc(cc3)C)(C)C)O 
1540 13.68 Fenazaquin (120928-09-8) 77874 CC(C)(C)c1ccc(cc1)CCOc2c3ccccc3ncn2 
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1541 13.69 JWH-018-Adamantoyl (or AB-001) (1345973-49-0) 26286891 CCCCCn1cc(c2c1cccc2)C(=O)C34CC5CC(C3)CC(C5)C4 
1542 13.73 Desoxycortone enanthate (1420-68-4) 28590147 CCCCCCC(=O)OCC(=O)C1CCC2C1(CCC3C2CCC4=CC(=O)CCC34C)C 
1543 13.75 Carbosulfan (55285-14-8) 37764 CCCCN(CCCC)SN(C)C(=O)Oc1cccc2c1OC(C2)(C)C 
1544 13.76 Pyridate (55512-33-9) 37831 CCCCCCCCSC(=O)Oc1cc(nnc1c2ccccc2)Cl 
1545 13.77 Leptophos (21609-90-5) 28496 COP(=S)(c1ccccc1)Oc2cc(c(cc2Cl)Br)Cl 
1546 13.82 Testosterone benzoate (2088-71-3) 312539 CC12CCC3C(C1CCC2OC(=O)c4ccccc4)CCC5=CC(=O)CCC35C 
1547 13.86 Flumethrin (69770-45-2) 82804 CC1(C(C1C(=O)OC(C#N)c2ccc(c(c2)Oc3ccccc3)F)/C=C(/c4ccc(cc4)Cl)\Cl)C 
1548 13.93 Permethrin  (cis-) (61949-76-6) 36845 CC1(C(C1C(=O)OCc2cccc(c2)Oc3ccccc3)C=C(Cl)Cl)C 
1549 13.97 THC (Delta9-Tetrahydrocannabinol) (1972-08-3) 2872 CCCCCc1cc(c2c(c1)OC(C3C2C=C(CC3)C)(C)C)O 
1550 14.02 Dibutylchlorendate (1770-80-5) 191879 CCCCOC(=O)C1C(C2(C(=C(C1(C2(Cl)Cl)Cl)Cl)Cl)Cl)C(=O)OCCCC 
1551 14.08 Etofenprox (as the NH4 adduct) (80844-07-1) 64377 CCOc1ccc(cc1)C(C)(C)COCc2cccc(c2)Oc3ccccc3 
1552 14.09 Bifenthrin (as the NH4 adduct) (82657-04-3) 4445165 Cc1c(cccc1c2ccccc2)COC(=O)C3C(C3(C)C)/C=C(/C(F)(F)F)\Cl 
1553 14.2 Ivermectin B1b (as the NH4 adduct) (70209-81-3) 23259889 CC1CCC2(CC3CC(O2)C/C=C(/C(C(/C=C/C=C/4\COC5C4(C(C=C(C5O)C)C(=O)O3)O)C)OC6
CC(C(C(O6)C)OC7CC(C(C(O7)C)O)OC)OC)\C)OC1C(C)C 
1554 14.27 Halfenprox (111872-58-3) 8315975 CC(C)(COCC1=CC(=CC=C1)OC2=CC=CC=C2)C3=CC=C(C=C3)OC(F)(F)Br 
1555 14.4 Ivermectin B1a (as the Na adduct) (70161-11-4) 3535064 CCC(C)C1C(CCC2(O1)CC3CC(O2)CC=C(C(C(C=CC=C4COC5C4(C(C=C(C5O)C)C(=O)O3)
O)C)OC6CC(C(C(O6)C)OC7CC(C(C(O7)C)O)OC)OC)C)C 
1556 14.5 Fenbutatin Oxide Fragm 519 (13356-08-6) 13754592 CC(C)(C[Sn+](CC(C)(C)c1ccccc1)CC(C)(C)c2ccccc2)c3ccccc3 
 
CAS Numbers (as listed in PubChem for vast majority of compounds but not all) SMILES obtained from Chemspider 
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